"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT00579683","Registry for Patients With Acquired Resistance to Small Molecule Kinase Inhibitors in Non-Small-Cell Lung Cancer",,"Completed","No Results Available","Unresectable or Metastatic Non-small Cell Lung Cancer (NSCLC)","Other: Tumor core biopsy for RNA isolation","To compare EGFR gene sequence in patients upon relapse with EGFR gene sequence prior to treatment with small molecule kinase inhibitors.|To identify novel mutations in the tyrosine kinase domain of EGFR in patients with acquired resistance to small molecule kinase inhibitors.|To more precisely characterize the frequency and clinical implications of T790M in patients with acquired resistance to small molecule kinase inhibitors.|To identify novel mechanisms of acquired resistance to EGFR small molecule kinase inhibitors.","Memorial Sloan Kettering Cancer Center","All","Child, Adult, Older Adult",,"228","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","04-103","August 2004","February 2016","February 2016","December 24, 2007",,"February 4, 2016","Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States|Memorial Sloan-Kettering Cancer Center @ Suffolk, Commack, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan-Kettering at Mercy Medical Center, Rockville Centre, New York, United States|Memoral Sloan Kettering Cancer Center at Phelps, Sleepy Hollow, New York, United States",,"https://ClinicalTrials.gov/show/NCT00579683"
2,"NCT00671671","Phase 1 Study To Evaluate Antiviral Activity Of Small Molecule Direct Antiviral Agent At Multiple Doses In Subjects With Chronically Infected Hepatitis C Virus.",,"Completed","Has Results","Hepatitis, Chronic|Hepatitis C Virus","Drug: Small Molecule Agent (PF-868554)","Change From Baseline in Plasma Log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Day 11 (Cohort A): Full Analysis Set|Change From Baseline in Plasma Log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Day 11 (Cohort A): Modified Analysis Set|Change From Baseline in Plasma Log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Day 4 (Cohort B): Full Analysis Set|Change From Baseline in Plasma Log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Day 4 (Cohort B): Modified Analysis Set|Change From Baseline in Plasma Log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Nadir: Full Analysis Set|Change From Baseline in Plasma Log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Nadir: Modified Analysis Set|Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)|Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]|Plasma Concentration at The End of Dosing Interval (Ctau)|Maximum Observed Plasma Concentration (Cmax)|Time to Reach Maximum Observed Plasma Concentration (Tmax)|Plasma Decay Half-Life (t1/2)","Pfizer","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","A8121006","April 2008","December 2008","December 2008","May 5, 2008","January 14, 2014","January 14, 2014","Pfizer Investigational Site, Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00671671"
3,"NCT02179671","Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer",,"Completed","Has Results","Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)","Drug: Gefitinib|Drug: AZD9291|Drug: Selumetinib+Docetaxel|Drug: Tremelimumab","Confirmed Complete Response (CR) Rate|Objective Response Rate (ORR)|Progression-free Survival|Duration of Response|Overall Survival","AstraZeneca|Quintiles, Inc.","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 2","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D4191C00011","July 25, 2014","June 11, 2016","June 11, 2016","July 2, 2014","August 2, 2019","August 2, 2019","Research Site, Goodyear, Arizona, United States|Research Site, Washington, District of Columbia, United States|Research Site, Augusta, Georgia, United States|Research Site, Marietta, Georgia, United States|Research Site, Ashland, Kentucky, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Mineola, New York, United States|Research Site, Huntersville, North Carolina, United States|Research Site, Spokane, Washington, United States|Research Site, Tacoma, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02179671"
4,"NCT02259114","A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)",,"Completed","Has Results","NUT Midline Carcinoma|Triple Negative Breast Cancer|Non-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation|Castrate-resistant Prostate Cancer|CRPC|Pancreatic Ductal Adenocarcinoma","Drug: Birabresib","Number of Participants Who Experienced a Dose Limiting Toxicity (DLT) During Cycle 1|Number of Participants Who Experienced at Least One Adverse Event (AE)|Number of Participants Who Discontinued Study Treatment Due to an AE|Best Overall Response as Assessed in Solid Tumors by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) or in Castration-resistant Prostate Cancer (CRPC) by Prostate Cancer Clinical Trials Working Group (PCWG2) Response Criteria|Observed Maximum Plasma Concentration (Cmax) of MK-8628|Time to Cmax (Tmax) of MK-8628|Area Under to Concentration-Time Curve From 0 to Infinity (AUC0-∞) of MK-8628|Volume of Distribution at Steady State (Vdss) of MK-8628|Terminal Half-Life (t1/2) of MK-8628|Total Plasma Clearance (CL) of MK-8628","Oncoethix GmbH","All","18 Years and older   (Adult, Older Adult)","Phase 1","47","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","8628-003|OTX015_108|2014-002680-15|MK-8628-003","October 23, 2014","March 3, 2017","March 3, 2017","October 8, 2014","October 1, 2018","January 26, 2021",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT02259114/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT02259114/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02259114"
5,"NCT02395601","A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas",,"Completed","No Results Available","B-Cell Lymphoma","Drug: CPI-1205","Frequency of Dose-limiting toxicities (DLTs)|Frequency of adverse events|Pharmacokinetic parameters of CPI-1205: AUC(0-t), AUC(0-inf), AUCtau,ss, Tmax, Cmax, Ctrough, T1/2, Vd/F, CL/F|Pharmacodynamic effects of CPI-1205 in lymphoma tissue: changes in levels of the trimethylated form of lysine residue 27 on histone 3; changes in the expression of genes whose transcription may be altered by EZH2 inhibition|Pharmacodynamic effects of CPI-1205 in bone marrow and in skin: changes in global levels of the trimethylated form of lysine residue 27 on histone 3 (H3K27me3)|Disease response assessment will be performed using the 2014 Lugano Response Criteria for Hodgkin and Non-Hodgkin Lymphoma","Constellation Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1","41","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1205-01","March 2015","December 2018","December 2018","March 23, 2015",,"September 6, 2019","Horizon Oncology Center, Lafayette, Indiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|John Theurer Cancer Center, Hackensack, New Jersey, United States|The Ohio State University James Cancer Hospital, Columbus, Ohio, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02395601"
6,"NCT01949883","A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma",,"Completed","No Results Available","Lymphoma","Drug: CPI-0610","Frequency of dose-limiting toxicities (DLTs) associated with CPI-0610 administration during the first cycle (first 21 days) of treatment|Safety and tolerability of CPI-0610 as assessed by: frequency of adverse events and serious adverse events; changes in hematology and clinical chemistry values; changes in physical examination, vital signs, electrocardiogram, ECHO and ECOG score|Pharmacokinetic parameters of CPI-0610: AUC(0-t), AUC(0-inf), AUCtau,ss, Tmax, Cmax, Ctrough, T1/2, Vd/F, CL/F|Pharmacodynamic effects of CPI-0610: Changes in the expression of MYC and other genes in tumor tissue; changes in cellular proliferation and in the extent of apoptosis; changes in tumor metabolism|Changes in the expression of a set of genes in peripheral blood mononuclear cells (PBMCs) that are sensitive to BET inhibition|Anti-lymphoma activity associated with CPI-0610 treatment","Constellation Pharmaceuticals|The Leukemia and Lymphoma Society","All","18 Years and older   (Adult, Older Adult)","Phase 1","64","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0610-01","September 2013","December 2017","February 2018","September 25, 2013",,"September 6, 2019",,,"https://ClinicalTrials.gov/show/NCT01949883"
7,"NCT02157636","A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma",,"Completed","No Results Available","Multiple Myeloma","Drug: CPI-0610","Frequency of dose-limiting toxicities (DLTs) associated with CPI-0610 administration during the first cycle (first 21 days) of treatment|Safety and tolerability of CPI-0610 as assessed by: frequency of adverse events and serious adverse events; changes in hematology and clinical chemistry values; changes in physical examination, vital signs, electrocardiogram, ECHO and ECOG score|Pharmacokinetic parameters of CPI-0610: AUC(0-t), AUC(0-inf), AUCtau,ss, Tmax, Cmax, Ctrough, T1/2, Vd/F, CL/F|Pharmacodynamic effects of CPI-0610: Changes in the expression of MYC and other genes in malignant tumor cells; changes in cellular proliferation and in the extent of apoptosis|Changes in the expression of a set of genes in peripheral blood mononuclear cells (PBMCs) that are sensitive to BET inhibition|Anti-myeloma activity associated with CPI-0610 treatment","Constellation Pharmaceuticals|The Leukemia and Lymphoma Society","All","18 Years and older   (Adult, Older Adult)","Phase 1","30","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0610-03","July 2014","November 2017","November 2017","June 6, 2014",,"June 7, 2018",,,"https://ClinicalTrials.gov/show/NCT02157636"
8,"NCT04685811","Evaluation of PSMA Antagonist Produced by Two Different Methods",,"Completed","No Results Available","Metastatic Prostate Adenocarcinoma","Drug: 68Ga-PSMA-cyclotron Versus 68Ga-PSMA-generator","Evaluate Equivalence between 68GA-PSMA-cyclotron and 68Ga-PSMA-generator (wCV)|Evaluate Equivalence between 68GA-PSMA-cyclotron and 68Ga-PSMA-generator (RC)|Compare Dosimetry between 68GA-PSMA-cyclotron vs. 68Ga-PSMA-generator|Compare Bio-Distribution between 68GA-PSMA-cyclotron vs. 68Ga-PSMA-generator|Compare Whole Body Excretion/Metabolism between 68GA-PSMA-cyclotron vs. 68Ga-PSMA-generator","Weill Medical College of Cornell University|National Institutes of Health (NIH)|National Cancer Institute (NCI)","Male","21 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","19","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","19-11021092|7R01CA207645-03","December 9, 2020","June 30, 2021","June 30, 2021","December 28, 2020",,"February 3, 2022","Weill Cornell Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04685811"
9,"NCT02038673","An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors",,"Completed","No Results Available","Solid Tumors","Drug: ASP5878","Dose-escalation part and Expansion part: Safety assessed by Adverse Events (AEs)|Dose-escalation part and Expansion part:Safety assessed by Vital signs|Dose-escalation part and Expansion part:Safety assessed by Body weight|Dose-escalation part and Expansion part:Safety assessed by Laboratory tests|Dose-escalation part and Expansion part:Safety assessed by 12-lead ECGs|Dose-escalation part and Expansion part: Ophthalmology|Dose-escalation part and Expansion part: Bone density measurement|Dose-escalation part and Expansion part: Computed tomography (CT) Imaging assessment|Expansion part only: Echocardiogram|Dose-escalation part: Pharmacokinetics (PK) parameter of ASP5878 in plasma: Cmax|Dose-escalation part:PK parameter of ASP5878 in plasma: tmax|Dose-escalation part:PK parameter of ASP5878 in plasma: AUClast|Dose-escalation part: PK parameter of ASP5878 in plasma: AUCinf|Dose-escalation part: PK parameter of ASP5878 in plasma: t1/2|Dose-escalation part: PK parameter of ASP5878 in plasma: CL/F|Dose-escalation part: PK parameter of ASP5878 in plasma: Vz/F|Dose-escalation part: PK parameter of ASP5878 in urine: Ae|Dose-escalation part: PK parameter of ASP5878 in urine: CLR|Dose-escalation part: Pharmacodynamic (PD) parameter: Serum FGF23 concentrations|Dose-escalation part: PD parameter: Serum inorganic phosphorus concentrations|Dose-escalation part: PD parameter: Serum calcium concentrations|Dose-escalation part: PD parameter: Serum iPTH concentrations|Dose-escalation part: PD parameter: Serum calcitriol concentrations|Expansion part: PK parameter of ASP5878 in plasma: Cmax|Expansion part: PK parameter of ASP5878 in plasma: tmax|Expansion part: PK parameter of ASP5878 in plasma: AUClast|Expansion part: PK parameter of ASP5878 in plasma: AUCinf|Expansion part: PK parameter of ASP5878 in plasma: t1/2|Expansion part: PK parameter of ASP5878 in plasma: CL/F|Expansion part: PK parameter of ASP5878 in plasma: Vz/F|Expansion part: PD parameter: Serum FGF19 concentrations|Expansion part: PD parameter: Serum FGF23 concentrations|Expansion part: PD parameter: Serum inorganic phosphorus concentrations|Expansion part: PD parameter: Serum iPTH concentrations|Expansion part: PD parameter: Serum calcitriol concentrations|Expansion part: PD parameter: Serum 7α-hydroxy-4-cholesten-3-one|Expansion part: Overall response|Expansion part: Maximum Shrinkage in Target Lesion|Expansion part: Progression free survival (PFS)|Expansion part: Time to progression (TTP)|Expansion part: Time to treatment failure (TTF)|Expansion part: Overall survival (OS)","Astellas Pharma Inc|Astellas Pharma Global Development, Inc.","All","20 Years and older   (Adult, Older Adult)","Phase 1","86","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","5878-CL-0101","November 5, 2013","July 19, 2017","July 19, 2017","January 16, 2014",,"October 22, 2018","Site US402, Orange, California, United States|Site US401, New York, New York, United States|Site US404, Cleveland, Ohio, United States|Site US406, Spartanburg, South Carolina, United States|Site US410, Fairfax, Virginia, United States|Site US403, Seattle, Washington, United States|Site JP122, Chiba, Japan|Site JP108, Fukuoka, Japan|Site JP115, Fukuoka, Japan|Site JP120, Fukuoka, Japan|Site JP116, Hokkaido, Japan|Site JP113, Hyogo, Japan|Site JP103, Ibaraki, Japan|Site JP111, Ishikawa, Japan|Site JP119, Kanagawa, Japan|Site JP101, Kyoto, Japan|Site JP109, Miyagi, Japan|Site JP110, Miyagi, Japan|Site JP112, Nagoya, Japan|Site JP117, Niigata, Japan|Site JP121, Okayama, Japan|Site JP104, Osaka, Japan|Site JP106, Osaka, Japan|Site JP118, Osaka, Japan|Site JP124, Shizuoka, Japan|Site JP102, Tokyo, Japan|Site JP107, Tokyo, Japan|Site JP123, Tokyo, Japan|Site KR202, Gyeonggi-do, Korea, Republic of|Site KR201, Seoul, Korea, Republic of|Site KR203, Seoul, Korea, Republic of|Site KR204, Seoul, Korea, Republic of|Site TW302, Tainan, Taiwan|Site TW301, Taipei, Taiwan|Site TW303, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT02038673"
10,"NCT03157310","Bone Metastasis on the Survival of Gefitinib Effective Patients",,"Completed","No Results Available","Overal Survival, Non-small Cell Lung Cancer","Drug: Gefitinib","Overal survival of patients|Survival of patients with both bone metastasis and brain metastasis","Qilu Hospital of Shandong University","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","265","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017-QLH-11","May 1, 2009","May 1, 2013","July 12, 2015","May 17, 2017",,"May 17, 2017",,,"https://ClinicalTrials.gov/show/NCT03157310"
11,"NCT02444884","MLN8237 to Treat Children With Relapsed/Refractory Solid Tumors",,"Completed","No Results Available","Unspecified Childhood Solid Tumor, Excluding CNS|Neuroblastoma","Drug: MLN8237","Determine maximum tolerated dose and RP2D administered once daily on Days 1-7|Determine maximum tolerated dose and RP2D administered po BID on Days 1-7|Adverse events as assessed by (CTCAE) version 4.0|PK Profile: MLN8237 concentrations in plasma samples","Children's Oncology Group|National Cancer Institute (NCI)","All","12 Months to 21 Years   (Child, Adult)","Phase 1","54","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ADVL0812","September 2008","December 2011","December 2011","May 15, 2015",,"February 9, 2016",,,"https://ClinicalTrials.gov/show/NCT02444884"
12,"NCT03722576","Vidofludimus Calcium for Primary Sclerosing Cholangitis","PSC","Completed","Has Results","Primary Sclerosing Cholangitis","Drug: Vidofludimus calcium","Subjects Who Experience a Positive Outcome as Measured by Combination of Serum Alkaline Phosphatase (ALP) and Aspartate Aminotransferase (AST) Levels.|Abnormal Aspartate Aminotransferase (AST)|Abnormal Alanine Aminotransferase (ALT)|Abnormal Total Bilirubin|Abnormal Direct Bilirubin","Elizabeth Carey|Arizona State University|Mayo Clinic","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","18","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IND140679","June 17, 2019","June 30, 2020","June 30, 2020","October 29, 2018","June 2, 2021","June 2, 2021","Mayo Clinic in Arizona, Phoenix, Arizona, United States|Arizona State University, Tempe, Arizona, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT03722576/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03722576"
13,"NCT02916537","A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057",,"Completed","No Results Available","Prostate Cancer","Drug: CTT1057|Procedure: Prostatectomy","Adverse event frequency as graded by Common Toxicity Criteria version 4.03|Organ dosimetry/tissue uptake of CTT1057 as measured by PET/MR imaging of prostate cancer|Pharmacokinetic profile of CTT1057 as measured by radiotracer detection in blood samples|Level of CTT1057 uptake on PET/MR imaging of localized prostate cancer with PSMA protein expression by immunohistochemistry from subsequent radical prostatectomy specimens|Optimal Standardized Uptake Value (SUV) ratio threshold on CTT1057 PET/MR for discriminating tumor pathology from primary prostate cancer tissue|Sensitivity and specificity of CTT1057 PET imaging on a lesion-by-lesion basis as compared with standard imaging in metastatic prostate cancer|Number of positive lesions on CTT1057 PET/MR in subjects with equivocal or negative conventional imaging scans|Location of positive lesions on CTT1057 PET/MR in subjects with equivocal or negative conventional imaging scans","Cancer Targeted Technology|University of California, San Francisco","Male","18 Years and older   (Adult, Older Adult)","Phase 1","20","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","1057-101","September 2016","August 28, 2017","August 28, 2017","September 27, 2016",,"November 6, 2017","University of California San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT02916537"
14,"NCT04313166","Treatment Continuation Study for Patients With ALS/MND Who Completed Study CMD-2019-001",,"Completed","No Results Available","Amyotrophic Lateral Sclerosis","Drug: Cu(II)ATSM","Treatment-related changes in disease severity|Treatment-related changes in cognitive function|Treatment-related changed in respiratory function|Treatment tolerance","Collaborative Medicinal Development Pty Limited","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","55","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CMD-2020-001","March 19, 2020","November 18, 2021","February 15, 2022","March 18, 2020",,"February 17, 2022","Macquarie University, Macquarie Park, New South Wales, Australia",,"https://ClinicalTrials.gov/show/NCT04313166"
15,"NCT01533181","Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer",,"Completed","Has Results","Recurrent Small Cell Lung Carcinoma","Other: Laboratory Biomarker Analysis|Drug: Linsitinib|Other: Pharmacological Study|Drug: Topotecan Hydrochloride","Median Progression Free Survival (PFS)|Disease Control Rate (DCR)|Incidence of Serious Adverse Events (SAEs) Possibly/Probably Definitely Related to Study Drugs|Overall Survival (OS)","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","44","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NCI-2012-00245|CDR0000724806|MCC-16628|MCC 16628|8873|N01CM00070|N01CM00099|N01CM00100|P30CA076292","February 2012","November 2014","November 2014","February 15, 2012","January 14, 2016","January 14, 2016","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University/Winship Cancer Institute, Atlanta, Georgia, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, Maryland, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Case Western Reserve University, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Johns Hopkins Singapore, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT01533181"
16,"NCT01605526","A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma",,"Completed","No Results Available","Sarcoma","Drug: RO5045337|Drug: doxorubicin","Maximum tolerated dose/dose-limiting toxicities|Safety: Incidence of adverse events|Pharmacokinetics of RO5045337 and doxorubicin in combination therapy: Area under the concentration-time curve (AUC)|Pharmacodynamics: Serum macrophage inhibitory cytokine-1 (MIC-1) levels","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 1","23","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NP28021|2011-006279-21","May 2012","June 2013","June 2013","May 25, 2012",,"November 2, 2016","Santa Monica, California, United States|Boston, Massachusetts, United States|Hackensack, New Jersey, United States|Philadelphia, Pennsylvania, United States|Salt Lake City, Utah, United States|Bordeaux, France|Lyon, France|Toulouse, France|Villejuif, France",,"https://ClinicalTrials.gov/show/NCT01605526"
17,"NCT02419417","Study of BMS-986158 in Subjects With Select Advanced Cancers","BET","Completed","No Results Available","Advanced Tumors","Drug: BMS-986158|Biological: Nivolumab","Number of Adverse Events (AEs)|Number of Serious Adverse Events (SAEs)|Number of AEs leading to discontinuation|Number of laboratory test toxicity grade shifting from baseline|Best Overall Response|Objective Response Rate (ORR)|Duration of Response|Maximum observed plasma concentration (Cmax)|Time of maximum observed plasma concentration (Tmax)|Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))|Area under the concentration-time curve in one dosing interval (AUC(TAU))|Apparent terminal phase half-life (T-HALF)|Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF))|Apparent total body clearance, reported only for parent, not for metabolite (CLT/F)|Apparent volume of distribution of terminal phase, reported only for parent, not for metabolite (Vz/F)|Minimum observed concentration within a dosing interval (Cmin)|Concentration at the end of a dosing interval (Ctau)|Trough observed plasma concentration (this includes predose concentrations (C0) and concentrations at the end of dosing interval (Ctau)) (Ctrough)|Degree of Fluctuation or Fluctuation Index ([Cmax-Cmin)/Css-avg])|[Cmax - Cmin] / Cmin; to be calculated at steady-state (Swing)|Accumulation Index (AI)|Effective elimination half-life that explains the degree of accumulation observed for a specific exposure measure (T-HALFeff)|Ratio of metabolite Cmax to parent Cmax, corrected for molecular weight (MR_Cmax)|Ratio of metabolite AUC(0-T) to parent AUC(0-T), corrected for molecular weight (MR_AUC(0-T))|Ratio of metabolite AUC(INF) to parent AUC(INF), corrected for molecular weight (following single dose only) (MR_AUC(INF))|Ratio of metabolite AUC(TAU) to parent AUC(TAU), corrected for molecular weight (MR_AUC(TAU))|Electrocardiogram (ECG) QT (time of ventricular activity including both depolarization and repolarization) Interval","Bristol-Myers Squibb","All","12 Years and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","83","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA011-001|2015-000324-29","June 19, 2015","March 17, 2021","March 17, 2021","April 17, 2015",,"February 24, 2022","City Of Hope National Medical Center, Duarte, California, United States|University Of Colorado, Aurora, Colorado, United States|Dana Farber Cancer Institute., Boston, Massachusetts, United States|Oregon Health & Science University, Portland, Oregon, United States|Univ. Of Pa, Philadelphia, Pennsylvania, United States|Institute for Translational Oncology Research-ITOR, Greenville, South Carolina, United States|Nucleus Network, Melbourne, Victoria, Australia|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada|Local Institution, Lyon Cedex 08, France|Local Institution, Villejuif, France|H. Univ. Vall dHebron, Barcelona, Spain|Centro Integral Oncologico Clara Campal, Madrid, Spain|Clinica Universidad de Navarra, Pamplona, Spain",,"https://ClinicalTrials.gov/show/NCT02419417"
18,"NCT01462175","A First-In-Human Study of RO5503781 in Participants With Advanced Malignancies Except Leukemia",,"Completed","No Results Available","Neoplasms","Drug: RO5503781","Maximum Tolerated Dose (MTD)|Percentage of Participants With Dose Limiting Toxicities (DLTs)|Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Plasma Concentration of RO5503781|Urine Concentration of RO5503781|Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST)|Percentage of Participants With Objective Response [Complete Response (CR) plus Partial Response(PR)] According to Response Evaluation Criteria in Solid Tumors (RECIST)|Standardized Uptake Value (SUV) obtained from the Positron Emission Tomography With 18-Fluorothymidine [(18F)-FLT-PET) Images|Pharmacodynamics: p21 Levels in Tumor as Measured by Immunohistochemistry|Pharmacodynamics: Tumor suppressor gene (p53) Levels in Tumor as Measured by Immunohistochemistry|Pharmacodynamics: Murine Double Minute 2 (MDM2) Levels in Tumor as Mesured by Reverse transcription polymerase chain reaction (RT-PCR)|Pharmacodynamics: Ki-67 Levels in Tumor as Measured by Immunohistochemistry|Pharmacodynamics: Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) Levels in Tumor as Measured by Immunohistochemistry|Progression Free Survival (PFS) According to Cheson Criteria|Pharmacodynamics: p53 Mutation Status in Tumor as Measured by AmpliChip p53 Test|Pharmacodynamics: Mouse Double Minute 2 Homolog (MDM2) Gene Copy Number in Tumor as Measured by in situ Hybridization|Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf)|Food-Effect: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf)|Area Under the Curve from Time Zero to end of dosing interval (AUCtau)|Food-Effect: Area Under the Curve From Time Zero to Extrapolated 168 hours [AUC(0-168)]|Maximum Observed Plasma Concentration (Cmax)|Food-Effect: Maximum Observed Plasma Concentration (Cmax)|Time to Reach Maximum Observed Plasma Concentration (Tmax)|Food-Effect: Time to Reach Maximum Observed Plasma Concentration (Tmax)|Plasma Decay Half-Life (t1/2)|Food-Effect: Plasma Decay Half-Life (t1/2)|Terminal Elimination Rate Constant (Kel)|Food-Effect: Terminal Elimination Rate Constant (Kel)|Apparent Oral Clearance (CL/F)|Apparent Volume of Distribution (Vz/F)|Percentage of Participants With Objective Response [Complete Response (CR) plus Partial Response(PR)] According to Cheson Criteria|Pharmacodynamics: Macrophage Inhibitory Cytokine 1 (MIC-1) Levels in Blood as Measured by Enzyme-linked Immunosorbent Assay (ELISA)","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 1","99","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NP27872|2011-002767-15","November 2011","July 2014","July 2014","October 31, 2011",,"November 2, 2016","Melbourne, Victoria, Australia|Hamilton, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Bordeaux, France|Lyon, France|Seoul, Korea, Republic of|Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT01462175"
19,"NCT01334177","TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck",,"Completed","No Results Available","Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Salivary Gland Squamous Cell Carcinoma|Stage III Salivary Gland Cancer|Stage III Squamous Cell Carcinoma of the Hypopharynx|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage III Squamous Cell Carcinoma of the Nasopharynx|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage III Verrucous Carcinoma of the Larynx|Stage III Verrucous Carcinoma of the Oral Cavity|Stage IV Salivary Gland Cancer|Stage IVA Squamous Cell Carcinoma of the Larynx|Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVA Squamous Cell Carcinoma of the Oropharynx|Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Verrucous Carcinoma of the Larynx|Stage IVA Verrucous Carcinoma of the Oral Cavity|Stage IVB Squamous Cell Carcinoma of the Larynx|Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVB Squamous Cell Carcinoma of the Oropharynx|Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Verrucous Carcinoma of the Larynx|Stage IVB Verrucous Carcinoma of the Oral Cavity|Stage IVC Squamous Cell Carcinoma of the Larynx|Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVC Squamous Cell Carcinoma of the Oropharynx|Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Verrucous Carcinoma of the Larynx|Stage IVC Verrucous Carcinoma of the Oral Cavity|Tongue Cancer","Drug: TLR8 agonist VTX-2337|Biological: cetuximab|Other: laboratory biomarker analysis|Other: pharmacogenomic studies","Maximum tolerated dose and the toxicities of TLR8 agonist VTX-2337 in combination with cetuximab|Pharmacodynamic immune response to TLR8 agonist VTX-2337 in combination with cetuximab","University of Washington|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","13","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","7406|NCI-2011-00240|P30CA015704","June 2011","June 2014",,"April 13, 2011",,"March 5, 2015","Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01334177"
20,"NCT02777710","Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers","MEDIPLEX","Completed","No Results Available","Colorectal Cancer|Pancreatic Cancer|Metastatic Cancer|Advanced Cancer","Drug: Pexidartinib|Drug: Durvalumab","part 1 (dose escalation part) : Dose-Limiting Toxicities (DLT)|part 2 (extension part) : objective response rate (ORR)|The duration of response (DoR)|Progression-Free Survival (PFS)|Adverse events reporting|Area under the Pexidartinib plasma concentration (AUC) versus time curve|Peak Pexidartinib plasma concentration (Cmax)","Centre Leon Berard|AstraZeneca|Plexxikon","All","18 Years and older   (Adult, Older Adult)","Phase 1","48","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ET15-037 (MEDIPLEX)|2015-002438-31","June 2016","November 2019","December 2019","May 19, 2016",,"September 5, 2021","Centre Léon Bérard, Lyon, France|IUCT-oncopole, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT02777710"
21,"NCT00939770","Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma",,"Completed","Has Results","Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Neuroblastoma|Refractory Anaplastic Large Cell Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Neuroblastoma","Drug: Crizotinib|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Other: Questionnaire Administration","Maximum-tolerated Dose and Recommended Phase 2 Dose of Crizotinib|Number of Participants With Toxicities of Crizotinib|Steady State C Max of Crizotinib|Steady State C Average of Crizotinib|Steady State AUC of Crizotinib|Steady State Clearance of Crizotinib|Number of Participants (Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma (ALCL))With Response to Crizotinib|Number of Participants (Relapsed or Refractory Neuroblastoma or Anaplastic Large Cell Lymphoma (ALCL)) With Response to Crizotinib|Number of Participants With Minimum Residual Disease (MRD)","Children's Oncology Group|National Cancer Institute (NCI)|Pfizer","All","1 Year to 21 Years   (Child, Adult)","Phase 1|Phase 2","122","Other|NIH|Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ADVL0912|NCI-2011-01937|P10666|COG-ADVL0912|CDR0000647587|UM1CA097452","September 21, 2009","December 31, 2018","December 31, 2018","July 15, 2009","May 5, 2020","June 9, 2020","Children's Hospital of Alabama, Birmingham, Alabama, United States|University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States|Children's Hospital of Orange County, Orange, California, United States|UCSF Medical Center-Parnassus, San Francisco, California, United States|UCSF Medical Center-Mission Bay, San Francisco, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States|Hospital for Sick Children, Toronto, Ontario, Canada","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT00939770/Prot_SAP_ICF_001.pdf","https://ClinicalTrials.gov/show/NCT00939770"
22,"NCT02806817","ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial Metabolism",,"Completed","No Results Available","Breast Cancer|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast|Early-Stage Breast Carcinoma","Drug: ME-344|Drug: Bevacizumab|Other: Normal saline","Reduction of FDG uptake|SDH (succinate dehydrogenase) levels staining|Toxicity profile: Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0|Ki67 changes|Cleaved caspase-3 changes","Centro Nacional de Investigaciones Oncologicas CARLOS III|Fundacion CRIS de Investigación para Vencer el Cáncer","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CNIO-BR-009|2015-005457-12","July 2016","October 2018","November 2018","June 21, 2016",,"July 23, 2019","Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain|H. Arnau de Vilanova Lleida, Lleida, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Clínica Quirón, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT02806817"
23,"NCT01261754","A Study of 99mTc-MIP-1404 and 99mTc-MIP-1405 in Patients With Metastatic Prostate Adenocarcinoma and Healthy Volunteers",,"Completed","No Results Available","Prostate Cancer","Radiation: 99mTc MIP 1404|Radiation: 99mTc MIP 1405","Safety of Administered dose|Pharmacokinetics of Administered Dose|Biodistribution of Administered Dose|Excretion of administered dose|Dosimetry of administered dose|Metabolism of administered dose","Molecular Insight Pharmaceuticals, Inc.","Male","21 Years and older   (Adult, Older Adult)","Phase 1","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic","TcTx-P101","December 2010","February 2012",,"December 16, 2010",,"November 25, 2015","New York Presbyterian Hospital - Weill Medical College of Cornell University, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01261754"
24,"NCT00712829","Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate Cancer Imaging Agents",,"Completed","No Results Available","Prostate Cancer","Drug: 123-I-MIP-1072|Drug: 123-I-MIP-1095","To examine the pharmacokinetics and organ radiation dosimetry of 123-I-MIP-1072 and 123I-MIP-1095 in patients with prior histological diagnosis of prostate cancer with evidence of recurrent metastatic disease.|To examine whole body excretion and metabolism of 123-I-MIP-1072 and 123-I-MIP-1095 in patients with recurrent metastatic prostate cancer.|To evaluate the safety of administering a 10.0 mCi dose of 123-I-MIP-1072 and 123-I-MIP-1095 to patients with recurrent metastatic prostate cancer.|Optimize imaging parameters","Molecular Insight Pharmaceuticals, Inc.","Male","18 Years and older   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic","TX-P101","May 2008","January 2009","January 2009","July 10, 2008",,"October 12, 2011","Johns Hopkins Medical Institutes - Neuroradiology Division, Baltimore, Maryland, United States|New York Weill Cornell Medical Center - New York Presbyterian Hospital, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00712829"
25,"NCT03626415","A Hepatic Impairment Study for PF-04965842.",,"Completed","Has Results","Hepatic Impairment","Drug: PF-04965842","Maximum Observed Plasma Concentration (Cmax) for PF-04965842|Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) for PF-04965842|Number of Participants With Treatment-Emergent Adverse Events (AEs) for PF-04965842|Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)|Number of Participants With Electrocardiogram (ECG) Findings of Potential Clinical Importance for PF-04965842|Number of Participants With Vital Sign Findings of Potential Clinical Importance for PF-04965842","Pfizer","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","B7451020","October 1, 2018","April 30, 2019","April 30, 2019","August 13, 2018","May 18, 2020","May 18, 2020","Orlando Clinical Research Center, Orlando, Florida, United States|Prism Clinical Research, LLC, Saint Paul, Minnesota, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT03626415/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT03626415/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03626415"
26,"NCT00835419","Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression","ENVER","Completed","No Results Available","Melanoma","Drug: P276-00","Progression Free Survival rate at Day 168|Overall survival rate at 1 year, objective response rate,duration of response","Piramal Enterprises Limited","All","18 Years and older   (Adult, Older Adult)","Phase 2","12","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P276-00/27/08","May 2009","April 2011","November 2012","February 3, 2009",,"December 4, 2012","University of Newcastle, School of Medicine and Public Health, Newcastle, New South Wales, Australia|Mater Adult Hospital Raymond Tce South Brisbane, QLD 4101, Brisbane, Australia|Peninsula Oncology Centre, Frankston, Australia|John Fawkner Cancer Trial Centre, Victoria, Australia|Curie Manavata Cancer Center, Nasik, Maharashtra, India|Chhatrapati Shahuji Maharaj Medical University, Lucknow, Uttar Pradesh, India|Christchurch Oncology Research Unit, Oncology Service, Christchurch Hospital, Riccarton Avenue, Private Bag 4710, Christchurch,, Christchurch, New Zealand",,"https://ClinicalTrials.gov/show/NCT00835419"
27,"NCT04040907","The the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XNW3009 in Health Subject",,"Completed","No Results Available","Gout","Drug: XNW3009|Drug: Placebo","Evaluate incidence and severity of adverse eventsadministration in healthy adult subjects.|Evaluate clinically significant changes from baseline in physical examinations|Evaluate the pharmacokinetic of maximum plasma concentration","Sinovent Pty Ltd.","All","18 Years to 45 Years   (Adult)","Phase 1","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","XNW3009-1-02","November 13, 2019","January 20, 2021","May 30, 2021","August 1, 2019",,"January 6, 2022","Linear Clinical Research, Perth, West Austrialia, Australia",,"https://ClinicalTrials.gov/show/NCT04040907"
28,"NCT02424617","A Study of BGB324(Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer",,"Completed","No Results Available","Non-Small Cell Lung Cancer","Drug: erlotinib|Drug: bemcentinib","Number of Participants with Treatment-emergent Adverse Events (TEAE)|Number of Participants with Clinically Significant Clinical Laboratory, Physical examination, Vital Signs, Echocardiogram or Multi-gated Acquisition (MUGA) Scan and Electrocardiogram (ECG) Abnormalities|Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status|Pharmacokinetics Parameter: Area Under The Curve Within A Dosing Interval (AUC0-t) of Bemcentinib|Pharmacokinetics Parameter: Maximum Observed Plasma Concentration (Cmax) of Bemcentinib|Pharmacokinetics Parameter: Time to Reach Maximum Plasma Concentration (Tmax) of Bemcentinib|Pharmacodynamic Parameter: Changes in the Phosphorylation Status of Signaling Proteins|Pharmacodynamic Parameter: Change from Baseline in Circulating Markers Levels|Pharmacodynamic Parameter: Changes in Gene Expression of Tumor Tissue or Circulating Nucleic Acids|Pharmacodynamic Parameter: Spectrum of Mutations (Including EGFR Mutations) Within Cancer Cell Population or In Circulating Nucleic Acids|Pharmacodynamic Parameter: Number of Participants with Epithelial-Mesenchymal Transition Gene Signature|Time To Progression","BerGenBio ASA","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","40","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BGBC004","March 2015","August 25, 2021","August 25, 2021","April 23, 2015",,"October 18, 2021","Norris Comprehensive Cancer Center, Los Angeles, California, United States|Moores UC San Diego Cancer Center, San Diego, California, United States|Moffit Cancer Centre, Tampa, Florida, United States|Horizon Oncology,1345 Unity Place, Lafayette, Indiana, United States|Henry Ford Hospital, Detroit, Michigan, United States|Tennessee Oncology, Nashville, Tennessee, United States|Mary Crowley Cancer Research Unit, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Oncology Consultants, Houston, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02424617"
29,"NCT00541190","Absorptive Clearance in the Cystic Fibrosis Airway",,"Completed","Has Results","Cystic Fibrosis","Other: Technetium [Tc-99m] sulfur colloid and Indium [In-111] DTPA","Absorptive Clearance Rate|Mucociliary Clearance Rate","University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Not Applicable","21","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","PRO07060240|NIH K25 HL081533-02","October 2007","April 2008","April 2008","October 10, 2007","February 3, 2012","August 24, 2017","University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00541190"
30,"NCT01682694","Glucosamine and Chondroitin Effects","GLANCE","Completed","No Results Available","Inflammation","Dietary Supplement: Glucosamine and Chondroitin|Dietary Supplement: placebo","hsCRP|untargeted (exploratory) serum metabolomics (differences in small molecule abundance ratios)","Fred Hutchinson Cancer Research Center","All","20 Years to 55 Years   (Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","7798","September 2012","August 2013","August 2013","September 11, 2012",,"May 28, 2014","Fred Hutchinson Cancer Research Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01682694"
31,"NCT01561456","Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung",,"Completed","No Results Available","Non-small-cell Lung Cancer|Squamous Cell Carcinoma|Adenocarcinoma of the Lung","Drug: AXL1717|Drug: Docetaxel","Rate of progression-free survival (PFS)|Rate of complete response (CR), partial response (PR), stable disease, (SD), progressive disease (PD), disease control (CR + PR + SD), and objective response (CR + PR)|Median time to disease progression (TTP), time to objective response and time to treatment failure (TTF)|Median duration of progression-free-survival (PFS), objective response and disease control|12-week survival|1 year survival|Investigational product toxicity profile|Overall survival","Axelar AB","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AXL-003|2011-002007-15","December 2011","December 2013","December 2013","March 23, 2012",,"December 5, 2013","State Medical Institution: Republic Scientific Oncology Center, Poselok, Minsk Region, Belarus|Gomel Regional Clinical Oncology Center, Gomel, Belarus|Minsk City Clinical Oncology Center, Minsk, Belarus|Vitebsk Regional Clinical Oncology Center, Vitebsk, Belarus|Semmelweis University; Clinic for Pulmonology, Budapest, Hungary|University of Debrecen Medical and Health Science Center, Clinic of Pulmonology, Debrecen, Hungary|Kenezy Gyula County Hospital, Debrecen, Hungary|Hospital for Thoracic Diseases of Csongrad County Local Government, Deszk, Hungary|Wladyslaw Bieganski Regional Specialist Hospital, Grudziadz, Poland|Maria Sklodowska-Curie Institute of Oncology in Warsaw, Warsaw, Poland|State Therapeutical and Prophylactic Institution: Chelyabinsk Regional Oncology Center, Chelyabinsk, Russian Federation|Sverdlovsk Regional Oncology Center, Ekaterinburg, Russian Federation|City Clinical Hospital #1, Novosibirsk, Russian Federation|Orel Oncology Center, Orel, Russian Federation|State Higher Educational Institution St. Petersburg State Medical University n. a. after I. P. Pavlov under Federal Agency for Healthcare and Social Development, Research Institute of Pulmonology, Saint Petersburg, Russian Federation|St. Petersburg State Medical Institution Municipal Clinical Oncology Center, St. Petersburg, Russian Federation|Tula Regional Oncology Center, Tula, Russian Federation|Dnipropetrovsk City Multispecialty Clinical Hospital #4, Dniepropetrovsk, Ukraine|Public Clinical Treatment and Prophylaxis Institution: Donetsk Regional Antitumor Center, Donetsk, Ukraine|Kharkiv, State Institution: S.P. Hryhoriev Institute of Medical Radiology under the Ukrainian Academy of Medical Sciences, Kharkiv, Ukraine|Public Healthcare Institution: Kharkiv Regional Clinical Oncology Center, Kharkiv, Ukraine|Kyiv City Oncology Hospital, Kyiv, Ukraine|Lviv State Regional Treatment and Diagnostics Oncology Center, Lviv, Ukraine|Zakarpattia Regional Clinical Oncology Center, Uzhhorod, Ukraine",,"https://ClinicalTrials.gov/show/NCT01561456"
32,"NCT00837551","Phase IIa Study of WBI-1001 Cream for Atopic Dermatitis","WBI-1001-201","Completed","No Results Available","Dermatitis, Atopic","Drug: WBI-1001","To evaluate skin lesion condition as a measure of safety and tolerability of WBI-1001 treated AD patients.|Assess systemic exposure of WBI-1001 treated AD patients by measuring plasma PK.|Explore efficacy of topically applied WBI-1001 cream in patients with AD.","Welichem Biotech Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","WBI-1001-201: Control # 119727","March 2008","June 2008","October 2008","February 5, 2009",,"February 5, 2009","Innovaderm Research Inc.,, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00837551"
33,"NCT01098734","Non-steroid, Atopic Dermatitis Phase IIb 12-week Trial; Topical WBI-1001 Cream",,"Completed","No Results Available","Dermatitis, Atopic","Drug: WBI-1001","Investigator's Global Assessment (IGA) score|Eczema Area and Severity Index (EASI) score|Scoring Atopic Dermatitis (SCORAD) Index.|Clinical laboratory tests (haematology, urine) and vital signs.|Adverse events|BSA and pruritus.|Longterm change in IGA score of WBI-1001 cream groups.|Statistically significant improvement in the rate of ""Treatment Success"" with 0.5% and 1.0% WBI-1001 creams compared with placebo.","Welichem Biotech Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","148","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","WBI-1001-202 : # 133148|# 133148","November 2009","October 2010","November 2010","April 5, 2010",,"June 13, 2011","Guilford Dermatology Associates, Surrey, British Columbia, Canada|Department of Dermatology and Skin Sciences, UBC, Vancouver, British Columbia, Canada|Windsor Clinical Research Inc., Windsor, Ontario, Canada|Innovaderm Research Inc., Montreal, Quebec, Canada|Centre de Recherche Dermatologique du Quebec, Quebec City, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01098734"
34,"NCT03011320","An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery",,"Completed","No Results Available","Ovary Cancer","Drug: EC1456|Drug: 99mTc-Etarfolatide","To assess tumor penetration of EC1456 in frozen tissue|To assess tumor penetration EC1456 in formalin fixed tissue samples (intratumoral levels of EC1456 in tissue blocks using anti-tubulysin IHC testing)|To assess correlation of tumor penetration of EC1456 with tumor uptake of 99m-Tc etarfolatide in SPECT or SPECT/CT scan","Endocyte","Female","18 Years and older   (Adult, Older Adult)","Phase 1","3","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","EC1456-02","January 24, 2017","December 30, 2017","August 28, 2018","January 5, 2017",,"February 7, 2019","Levine Cancer Institute-Concord/Clinical Trials, Concord, North Carolina, United States|Ottawa Hospital, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03011320"
35,"NCT01335256","Clinical Study to Evaluate Safety and Maximum Tolerated Dose of BAY1000394 Given in a 4 Week on / 2 Week Off Schedule in Subjects With Advanced Malignancies",,"Completed","No Results Available","Neoplasms","Drug: BAY1000394","Number of subjects with Adverse Events as a measure safety|Maximum tolerated dose: Measured by adverse event profile|Biomarkers evaluation measured by Enzyme-linked immunosorbent assay (ELISA)|Tumor Response evaluation measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1)|Peak Plasma Concentration (Cmax) of BAY1000394|Pharmacokinetics parameters will be measured using Peak Plasma Time (tmax) of BAY1000394|Area under the plasma concentration versus time curve from 0 to tn (AUC(0 tn)) of BAY1000394|Area under the plasma concentration versus time curve (AUC) of BAY1000394|Half-life of BAY1000394","Bayer","Female","18 Years and older   (Adult, Older Adult)","Phase 1","10","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14856|2010-019191-79","December 2010","September 2011","September 2011","April 14, 2011",,"May 3, 2013","Scottsdale, Arizona, United States|St. Louis, Missouri, United States|Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01335256"
36,"NCT02935894","Investigating the Stability, Variability and Mechanism of Incorporation of Lipid Mediators Into Eccrine Sweat",,"Completed","Has Results","Stability & Variability of Lipid-derived Molecules in Sweat","Drug: Ibuprofen|Other: Physiological induction of sweating|Drug: Pilocarpine","Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation|Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise|Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation|Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation|Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration|Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration|Change in Plasma Ibuprofen Concentrations|Change in Sweat Ibuprofen Concentrations","USDA, Western Human Nutrition Research Center|University of California, Davis","Male","20 Years to 40 Years   (Adult)","Not Applicable","14","U.S. Fed|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","929370","November 28, 2016","June 8, 2017","June 8, 2017","October 18, 2016","June 1, 2018","June 1, 2018","Western Human Nutrition Research Center, Davis, California, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02935894/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02935894/ICF_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02935894/SAP_002.pdf","https://ClinicalTrials.gov/show/NCT02935894"
37,"NCT02797535","GI Fluids Collection for an Ex-Vivo Development of Ingestible Capsule Devices With Real Time Biosensors","CLARINET","Completed","No Results Available","Chronic Inflammatory Small Bowel Disease","Procedure: Endoscopy procedures","Characterization and quantification of small molecules- and protein biomarkers of GI diseases will be performed. Examples of such biomarkers include - calprotectin, lactoferrin, albumin, hemoglobin, CEA, CA19-9, CA 72-4, LYVE-1, REG1A, TFF1 and ammonia.","Medtronic - MITG","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","66","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","COVGIBD0533","July 2016","February 7, 2019","February 7, 2019","June 13, 2016",,"February 15, 2019","Sheba Medical Center, Ramat-Gan, Israel|The Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel",,"https://ClinicalTrials.gov/show/NCT02797535"
38,"NCT02534480","Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Young Volunteers (Single-ascending Dose)",,"Completed","No Results Available","Alzheimer's Disease","Drug: NGP 555","Number of subjects with adverse events as a measure of safety and tolerability","NeuroGenetic Pharmaceuticals Inc","All","18 Years to 55 Years   (Adult)","Phase 1","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","NGP 555-001","March 2015","October 2015","November 2015","August 27, 2015",,"January 13, 2016","WCCT, Cypress, California, United States",,"https://ClinicalTrials.gov/show/NCT02534480"
39,"NCT01286467","A Study Of PF-04449913 Administered Alone In Select Solid Tumors",,"Completed","No Results Available","Solid Tumors","Drug: PF-04449913","First cycle dose limiting toxicities (DLTs)|Type, incidence, severity (graded by the national cancer institute [NCI] common criteria for Adverse events [CTCAE], timing, seriousness and relatedness of adverse events to PF-04449913|Hedgehog biomarker modulation|Area under the plasma concentration versus time curve (AUC) and peak plasma concentration (Cmax) of PF-04449913|QTc interval|Objective tumor response|Progression free survival|Time to progression|Duration of response","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 1","23","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B1371002","May 2011","May 2012","December 2012","January 31, 2011",,"June 6, 2013","Pfizer Investigational Site, Los Angeles, California, United States|Pfizer Investigational Site, Aurora, Colorado, United States|Pfizer Investigational Site, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01286467"
40,"NCT04118842","A Study in Healthy Subjects to Assess the Pharmacokinetics of Savolitinib When Administered Alone and in Combination With Rifampicin",,"Completed","No Results Available","Solid Tumors","Drug: Savolitinib|Drug: Rifampicin","Savolitinib: Maximum plasma concentration (Cmax) ratios of geometric means of test treatment (savolitinib+rifampicin), relative to reference treatment (savolitinib alone)|Area under the curve (AUC) ratios of geometric means of test treatment (savolitnib+rifampicin) relative to reference treatment (savolitinib alone)|Number of subjects with adverse events|Number of subjects with abnormal findings in systolic blood pressure (BP)|Number of subjects with abnormal findings in diastolic BP|Number of subjects with abnormal findings in pulse rate|Number of subjects with abnormal findings in electrocardiograms (ECGs) (12-lead ECGs)|Number of subjects with abnormal findings in physical examinations|Number of subjects with abnormal findings in white blood cell (WBC) count|Number of subjects with abnormal findings in red blood cell (RBC) count|Number of subjects with abnormal findings in hemoglobin (Hb)|Number of subjects with abnormal findings in hematocrit (HCT)|Number of subjects with abnormal findings in mean corpuscular volume (MCV)|Number of subjects with abnormal findings in mean corpuscular hemoglobin (MCH)|Number of subjects with abnormal findings in mean corpuscular hemoglobin concentration (MCHC)|Number of subjects with abnormal findings in neutrophils absolute count|Number of subjects with abnormal findings in lymphocytes absolute count|Number of subjects with abnormal findings in monocytes absolute count|Number of subjects with abnormal findings in eosinophils absolute count|Number of subjects with abnormal findings in basophils absolute count|Number of subjects with abnormal findings in platelets|Number of subjects with abnormal findings in reticulocytes absolute count|Number of subjects with abnormal findings in sodium|Number of subjects with abnormal findings in potassium|Number of subjects with abnormal findings in urea|Number of subjects with abnormal findings in creatinine|Number of subjects with abnormal findings in albumin|Number of subjects with abnormal findings in calcium|Number of subjects with abnormal findings in phosphate|Number of subjects with abnormal findings in glucose (fasting)|Number of subjects with abnormal findings in c-reactive protein (CRP)|Number of participants with abnormal findings in liver enzymes|Number of subjects with abnormal findings in total bilirubin|Number of subjects with abnormal findings in unconjugated bilirubin|Number of subjects with abnormal findings in urinalysis|Number of subjects with abnormal findings in urinalysis (microscopy)|Savolitinib: Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC[0-t]) ratios of geometric means of test treatment (savolitinib+rifampicin), relative to reference treatment (savolitinib alone)|M2 and M3: Cmax ratios of geometric means of test treatment (savolitinib+rifampicin), relative to reference treatment (savolitinib alone)|M2 and M3: AUC ratios of geometric means of test treatment (savolitinib+rifampicin), relative to reference treatment (savolitinib alone)|M2 and M3: AUC(0-t) ratios of geometric means of test treatment (savolitinib+rifampicin), relative to reference treatment (savolitinib alone)|Savolitinib, M2 and M3: summary PK profiles and descriptive statistics of Cmax|Savolitinib, M2 and M3: summary PK profiles and descriptive statistics of AUC|Savolitinib, M2 and M3: summary PK profiles and descriptive statistics of AUC(0 t)|Savolitinib, M2 and M3: Ratio of metabolite AUC to parent AUC (MRCAUC)|Savolitinib, M2 and M3: Ratio of metabolite AUC(0-t) to parent AUC(0-t) (MRCAUC[0-t])|Savolitinib, M2 and M3: metabolite-to-parent ratios for Time to reach maximum observed plasma concentration (tmax)|Savolitinib, M2 and M3: metabolite-to-parent ratios for Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t1/2,λz)|Savolitinib, M2 and M3: metabolite-to-parent ratios for terminal elimination rate constant (λz)|Savolitinib: Apparent total body clearance of drug from plasms after extravascular administration (parent drug only)CL/F|Savolitinib, M2 and M3: Ratio of metabolite Cmax to parent Cmax (MRCmax)|Savolitinib: Apparent volume of distribution during the terminal phase after extravascular administration (parent drug only) (Vz/F)","AstraZeneca","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","40","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","D5084C00003","October 17, 2019","February 26, 2020","February 26, 2020","October 8, 2019",,"April 3, 2020","Research Site, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04118842"
41,"NCT00953758","A Study Of PF-04449913 In Select Hematologic Malignancies",,"Completed","No Results Available","Hematologic Malignancies","Drug: PF-04449913","First cycle dose limiting toxicities (Phase 1a)|Modulation of Pharmacodynamic biomarkers|Area under the plasma concentration curve (AUC) of PF-04449913. Maximum plasma concentration of PF-04449913|Overall response (OR), time to progression (TTP), duration of response and progression-free survival (PFS) as defined by disease specific clinical practice guidelines|QTc interval","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 1","47","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B1371001","March 2010","September 2012","February 2013","August 6, 2009",,"December 10, 2013","Pfizer Investigational Site, La Jolla, California, United States|Pfizer Investigational Site, La Jolla, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, Seattle, Washington, United States|Pfizer Investigational Site, Bologna, Italy",,"https://ClinicalTrials.gov/show/NCT00953758"
42,"NCT04280328","Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma",,"Completed","No Results Available","Multiple Myeloma","Drug: Ciforadenant|Drug: daratumumab","Safety and tolerability of ciforadenant in combination with daratumumab relapsed / refractory multiple myeloma.|Overall response rate.|Duration of response.|Disease control rate.|Time to next therapy.|Progression free survival.|Minimal Residual Disease.","Corvus Pharmaceuticals, Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","7","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CPI-444-003","February 20, 2020","September 21, 2021","March 1, 2022","February 21, 2020",,"March 11, 2022","The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04280328"
43,"NCT03014908","Metabolic Profiling of Type 1 Diabetes Mellitus in Children and Adolescents","T1DM","Completed","No Results Available","Type1diabetes","Other: Blood sampling","Metabolic phenotype of type 1 diabetes mellitus","Hasselt University|Jessa Hospital","All","8 Years to 18 Years   (Child, Adult)",,"14","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","LCRP-obesitas","January 2014","September 2014","December 2014","January 9, 2017",,"January 9, 2017","Hasselt University, Hasselt, Limburg, Belgium",,"https://ClinicalTrials.gov/show/NCT03014908"
44,"NCT03709628","A Study of a FimH Blocker, EB8018, in Crohn's Disease Patients","EBFIM117","Completed","No Results Available","Crohn Disease","Drug: EB8018 (First-in-class FimH blocker)","Cmax|Tmax|AUC0-24|T1/2|AE|RR|QRS complex|QT|PR|HR|BP|Temp","Enterome","All","18 Years and older   (Adult, Older Adult)","Phase 1","8","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Enterome","March 7, 2018","November 12, 2019","December 4, 2019","October 17, 2018",,"February 2, 2021","Medical University Vienna, Wien, Austria|Hôpital Claude Huriez, Lille, France|Hôpital de l'Archet 2, Nice, France|Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany|Istituto Clinico Humanitas, Rozzano, Italy",,"https://ClinicalTrials.gov/show/NCT03709628"
45,"NCT00639002","A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma",,"Completed","Has Results","Multiple Myeloma","Drug: Ruxolitinib 25 mg|Drug: Dexamethasone 40 mg","Number of Responders According to the International Uniform Response Criteria for Multiple Myeloma|Time to Disease Progression According to the International Uniform Response Criteria for Multiple Myeloma","Incyte Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","13","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INCB 18424-255","March 2008","July 2010","July 2010","March 19, 2008","January 23, 2012","February 13, 2018","Highland, California, United States|Boynton Beach, Florida, United States|New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00639002"
46,"NCT01975077","A Phase Ib Study of Fruquintinib in 3rd Line mCRC",,"Completed","No Results Available","Colorectal Cancer","Drug: fruquintinib","safety and tolerability|objective response rate(ORR)|pharmacokinetic profiles|disease control rate (DCR)|progression-free survival (PFS)|overall survival (OS)","Hutchison Medipharma Limited|Fudan University|Sun Yat-sen University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","62","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2012-013-00CH3","December 2012","April 2014","October 2014","November 3, 2013",,"February 17, 2020","Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Fudan University Cancer Center, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT01975077"
47,"NCT02847377","A Positron Emission Tomography (PET) Imaging Agent [18F]-ODS2004436 as a Marker of EGFR Mutation in Subjects With NSCLC","IMKRUN 2","Completed","No Results Available","Carcinoma, Non-Small-Cell Lung","Other: Injection of [18F]-ODS2004436 radiotracer","Evaluation of sensibility of [18F] ODS2004436|Evaluation of specificity of [18F] ODS2004436","Centre Georges Francois Leclerc","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IMK RUN 2","September 27, 2016","September 27, 2016","March 19, 2019","July 28, 2016",,"January 27, 2020","CGFL, Dijon, France",,"https://ClinicalTrials.gov/show/NCT02847377"
48,"NCT03258515","A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers",,"Completed","No Results Available","Solid Tumors","Drug: AZD6094 200 mg|Other: Placebo|Drug: Moxifloxacin","Effect of AZD6094 at single therapeutic dose (600 mg) on ventricular repolarization by analysis of change from baseline-corrected QT|Effect of AZD6094 at therapeutic dose (600 mg) on additional time-matched ECG variables|Effect of moxifloxacin 400 mg on Fridericia-corrected QT interval (QTcF) compared to placebo.|Area under the plasma concentration-curve from time zero to the time of last quantifiable analyte concentration (AUC(0-∞)) assessment for AZD6094, its metabolites (M2 and M3) and moxifloxacin|Area under the plasma concentration-time curve from time zero to t hours after dosing (AUC(0-t)) assessment for AZD6094, its metabolites (M2 and M3) and moxifloxacin|Observed maximum concentration (Cmax) assessment for AZD6094, its metabolites (M2 and M3) and moxifloxacin|Time to reach maximum concentration (tmax) assessment for AZD6094, its metabolites (M2 and M3) and moxifloxacin|Lag-time (tlag - from the individual concentration-time curve) assessment for AZD6094, its metabolites (M2 and M3) and moxifloxacin|Terminal rate constant (λz) assessment for AZD6094, its metabolites (M2 and M3) and moxifloxacin|Terminal half-life (t½) assessment for AZD6094, its metabolites (M2 and M3) and moxifloxacin|Apparent clearance for parent drug estimated as dose divided by AUC (CL/F) assessment for AZD6094, its metabolites (M2 and M3) and moxifloxacin|Apparent volume of distribution for parent drug at terminal phase (Vz/F, extravascular administration) assessment for AZD6094, its metabolites (M2 and M3) and moxifloxacin|Assessment of relationship between the plasma concentration of AZD6094 and moxifloxacin and ECG variables, including baseline-adjusted and placebo-subtracted QTc interval.|Number of participants with adverse events (AEs) of AZD6094|Systolic blood pressure [SBP]|Diastolic blood pressure [DBP]|Pulse rate|Twelve-lead (12-Lead) electrocardiograms (ECGs)|Physical examination|Laboratory assessments of Hematology|Laboratory assessments of Clinical chemistry|Laboratory assessments of urinalysis|Effect of AZD6094 at therapeutic dose (600 mg) on time-matched ECG variable - heart rate (HR)","AstraZeneca|Parexel","Male","18 Years to 55 Years   (Adult)","Phase 1","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","D5084C00001","September 6, 2017","March 24, 2018","March 24, 2018","August 23, 2017",,"February 20, 2020","Research Site, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03258515"
49,"NCT01583374","Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis","POSTURE","Completed","Has Results","Ankylosing Spondyloarthritis","Drug: Apremilast tablet 20 mg|Drug: Apremilast tablet 30 mg BID|Drug: Placebo","Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS 20) Response at Week 16|Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 24|Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 24|Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS) Response at Week 24|Change From Baseline in the Ankylosing Spondylitis Quality of Life (ASQoL) Summary Score at Week 24|Change From Baseline in the Physical Component Summary Score (PCS) of Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) at Week 24|Change From Baseline in Bath Ankylosing Spondylitis Metrology Index-Linear (BASMI-Linear) at Week 24|Change From Baseline in the Radiographic Score Using the Modified Stoke Ankylosing Spondylitis Spine Score (m-SASSS) at Week 104 and Week 260|Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Placebo Controlled Phase|Number of Participants With Treatment Emergent Adverse Events During the Apremilast Exposure Period","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","490","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CC-10004-AS-001|2011-001555-37","May 2, 2012","February 24, 2014","October 25, 2018","April 24, 2012","March 17, 2015","May 12, 2020","Sun Valley Arthritis Center, Peoria, Arizona, United States|University of California, San Diego, La Jolla, California, United States|Desert Medical Advances, Palm Desert, California, United States|UCSF Arthritis Center, San Francisco, California, United States|Advent Clinical Research Centers, Inc, Pinellas Park, Florida, United States|Burnette & Silverfield, MDS PLC, Tampa, Florida, United States|Alastair Kennedy, MD Research, Vero Beach, Florida, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|Klein and Associates MD, PA, Cumberland, Maryland, United States|Klein and Associates MD, PA, Hagerstown, Maryland, United States|Clinical Pharmacology Study Group, Worcester, Massachusetts, United States|Saint Paul Rheumatology, PA, Eagan, Minnesota, United States|MetroHealth Medical Systems, Cleveland, Ohio, United States|STAT Research, Inc., Dayton, Ohio, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|The Arthritis Clinic, Jackson, Tennessee, United States|Ramesh C Gupta MD, Memphis, Tennessee, United States|Austin Regional Clinic, Austin, Texas, United States|University of Utah Hospitals and Clinics, Salt Lake City, Utah, United States|Rheumatology and Immunotherapy Center, Franklin, Wisconsin, United States|Southern Clinical Research, Hobart, Tasmania, Australia|Emeritus Research, Camberwell, Victoria, Australia|Coastal Joint Care, Maroochydore, Australia|Royal Perth Hospital, Perth, Australia|The Queen Elizabeth Hospital, Woodville South, Australia|Krankenhaus Wien-Hietzing, Wien, Austria|Diagnostic and Consulting Center Sv. Pantaleymon, Pleven, Bulgaria|National Multiprofile Transport Hospital Tzar Boris III, Sofia, Bulgaria|17 Diagnostic and Consulting Centre, Sofia, Bulgaria|Military Medical Academy - MHAT, Sofia, Bulgaria|Diagnostic Consulting Center N4, Varna, Bulgaria|Clinic: University of Calgary Heritage Medical Research Clinic (HMRC),Teaching Research and Wellness (TRW), Calgary, Alberta, Canada|Nexus Clinical Research, St John's, Newfoundland and Labrador, Canada|Cividino Medicine Professional Corporation, Hamilton, Ontario, Canada|Dr. William G. Bensen Medicine Professional Corporation, Hamilton, Ontario, Canada|Credit Valley Professional Building, Mississauga, Ontario, Canada|The Arthritis Program Research Group Inc., Newmarket, Ontario, Canada|Rheumatology Research Associates, Ottawa, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Centre de Recherche Saint-Louis, Saint-Louis, Quebec, Canada|Revmatologie s.r.o., Brno, Czechia|ARTMEDI UPD s.r.o., Hostivice, Czechia|ARTHROMED s.r.o., Pardubice, Czechia|Medifin a.s, Šustova, Praha 11, Czechia|Revmatologicka Ambulance, Praha 4, Czechia|Fakultni Thomayerova nemocnice s poliklinikou - Klinicko-farmakologicka jednotka, Praha, Czechia|Revmatologicka Ambulance, Sokolov, Czechia|PV-Medical s.r.o., Zlin, Czechia|Innomedica Medical and Research Centre, Tallinn, Estonia|East Tallinn Central Hospital, Tallinn, Estonia|Clinical Research Centre Ltd, Tartu, Estonia|Tartu University Hospital, Tartu, Estonia|Hopital Ambroise-Pare, Boulogne, France|Hopital Henri Mondor, Créteil, France|IPROS - CHR ORLEANS - Hôpital de la Source, Orléans Cedex 2, France|Hopital Cochin, Paris, France|Groupe Hospitalier Pitié- Salpétrière, Paris, France|Charite - Universitätsmedizin Berlin, Berlin, Germany|Universitatsklinikum Erlangen, Erlangen, Germany|Centrum fur innovative Diagnostik und Therapie Rheumatologie Immunologie GmbH, Frankfurt, Germany|Schön Klink Hamburg-Eilbek, Hamburg, Germany|Universitatsklinikum Heidelberg, Heidelberg, Germany|Rheumazentrum Ruhrgebiet, Herne, Germany|Qualiclinic kft, Budapest, Hungary|Synexus Magyarország Kft., Budapest, Hungary|Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum, Debrecen, Hungary|Pest Megyei Flor Ferenc Korhaz, Kistarcsa, Hungary|Veszprem Megyei Csolnoky Ferenc Korhaz-Rendelointezet, Veszprém, Hungary|Leiden Universitair Medisch Centrum, Leiden, Netherlands|Academisch Ziekenhuis Maastricht, Maastricht, Netherlands|Gabinet Internistyczno-Reumatologiczny Piotr Adrian Klimiuk, Bialystok, Poland|NZOZ Osteo-Medic sc A. Racewicz J. Supronik, Bialystok, Poland|Szpital Uniwersytecki nr 2 im. Dr Jana Biziela w Bydgoszczy, Bydgoszcz, Poland|Synexus SCM Sp. z o.o., Gdynia, Poland|Zespol Poradni Specjalistycznych, Lublin, Poland|Prywatna Praktyka Lekarska Pawel Hrycaj, Poznan, Poland|NZOZ NASZ LEKARZ Praktyka Grupowa Lekarzy Rodzinnych z Przychodnia Specjalistyczna, Torun, Poland|Synexus SCM Sp. z o.o., Wroclaw, Poland|Cristei R. Rodica - Private Medical Practice, Braila, Romania|Sf. Maria Clinical Hospital, Bucharest, Romania|Emergency County Clinical Hospital, Cluj-Napoca, Romania|Sf Apostol Andrei Emergency Clinical County Hospital, Galati, Romania|RK Medcenter SRL, Iasi, Romania|Sverdlovsk Regional Clinical Hospital 1, Ekaterinburg, Russian Federation|Research Medical Complex Vashe Zdorovie, Kazan, Russian Federation|Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation|Federal State Budget Institution ""Rheumatology Research Institute RAMS"", Moscow, Russian Federation|Nizhniy Novgorod State Medical Academy of Roszdrav, Nizhniy Novgorod, Russian Federation|Departmental Hospital at Smolensk Station RZhD JSC, Smolensk, Russian Federation|Regional Clinical Hospital, Vladimir, Russian Federation|Narodny ustav reumatickych chorob, Piestany, Slovakia|MUDr. Zuzana Cizmarikova, s.r.o., Reumatologick ambulancia, Poprad, Slovakia|Hospital Universitario a Coruna, A Coruña, Spain|Hospital de Bellvitge, Barcelona, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Corporacio Sanitaria Parc Tauli de Sabadell, Sabadell, Spain|Complejo Hospitalario Universitario de Santiago de Compostela Travesía de la Choupana s/n, Santiago de Compostela, Spain|Skånes Universitetssjukhus- Malmö, Malmö, Sweden|Barnsley Hospital, Barnsley, United Kingdom|Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom|Chapel Allerton Hospital, Leeds, United Kingdom|Nuffield Orthopaedic Centre, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01583374"
50,"NCT01262911","Effect of SRT2379 on Endotoxin-Induced Inflammation",,"Completed","No Results Available","Sepsis","Drug: SRT2379|Drug: Placebo","To determine if a single dose of SRT2379 attenuates the inflammatory response in normal healthy male subjects after exposure to low-dose endotoxin (LPS).|To determine PK of SRT2379 in normal healthy male subjects exposed to low-dose endotoxin (LPS).|To determine the safety profile of SRT2379 in healthy male subjects exposed to low-dose endotoxin (LPS).","Sirtris, a GSK Company|GlaxoSmithKline","Male","18 Years to 35 Years   (Adult)","Phase 1","17","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","115083","February 17, 2011","April 26, 2011","April 26, 2011","December 17, 2010",,"August 4, 2017","GSK Investigational Site, Amsterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT01262911"
51,"NCT01014117","Effect of SRT2104 on Endotoxin-induced Inflammation",,"Completed","No Results Available","Sepsis","Drug: Placebo|Drug: SRT2104","To determine if a single or 7 daily doses of SRT2104 attenuates the inflammatory response in normal healthy male subjects after exposure to low-dose endotoxin (LPS).|To determine PK of SRT2104 in normal healthy male subjects exposed to low-dose endotoxin (LPS).|To determine the safety profile of SRT2104 in healthy male subjects exposed to low-dose endotoxin (LPS).|To determine the effect of SRT2104 on other parameters following low-dose endotoxin (LPS) exposure in humans e.g., lipid profile, serum amyloid phospholipids, metabolic profiles and gene expression analysis etc.","GlaxoSmithKline","Male","18 Years to 35 Years   (Adult)","Phase 1","41","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","114009","December 9, 2009","May 10, 2010","May 10, 2010","November 16, 2009",,"June 22, 2017","GSK Investigational Site, Amsterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT01014117"
52,"NCT01416376","Effect of Multiple Dose Levels of SRT2379 on Endotoxin-Induced Inflammation",,"Completed","No Results Available","Sepsis","Drug: SRT2379|Drug: Placebo","Clinical signs and symptoms of inflammation will be used as a measure of the effect of multiple-dose levels of SRT2379 on the inflammatory response in normal healthy male subjects exposed to low-dose endotoxin (LPS).|Laboratory parameters of inflammation will be used as a measure of the effect of multiple-dose levels of SRT2379 on the inflammatory response in normal healthy male subjects exposed to low-dose endotoxin (LPS).|Plasma levels of SRT2379 will be measured to assess the pharmacokinetics of SRT2379 in healthy male subjects exposed to low-dose endotoxin (LPS).|Number of participants with adverse events and incidence of adverse events will be used as a measure of safety and tolerability of multiple-dose levels of SRT2379 in healthy male subjects exposed to low-dose endotoxin (LPS).","Sirtris, a GSK Company|GlaxoSmithKline","Male","18 Years to 35 Years   (Adult)","Phase 1","39","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","115830","August 30, 2011","December 12, 2011","December 12, 2011","August 15, 2011",,"June 15, 2017","GSK Investigational Site, Amsterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT01416376"
53,"NCT04355156","Axitinib Monotherapy With Early Dynamic Contrast Enhanced Ultrasound Monitoring in Chemorefractory Third Line Metastatic Colorectal Cancer","AXMUS-C","Completed","No Results Available","Colorectal Cancer","Drug: Axitinib|Drug: Placebo","Overall survival|Imaging|Objective response rate|Monitoring of adverse reactions|Progression free survival|Progression free survival secondary outcome|Monitoring dose reductions and the reasons behind them","Imperial College London|Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 2","52","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","WS913975|2011-002598-49","September 17, 2012","February 22, 2019","February 22, 2019","April 21, 2020",,"April 21, 2020","Imperial College Healthcare NHS Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04355156"
54,"NCT00567554","Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer","GeparQuinto","Completed","No Results Available","Breast Cancer","Drug: epirubicin - cyclophosphamide / docetaxel|Drug: epirubicin - cyclophosphamide / docetaxel + bevacizumab|Drug: paclitaxel|Drug: paclitaxel + everolimus (RAD001)|Drug: epirubicin - cyclophosphamide / docetaxel + trastuzumab|Drug: epirubicin - cyclophosphamide / docetaxel + lapatinib","To compare the pCR rates of neoadjuvant treatment in all 3 Settings|To assess the toxicity of and compliance to all six treatments.|To determine the breast conservation rate after each treatment.|To determine the (loco-regional and distant) disease-free and overall survival after each treatment. In Her-2 positive disease the cerebral disease-free survival will be determined separately.|To assess treatment efficacies in subgroups defined according to tumor stage (T2-3 vs T4) receptor status (ER and/or PR pos. vs ER and PR neg.) and response by best appropriate imaging method to the first 4 cycles of treatment (complete vs partial vs no)|To examine and compare prespecified molecular markers on core biopsy before and after end of chemotherapy","German Breast Group|AGO Study Group","Female","18 Years and older   (Adult, Older Adult)","Phase 3","2600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GBG 44|2006-005834-19","October 2007","August 2011","October 2015","December 5, 2007",,"February 10, 2016","Universitätsfrauenklinik Frankfurt / Main, Frankfurt / Main, Germany",,"https://ClinicalTrials.gov/show/NCT00567554"
55,"NCT02812875","A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas",,"Completed","No Results Available","Advanced Solid Tumors or Lymphomas","Drug: CA-170","The number of patients with a dose-limiting toxicity (DLT) in the first treatment cycle|Maximum tolerated dose (MTD) of CA-170|Recommended Phase 2 Dose (RP2D) of CA-170|Pharmacokinetic (PK) Profile of CA-170|Preliminary Anti-tumor Activity of CA-170 based on RECIST and Immune Related Response Criterion (irRC) for Solid Tumors or Cheson for Lymphoma","Curis, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","71","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA-170-101","May 2016","May 7, 2020","May 7, 2020","June 24, 2016",,"June 26, 2020","University of California San Francisco, San Francisco, California, United States|Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States|Sarah Cannon Research Institute, Sarasota, Florida, United States|Northwestern University, Chicago, Illinois, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Icahn School of Medicine at Mt. Sinai, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Carolina BioOncology Institute, Huntersville, North Carolina, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Seoul National University Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Yonsei University Health System - Severance Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Hospital Clinic i Provincial, Barcelona, Spain|Catalan Institute of Oncology, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom|Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02812875"
56,"NCT02133157","Phase I Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors","HMPL","Completed","No Results Available","Tumor","Drug: Sulfatinib","To assess number of participants with adverse events as a measure of safety and tolerability during dose escalating|To measure the plasma concentration of HMPL-012 in single and repeated doses","Hutchison Medipharma Limited","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","71","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2009-012-00CH1","April 2010","October 2014","October 2014","May 7, 2014",,"July 8, 2020","Academy of Military Medical Affiliated Hopital, Beijing, China",,"https://ClinicalTrials.gov/show/NCT02133157"
57,"NCT03208959","A Trial of HTI-1090 in Subjects With Advanced Solid Tumors",,"Completed","No Results Available","Advanced Solid Tumors","Drug: HTI-1090","Adverse events|Laboratory results|Vital signs|Electrocardiogram","Atridia Pty Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 1","18","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HTI-1090-101","August 30, 2017","November 1, 2018","January 23, 2019","July 6, 2017",,"September 30, 2019","Icon Cancer Care Centre, South Brisbane, New South Wales, Australia",,"https://ClinicalTrials.gov/show/NCT03208959"
58,"NCT01645215","Phase I Study of Fruquintinib(HMPL-013) in Patients With Advanced Solid Tumors",,"Completed","No Results Available","Tumor","Drug: Fruquintinib","Safety in the first 28-Days of Therapy|Objective Response Rate （ORR)|Pharmacokinetic Assessments for AUC, Cmax and Tmax","Hutchison Medipharma Limited|Fudan University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","40","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2009-013-00CH1","January 2011","October 2012","October 2012","July 20, 2012",,"February 17, 2020","Fudan University Cancer Center, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT01645215"
59,"NCT00736372","A Trial of PX-12 in Patients With a Histologically or Cytologically Confirmed Diagnosis of Advanced or Metastatic Cancer",,"Completed","No Results Available","Metastatic Cancer|Advanced Cancer","Drug: PX-12","To determine the MTD of PX-12 delivered as a 72-hour infusion over days 1, 2, and 3 of a 21-day cycle|When delivered as a 72 hour intravenous infusion on days 1, 2, and 3 of a 21-day cycle: Evaluate the safety profile of PX-12|When delivered as a 72 hour intravenous infusion on days 1, 2, and 3 of a 21-day cycle: Assess the pharmacodynamics of PX-12 using surrogate tissues obtained pre- and post-drug treatment|When delivered as a 72 hour intravenous infusion on days 1, 2, and 3 of a 21-day cycle: Assess pharmacokinetic profiles of PX-12 in plasma samples|When delivered as a 72 hour intravenous infusion on days 1, 2, and 3 of a 21-day cycle: Identify any antitumor activity of PX-12 in this patient population","Cascadian Therapeutics Inc.|Seagen Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","14","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PX-12-004","June 2008","August 2009","August 2009","August 15, 2008",,"May 17, 2018","TGen Clinical Research Services at Scottsdale Healthcare, Scottsdale, Arizona, United States|Cancer Centers of the Carolinas, Greenville, South Carolina, United States|Tyler Cancer Center, Tyler, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00736372"
60,"NCT03815695","A SAD/MAD to Assess the Safety, Pharmacokinetics and Pharmacodynamics of FT-4202 in Healthy Volunteers and Sickle Cell Disease Patients",,"Completed","No Results Available","Healthy Volunteers|Sickle Cell Disease","Drug: FT-4202/Placebo|Drug: FT-4202","Incidence, frequency, and severity of adverse events (AEs) per CTCAE v5.0 of a single ascending dose and multiple ascending doses of FT-4202 in adult healthy volunteers and SCD patients.|Maximum observed plasma concentration (Cmax)|Time to maximum observed plasma concentration (Tmax)|Area under the plasma concentration-time curve from time zero until the 24-hour time point (AUC0-24)|Area under the plasma concentration-time curve from time zero until the last quantifiable time point (AUC0-last)|Area under the plasma concentration-time curve from time zero to infinity (AUC0-inf)|Terminal elimination half-life (t1/2)|Apparent clearance (CL/F)|Apparent volume of distribution (Vd/F)|Terminal disposition rate constant (Lz)|Renal clearance (ClR)|Change from baseline in the levels of 2,3-diphosphoglycerate (DPG) and adenosine triphosphate (ATP) in the red blood cells (RBCs) of healthy volunteers and SCD patients after single and multiple doses of FT-4202.|Model-based estimate of change from baseline QT interval corrected using Fridericia's correction formula (QTcF) and 90% confidence interval at the estimated Cmax after a single dose of FT-4202 in healthy volunteers|Change from baseline heart rate after a single dose of FT-4202 in healthy volunteers|Change from baseline PR after a single dose of FT-4202 in healthy volunteers|Change from baseline QRS after a single dose of FT-4202 in healthy volunteers|Change from baseline T-wave morphology after a single dose of FT-4202 in healthy volunteers","Forma Therapeutics, Inc.|Medpace, Inc.","All","12 Years to 65 Years   (Child, Adult, Older Adult)","Phase 1","130","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","4202-HVS-101","December 11, 2018","December 17, 2021","December 17, 2021","January 24, 2019",,"December 22, 2021","Woodland International Research Group (SCD subjects only), Little Rock, Arkansas, United States|Collaborative Neuroscience Research, LLC (SCD subjects only), Long Beach, California, United States|Pacific Research Partners (SCD subjects only), Oakland, California, United States|UCSF Benioff Children's Hospital Oakland (SCD subjects only), Oakland, California, United States|Advanced Pharma CR, LLC (SCD subjects only), Miami, Florida, United States|Children's Healthcare of Atlanta (SCD subjects only), Atlanta, Georgia, United States|Augusta University Medical Center (SCD subjects only), Augusta, Georgia, United States|University of Illinois at Chicago (SCD subjects only), Chicago, Illinois, United States|University of Maryland, Greenebaum Comprehensive Cancer Center (SCD subjects only), Baltimore, Maryland, United States|Columbia University Medical Center (SCD subjects only), New York, New York, United States|Levine Cancer Institute (SCD subjects only), Charlotte, North Carolina, United States|Duke University Medical Center (SCD subjects only), Durham, North Carolina, United States|University of Cincinnati Medical Center (SCD subjects only), Cincinnati, Ohio, United States|Medpace Clinical Pharmacology Unit (Healthy Volunteers only), Cincinnati, Ohio, United States|Cincinnati Children's Hospital Medical Center (SCD subjects only), Cincinnati, Ohio, United States|Lynn Institute of Tulsa (SCD subjects only), Tulsa, Oklahoma, United States|St. Jude Children's Research Hospital (SCD subjects only), Memphis, Tennessee, United States|The University of Texas Health Science Center at Houston (SCD subjects only), Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03815695"
61,"NCT04120233","MW151-101: First-in-human Study of MW151",,"Completed","No Results Available","Drug Toxicity","Drug: Placebo|Drug: MW151, 10mg|Drug: MW151, 20mg|Drug: MW151, 40mg|Drug: MW151, 80mg|Drug: MW151, 160mg","Percentage of participants experiencing drug-related serious adverse events.","Linda Van Eldik|Duke Clinical Research Institute|National Institute on Aging (NIA)|University of Kentucky","Female","18 Years to 50 Years   (Adult)","Phase 1","40","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","Pro00103072, IND143222|R01AG061898","October 22, 2019","September 16, 2021","September 16, 2021","October 9, 2019",,"December 7, 2021","Duke Clinical Research Institute, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04120233"
62,"NCT05135871","Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese Subjects",,"Completed","No Results Available","Hypertrophic Cardiomyopathy","Drug: Mavacamten","Area under the curve (AUC) (0-last), AUC(0-inf)|Maximum concentration (Cmax)|Time to maximum concentration (Tmax)|Elimination half-life (T1⁄2)|Apparent volume of distribution (Vd/F)|Apparent clearance (CL/F)|Incidence of adverse events|Vital signs|Physical examination findings|Electrocardiogram (ECG) parameters|Clinical laboratory tests data","LianBio LLC","All","18 Years to 60 Years   (Adult)","Phase 1","45","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LB2001-101","October 31, 2021","February 5, 2022","February 28, 2022","November 26, 2021",,"March 25, 2022","Huashan Hospital Fudan University, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT05135871"
63,"NCT02703298","Safety and Pharmacokinetic Study of TRX-818 in Asian Solid Tumor Patients",,"Completed","No Results Available","Carcinoma|Advanced Cancer","Drug: TRX-818 capsules","Dose limiting toxicity (DLT) of TRX-818 in Asians|Maximum tolerated dose (MTD) of TRX-818 in Asians|Preliminary assessment of anti-tumor activity by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1)|Composite measure of pharmacokinetics (PK) parameters of TRX-818: AUC(0-last)|Composite measure of pharmacokinetics (PK) parameters of TRX-818:Cmax|Composite measure of pharmacokinetics (PK) parameters of TRX-818: Tmax|Composite measure of pharmacokinetics (PK) parameters of TRX-818: T(1/2)|Time to tumor progression (TTP)","TaiRx, Inc.","All","20 Years and older   (Adult, Older Adult)","Phase 1","19","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CVM-002","March 25, 2016","January 23, 2018","May 3, 2018","March 9, 2016",,"March 28, 2019","National Cheng Kung University Hospital, Tainan City, Tainan, Taiwan",,"https://ClinicalTrials.gov/show/NCT02703298"
64,"NCT02507544","A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer",,"Completed","No Results Available","Carcinoma|Advanced Cancer","Drug: TRX-818 capsules","Dose limiting toxicity (DLT) of TRX-818|Maximum tolerated dose (MTD) of TRX-818|Preliminary assessment of anti-tumor activity by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1)|Composite measure of pharmacokinetics (PK) parameters of TRX-818 and its metabolites TRX-818M1 to include AUC(0-last), Cmax, Tmax, T(1/2).|Time to tumor progression (TTP)","TaiRx, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","36","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CVM-001","September 2015","April 29, 2017","May 20, 2019","July 24, 2015",,"May 21, 2020","START Midwest, Grand Rapids, Michigan, United States|South Texas Accelerated Research Therapeutics, LLC (START), San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02507544"
65,"NCT04100642","A Phase I Clinical Study of Hemay808",,"Completed","No Results Available","Safety Issues","Drug: Hemay808|Drug: Placebo","Number of adverse events and serious adverse events.|Cmax|Tmax|AUCt|AUC∞","Tianjin Hemay Pharmaceutical Co.,Ltd","All","18 Years to 45 Years   (Adult)","Phase 1","42","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","YQ-M-18-08","April 8, 2019","October 23, 2019","December 22, 2019","September 24, 2019",,"April 27, 2020","Dermotology hospital, Chinese academy of medical science, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT04100642"
66,"NCT02048488","A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas",,"Completed","No Results Available","Solid Tumors|Lymphomas","Drug: TSR-011","Incidence of Adverse Events (AEs)|Area Under the Concentration-Time Curve (AUC)|Maximum Tolerated Dose (MTD)|Response Rate (RR)|Dose limiting toxicity (DLT)|Progression Free Survival (PFS)|Recommended Phase 2 Dose (RP2D)","Tesaro, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","72","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PR-20-5006-C","October 2012","September 2016","June 2018","January 29, 2014",,"March 26, 2019","Goodyear, Arizona, United States|Scottsdale, Arizona, United States|Los Angeles, California, United States|Nashville, Tennessee, United States|Norfolk, Virginia, United States|Spokane, Washington, United States|Warsaw, Mazowieckie, Poland|Gdansk, Pomorskie, Poland|Olsztyn, Warminsko-Mazurskie, Poland|Poznan, Wielkopolskie, Poland|Madrid, Spain|Santiago de Compostela, Spain|Tainan City, Taiwan|Taipei, Taiwan|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02048488"
67,"NCT02478866","Safety and Pharmacokinetics of BPI-9016M in Patients With Advanced Solid Tumors",,"Completed","No Results Available","Solid Tumors","Drug: BPI-9016M","Participants with Adverse Events|Cmax|Half-life time|Tmax","Betta Pharmaceuticals Co., Ltd.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BD-CM-I01","August 11, 2015","June 30, 2017","November 2017","June 23, 2015",,"September 16, 2021","Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China|Peking Union College Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT02478866"
68,"NCT04481685","A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)",,"Completed","No Results Available","Covid19","Drug: ATI-450|Drug: Placebo","Respiratory failure-free survival in participants with moderate-severe COVID-19 who are treated with ATI-450|Change in 7 point-ordinal scale|Change in oxygen saturation-normalization|Need for advanced respiratory care|All-cause mortality|Percentage of adverse events (AEs)|Percentage of serious adverse events (SAEs)|Proportion of participants with normalization of fever for 24 hours|Number of participants who develop new bacterial infection|Number of participants who develop new fungal infection|Incidence of Adult Respiratory distress Syndrome (ARDS2)|Change in serum cytokine Interleukin (IL)-6|Change in serum cytokine IL-8|Change in serum cytokines IL-1β|Change in serum cytokine Tumor Necrosis Factor (TNF-α)","University of Kansas Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","IIT-2020-ATI-450-COVID-19","July 20, 2020","February 25, 2021","June 1, 2021","July 22, 2020",,"June 23, 2021","The University of Kansas Medical Center, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT04481685"
69,"NCT02218346","Food Effect Study of AG-221 in Healthy Male Subjects",,"Completed","No Results Available","Healthy Volunteers","Drug: AG221","Pharmacokinetic (PK) profile of AG-221|Incidence of adverse events","Agios Pharmaceuticals, Inc.|Celgene Corporation","Male","18 Years to 56 Years   (Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AG221-C-002","August 2014","December 2014","March 2015","August 18, 2014",,"December 14, 2015","Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02218346"
70,"NCT03402659","Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease","REVERSE-SD","Completed","Has Results","Alzheimer Disease","Drug: neflamapimod|Other: placebo","Total and Delayed Recall on the Hopkins Verbal Learning Test - Revised (HVLT-R)|Wechsler Memory Scale (WMS) Immediate and Delayed Recall|Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB)|Mini-Mental State Examination (MMSE)|Cerebrospinal Fluid Total Tau|Cerebrospinal Fluid Phospho-tau|Cerebrospinal Fluid Amyloid Beta 1-40|Cerebrospinal Fluid Amyloid Beta 1-42|Cerebrospinal Fluid Neurogranin|Cerebrospinal Fluid Neurofilament Light Chain|Cerebrospinal Fluid P-tau/AB1-42 Ratio","EIP Pharma Inc|Worldwide Clinical Trials|VU University Medical Center","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2","161","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EIP-VX17-745-304","December 29, 2017","June 30, 2019","July 31, 2019","January 18, 2018","October 27, 2021","October 27, 2021","Alliance for Research, Long Beach, California, United States|Pacific Research Network, San Diego, California, United States|CITrials, Santa Ana, California, United States|Southern California Research, LLC, Simi Valley, California, United States|Viking Clinical Research, Temecula, California, United States|Miami Dade Medical Research Institute, Miami, Florida, United States|Sensible Healthcare, LLC, Ocoee, Florida, United States|Anchor Neuroscience, Pensacola, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Suncoast Neuroscience Associates, Inc., Saint Petersburg, Florida, United States|Florida Premier Research Institute, Winter Park, Florida, United States|Northwest Clinical Trials, Boise, Idaho, United States|MassGeneral Institute for Neurodegenerative Disease, Charlestown, Massachusetts, United States|Manhattan Behavioral Medicine, New York, New York, United States|Alzheimer's Memory Center and Research Institute, Charlotte, North Carolina, United States|Northwest Clinical Research Center, Seattle, Washington, United States|Neuro HK, s.r.o. POLIKLINIKA CHOCEŇ, a.s., Choceň, Czechia|Cerebrovaskulární poradna s.r.o., Moravská Ostrava, Czechia|Clintrial S.R.O, Prague, Czechia|Private Psychiatric Centre, Prague, Czechia|Vestra Clinics S.R.O, Rychnov Nad Kněžnou, Czechia|CCBR Clinical Research, Aalborg, Aalborg, Denmark|CCBR Clinical Research, Ballerup, Ballerup, Denmark|CCBR Clinical Research, Vejle, Vejle, Denmark|Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands|Alzheimer Research Center, Amsterdam, Netherlands|Amphia Ziekhuis, Breda, Netherlands|MAC Clinical Research Tankersley, Barnsley, United Kingdom|Re:Cognition Health Birmingham, Birmingham, United Kingdom|MAC Clinical Research Blackpool, Blackpool, United Kingdom|Fulbourn Hospital, Cambridge, United Kingdom|MAC Clinical Research Leeds, Leeds, United Kingdom|MAC Clinical Research Liverpool, Liverpool, United Kingdom|Re:Cognition Health London, London, United Kingdom|St. Pancras Clinical Research, London, United Kingdom|MAC Clinical Research Manchester, Manchester, United Kingdom|Re:Cognition Health Plymouth, Plymouth, United Kingdom|5 Boroughs/North West Boroughs Healthcare NHS Foundation Trust, Warrington, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT03402659/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT03402659/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03402659"
71,"NCT01773018","Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors","HMPL-504","Completed","No Results Available","Tumor","Drug: Volitinib","The safety and tolerability of single and multiple doses of HMPL-504 administered to patients.|Pharmacokinetic Assessments for area under curve (AUC), Cmax and Tmax .","Hutchison Medipharma Limited|Sir Charles Gairdner Hospital|Austin Hospital, Melbourne Australia|Monash University","All","18 Years and older   (Adult, Older Adult)","Phase 1","47","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2011-504-00AU1","February 2012","December 2015","May 2016","January 21, 2013",,"June 1, 2016","Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Southern Health and Monash Institute of Medical Research, Clayton, Australia|Austin Health, Melbourne, Australia",,"https://ClinicalTrials.gov/show/NCT01773018"
72,"NCT00257114","Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability",,"Completed","No Results Available","Multiple Myeloma","Drug: bortezomib",,"Millennium Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 4",,"Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C05004",,"March 2007",,"November 22, 2005",,"February 11, 2008","Sinai Hospital of Baltimore, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00257114"
73,"NCT00118456","Study of Oral AEE788 in Adults With Advanced Cancer",,"Completed","No Results Available","Cancer","Drug: AEE788","Maximum-tolerated dose and dose-limiting toxicity of AEE788|Maximum-tolerated dose, safety and tolerability of AEE788|Single dose and repeated dose pharmacokinetic profile of AEE788|Pharmacodynamic effects|Changes in glucose metabolism/cell viability","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 1","189","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CAEE788A2101","July 2003","January 2008",,"July 11, 2005",,"January 9, 2012","Yale Cancer Center, New Haven, Connecticut, United States|Nevada Cancer Institute, Las Vegas, Nevada, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States|Institute of Drug Development/Cancer Therapy and Research Center, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00118456"
74,"NCT00116376","Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM)",,"Completed","No Results Available","Glioblastoma Multiforme","Drug: AEE788","Maximum tolerated dose|Dose limiting toxicity|Safety, tolerability, pharmacokinetic profiles, change in plasma markers of angiogenesis, tumor PK levels","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","64","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CAEE788A2103","January 2004","November 2005","November 2005","June 29, 2005",,"November 10, 2015","University of California at Los Angeles, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|The Brain Tumor Center at Duke, Duke University Medical Center, Box 3624 DUMC, Trent Drive, Durham, North Carolina, United States|University of Texas, MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00116376"
75,"NCT03163966","A Study of the EP4 Antagonist CR6086 in Combination With Methotrexate, in DMARD-naïve Patients With Early Rheumatoid Arthritis",,"Completed","No Results Available","Rheumatoid Arthritis, DMARD-naive and Early Disease Patients","Drug: CR6086|Drug: Methotrexate|Drug: Placebo","American College of Rheumatology 20% improvement (ACR20) responder rate|ACR50 responder rate|ACR70 responder rate|Disease Activity Score on 28-joint count (DAS28)|Clinical Disease Activity Index (CDAI)|Simplified Disease Activity Index (SDAI)|ACR/EULAR remission criteria|Adverse Events|Routine Laboratory determinations|Pharmacokinetics (PK) of Methotrexate and CR6086 in combination|Biochemical markers|Imaging biomarkers","Rottapharm Biotech","All","18 Years and older   (Adult, Older Adult)","Phase 2","248","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CR6086-2-02","October 5, 2017","January 8, 2019","January 8, 2019","May 23, 2017",,"October 5, 2021","Institute of Rheumatology, Prague, Czechia",,"https://ClinicalTrials.gov/show/NCT03163966"
76,"NCT02655822","Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers",,"Completed","No Results Available","Renal Cell Cancer|Metastatic Castration Resistant Prostate Cancer","Drug: Ciforadenant|Drug: Ciforadenant + atezolizumab","Incidence of dose-limiting toxicities (DLTs) of ciforadenant as a single agent and in combination with atezolizumab|Objective response rate per RECIST v1.1 criteria of ciforadenant as a single agent and in combination with atezolizumab|Incidence of treatment-emergent adverse events, as assessed by NCI CTCAE v.4.03, of ciforadenant as a single agent and in combination with atezolizumab|Mean and median Area under the curve (AUC) of ciforadenant|Mean and median Maximum concentration (Cmax) of ciforadenant|Identify the MDL (maximum dose level) of single agent ciforadenant","Corvus Pharmaceuticals, Inc.|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","502","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CPI-444-001","January 2016","June 2021","July 2021","January 14, 2016",,"August 30, 2021","University of Arizona Cancer Center, Tucson, Arizona, United States|University of California - San Francisco, San Francisco, California, United States|Stanford Cancer Institute, Stanford, California, United States|Yale University, New Haven, Connecticut, United States|University of Miami Hospital and Clinics, Miami, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Sidney Kimmel Comprehensive Cancer Center - Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|University of Pittsburgh Medical Center Cancer Center, Pittsburgh, Pennsylvania, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia|Monash Health, Clayton, Victoria, Australia|Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02655822"
77,"NCT02847325","Study of AC0058TA in Healthy Male and Female Subjects",,"Completed","No Results Available","Healthy Volunteers","Drug: AC0058TA|Drug: Placebo capsules","Safety and tolerability of single and multiple oral doses of AC0058TA determined by adverse events|Plasma concentrations of single dose or multiple doses of AC0058TA|Time to maximum observed concentration (Tmax)|Area under the concentration-time curve (AUC)|The effect of food on AUC of the single-oral-dose AC0058TA","ACEA Therapeutics, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AC00582015-101","May 2016","April 2017","April 2017","July 28, 2016",,"February 28, 2019","Covance Clinical Development Services, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02847325"
78,"NCT03703882","Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy","PolarisDMD","Completed","No Results Available","Muscular Dystrophy, Duchenne","Drug: Edasalonexent|Drug: Placebo","Change from baseline in North Star Ambulatory Assessment (NSAA)|Safety and tolerability measured by number of treatment- emergent adverse events (TEAEs) and serious adverse events (SAEs)|Change from baseline in 10-meter walk/run test|Change from baseline in time to stand from supine|Change from baseline in 4-stair climb","Catabasis Pharmaceuticals","Male","4 Years to 7 Years   (Child)","Phase 3","131","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CAT-1004-301","October 2, 2018","September 22, 2020","September 22, 2020","October 12, 2018",,"November 20, 2020","Arkansas Children's Hospital, Little Rock, Arkansas, United States|Children's Hospital of Los Angeles, Los Angeles, California, United States|UC Davis, Sacramento, California, United States|Nemours Children's Hospital, Orlando, Florida, United States|Rare Disease Research, LLC, Atlanta, Georgia, United States|Rush University Children's Hospital, Chicago, Illinois, United States|University of Iowa Children's Hospital, Iowa City, Iowa, United States|University of Kansas Medical Center, Fairway, Kansas, United States|Kennedy Krieger Institute, Baltimore, Maryland, United States|Johns Hopkins School of Medicine, Baltimore, Maryland, United States|Boston Children's Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Las Vegas Clinic, Las Vegas, Nevada, United States|Cincinnati Children's Hospital, Cincinnati, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Shriners Hospitals for Children, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Children's Hospital of the King's Daughters, Norfolk, Virginia, United States|Children's Hospital of Richmond at VCU, Richmond, Virginia, United States|The Children's Hospital at Westmead, Westmead, New South Wales, Australia|Children's Health Queensland Children's Hospital and Health Service, South Brisbane, Queensland, Australia|Royal Children's Hospital, Parkville, Victoria, Australia|Alberta Children's Hospital, Calgary, Alberta, Canada|London Health Sciences Centre - Children's Hospital, London, Ontario, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|CHU Sainte-Justine, Montréal, Quebec, Canada|University of Hamburg, Hamburg, Germany|University of Munich, Munich, Germany|Children's University Hospital, Dublin, Ireland|Hadassah Medical Center, Jerusalem, Israel|Queen Silvia Children's Hospital, Gothenburg, Sweden|Bristol Children's Hospital, Bristol, United Kingdom|Evelina Children's Hospital, London, United Kingdom|Great Ormond Street Hospital (GOSH), London, United Kingdom|Royal Manchester Children's Hospital, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03703882"
79,"NCT01200238","STA-9090(Ganetespib) in Metastatic Ocular Melanoma",,"Completed","Has Results","Ocular Melanoma","Drug: STA-9090","4-month Progression Free Survival (PFS) Rate|Expression of cMET|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Progression-Free Survival (PFS)|Overall Survival (OS)|Grade 3-4 Treatment-Related Toxicity Rate","Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Massachusetts General Hospital|Brigham and Women's Hospital|Synta Pharmaceuticals Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 2","17","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10-137","September 17, 2010","October 12, 2014","November 11, 2016","September 13, 2010","June 27, 2018","October 18, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01200238"
80,"NCT02348372","Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of GSK1278863A in Healthy Subjects",,"Completed","No Results Available","Anaemia","Drug: GSK1278863A Placebo|Drug: GSK1278863A","Number of Participants with Adverse Events as a Measure of Safety and Tolerability|AUC(0-t), AUC(0-∞), Cmax, tmax and t½ of GSK1278863A|Changes from Baseline of Clinical laboratory tests|Changes from Baseline of Vital signs|Change from Baseline of 12-lead ECG|Hemoglobin endpoints: Hemoglobin actual values, change from baseline, rate of rise/decline, maximum change from baseline, and maximum % change from baseline","GlaxoSmithKline","All","20 Years to 55 Years   (Adult)","Phase 1","34","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Other","115385","March 31, 2011","June 3, 2011","June 3, 2011","January 28, 2015",,"June 22, 2017","GSK Investigational Site, Randwick, Sydney, New South Wales, Australia",,"https://ClinicalTrials.gov/show/NCT02348372"
81,"NCT03368170","Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia",,"Completed","Has Results","Parkinson Disease","Drug: Mesdopetam (IRL790)","Unified Dyskinesia Rating Scale (UDysRS)|Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV, Question 4.1 and 4.2|Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Part II and III","Integrative Research Laboratories AB|The Clinical Trial Company","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 2","75","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRL790C003","April 12, 2018","June 12, 2019","June 12, 2019","December 11, 2017","March 24, 2020","August 25, 2020","Sahlgrenska University hospital, Göteborg, Sweden|University hospital, Linköping, Sweden|University hospital, Lund, Sweden|Karolinska University hospital, Stockholm, Sweden|Bristol Brain Centre, Southmead Hospital, Bristol, United Kingdom|Fairfield General Hospital (Pennine Acute NHS Trust), Bury, United Kingdom|Ninewells Hospital, Dundee, United Kingdom|Lincoln County Hospital, Lincoln, United Kingdom|Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom|The National Hospital of Neurology and Neurosurgery (UCL), London, United Kingdom|Luton and Dunstable University Hospital NHS Foundation Trust, Luton, United Kingdom|North Tyneside General Hospital, North Shields, United Kingdom|Qeens' Medical Centre, Nottingham, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom|Peterborough City Hospital, Peterborough, United Kingdom|Plymouth Hospitals NHS Trust - Derriford Hospital, Plymouth, United Kingdom|Queens's Hospital, Romford, United Kingdom|Royal Stoke University Hospital, Stoke-on-Trent, United Kingdom|Torbay hospital, Torquay, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT03368170/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT03368170/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03368170"
82,"NCT02355535","Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1",,"Completed","No Results Available","Solid Tumor|Pancreatic Neuroendocrine Tumor|Neuroendocrine Tumors","Drug: PAC-1","Maximum Tolerated Dose|Adverse Effects|Disease Response based on RECIST Criteria for patients with solid tumors|Disease Response based on Deauville PET Criteria for patients with lymphoma","Vanquish Oncology, Inc.|University of Illinois at Chicago","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","48","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015-0057","February 2015","May 18, 2020","May 18, 2020","February 4, 2015",,"September 24, 2020","University of Illinois at Chicago, Chicago, Illinois, United States|Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland, United States|Regions Hospital, Saint Paul, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02355535"
83,"NCT01410981","Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma",,"Completed","No Results Available","Multiple Myeloma",,"Measure the expression levels of CXCR4, CD47, and pS6 by flow cytometry in myeloma patient's marrow aspirate|Determine if Pim kinase inhibitors or sphingosine kinase 2 inhibitors will inhibit patients' myeloma cells","Medical University of South Carolina|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)",,"73","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","101565","August 2011","June 2014","June 2014","August 5, 2011",,"April 5, 2018","Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01410981"
84,"NCT01486199","Imaging Airway Liquid Absorption in Cystic Fibrosis",,"Completed","Has Results","Cystic Fibrosis","Other: Absorptive clearance scan","Absorptive Clearance Rate|Mucociliary Clearance Rate","University of Pittsburgh|National Institutes of Health (NIH)|National Heart, Lung, and Blood Institute (NHLBI)","All","6 Years and older   (Child, Adult, Older Adult)","Not Applicable","20","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","1R01HL108929-01|R01HL108929","October 2011","October 2014","October 2014","December 6, 2011","September 25, 2017","September 25, 2017","University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01486199"
85,"NCT01340846","A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors",,"Completed","No Results Available","Cancer","Drug: Warfarin|Drug: Ketoconazole|Drug: Gemfibrozil|Drug: GSK2118436 150mg|Drug: GSK2118436 75mg","Maximum plasma concentration (Cmax) of S-warfarin with and without GSK2118436|Area under the concentration time curve (AUC) of S-warfarin with and without GSK2118436|Maximum plasma concentration (Cmax) of GSK2118436 with and without an inhibitor|Area under the concentration time curve (AUC) of GSK2118436 with and without an inhibitor|Cmax of GSK2118436 and metabolites after single and multiple 75mg HPMC dose|AUC of GSK2118436 and metabolites after single and multiple 75mg HPMC dose|Time to Cmax (Tmax) of GSK2118436 and metabolites after single and multiple 75mg HPMC dose|Half-life of GSK2118436 and metabolites after single 75mg HPMC dose|Cmax of GSK2118436 and metabolites after single and multiple 150mg HPMC dose|AUC of GSK2118436 and metabolites after single and multiple 150mg HPMC dose|Tmax of GSK2118436 and metabolites after single and multiple 150mg HPMC dose|Half-life of GSK2118436 and metabolites after single 150mg HPMC dose|Cmax of R-warfarin with and without GSK2118436|Time to Cmax (Tmax) of R-warfarin|Trough concentration of GSK2118436|Number of subjects with adverse events as a measure of safety and tolerability|Tmax for GSK2118436 with and without an inhibitor|AUC, Cmax, Tmax and trough concentration of GSK2118436 metabolites with and without an inhibitor, and AUC ratio of metabolites to parent|Inhibitor concentrations in combination with GSK2118436|AUC of R-warfarin with and without GSK2118436|Terminal half-life (t1/2) of R-warfarin|Cmax of GSK2118436|Trough concentration for GSK2118436 with and without an inhibitor|Cmax of GSK2118436 metabolites with and without an inhibitor|Tmax of GSK2118436 metabolites with and without an inhibitor|Trough concentration of GSK2118436 metabolites with and without an inhibitor|AUC ratio of metabolites to parent with and without an inhibitor","GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 1","48","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","113771","September 3, 2012","November 14, 2012","November 14, 2012","April 25, 2011",,"November 13, 2017","GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Sarasota, Florida, United States|GSK Investigational Site, Detroit, Michigan, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Greenville, South Carolina, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Salt Lake City, Utah, United States|GSK Investigational Site, Nedlands, Western Australia, Australia|GSK Investigational Site, Headington, United Kingdom|GSK Investigational Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01340846"
86,"NCT02605746","Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis",,"Completed","No Results Available","Glioblastoma|Brain Metastases","Drug: ceritinib 750mg","Plasma Concentration|Cerebrospinal Concentration|Intratumoral Concentration|Tumor Tissue|Tumor Cells in M-Phase|Double Strand DNA|Tissue Concentration","St. Joseph's Hospital and Medical Center, Phoenix|Novartis|Wayne State University|Translational Genomics Research Institute","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","PHX15BN068","February 17, 2016","November 29, 2018","July 12, 2019","November 16, 2015",,"December 11, 2020","Barrow Brain and Spine, Phoenix, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT02605746"
87,"NCT02308761","A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome",,"Completed","No Results Available","Acute Myeloid Leukemia|Myelodysplastic Syndromes","Drug: RO6870810","Percentage of Participants With Dose-Limiting Toxicities (DLTs)|MTD of RO6870810|Percentage of Participants With Adverse Events (AEs)|Area Under the Concentration Versus Time Curve from Time Zero to the End of Dosing Interval 24 Hours Later (AUC0-24) of RO6870810|Maximum Observed Plasma Concentration (Cmax) of RO6870810|Time to Cmax (Tmax) of RO6870810","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 1","26","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NP39142","November 6, 2014","August 9, 2017","August 9, 2017","December 4, 2014",,"December 11, 2017","Dana Farber Cancer Institute, Boston, Massachusetts, United States|Weill Cornell Medical College, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02308761"
88,"NCT03497377","Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer.",,"Completed","No Results Available","Metastatic Prostate Cancer","Drug: 18F-DCFPyL Injection|Drug: 18F-NaF","Comparison of DCFPyL- PET/CT (or PET/MRI imaging) to NaF-PET/CT|Estimation of new or progressive metastatic lesions found on NaF and 18F-DCFPyL","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)","Male","18 Years to 100 Years   (Adult, Older Adult)","Phase 1","25","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","J1559|IRB00065679|1U01CA183031-01A1","May 16, 2016","April 2020","April 2020","April 13, 2018",,"May 7, 2020","Johns Hopkins University, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03497377"
89,"NCT01595139","MicroRNAs in Patients With Neurofibromatosis Type 1",,"Completed","No Results Available","Glioma|Neurofibromatosis Type 1",,"Evaluate miRNA expression patterns in tissue of low grade gliomas|Evaluated miRNA expression patterns between patients with and without imaging findings of gliomas","Ann & Robert H Lurie Children's Hospital of Chicago","All","2 Years to 21 Years   (Child, Adult)",,"9","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2012-14927","February 2012","July 2015","July 2015","May 9, 2012",,"February 5, 2016","Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01595139"
90,"NCT02096913","Safety Study of Ibuprofen to Treat Acute Traumatic Spinal Cord Injury",,"Completed","No Results Available","Spinal Cord Injury","Drug: Dolormin® extra (Ibuprofen)","Number of patients with severe gastroduodenal bleedings as a measure of safety|Spasticity on the Modified Ashworth Scale (MAS)|Pain on the Neuropathic Pain Scale (NPS)|International standards for neurological classification of spinal cord injury (ISNCSCI) - ASIA impairment scale (AIS) change from baseline|Neurological motor function on the ISNCSCI/ASIA motor scores change from baseline|Neurological sensory function on the ISNCSCI/ASIA sensory score change from baseline|Number of participants with adverse events as a measure of safety and tolerability|Ibuprofen levels in plasma|Ibuprofen levels in cerebrospinal fluid (CSF)","Jan M. Schwab, MD, PhD|Else Kröner Fresenius Foundation|Charite University, Berlin, Germany","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Ibuprofen-SCI-Safety|2011-000584-28","June 2013","September 2017","September 2017","March 26, 2014",,"October 30, 2017","Unfallkrankenhaus Berlin, Treatment Centre for Spinal Cord Injuries, Warener Straße 7, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT02096913"
91,"NCT03130790","Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line)",,"Completed","No Results Available","Gastric Cancer","Drug: Varlitinib|Drug: mFOLFOX6|Drug: Placebo","Percentage change from baseline in tumor size at Week 12 - Phase 2 part|Overall Survival (OS) - Phase 3 part|Objective Response Rate (ORR) - Phase 2 part|Progression-free survival (PFS) - Phase 2 part|Time to response (TTR) - Phase 2 part|Duration of Response (DoR) - Phase 2 part|Disease Control Rate (DCR) - Phase 2 part|Overall Survival (OS) - Phase 2 part|Pharmacokinetic: area under the plasma concentration time curve (AUC) from 0 to 6 hours (AUC0-6) - Phase 2 part|Pharmacokinetic: maximum observed plasma concentration (Cmax) - Phase 2 part|Pharmacokinetic: time to Cmax (tmax) - Phase 2 part|Pharmacokinetic: accumulation ratio for AUC (Rac AUC0-6) - Phase 2 part|Pharmacokinetic: accumulation ratio for Cmax (Rac Cmax) - Phase 2 part|Objective Response Rate (ORR) - Phase 3 part|Progression-free survival (PFS) - Phase 3 part|Time to response (TTR) - Phase 3 part|Duration of Response (DoR) - Phase 3 part|Disease Control Rate (DCR) - Phase 3 part|Incidence of Adverse Events (AEs) - Phase 3 part|Health-related quality of life (QoL) - Phase 3 part|European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 items (EORTC QLQ-C30) measuring patients general cancer symptoms and functioning - Phase 3 part|European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Gastric Cancer 22 items (EORTC QLQ STO22) measuring patients general cancer symptoms and functioning - Phase 3 part","Aslan Pharmaceuticals","All","21 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ASLAN001-012","August 31, 2017","December 20, 2018","February 22, 2019","April 26, 2017",,"February 15, 2022","2 Sites, Tallinn, Estonia|1 Site, Hong Kong, Hong Kong|2 Sites, Daegu, Korea, Republic of|1 Site, Incheon, Korea, Republic of|1 Site, Jeongnam, Korea, Republic of|11 Sites, Seoul, Korea, Republic of|2 Sites, Suwon, Korea, Republic of|2 Sites, Kaunas, Lithuania|1 Site, Vilnius, Lithuania|2 Sites, Kuala Lumpur, Malaysia|1 Site, Singapore, Singapore|1 Site, Kaohsiung, Taiwan|1 Site, Taichung, Taiwan|1 Site, Taipei, Taiwan|1 Site, Khon Kaen, Thailand|1 Site, Pathum Thani, Thailand",,"https://ClinicalTrials.gov/show/NCT03130790"
92,"NCT03223337","Daprodustat Hepatic Impairment Study",,"Completed","Has Results","Anaemia","Drug: Daprodustat (GSK1278863)","Part 1: Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0-infinity]) of GSK1278863 and Its Metabolites|Part 2: AUC (0-infinity) of GSK1278863 and Its Metabolites|Part 1: Percentage of AUC (0-infinity) Obtained by Extrapolation (Percentage AUCex) of GSK1278863 and Its Metabolites|Part 2: Percentage AUCex of GSK1278863 and Its Metabolites|Part 1: Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration (AUC [0-t]) of GSK1278863 and Its Metabolites|Part 2: AUC (0-t) of GSK1278863 and Its Metabolites|Part 1: Maximum Observed Concentration (Cmax) of GSK1278863 and Its Metabolites|Part 2: Cmax of GSK1278863 and Its Metabolites.|Part 1: Apparent Terminal Phase Half-life (t1/2) of GSK1278863 and Its Metabolites|Part 2: T1/2 of GSK1278863 and Its Metabolites|Part 1: Time of Occurrence of Cmax (Tmax) of GSK1278863 and Its Metabolites|Part 2: Tmax of GSK1278863 and Its Metabolites|Part 1: Unbound Concentration in Plasma of GSK1278863 and Its Metabolites|Part 2: Unbound Concentration in Plasma of GSK1278863 and Its Metabolites|Part 1: Unbound Fraction in Plasma of GSK1278863 and Its Metabolites|Part 2: Unbound Fraction in Plasma of GSK1278863 and Its Metabolites|Part 1: Maximum Observed Erythropoietin Concentration (Cmax, EPO) Following Administration of GSK1278863|Part 2: Cmax, EPO Following Administration of GSK1278863|Part 1: Time of the Maximum Observed Erythropoietin Concentration (Tmax, EPO) Following Administration of GSK1278863|Part 2: Tmax, EPO Following Administration of GSK1278863|Part 1: Erythropoietin Area Under the Concentration-time Curve From Time Zero (Pre-dose) to the Last Time of Quantifiable Concentration (AUC [0-t, EPO]) Following Administration of GSK1278863|Part 2: AUC (0-t, EPO) Following Administration of GSK1278863|Part 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Part 2: Number of Participants With AEs and SAEs|Part 1: Number of Participants With Worst Case Hematology Results Relative to Potential Clinical Importance (PCI) Criteria Post-Baseline Relative to Baseline|Part 2: Number of Participants With Worst Case Hematology Results Relative to PCI Criteria Post-Baseline Relative to Baseline|Part 1: Number of Participants With Worst Case Chemistry Results Relative to PCI Criteria Post-Baseline Relative to Baseline|Part 2: Number of Participants With Worst Case Chemistry Results Relative to PCI Criteria Post-Baseline Relative to Baseline|Part 1: Number of Participants With Abnormal Urinalysis Findings|Part 2: Number of Participants With Abnormal Urinalysis Findings","GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 1","37","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","200231","July 24, 2017","August 20, 2018","August 20, 2018","July 21, 2017","September 4, 2019","September 4, 2019","GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Orlando, Florida, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT03223337/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT03223337/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03223337"
93,"NCT02935907","APG-115 in Patients With Advanced Solid Tumors or Lymphomas","APG-115","Completed","No Results Available","Patients With Advanced Solid Tumor or Lymphoma","Drug: APG-115","Maximum Tolerated Dose (MTD)|Response will be evaluated every 2 cycles (8 weeks), according to the revised RECIST Guideline, Version 1.1|Maximum plasma concentration (Cmax) of APG-115 on Day 1-3 and Day 21-23 post APG-115 treatment on cycle 1|Area under the plasma concentration versus time curve (AUC) of APG-115 on Day 1 -3 and Day 21 - 23 post APG-115 treatment on cycle 1","Ascentage Pharma Group Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","50","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APG-115-US-001","October 2016","June 28, 2019","June 28, 2019","October 18, 2016",,"January 11, 2022","START Midwest, Grand Rapids, Michigan, United States|The START Center for Cancer Care, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02935907"
94,"NCT01300429","Molecular Determinants of Acquired Clinical Resistance to Crizotinib in Non-small Cell Lung Cancer Harboring a Translocation or Inversion Event Involving the ALK Gene Locus",,"Completed","No Results Available","Lung Cancer","Genetic: obtain tissue specimens","the frequency of acquired mutations","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","11-014","February 8, 2011","January 5, 2021","January 5, 2021","February 21, 2011",,"January 7, 2021","Memorial Sloan Kettering Cancer Center, New York, New York, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/29/NCT01300429/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT01300429"
95,"NCT01340833","Determination of the Absolute Bioavailability of GSK2118436 Following a Single Oral Dose Co-Administered With an Intravenous Radiolabelled Microtracer of GSK2118436 in Subjects With BRAF Mutant Solid Tumors",,"Completed","No Results Available","Cancer","Drug: GSK2118436","The percent of absolute bioavailability (F) of GSK2118436 following single-dose oral HPMC capsule and a concomitant IV microdose|Maximum plasma concentration (Cmax) of plasma GSK2118436 and [14C]GSK2118436|Time to Cmax (Tmax) of plasma GSK2118436 and [14C]GSK2118436|Area under the plasma-concentration time curve (AUC) of plasma GSK2118436 and [14C]GSK2118436|Terminal half-life (t1/2) of plasma GSK2118436 and [14C]GSK2118436|Oral clearance (CL/F) of GSK2118436|Clearance (CL) of [14C]GSK2118436|Volume of distribution (Vd) of [14C]GSK2118436|Number of subjects with adverse events as a measure of safety and tolerability","GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 1","6","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","113479","June 8, 2011","September 12, 2011","September 12, 2011","April 25, 2011",,"November 13, 2017","GSK Investigational Site, Tacoma, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01340833"
96,"NCT03231176","Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer",,"Completed","No Results Available","Biliary Tract Cancer","Drug: Varlitinib|Drug: Capecitabine","Objective Response Rate (ORR)|Progression-free survival (PFS)|Disease Control Rate (DCR)|Duration of Response (DoR)|Overall Survival (OS)|Safety and tolerability of varlitinib when combined with capecitabine","Aslan Pharmaceuticals","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","62","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ASLAN001-008","December 19, 2017","July 5, 2019","April 13, 2020","July 27, 2017",,"November 19, 2020","No.81 Hospital of The Chinese People's Liberation Army, Nanjing, China|There is 22 sites located in other cities of China, including Nanjing, Nanjing, China",,"https://ClinicalTrials.gov/show/NCT03231176"
97,"NCT00364780","Study of XL647 in Subjects With Non-Small-Cell Lung Cancer",,"Completed","No Results Available","Non-small-cell Lung Cancer","Drug: XL647","Response rate|Safety and tolerability|Progression-free survival|Duration of response|Overall survival|Pharmacokinetic and pharmacodynamic parameters","Kadmon Corporation, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 2","55","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","XL647-201","July 2006","May 2010","August 2010","August 16, 2006",,"January 30, 2012","Hematology Oncology Associates of the Treasure Coast, Port St. Lucie, Florida, United States|University of Chicago, Chicago, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Wayne University, Wertz Clinical Cancer Center, Karmanos Center, Detroit, Michigan, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Case Western Reserve University, University Hospitals of Cleveland, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00364780"
98,"NCT03093870","Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer","TreeTopp","Completed","Has Results","Biliary Tract Cancer","Drug: Varlitinib|Drug: Capecitabine|Drug: Placebo (for Varlitinib)","Objective Response Rate (ORR) - Part 1|Progression-free Survival (PFS) - Part 1|Object Response Rates (ORR) - Safety Lead-In|Overall Survival (OS) - Part 1|Overall Survival (OS) - Safety Lead-In|Duration of Response (DoR) - Part 1|Disease Control Rate DCR - Part 1|Tumor Size - Part 1|Number of Participants With Clinically Significant Laboratory Tests- Safety Lead-in|Number of Participants With Clinically Significant Laboratory Tests - Part 1|Number of Participants With Clinically Significant Change in Vital Signs and Physical Examinations - Safety Lead-In|Number of Participants With Clinically Significant Change in Vital Signs and Physical Examinations - Part 1|Number of Participants With ECG Parameters of Interest - Safety Lead-In|Number of Participants With ECG Parameters of Interest - Part 1|ECOG Performance Status - Part 1","Aslan Pharmaceuticals|bioRASI, LLC|CMIC Co, Ltd. Japan|Syneos Health","All","Child, Adult, Older Adult","Phase 2|Phase 3","151","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ASLAN001-009","July 4, 2017","November 12, 2019","April 17, 2020","March 28, 2017","August 3, 2021","August 3, 2021","Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Karmanos Cancer Institute/Wayne State University, Detroit, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|CCCN, Las Vegas, Nevada, United States|Ruttenberg Cancer Center, Mount Sinai Hospital, New York, New York, United States|Levine Cancer Institute, Carolinas Healthcare System, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Texas Oncology, P.A., Dallas, Texas, United States|UT MD Anderson Cancer Center, Houston, Texas, United States|There are 5 sites in different cities in Australia, Camperdown, Australia|There are 6 sites in different cities in China, Nanjing, Nanjing, China|There are 2 sites in Hong Kong, Hong Kong, Hong Kong|There are 2 sites in Hungary, Budapest, Hungary|There are 7 sites in different cities in Japan, Chiba, Japan|There are 15 sites in different cities in South Korea, Seoul, Korea, Republic of|There are 2 sites in different cities in Poland, Otwock, Poland|There are 2 sites in Singapore., Singapore, Singapore|There are 5 sites in different cities in Spain, Barcelona, Spain|There are 5 sites in different cities in Taiwan, Taipei, Taiwan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT03093870/Prot_002.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT03093870/SAP_003.pdf","https://ClinicalTrials.gov/show/NCT03093870"
99,"NCT01173380","Soy Nut Study on Markers of Health",,"Completed","No Results Available","Metabolic Syndrome X","Other: Soy nuts|Other: Matched food","Improve lipid profile|Increase endothelial function|Attenuate glycemic responses|Decrease inflammatory markers|Follow anthropometrics for stable weight","University of California, Davis","All","21 Years and older   (Adult, Older Adult)","Not Applicable","18","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","200715715-4","August 2010","September 2012","September 2012","August 2, 2010",,"May 30, 2017","Ragle Human Nutrition Center, Davis, California, United States",,"https://ClinicalTrials.gov/show/NCT01173380"
100,"NCT02447380","Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Overexpression as a Second-line Treatment",,"Completed","No Results Available","Advanced Gastric Adenocarcinoma","Drug: AZD6094|Drug: Docetaxel","Objective response rate (ORR) by RECIST 1.1|Duration of response|Disease control rate|Overall survival (OS)|progression-free survival (PFS)|Number of subjects with Adverse Events as a Measure of safety and Tolerability|Biomarker analysis","Samsung Medical Center","All","up to 20 Years   (Child, Adult)","Phase 2","2","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014-07-168","July 10, 2017","February 18, 2019","February 18, 2019","May 18, 2015",,"December 30, 2019","Samsung Medical Center, Seoul, Seoul, Korea, Republic Of, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02447380"
101,"NCT02215850","Safety Study of SLC-0111 in Subjects With Advanced Solid Tumours",,"Completed","No Results Available","Solid Tumours","Drug: SLC-0111","Number of participants with adverse events|Area under the plasma concentration versus time curve (AUC) of SLC-0111","Welichem Biotech Inc.|Ozmosis Research Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OZM-055/SLC0111-14-C01","October 2014","March 2016","March 2016","August 13, 2014",,"May 17, 2016","Alberta Health Services - Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Agency, Vancouver, British Columbia, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02215850"
102,"NCT02243306","Study to Assess the Pharmacokinetics of GSK1278863 in Subjects With End Stage Renal Disease Undergoing Peritoneal Dialysis",,"Completed","Has Results","Anaemia","Drug: GSK1278863","Area Under the Concentration-time Curve (AUC) Over the Dosing Interval (AUC[0-tau]) of GSK1278863 and Its Metabolites|AUC From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0-inf]) of GSK1278863 and Its Metabolites|Maximum Observed Concentration (Cmax) of GSK1278863 and Its Metabolites|Number of Participants With Non-serious Adverse Events (AEs) and Serious AEs (SAEs)|Change From Baseline in Glucose, Calcium, Chloride, Carbon-dioxide (CO2), Potassium, Sodium and Urea Levels|Change From Baseline in Albumin and Protein Levels|Change From Baseline in Direct Bilirubin, Bilirubin, Creatinine and Urate Levels|Change From Baseline in Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Gamma Glutamyl Aminotransferase (GGT) Levels|Change From Baseline in Alanine Aminotransferase (ALT) and Creatinine Kinase Levels|Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes Levels|Change From Baseline in Erythrocyte and Reticulocyte Levels|Change From Baseline in Hematocrit Levels|Change From Baseline in Hemoglobin Levels|Change From Baseline in Mean Corpuscular Hemoglobin Concentration (MCHC)|Change From Baseline in Mean Corpuscular Volume (MCV)|Change From Baseline in Mean Corpuscular Hemoglobin (MCH) Levels|Number of Participants With Abnormal Electrocardiogram (ECG) Findings|Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)|Change From Baseline in Pulse Rate|Change From Baseline in Body Temperature|Number of Participants With Abnormal Physical Examination Findings|Peritoneal Dialysis Clearance of GSK1278863 and Metabolites|Terminal Phase Half-life (t 1/2) of GSK1278863 and Metabolites|Time of Occurrence of Cmax (Tmax) of GSK1278863 and Metabolites|Accumulation Ratio of GSK1278863 and Metabolites|Time Invariance Ratio of GSK1278863 and Metabolites|Plasma Concentration of Erythropoietin|Plasma Concentration of Hepcidin","GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 1","8","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","200942|2014-001197-34","October 24, 2014","May 10, 2017","May 10, 2017","September 17, 2014","March 11, 2019","April 9, 2019","GSK Investigational Site, Lakewood, Colorado, United States|GSK Investigational Site, Minneapolis, Minnesota, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT02243306/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT02243306/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02243306"
103,"NCT03243604","cARdiotoxicity Profile of aBIraTeRone in prostAte Cancer : a pharmacoviGilancE Study","ARBITRAGE","Completed","No Results Available","Arrhythmias, Cardiac|Atrial Fibrillation and Flutter|Tachycardia, Supraventricular|Cardiac Failure","Drug: L02 (sex hormones used in treatment of neoplastic diseases) and G03 (sex hormones)","Analysis of disproportionality of reports for cardiotoxicity associated with abiraterone as compared to enzalutamide by performing a case- non-case study|Compare the reporting of suspected drug-induced supraventricular arrhythmias with abiraterone as compared to enzalutamide by performing a disproportionality analysis|Compare the reporting of drug-induced cardiac failure with abiraterone as compared to enzalutamide by performing a disproportionality analysis|Compare the reporting of drug-induced cardiac failure and/or supraventricular arrhythmias with abiraterone as compared to other androgen-deprivation therapies by performing a disproportionality analysis|Description of other mineralocorticoid related adverse events (hypokaliemia, fluid retention, and hypertension) when the cardio toxicity occurs|Description of the population of patients having a cardio-vascular adverse event|Description of the duration of treatment when the toxicity happens (role of cumulative dose)|Description of the drug-drug interactions associated with adverse events|Causality assessment of reported cardiovascular events according to the WHO-UMC system","Groupe Hospitalier Pitie-Salpetriere","Male","18 Years and older   (Adult, Older Adult)",,"1717","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","CIC1421-17-08","May 16, 2017","July 13, 2017","July 13, 2017","August 9, 2017",,"October 18, 2018","Centre Régional de Pharmaco-vigilance - Paris, Pitié-Salpétrière, Paris, Ile De France, France",,"https://ClinicalTrials.gov/show/NCT03243604"
104,"NCT01765478","Safety,PK/PD, Food Effect Study of Orally Administered HM71224 in Healthy Adult Male Volunteers",,"Completed","No Results Available","Rheumatoid Arthritis","Drug: HM71224 single ascending dose|Drug: HM71224 food effect|Drug: HM71224 Multiple ascending dose","To investigate safety and tolerability|To determine plasma PK parameters|To determine urine PK parameters","Hanmi Pharmaceutical Company Limited","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","62","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","12-HM71224-101","January 2013","November 2014","November 2014","January 10, 2013",,"May 18, 2015","PRA Clinical research center, Zuidlaren, Netherlands",,"https://ClinicalTrials.gov/show/NCT01765478"
105,"NCT01262898","Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis",,"Completed","Has Results","Gastroparesis","Drug: GSK962040 (5 mg tablet)|Drug: GSK962040 (25 mg tablet)|Drug: GSK962040 (125 mg tablet)|Drug: Placebo","Gastric Half Emptying Time (GEt1/2)|Number of Participants With On-treatment Adverse Events (AES) and Serious Adverse Events(SAEs)|Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure(DBP) at Specified Time Points in Semi-supine Position|Change From Baseline in Heart Rate at Specified Time Points in Semi-supine Position|Change From Baseline in Electrocardiography Parameters (12-lead ECG)|Number of Participants Outside the Normal Range for SBP and DBP|Number of Participants Outside the Normal Range for Heart Rate|Number of Participants Outside the Normal Range for 12-lead ECG|Mean Change From Baseline in Clinical Chemistry: Alkaline Phosphatase, Alanine Amino Transferase, Aspartate Amino Transferase, Gamma Glutamyl Transferase, Creatine Kinase, Lactate Dehydrogenase|Mean Change From Baseline in Clinical Chemistry: Direct Bilirubin, Total Bilirubin, Creatinine, Uric Acid|Mean Change From Baseline in Clinical Chemistry : Albumin, Total Protein|Mean Change From Baseline in Clinical Chemistry : Calcium, Chloride, Glucose, Potassium, Sodium, Urea/BUN, Carbon Dioxide Content/Bicarbonate|Mean Change From Baseline in Hematology Parameters : Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils (Total ANC - Total Absolute Neutrophil Count), Platelet Count, White Blood Cell Count|Mean Change From Baseline in Hematology Parameters : Hematocrit|Mean Change From Baseline in Hematology Parameters : Mean Corpuscle Hemoglobin|Mean Change From Baseline in Hematology Parameters : Hemoglobin, Mean Corpuscle Hemoglobin Concentration|Mean Change From Baseline in Hematology Parameters : Mean Corpuscle Volume|Mean Change From Baseline in Hematology Parameters : Red Blood Cell Count, Reticulocytes|Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration AUC(0-t) at Specified Time Points|Maximum Observed Concentration (Cmax) at Specified Time Points|Time of Occurrence of Cmax (Tmax) at Specified Time Points|Pre-dose (Trough) Concentration at the End of the Dosing Interval (Ct) at Specified Time Points|Apparent Clearance Following Oral Dosing (CL/F) at Specified Time Points|Apparent Volume of Distribution (V/F) at Specified Time Points|Apparent Terminal Elimination Half-life (t1/2) at Specified Time Points|Time to First Bowel Movement After First Dose|Daily Bowel Movement Frequency|Daily Average Stool Consistency|Change From Baseline in Upper Gastrointestinal (GI) Symptoms as Assessed by Total Gastrointestinal Cardinal Symptom Index - Daily Diary (GCSI-DD)|Change From Baseline in Whole Bowel Transit Time, 100 % Gastric Emptying Time (Truncated at 240 Minutes), Small Bowel Transit Time, Colonic Transit Time as Determined by Wireless Motility Capsule (WMC)","GlaxoSmithKline","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","79","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","114479|2010-023186-21","May 3, 2011","February 26, 2013","February 26, 2013","December 17, 2010","October 13, 2017","July 15, 2021","GSK Investigational Site, Concord, California, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Chevy Chase, Maryland, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Great Neck, New York, United States|GSK Investigational Site, Chattanooga, Tennessee, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Milwaukee, Wisconsin, United States|GSK Investigational Site, Randwick, New South Wales, Australia|GSK Investigational Site, Brussels, Belgium|GSK Investigational Site, Leuven, Belgium|GSK Investigational Site, Calgary, Alberta, Canada|GSK Investigational Site, Edmonton, Alberta, Canada|GSK Investigational Site, Thornhill, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Uppsala, Sweden|GSK Investigational Site, Cambridge, United Kingdom|GSK Investigational Site, Dundee, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Salford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01262898"
106,"NCT01083524","Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension",,"Completed","No Results Available","Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)","Drug: Dichloroacetate Sodium","Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension.|The change in pulmonary vascular resistance from baseline at 16 weeks, measured by cardiac catheterization;|Functional capacity: change from baseline in Functional Class and 6 min walk|Changes in Right Ventricular size/function (measured by MRI), biomarkers (NT-proBNP), lung/RV metabolism (measured by FDG-PET)","University of Alberta|Imperial College London","All","18 Years and older   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DCA 20001","March 2010","September 2013","September 2013","March 9, 2010",,"June 3, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada|Imperial College, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01083524"
107,"NCT01837667","Phase I Study of LB-100 With Docetaxel in Solid Tumors",,"Completed","No Results Available","Tumors|Neoplasms|Cancer","Drug: LB-100 for Injection|Drug: Docetaxel","Number of patients with adverse events as a measure of safety and tolerability of LB-100 for Injection treatment plus docetaxel.","Lixte Biotechnology Holdings, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","29","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","L12-20661","February 2013","September 2016","September 2016","April 23, 2013",,"January 24, 2017","City of Hope National Medical Center, Duarte, California, United States|Mayo Clinic, Rochester, Minnesota, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology - Tyler, Tyler, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01837667"
108,"NCT00312780","Study of XL784 in Patients With Albuminuria Due to Diabetic Nephropathy",,"Completed","No Results Available","Albuminuria|Diabetic Nephropathy","Drug: XL784","Reduction in albumin excretion relative to creatinine|Safety and tolerability|Pharmacokinetics and renal elimination","Symphony Evolution, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","125","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","XL784-201","March 2006","October 2007","December 2007","April 11, 2006",,"February 23, 2010","Parkway Medical Center, Birmingham, Alabama, United States|Winston Technology, Inc., Haleyville, Alabama, United States|Redpoint Research, Phoenix, Arizona, United States|International Clinical Research Network, Inc., Chula Vista, California, United States|Scripps Clinic, Torrey Pines, Division of Nephrology, La Jolla, California, United States|National Research Institute, Los Angeles, California, United States|West Los Angeles VA Medical Center, Los Angeles, California, United States|UCLA Medical Center, Center for the Health Sciences, Los Angeles, California, United States|Arroyo Research Inc., Pasadena, California, United States|Western Nephrology and Metabolic Bone Disease, PC, Lakewood, Colorado, United States|Western Nephrology and Metabolic Bone Disease, PC, Thornton, Colorado, United States|Soundview Research Associates, Norwalk, Connecticut, United States|Chase Medical Research, LLC, Waterbury, Connecticut, United States|MedStar Clinical Research Center, Washington, District of Columbia, United States|Clinical Research of South Florida, Coral Gables, Florida, United States|The Center for Diabetes and Endocrine Care, Hollywood, Florida, United States|FPA Clinical Research, Kissimmee, Florida, United States|Pines Clinical Research, Inc., Pembroke Pines, Florida, United States|Rocky Mountain Diabetes and Osteoporosis Center, PA, Idaho Falls, Idaho, United States|Renal Associate of Baton Rouge, Baton Rouge, Louisiana, United States|Intermed, Portland, Maine, United States|MODEL Clinical Research, Baltimore, Maryland, United States|Renal Unit, Joslin Diabetes Center, Boston, Massachusetts, United States|Fallon Clinic Inc. at Worcester Medical Center, Department of Nephrology, Worchester, Massachusetts, United States|Center for Urban and African American Health, Detroit, Michigan, United States|South Mississippi Nephrology, Gulfport, Mississippi, United States|Kansas City VA Medical Center, Kansas City, Missouri, United States|Clayton Medical Research, St. Louis, Missouri, United States|Creighton Dibetes Center, Omaha, Nebraska, United States|University of Nebraska Medical Center - Nephrology, Omaha, Nebraska, United States|LAND Clinical Studies, LLC, West Caldwell, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Duke South, Durham, North Carolina, United States|Division of Nephrology/Department of Medicine, Case Western Rserve University, MetroHealth Medical Center Campus, Cleveland, Ohio, United States|The Ohio State University Medical Center, Division of Nephrology, Columbus, Ohio, United States|COR Clinical Research, LLC, Oklahoma City, Oklahoma, United States|Clinical Research Institute of Southern Oregon, PC, Medford, Oregon, United States|Mountain View Clinical Research, Inc., Greer, South Carolina, United States|Nephrology Associates, PC, Nashville, Tennessee, United States|Heartland Medical, PC, New Tazewell, Tennessee, United States|Diabetes Center of the Southwest, Midland, Texas, United States|dgd Research, San Antonio, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|University of Virginia Health System, Nephrology Division, Charlottesville, Virginia, United States|Zablocki Veterans Affairs Medical Center, Nephrology Section, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00312780"
109,"NCT01887197","Repeatability and Response Study of Absorptive Clearance Scans",,"Completed","No Results Available","Cystic Fibrosis","Other: Absorptive clearance scan|Drug: inhaled hypertonic saline (7%)|Drug: mannitol inhalation powder","absorptive clearance variability|absorptive clearance response","Tim Corcoran|University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Phase 1","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","1RO1 HL108929-01 (B)","June 2013","December 2017","May 2018","June 26, 2013",,"November 6, 2018","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01887197"
110,"NCT02406209","A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis",,"Completed","No Results Available","Non-infectious Anterior Uveitis","Drug: NS2|Drug: Prednisolone acetate ophthalmic suspension (1%)","Grade of anterior chamber cell count measured by slit lamp examination. The primary outcome is not specifically defined however anterior uveitis clinical outcomes will be measured.|Grade of anterior chamber flare measured by slit lamp examination|Grade of limbal injection measured by slit lamp examination|Grade of hypopion measured by slit lamp examination|Grade of peripheral anterior synechiae measured by slit lamp examination|Grade of keratic precipitates measured by slit lamp examination|Grade of posterior synechiae measured by slit lamp examination|Ocular pain score on the visual analog scale|Visual acuity measured by a standardized eye chart (ETDRS or Snellen)|Number of subjects with treatment emergent adverse events as a measure of safety and tolerability","Aldeyra Therapeutics, Inc.","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NS2-02","March 2015","April 2016","April 2016","April 2, 2015",,"March 12, 2019","Hull Eye Center, Lancaster, California, United States|Colorado Retina Associates,PC, Golden, Colorado, United States|Eye Center of Southern Connecticut, Hamden, Connecticut, United States|Bascom Palmer Eye Institute, Plantation, Florida, United States|Valley Eye Physicians & Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States|Oakland Ophthalmic Surgery, Birmingham, Michigan, United States|Lifelong Vision Foundation, Chesterfield, Missouri, United States|Tauber Eye Center, Kansas City, Missouri, United States|UNMC Stanley Truhlsen Eye Institute, Omaha, Nebraska, United States|Metropolitan Eye Research & Surgery Institute, Palisades Park, New Jersey, United States|Mid-Atlantic Retina, Philadelphia, Pennsylvania, United States|Houston Eye Associates, Houston, Texas, United States|Virginia Eye Consultants, Norfolk, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02406209"
111,"NCT04682444","Efficacy and Safety of Enisamium Iodide for the Treatment of Acute Respiratory Viral Infections, Including Influenza.",,"Completed","No Results Available","Acute Respiratory Viral Infections|Human Influenza","Drug: Enisamium Iodide|Drug: Placebo","Efficacy - Clinical improvement from Day 3 after therapy start|Efficacy - Time of disappearance of respiratory tract affection symptoms|Efficacy - Body temperature normalization|Efficacy - General symptoms of ARVI including influenza|Efficacy - Viral antigens|Safety - Adverse events|Safety - Laboratory parameters - Immune status","Joint Stock Company ""Farmak""","All","18 Years to 60 Years   (Adult)","Phase 2|Phase 3","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","AM-STP-2-2008","April 13, 2009","January 28, 2010","May 15, 2010","December 23, 2020",,"December 23, 2020",,,"https://ClinicalTrials.gov/show/NCT04682444"
112,"NCT01294566","FTIH to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses of GSK1322888 in Healthy Caucasian and Japanese Volunteers",,"Completed","No Results Available","Gastroparesis","Drug: GSK1322888|Drug: Placebo","Adverse Events following single oral doses of GSK1322888|pharmacokinetics of GSK1322888 following single, oral doses|gastric emptying of a radio-labeled test meal, as measured by the 13C-octanoic acid breath test following single oral doses of GSK1322888|dose/exposure response relationship for gastric emptying of a radio-labeled test meal, as measured by the 13C-octanoic acid breath test following single oral doses of GSK1322888|dose proportionality following single dose administration|steady-state PK based on single dose data|accumulation based on single dose data|ethnicity differences in safety, tolerability, pharmacokinetics, and pharmacodynamics between volunteers of Caucasian or Japanese ethnicity","GlaxoSmithKline","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","17","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","114422","November 29, 2010","March 23, 2011","March 23, 2011","February 11, 2011",,"June 28, 2017","GSK Investigational Site, Randwick, New South Wales, Australia",,"https://ClinicalTrials.gov/show/NCT01294566"
113,"NCT03204929","Dose Escalation Study of Cu(II)ATSM in Parkinson's Disease",,"Completed","No Results Available","Parkinson Disease","Drug: Cu(II)ATSM","Recommended phase 2 dose|Treatment-related changes in disease severity|Treatment-related changes in motor function|Treatment-related changes in cognitive function|Treatment-related changes in quality of life|Treatment-related changes in constipation","Collaborative Medicinal Development Pty Limited","All","30 Years and older   (Adult, Older Adult)","Phase 1","31","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CMD-2016-002","August 14, 2017","November 30, 2019","February 29, 2020","July 2, 2017",,"March 17, 2020","Macquarie University, Macquarie Park, New South Wales, Australia|The Royal Melbourne Hospital, Melbourne, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT03204929"
114,"NCT02870634","Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND",,"Completed","No Results Available","Amyotrophic Lateral Sclerosis|Motor Neuron Disease","Drug: Cu(II)ATSM","recommended phase 2 dose as determined by the number of participants at each dose level with dose limiting toxicities|Treatment-related change in disease severity by ALS Functional Rating Scale - Revised (ALSFRS-R)|Treatment-related change in cognitive function by Edinburgh Cognitive and Behavioral Assessment (ECAS) score|Treatment-related change in respiratory function by seated forced vital capacity (FCV)|Treatment-related change in quality of life by ALSSQOL-R score|Treatment-related change in disease severity by transcranial magnetic stimulation (TMS) response|Peak Cu(II)ATSM plasma concentration following administration of a single dose based on blood draws taken at 1, 2, 4, 8 and 24 hours after dosing|Area under the Cu(II)ATSM plasma concentration versus time curve (AUC) following administration of a single dose based on blood draws taken at 1, 2, 4, 8 and 24 hours after dosing|Treatment-related change in respiratory function by sniff nasal pressure (SNP) test","Collaborative Medicinal Development Pty Limited","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","50","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CMD-2016-001","November 16, 2016","October 30, 2019","January 30, 2020","August 17, 2016",,"March 17, 2020","Macquarie University, Sydenham, New South Wales, Australia|Calvary Health Care Bethlehem, Caulfield, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT02870634"
115,"NCT02439216","Phase 1/2 Study in Boys With Duchenne Muscular Dystrophy","MoveDMD®","Completed","No Results Available","Muscular Dystrophy, Duchenne","Drug: Edasalonexent|Drug: Placebo","Safety and tolerability (Adverse Events)|Muscle composition and inflammation as measured by MRI|Physical function, muscle strength, and parent/proxy reported physical functioning/quality of life|Edasalonexent PK and PD measures","Catabasis Pharmaceuticals","Male","4 Years to 7 Years   (Child)","Phase 1|Phase 2","31","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CAT-1004-201","April 2016","January 12, 2017","August 2019","May 8, 2015",,"November 15, 2019","Los Angeles, California, United States|Gainesville, Florida, United States|Orlando, Florida, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02439216"
116,"NCT02029716","RTA 408 Lotion in Healthy Volunteers",,"Completed","No Results Available","Healthy","Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo","Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle","Reata Pharmaceuticals, Inc.|AbbVie","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","109","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","RTA 408-C-1305","December 2013","April 2014","April 2014","January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02029716"
117,"NCT02578914","A Safety and Activity Study of NS2 in Subjects With Allergic Conjunctivitis",,"Completed","No Results Available","Allergic Conjunctivitis|Seasonal Allergies","Drug: NS2 Ophthalmic Drops (0.5%)|Drug: NS2 Ophthalmic Drops Vehicle (0.0%)","Mean change from baseline in Ocular itching scores.|Mean change from baseline in Conjunctival redness scores based on modified validated bulbar redness TM descriptive and photgraphic scale.|Mean change from baseline in Lid swelling scores.|Mean change from baseline in Ocular tearing scores.|Change from baseline in abnormal slit lamp examination findings.Grade of lids, tear film, conjunctiva, sclera, cornea, iris, anterior/posterior chamber and lens will be reported.|Number of eyes with undilated fundoscopy changes from baseline.|Change from baseline in Intraocular pressure measurement (IOP).|Frequency of treatment emergent adverse events (AEs) as a measure of safety and tolerability.|Visual acuity measured by a standardized eye chart.","Aldeyra Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ALDNS2-203-D1|15-MO-001","August 2015","December 2015","December 2015","October 19, 2015",,"May 27, 2016","Inflamax Research Inc., Mississauga, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02578914"
118,"NCT03243838","Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer","LANCET","Completed","No Results Available","Triple-Negative Breast Cancer","Drug: Apatinib","The pathological complete response (pCR) rate in the breast and lymph nodes (ypTis/0ypN0)|Objective response rate (ORR)|Event-free survival (EFS)|Overall survival (OS)|Adverse events","Guangdong Provincial People's Hospital","Female","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","31","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20170328","August 1, 2018","October 13, 2021","December 31, 2021","August 9, 2017",,"February 2, 2022","Guangdong general hospital, Guangzhou, Guangdong, China|Guangdong General Hospital, Guangzhou, China",,"https://ClinicalTrials.gov/show/NCT03243838"
119,"NCT00000180","AIT-082 Phase 1B Study",,"Completed","No Results Available","Memory Disorders","Drug: AIT-082",,"National Institute on Aging (NIA)","All","Child, Adult, Older Adult","Phase 1",,"NIH","Interventional","Allocation: Randomized|Masking: Double|Primary Purpose: Treatment","IA0008|3U01AG010483-08S2",,"June 2005","June 2005","November 1, 1999",,"December 11, 2009","University of California, San Diego, San Diego, California, United States|Indiana University Alzheimer's Center, Indianapolis, Indiana, United States|University of Michigan, Ann Arbor, Michigan, United States|Washington University, St. Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT00000180"
120,"NCT04821648","RJV001 Study in Adults Receiving Abdominoplasty",,"Completed","No Results Available","Submental Fat (SMF)|Double Chin","Drug: RJV001|Drug: Placebo","Local and systemic adverse events following administration of RJV001","Rejuven Dermaceutical Co., Ltd.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RJV001-PH1-01","April 16, 2021","December 16, 2021","December 16, 2021","March 29, 2021",,"January 18, 2022","Study site: Arizona Research Center, Phoenix, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT04821648"
121,"NCT01666444","VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer",,"Completed","Has Results","Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer","Drug: pegylated liposomal doxorubicin (PLD)|Drug: VTX-2337|Drug: Placebo","Overall Survival|Progression-free Survival (PFS)|Frequency and Severity of Adverse Events (AEs)","Celgene|Gynecologic Oncology Group","Female","18 Years and older   (Adult, Older Adult)","Phase 2","297","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GOG-3003","October 31, 2012","July 31, 2016","July 31, 2016","August 16, 2012","September 26, 2019","September 26, 2019","St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Winthrop P. Rockefeller Cancer Institute - University of Arkansas, Little Rock, Arkansas, United States|Providence Saint Joseph Medical Center, Burbank, California, United States|Kaiser Permanente Medical Center, Hayward, California, United States|Long Beach Memorial Medical Center, Long Beach, California, United States|Kaiser Permanente Medical Center, Oakland, California, United States|Kaiser Permanente Medical Center, Roseville, California, United States|Sutter Cancer Center, Sacramento, California, United States|Kaiser Permanente Medical Center, Sacramento, California, United States|Kaiser Permanente Medical Center, San Francisco, California, United States|Kaiser Permanente Medical Center, San Jose, California, United States|Kaiser Permanente Medical Center, Santa Clara, California, United States|Kaiser Permanente Medical Center, South San Francisco, California, United States|Stanford University School of Medicine, Stanford, California, United States|Kaiser Permanente Medical Center, Vallejo, California, United States|Kaiser Permanente Medical Center, Walnut Creek, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Hartford Hospital, Hartford, Connecticut, United States|St. Francis Hospital and Medical Center, Hartford, Connecticut, United States|The Hospital of Central Connecticut, New Britain, Connecticut, United States|Yale - New Haven Hospital, New Haven, Connecticut, United States|MD Anderson Cancer Center - Orlando, Orlando, Florida, United States|Women's Cancer Associates, Saint Petersburg, Florida, United States|Northside Hospital, Atlanta, Georgia, United States|Georgia Regents University, Augusta, Georgia, United States|Northeast Georgia Medical Center, Gainesville, Georgia, United States|Central Georgia Gynecologic Oncology, Macon, Georgia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|St. Joseph's - Candler Gynecologic Oncology, Savannah, Georgia, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Northwestern University - Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Sudarshan K. Sharma, MD, LTD, Hinsdale, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|St. Vincent Gynecologic Oncology, Indianapolis, Indiana, United States|McFarland Clinic, Ames, Iowa, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas Medical Center, Westwood, Kansas, United States|Maine Medical Partners Women's Health, Scarborough, Maine, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Johns Hopkins Medical Institution, Baltimore, Maryland, United States|Lahey Hospital & Medical Center, Burlington, Massachusetts, United States|University of Massachusetts Memorial Healthcare, Worcester, Massachusetts, United States|St. Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Bronson Battle Creek, Battle Creek, Michigan, United States|Karmanos Cancer Institute - Wayne State University, Detroit, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Grand Rapids Clinical Oncology, Grand Rapids, Michigan, United States|Saint Mary's Health Care, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Gynecologic Oncology of West Michigan, Grand Rapids, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Mercy Health Partners - Mercy Campus, Muskegon, Michigan, United States|Reed City Hospital - Spectrum Health, Reed City, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Minnesota Oncology Coon Rapids Clinic, Coon Rapids, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Abbott Northwestern Hospital, Minneapolis, Minnesota, United States|Metro Minnesota Clinical Oncology Program, Saint Louis Park, Minnesota, United States|Park Nicollet Frauenshuh Cancer Center, Saint Louis Park, Minnesota, United States|Minnesota Oncology Hematology - St. Paul Cancer Center, Saint Paul, Minnesota, United States|Woodbury Clinic - CornerStone Medical Specialty Centre, Woodbury, Minnesota, United States|St. Dominic-Jackson Memorial Hospital, Jackson, Mississippi, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Ellis Fischel Cancer Center - University of Missouri, Columbia, Missouri, United States|Women's Cancer Care Center of Nevada, Las Vegas, Nevada, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Cooper University Hospital, Camden, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Southwest Gynecologic Oncology Associates, Albuquerque, New Mexico, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Memorial Medical Center, Las Cruces, New Mexico, United States|Women's Cancer Care Associates, Albany, New York, United States|SUNY Downstate Medical Center, Brooklyn, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Monter Cancer Center, Lake Success, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Long Island Jewish Medical Center, New Hyde Park, New York, United States|NYU Langone Medical Center - Cancer Institute, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Gynecologic Oncology of Central New York - SUNY Upstate, Syracuse, New York, United States|Hope Women's Cancer Center, Asheville, North Carolina, United States|Alamance Regional Cancer Center, Burlington, North Carolina, United States|Carolinas Medical Center / Levine Cancer Institute, Charlotte, North Carolina, United States|Carolinas Medical Center - Northeast, Concord, North Carolina, United States|Wake Forest University Health Science, Winston-Salem, North Carolina, United States|Summa Health System, Akron, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Fairview Hospital Moll Pavilion Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Medical Center, Columbus, Ohio, United States|Women's Cancer Center at Kettering Medical Center, Kettering, Ohio, United States|Hillcrest Hospital - Cleveland Clinic, Mayfield Heights, Ohio, United States|Lake University Seidman Cancer Center, Mentor, Ohio, United States|Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Tulsa Cancer Institute, Tulsa, Oklahoma, United States|Abington Memorial Hospital; Hanjani Institute for Gynecologic Oncology, Abington, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Hillman Cancer Center - University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|Reading Hospital (McGlinn Family Regional Cancer Center), West Reading, Pennsylvania, United States|Women and Infants Hospital of Rhode Island, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Bon Secours St. Francis Hospital, Greenville, South Carolina, United States|Gibbs Cancer Center, Spartanburg, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|UT Southwestern Medical Center, Dallas, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|The Methodist Hospital, Houston, Texas, United States|Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States|Mid Atlantic Pelvic Surgery Associates, Annandale, Virginia, United States|Virginia Gynecology Oncology, Richmond, Virginia, United States|Carilion Clinic Gynecological Oncology, Roanoke, Virginia, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Northwest Hospital - UW Medicine, Seattle, Washington, United States|Women's Cancer Care of Seattle, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|Green Bay Oncology at St. Vincent's Hospital, Green Bay, Wisconsin, United States|St Vincent Hospital, Green Bay, Wisconsin, United States|Green Bay Oncology at St. Mary's Hospital, Green Bay, Wisconsin, United States|University of Wisconsin-Madison, Madison, Wisconsin, United States|Holy Family Memorial Medical Center, Manitowoc, Wisconsin, United States|Bay Area Medical Center, Marinette, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Aurora St. Luke's Medical Center Gynecologic Oncology, Milwaukee, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Aspirus Regional Cancer Center, Wausau, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01666444"
122,"NCT01251484","BIBF 1120 in Recurrent Glioblastoma Multiforme",,"Completed","No Results Available","Recurrent Glioblastoma","Drug: BIBF1120","Response rate|Adverse events","Ulrik Lassen|Boehringer Ingelheim|University of Copenhagen|Rigshospitalet, Denmark","All","18 Years and older   (Adult, Older Adult)","Phase 2","25","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BIBF1120 GBM","January 2011","August 2012","August 2012","December 2, 2010",,"October 4, 2012","Rigshospitalet, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT01251484"
123,"NCT03838237","Effect of Migalastat on Cardiac Involvement in Fabry Disease","MAIORA","Completed","No Results Available","Fabry Disease|Heart Diseases","Diagnostic Test: Cardiological evaluation","Delta left ventricular mass|Delta native myocardial T1 values|Delta left ventricular global longitudinal strain|Delta 3 plasmatic microRNAs levels","Ospedale San Donato|Amicus Therapeutics|Institute of Biomedicine and Molecular Immunology - CNR","All","16 Years and older   (Child, Adult, Older Adult)",,"18","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","148/int/2017","January 10, 2018","January 22, 2021","January 22, 2021","February 12, 2019",,"March 18, 2021","IRCCS Policlinico San Donato, San Donato Milanese, Milano, Italy",,"https://ClinicalTrials.gov/show/NCT03838237"
124,"NCT04301804","A Trial of SHR6390 in Healthy Caucasian Volunteers",,"Completed","No Results Available","Healthy Volunteers","Drug: SHR6390","Number of subjects with laboratory tests findings of potential clinical importance|Number of subjects with adverse events (AEs)|Number of subjects with clinically significant abnormal ECG QT Interval|Pharmacokinetic - Cmax|Pharmacokinetic - AUC∞|AUC from time 0 to the time of the last quantifiable concentration (AUClast) of SHR6390|Pharmacokinetic - AUClast|Pharmacokinetic - Tmax|Pharmacokinetic - CL/F|Pharmacokinetic - Vz/F|Pharmacokinetic - t1/2","Atridia Pty Ltd.","All","18 Years to 45 Years   (Adult)","Phase 1","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","SHR6390-001AUS","March 12, 2020","May 28, 2020","September 28, 2020","March 10, 2020",,"October 1, 2020","Linear Clinical Research, Melbourne, Western Australia, Australia",,"https://ClinicalTrials.gov/show/NCT04301804"
125,"NCT03288285","Comparison of Post- and Pre-dilutional Hemodiafiltration in Hemodialysis Patients",,"Completed","No Results Available","Hemodiafiltration",,"Removal of a wide spectrum of solutes|Intradialytic tolerance","Tungs' Taichung Metroharbour Hospital","All","20 Years and older   (Adult, Older Adult)",,"49","Other","Observational","Observational Model: Case-Crossover|Time Perspective: Cross-Sectional","106042","September 1, 2017","October 31, 2018","April 7, 2019","September 20, 2017",,"April 23, 2019","Tungs' Taichung Metroharbour Hospital, Taichung, Taiwan",,"https://ClinicalTrials.gov/show/NCT03288285"
126,"NCT01496157","Evaluation of Prostate-specific Membrane Antigen (PSMA)-Based PET Imaging of Primary Prostate Cancer",,"Completed","Has Results","Prostate Cancer","Drug: 18F-DCFBC","PET Detection of Primary Prostate Cancer|PET Detection of Metastatic Disease at Initial Staging","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","Male","18 Years to 90 Years   (Adult, Older Adult)","Phase 1|Phase 2","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","J1191|NA_00051395","September 11, 2012","January 2015","September 17, 2017","December 21, 2011","August 28, 2018","August 28, 2018","Johns Hopkins University, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01496157"
127,"NCT04670757","Safety and Pharmacokinetics of JAK/ROCK Inhibitor in Healthy Volunteers",,"Completed","No Results Available","Healthy","Drug: CPL409116|Drug: Placebo","Determination of maximum tolerated dose (MTD) or administration of the maximum dose provided in the protocol after single and multiple oral administration of IMP.|Safety and tolerability of IMP after single and multiple oral administration|Cmax - maximum plasma concentration|AUC(0-48) - area under the plasma concentration - time curve from time 0 to 48h after IMP administration|AUC(0-24) - area under the plasma concentration - time curve from time 0 to 24h after IMP administration|AUC(0-inf) - area under the plasma concentration - time curve from time 0 to infinity time|Tmax - time to reach maximum concentration|Kel - terminal elimination rate constant|T1/2 - The plasma elimination half-life|C (1,t) - CPL207280 concentration|C (Tmax, t) - CPL207280 concentration","Celon Pharma SA|National Center for Research and Development, Poland","All","18 Years to 55 Years   (Adult)","Phase 1","65","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","01JAK2020","December 8, 2020","September 8, 2021","September 8, 2021","December 17, 2020",,"March 25, 2022","BioResearch Group Sp. z o.o., Kajetany, Nadarzyn, Poland",,"https://ClinicalTrials.gov/show/NCT04670757"
128,"NCT03359018","Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma","APFAO","Completed","No Results Available","Progression-free Survival|Overall Survival|Clinical Benefit Rate|Toxicity","Drug: Apatinib|Drug: SHR-1210","progression-free survival|clinical benefit rate|overall survival","Peking University People's Hospital|Jiangsu HengRui Medicine Co., Ltd.","All","11 Years and older   (Child, Adult, Older Adult)","Phase 2","43","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PKUPH-sarcoma 02","January 1, 2018","October 22, 2019","January 30, 2020","December 2, 2017",,"May 19, 2020","Musculoskeletal Tumor Center of Peking University People's Hospital, Beijing, China|Peking University Shougang Hospital, Beijing, China","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT03359018/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03359018"
129,"NCT03765554","Clinical Study to Evaluate Blood Concentrations of PF-06700841 After Oral Dose as Different Formulations",,"Completed","No Results Available","Healthy Participants","Drug: PF-06700841 Immediate release tablets|Drug: PF-06700841 Modified release tablets","Maximum Observed Plasma Concentration (Cmax) of PF-06700841|Area under the plasma concentration-time curve from time zero to the last measured concentration (AUClast) of PF-06700841|Time to reach maximum observed plasma concentration (Tmax) of PF-06700841|Area under the plasma concentration-time curve from time zero to extrapolated infinite time (AUCinf) of PF-06700841 if data permit|Change from baseline in 12-Lead Electrocardiogram (ECG) parameters - PR interval, QRS complex, QT interval and QTC interval|Change from baseline in heart rate|Change from baseline in blood pressure|Change from baseline in pulse rate|Change from baseline in oral temperature|Number of participants with laboratory abnormalities|Number of participants with Treatment -Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Discontinuation Due to AEs","Pfizer","All","18 Years to 55 Years   (Adult)","Phase 1","8","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","B7931010|2018-003512-41","January 7, 2019","April 3, 2019","April 3, 2019","December 5, 2018",,"May 9, 2019","Pfizer Clinical Research Unit, Brussels, Belgium",,"https://ClinicalTrials.gov/show/NCT03765554"
130,"NCT02342587","Safety and Clinical Activity of Lapatinib in Patients With HER2-positive Refractory Advanced Cancer",,"Completed","No Results Available","HER2-positive Refractory Advanced Cancer","Drug: Lapatinib","overall response rate","Samsung Medical Center","All","20 Years and older   (Adult, Older Adult)","Phase 2","7","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014-10-028","December 3, 2014","January 2016","August 21, 2016","January 21, 2015",,"February 17, 2017","Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02342587"
131,"NCT00566410","A Phase I, Open-Labeled, Single-Arm, Dose Escalation, Clinical and Pharmacology Study of Dichloroacetate (DCA) in Patients With Recurrent and/or Metastatic Solid Tumours","DCA","Completed","No Results Available","Neoplasms","Drug: Dichloroacetate","To assess safety and tolerability of oral DCA|To determine the dose-limiting toxicity (DLT) and phase II dose|To characterize pharmacokinetic (PK) profile|To evaluate the effect of oral DCA|To evaluate the clinical response rate|To evaluate the change in standard uptake value by FDG-PET scans before and after treatment with DCA","AHS Cancer Control Alberta|Cross Cancer Institute","All","18 Years and older   (Adult, Older Adult)","Phase 1","23","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","23596","December 2007","March 2013","March 2013","December 3, 2007",,"March 11, 2016","Cross Cancer Institute, Edmonton, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT00566410"
132,"NCT03443830","Safety and Tolerability of an Antibody Against Zika Virus (Tyzivumab) in Humans",,"Completed","No Results Available","Treatment of Acute Zika Virus Infection","Drug: Tyzivumab","Incidence of Treatment-Emergent Adverse Event (Safety and Tolerability)|Maximum Concentration (Cmax) - Pharmacokinetic Assessment|Time to Maximum Concentration (Tmax) - Pharmacokinetic Assessment|Area Under the Curve Extrapolated to Infinity (AUC0-∞) - Pharmacokinetic Assessment|AUC calculated from time of administration to the last measurable concentration (AUC0-last) - Pharmacokinetic Assessment|Half-Life (t1/2) - Pharmacokinetic Assessment|Volume of Distribution (Vd) - Pharmacokinetic Assessment|Clearance [CL] - Pharmacokinetic Assessment|Anti-Drug Antibody Assessment","Tychan Pte Ltd.|Duke-NUS Graduate Medical School|Singapore Clinical Research Institute|National University, Singapore|National University Hospital, Singapore","All","21 Years to 45 Years   (Adult)","Phase 1","24","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ZKT-001","February 8, 2018","September 12, 2018","December 4, 2018","February 23, 2018",,"April 10, 2019","SingHealth Investigational Medicine Unit, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT03443830"
133,"NCT01173523","Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer",,"Completed","Has Results","Small Cell Lung Cancer","Drug: STA-9090","8-Week Progression-Free Rate|Overall Response Rate|Progression-Free Survival|Overall Survival","David M. Jackman, MD|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Synta Pharmaceuticals Corp.|Dana-Farber Cancer Institute","All","18 Years and older   (Adult, Older Adult)","Phase 2","25","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10-048","July 28, 2010","June 7, 2013","November 4, 2016","August 2, 2010","April 11, 2017","April 16, 2019","Massacusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01173523"
134,"NCT03731962","Using Preprocedural Urine NMR(Nuclear Magnetic Resonance) -Based Metabolomics Analysis",,"Completed","No Results Available","Contrast-induced Nephropathy|Coronary Angiography","Procedure: Coronary Angiography","developing CIN|Urine Metabolomics","Shahid Beheshti University of Medical Sciences","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","SBMU23567/J","August 1, 2018","September 1, 2018","November 1, 2018","November 6, 2018",,"November 7, 2018","Nooshin Dalili, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT03731962"
135,"NCT01987362","A Two Part Study of RO6870810. Dose-Escalation Study in Participants With Advanced Solid Tumors and Expansion Study in Participants With Selected Malignancies",,"Completed","No Results Available","Solid Tumors, Advanced Solid Tumors","Drug: RO6870810","Number of Participants with DLTs|MTD of RO6870810|Percentage of Participants with Adverse Events|Area Under the Concentration Versus Time Curve from Time 0 (Pre-dose) to Time 24 Hours (AUC0-24) of RO6870810|Maximum Plasma Concentration (Cmax) of RO6870810|Time to Reach Cmax (Tmax) of RO6870810|Percentage of Participants with Objective Response (Complete Response [CR] or Partial Response [PR]) Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 as Determined by the Investigator|Median Time Taken for the First Response Based on RECIST v 1.1 as Determined by the Investigator|Median Time Taken for the Best Overall Response Based on RECIST v 1.1 as Determined by the Investigator|Progression Free Survival Based on RECIST v 1.1 as Determined by the Investigator|Duration of Response Based on RECIST v 1.1 as Determined by the Investigator|Overall Survival","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 1","52","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NP39141|TEN-010-001","October 16, 2013","October 11, 2017","October 11, 2017","November 19, 2013",,"January 5, 2018","Yale Cancer Center, New Haven, Connecticut, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Karmanos Cancer Center, Detroit, Michigan, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01987362"
136,"NCT03663686","The Safety, Tolerability and Pharmacokinetic Study of Litapiprant Tablets in Healthy Male and Female Subjects",,"Completed","No Results Available","Asthma","Drug: Litapiprant Tablet","Adverse events|AUC0-∞|AUC0-t|Cmax|tmax|t½|Vz/F","Sunshine Lake Pharma Co., Ltd.","All","18 Years to 45 Years   (Adult)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HEC46877-P-01","October 25, 2018","January 30, 2019","January 30, 2019","September 10, 2018",,"July 27, 2020","Beijing shijitan hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT03663686"
137,"NCT02436408","VISmodegib for ORbital and Periocular Basal Cell Carcinoma","VISORB","Completed","Has Results","Carcinoma, Basal Cell","Drug: Vismodegib","The Number of Patients With a Score of 21 or Greater by the Visual Assessment Weighted Score (VAWS).|Number of Patients With Progressive Disease (PD)|Number of Patients With a Complete Response (CR), Partial Response (PR) or Stable Disease (SD) AND Good Tolerance of Vismodegib|Number of Patients With a Complete Response (CR), Partial Response (PR) or Stable Disease (SD) AND Poor Tolerance of Vismodegib","University of Michigan Rogel Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 4","35","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UMCC 2014.022|HUM00082579","July 15, 2015","September 2020","September 2020","May 6, 2015","October 28, 2021","October 28, 2021","University of Michigan Hospital, Ann Arbor, Michigan, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT02436408/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02436408"
138,"NCT04682873","A Clinical Study to Assess the Efficacy and Safety of Amizon® Max in the Treatment of Moderate Covid-19, Caused by the SARS-CoV-2 Virus",,"Completed","No Results Available","Covid-19 Disease","Drug: Enisamium Iodide|Drug: Placebo","Efficacy - Time from day of randomization to an improvement of at least two points (from the status at randomization) on severity rating (SR) scale in days|Efficacy - Time to recovery (TTR) from Day 1 (randomization and start of IMP treatment)|Time to Clinical Recovery (TTCR) of main Covid-19 symptoms/complications or discharge|Sum of Severity Rating from Day 2 to Day 15 (SSR-15)|Severity Rating on Day 15 (SR-15):|Days Alive and Out of Hospital until Day 15 (DAOH-14)|Proportion of Subjects Discharged by Day 8, 15, 22, 29|Incidence of non-invasive ventilation|Days until non-invasive ventilation|Total days of non-invasive ventilation|Incidence of invasive mechanical ventilation or ECMO|Days until invasive mechanical ventilation or ECMO|Course of qualitative RT-PCR viral test results|Viral test evaluation - Proportion of subjects free of SARS-CoV-2|Overall assessment of efficacy (patient and investigator)|Adverse events (AEs)|Overall assessment of tolerability of treatment (patient and investigator)","Joint Stock Company ""Farmak""","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","592","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","FK/FAV00А-CoV/2020","May 15, 2020","March 26, 2021","March 26, 2021","December 24, 2020",,"December 29, 2021","Municipal Enterprise ""Volyn Regional Clinical Hospital"" of Volyn Regional Council, Dept. Pulmonology, Lutsk, Volynsk, Ukraine|Municipal Non-Commercial Enterprise 'City Clinical Hospital #3' Chernivtsi City Council, Dept. Therapeutics #1, Dept. Therapeutics #2, Higher State Educational Institution of Ukraine 'Bukovinian State University', Chernivtsi, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Infection Hospital Ivano-Frankivsk Regional Council', Dept. #2, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Hospital Ivano-Frankivsk Regional Council', Dept. Allergology, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise 'City Clinical Hospital #1 Ivano-Frankivsk City Council', Dept. Therapeutics, Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise Kharkiv Regional Council 'Regional Clinical Infection Hospital', 1st Department, Kharkiv National Medical University, Chair of Infectious Diseases, Kharkiv, Ukraine|Municipal Non-Commercial Enterprise 'Olexandrivska Clinical Hospital of Kyiv' Executive Authority of Kyiv City Council, Dept. Infections, Kyiv, Ukraine|Municipal Non-Commercial Enterprise ""Kyiv City Clinical Hospital #9"" Executive Authority of Kyiv City Council, Dept. Infections, Kyiv, Ukraine|Municipal Non-Commercial Enterprise Lviv Regional Council 'Lviv Regional Infection Hospital', Fourth Diagnostic Department, Lviv, Ukraine|Ukraine Medical Stomatological Academy, Chair of Infectious Diseases with Epidemiology, Municipal Non-Commercial Enterprise 'Poltava Regional Infection Hospital Poltava Regional Council', Dept. Respiratory Infections, Poltava, Ukraine|Municipal Non-Commercial Enterprise 'Central Clinical Hospital' of Rivne City Council, Hepatic Centre - Infections, Rivne, Ukraine|Municipal Non-Commercial Enterprise 'Regional Clinical Infectional Hospital' Transcarpathian Regional Council, Dept. Infections (Adult), Uzhhorod, Ukraine|Municipal Non-Сommercial Enterprise 'Vinnytsya City Clinical Hospital #1', Infectious Department, National Pirogov Memorial Medical University, Dept. Infections, Vinnytsya, Ukraine",,"https://ClinicalTrials.gov/show/NCT04682873"
139,"NCT04106310","Theranova vs High-flux HD Comparison",,"Completed","No Results Available","End Stage Renal Failure on Dialysis","Device: High-flux dialyzer|Device: Theranova dialyzer","lean tissue index|Body Mass Index|asymmetrical dimethylarginine|fibroblast growth factor 23|Klotho|Kt/V urea|beta-2 microglobulin|Pentraxin-3|soluble endothelial protein C receptor|soluble thrombomodulin|hemoglobulin|high-sensitive C reactive protein|interleukin 6|tumor necrosis factor alpha|albumin|Leptin|adiponectin|phosphate|low-density lipoprotein|high-density lipoprotein|triglyceride|Malnutrition-Inflammation Score|Subjective Global Assesment questionnaire|fat tissue index|admission rate due to cardiovascular events|admission rate due to infection|mortality rate|5-D itch scale|Numeric rating scale for itchiness|The Functional Assessment of Anorexia/Cachexia Therapy (FAACT) score|Visual analogue scale for appetite|Postdialysis recovery time|Self-reported sleep quality|Hong Kong Montreal Cognitive Assessment|KDQOLSFTMv1.3 questionnaire|DNA methylation analysis of TRPV1 gene|DNA methylation analysis of LY96 gene|DNA methylation analysis of IFNGR1 gene","The University of Hong Kong|Baxter Healthcare Corporation","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Version 1 13th Aug 2019","November 1, 2019","June 30, 2021","June 30, 2021","September 27, 2019",,"September 29, 2021","Division of Nephrology, Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong|Tung Wah Hospital, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04106310"
140,"NCT03740217","Comparison of the Relative Oral Bioavailability of GKT137831 Formulated in Capsules or in Tablets",,"Completed","No Results Available","Phase 1","Drug: GKT137831","Oral bioavailability (Fz)|Food effect on Oral bioavailability (Fz)|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Oral bioavailability of GKT138184|Food effect on oral bioavailability of GKT138184","Genkyotex SA|Eurofins Optimed|York Bioanalytical Solution","Male","18 Years to 60 Years   (Adult)","Phase 1","15","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","GSN000299","December 19, 2018","February 6, 2019","February 6, 2019","November 14, 2018",,"February 12, 2019","Eurofins Optimed, Gières, France",,"https://ClinicalTrials.gov/show/NCT03740217"
141,"NCT02417350","Ketogenic Diet - a Randomized, Controlled, Cross-over Study",,"Completed","No Results Available","Healthy","Other: Ketogenic diet for four weeks, then a 15 week washout, and finally a NFA recommended diet for four weeks|Other: NFA recommended diet for four weeks, then a 15 week washout, and finally a ketogenic diet for four weeks.","Biomarkers in blood Measured with gaschromatography (GC)-time-of-flight/mass spectrometry (MS) and Bio-Plex Assays|Blood lipids Measured with LipoPrint System|Body composition Measured with DXA (Dual Energy X-Ray Absorptiometry)|Gut microbiota measured with High-throughput sequencing of nucleic acids (DNA/RNA), short-chain fatty acids|Energy substrate utilization during submaximal exercise Measured with indirect calorimetry during ergometer cycling, lactate in blood.|Exercise performance|Hand grip endurance|Resting metabolic rate Measured with indirect calorimetry|Hormones Measured with Bio-Plex Assays and ELISA|Cognition Measured with the Stroop color-word test|Sweet cravings Measured with a likert scale questionnaire|Mood and appetite Measured with a likert scale questionnaire|Experiences of following a particular dietary regime measured with Semi-structured interviews analyzed with content analysis","Umeå University","Female","18 Years to 30 Years   (Adult)","Not Applicable","24","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","LCHF-100","April 2015","October 2015","October 2015","April 15, 2015",,"November 5, 2015","Department of Food and Nutrition, Umeå, Sweden",,"https://ClinicalTrials.gov/show/NCT02417350"
142,"NCT00806312","The Expression and Significance of MiRNA",,"Completed","No Results Available","Pulmonary Arterial Hypertension",,"evaluate if miRNa profile and markers of inflammation in patients with PAH. These profiles may enable us differentiate patients that have PAH. This may assist in predicting response to therapy and enable us to optimize their treatment. may also shed s","Megan Ballinger|Ohio State University","All","18 Years and older   (Adult, Older Adult)",,"207","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2008H0070","July 2008","August 16, 2018","August 16, 2018","December 10, 2008",,"November 2, 2021","The Ohio State University, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00806312"
143,"NCT01609595","Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand","ST20-P2T","Completed","No Results Available","Beta Thalassemia Intermedia","Drug: sodium 2,2 dimethylbutyrate","The number of participants in which an increase in total hemoglobin of at least 1.5 g/dl above average baseline occurs with study drug treatment.|The proportion of participants in which an increase in fetal hemoglobin occurs above the subjects' averaged baseline levels.","Boston University|Mahidol University","All","18 Years to 55 Years   (Adult)","Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ST20-P2T|HQK-1001-Thal P2","March 2012","November 2012","December 2012","June 1, 2012",,"March 13, 2013","Mahidol University Thalassemia Research Centre, Nakhonpathom, Thailand",,"https://ClinicalTrials.gov/show/NCT01609595"
144,"NCT01209884","Metabolomics of Aging: Sub-study of the Healthy Elderly Active Longevity (HEAL) Study","Metabolomics","Completed","No Results Available","Healthy",,"Study the metabolomics of the healthy aging","Scripps Translational Science Institute","Male","80 Years to 85 Years   (Older Adult)",,"14","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SIRB# 10-5416","February 2010","December 2012","December 2012","September 27, 2010",,"January 9, 2014","Scripps Translational Science Institute, La Jolla, California, United States",,"https://ClinicalTrials.gov/show/NCT01209884"
145,"NCT00675818","The Optimal Mode of Renal Replacement Therapy in Acute Kidney Injury (OMAKI) Study","OMAKI","Completed","No Results Available","Acute Kidney Injury","Device: Continuous venvenous hemofiltration (CVVH)|Device: Continuous venovenous hemodialysis (CVVHD)","We will study the feasibility of recruiting ther target population, administering the study therapies according to pre-defined protocols and following patients for clinical endpoints.|Change in Sequential Organ Failure Assessment (SOFA) score.","Unity Health Toronto|University of Toronto","All","16 Years and older   (Child, Adult, Older Adult)","Phase 4","78","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","07097","May 2008","October 2010","October 2010","May 12, 2008",,"March 12, 2012","University of Alberta, Edmonton, Alberta, Canada|London Health Sciences Centre, London, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Mt. Sinai Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00675818"
146,"NCT03776786","Safety and Tolerability of an Antibody Against Yellow Fever Virus (TY014) in Humans",,"Completed","No Results Available","Treatment of Acute Yellow Fever Virus Infection","Biological: TY014|Other: 0.9% Saline","Incidence of Treatment-Emergent Adverse Event (Safety and Tolerability)|Percentage Aviremia Post Treatment (Efficacy Arm only)|Maximum Concentration (Cmax) - Pharmacokinetic Assessment|Time to Maximum Concentration (Tmax) - Pharmacokinetic Assessment|Area Under the Curve Extrapolated to Infinity (AUC0-∞) - Pharmacokinetic Assessment|AUC calculated from time of administration to the last measurable concentration (AUC0-last) - Pharmacokinetic Assessment|Half-Life (t1/2) - Pharmacokinetic Assessment|Volume of Distribution (Vd) - Pharmacokinetic Assessment|Clearance [CL] - Pharmacokinetic Assessment|Viral Load Reduction (Efficacy Arm only)","Tysana Pte Ltd","All","21 Years to 50 Years   (Adult)","Phase 1","37","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","YFT-001|CTA1800118","December 6, 2018","July 1, 2019","October 10, 2019","December 17, 2018",,"October 25, 2019","SingHealth Investigational Medicine Unit, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT03776786"
147,"NCT04829305","A Trial of SHR2285 in Healthy Subjects",,"Completed","No Results Available","Healthy Volunteers","Drug: SHR2285","Adverse events|Pharmacokinetics-AUC0-last|Pharmacokinetics-AUC0-inf|Pharmacokinetics-Tmax|Pharmacokinetics-Cmax|Pharmacokinetics-CL/F|Pharmacokinetics-Vz/F|Pharmacokinetics-t1/2|Coagulation factor XI (FXI) activity|Percentage change of coagulation factor XI (FXI) activity thromboplastin time (APTT) and fold change from baseline|Activated partial thromboplastin time|Fold change of activated partial thromboplastin time from baseline|Prothrombin time|Fold change of prothrombin time from baseline|International normalized ratio|Fold change of international normalized ratio from baseline","Atridia Pty Ltd.","All","18 Years to 55 Years   (Adult)","Phase 1","31","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SHR2285-105","May 20, 2021","September 6, 2021","September 6, 2021","April 2, 2021",,"March 8, 2022","Linear Clinical research, Perth, Western Australia, Australia",,"https://ClinicalTrials.gov/show/NCT04829305"
148,"NCT00205257","Prediction of Acute Rejection in Renal Transplant",,"Completed","No Results Available","Kidney Transplant",,"kidney biopsy pathology|urinary chemokines","University of Wisconsin, Madison","All","18 Years and older   (Adult, Older Adult)",,,"Other","Observational",,"2001-252","September 2001","February 2007","February 2007","September 20, 2005",,"October 5, 2015",,,"https://ClinicalTrials.gov/show/NCT00205257"
149,"NCT01538238","pazopanib_NCRCC,Ph2 STUDY",,"Completed","No Results Available","Locally Advanced or Metastatic Non-clear Cell Type Renal Cell Carcinoma","Drug: pazopanib","Overall response rates|Progression-free survival|Overall survival|Number of Adverse Events|Exploratory analysis","Samsung Medical Center","All","19 Years and older   (Adult, Older Adult)","Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2012-01-056","May 2, 2012","February 28, 2015","November 14, 2015","February 24, 2012",,"April 26, 2017","Samsung medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01538238"
150,"NCT00978926","A Study of the Pharmacodynamic Effects of Anti-Vascular Endothelial Growth Factor Therapy in Patients With Advanced Malignancies",,"Completed","No Results Available","Advanced Malignancy",,,"National University Hospital, Singapore","All","21 Years and older   (Adult, Older Adult)",,,"Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","MC02/15/07","September 2009",,,"September 17, 2009",,"April 9, 2010","National University Hospital, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT00978926"
151,"NCT03010982","Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors",,"Completed","No Results Available","Diffuse Large B Cell Lymphoma|Primary Mediastinal Lymphoma|Mantle-Cell Lymphoma|Follicular Lymphoma|Marginal Zone Lymphoma|Advanced Solid Tumors","Drug: Tazemetostat and [14C] Tazemetostat","Plasma PK of [14C] tazemetostat, tazemetostat, and its metabolite EPZ-6930 after IV administration of approximately 12 µg of [14C] tazemetostat containing approximately 500 nCi of radioactivity and oral BID administration of 800 mg tazemetostat (AUC 0-7)|Total recovery and relative excretion of radioactivity in urine and feces after an oral 800 mg dose of [14C] tazemetostat containing approximately 400 µCi (14.8 MBq) of radioactivity|Estimate tazemetostat absolute bioavailability (F) after repeated oral administration of 800 mg BID (AUC 0-12 and AUC 0-~)|Compare the total radioactivity concentration-time profiles in blood and plasma after oral administration of [14C] tazemetostat (AUC 0-t, AUC 0-12, AUC 0-~)|Determine peak plasma concentration (Cmax) after oral administration of [14C] tazemetostat|Determine the plasma terminal half-life (t1/2) after oral administration of [14C] tazemetostat|Plasma PK of tazemetostat and EPZ6930 after administration of an oral 800 mg dose of [14C] tazemetostat containing approximately 400 µCi (14.8 MBq) of radioactivity (Plasma AUC 0-t, AUC 0-12)|Determine the peak plasma concentration (Cmax) of tazemetostat and EPZ6930 after administration of an oral 800 mg dose of [14C] tazemetostat containing approximately 400 µCi (14.8 MBq) of radioactivity|Determine the time to peak plasma concentration (Tmax) tazemetostat and EPZ6930 after administration of an oral 800 mg dose of [14C] tazemetostat containing approximately 400 µCi (14.8 MBq) of radioactivity","Epizyme, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","3","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EZH-103","June 20, 2018","January 8, 2019","January 8, 2019","January 5, 2017",,"January 13, 2020","The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, Wirral, United Kingdom|Royal Liverpool and Broadgreen University Hospital Trust, Liverpool, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03010982"
152,"NCT02363309","Palmitate Breath Test to Assess Fatty Acid Oxidation in Non Alcoholic Fatty Liver Disease (NAFLD)",,"Completed","No Results Available","Fatty Liver",,"Measure rates of fatty acid oxidation in patients with non alcoholic fatty liver disease","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","All","21 Years and older   (Adult, Older Adult)",,"74","NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","150080|15-DK-0080","March 27, 2015","June 28, 2018","November 29, 2018","February 16, 2015",,"August 13, 2021","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02363309"
153,"NCT02544633","Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET",,"Completed","Has Results","Non-Small Cell Lung Cancer","Drug: MGCD265","Objective Response Rate|Duration of Response|Progression Free Survival|1-Year Survival Rate|Overall Survival|Number of Patients Experiencing Treatment-emergent Adverse Events|Blood Plasma Concentration of MGCD265 - AUC0-6|Blood Plasma Concentration of MGCD265 - Cmax|Blood Plasma Concentration of MGCD265 - Ctrough|Blood Plasma Concentration of MGCD265 - Accumulation Ratio AUC0-6|Blood Plasma Concentration of MGCD265 - Accumulation Ratio Cmax|Blood Plasma Concentration of MGCD265 - Peak to Trough Ratio|Blood Plasma Concentration of MGCD265 - Tmax|Assess Correlation Between Selected Tumor Gene Alterations Using Different Analytical Techniques in Tumor Tissue and Circulating Tumor Deoxyribonucleic Acid (ctDNA) - MET Activating Mutations|Assess Correlation Between Selected Tumor Gene Alterations Using Different Analytical Techniques in Tumor Tissue and Circulating Tumor Deoxyribonucleic Acid (ctDNA) - MET Gene Amplifications|Assess Change in Genetic Alteration Status in ctDNA With MGCD265 Treatment Over Time in the Selected Population|Blood Plasma Concentration of Soluble MET (sMET) Biomarker","Mirati Therapeutics Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","68","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","265-109","October 2015","April 30, 2018","January 2019","September 9, 2015","September 10, 2019","March 4, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|Clearview Cancer Institute, Huntsville, Alabama, United States|Fowler Family Center for Cancer Care, Jonesboro, Arkansas, United States|Providence Saint Joseph Medical Center, Burbank, California, United States|Saint Joseph Heritage Healthcare, Fullerton, California, United States|University of California San Diego, La Jolla, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|University of California, San Francisco, San Francisco, California, United States|Innovative Clinical Reseach Institute, Whittier, California, United States|St. Mary's Regional Cancer Center, Grand Junction, Colorado, United States|Eastern Connecticut Hematology and Oncology Associates, Norwich, Connecticut, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Boca Raton Regional Hospital - Eugene M. & Christine E. Lynn Cancer Institute, Boca Raton, Florida, United States|Sylvester Comprehensive Cancer Center, Deerfield Beach, Florida, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|Memorial Hospital West, Pembroke Pines, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|NorthShore University HealthSystem, Evanston, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Goshen Center for Cancer Care, Goshen, Indiana, United States|Mercy Cancer Center, Mason City, Iowa, United States|Oncology-Hematology Associates, PA, Danville, Kentucky, United States|Lexington Oncology Associates, LLC, Lexington, Kentucky, United States|Kentuckyone Health Cancer and Blood Speacialists, Louisville, Kentucky, United States|Christus Saint Frances Cabrini Hospital, Alexandria, Louisiana, United States|Tufts Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|The University of New Mexico Cancer Research and Treatment Center, Albuquerque, New Mexico, United States|Montefiore Medical Center, Bronx, New York, United States|Queens Cancer Center, Jamaica, New York, United States|Clinical Research Alliance, New York, New York, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Guthrie Cancer Center, Sayre, Pennsylvania, United States|Greenville Health System, Greenville, South Carolina, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Mary Crowley Cancer Research Centers, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Concord Repatriation General Hospital, Concord, New South Wales, Australia|Saint George Hospital, Kogarah, New South Wales, Australia|Royal North Shore Hospital, Saint Leonards, New South Wales, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Monash Cancer Centre, Clayton, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Flinders Medical Centre, Bedford Park, Australia|Monash Health, Clayton, Australia|The Tweed Hospital, Tweed Heads, Australia|Princess Alexandra Hospital, Woolloongabba, Australia|McGill University Health Centre, Montréal, Canada|Szent Borbála Kórház, Tatabánya, Komarom-esztergom, Hungary|Országos Korányi TBC és Pulmonológiai Intézet, Budapest, Hungary|Országos Onkológiai Intézet, Budapest, Hungary|Semmelweis Egyetem, Budapest, Hungary|Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy|Ospedale Unico Versilia, Lucca, Italy|IRCCS Ospedale San Raffaele, Milano, Italy|Istituto Europeo di Oncologia Milano, Milano, Italy|Ospedale San Raffaele, Milano, Italy|Azienda Unità Sanitaria Locale di Piacenza-Ospedale Guglielmo da Saliceto, Piacenza, Italy|Azienda Unita Sanitaria Locale di Ravenna, Ravenna, Italy|Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy|Chungbuk National University Hospital, Cheongju, Chungcheongbuk-do, Korea, Republic of|National Cancer Center, Goyang, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Saint Vincent Hospital, Suwon-si, Gyeonggi-do, Korea, Republic of|The Catholic University of Korea Saint Vincent's Hospital, Suwon-si, Gyeonggi-do, Korea, Republic of|Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Veterans Health Service Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Uniwersyteckie Centrum Kliniczne, Gdańsk, Pomorskie, Poland|Samodzielny Publiczny Zespól Gruzlicy i Chorób Pluc w Olsztynie, Olsztyn, Warminsko-mazurskie, Poland|Med Polonia Sp. z o.o., Poznan, Wielkopolskie, Poland|National Cheng Kung University, Tainan, Tainan CITY, Taiwan|Chi Mei Hospital Liouying, Tainan City, Tainan, Taiwan|Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien City, Taiwan|Kaohsiung Medical University Hospital, Kaohsiung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|North Bristol NHS Trust, Westbury on Trym, Bristol, England, United Kingdom|University College London Hospitals NHS Foundation Trust, London, England, United Kingdom|East and North Hertordshire NHS Trust, Northwood, England, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT02544633/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02544633"
154,"NCT03964558","Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-Acebilustat (CTX-4430)",,"Completed","No Results Available","Heathy Volunteers","Drug: [14C]-acebilustat solution","Mass balance recovery of total radioactivity in all excreta: amount excreted (Ae) and Ae as a percentage of the administered dose (%Ae), cumulative recovery (CumAe), and cumulative recovery expressed as a percentage of the administered dose (Cum%Ae)","Celtaxsys, Inc.|Quotient Sciences","Male","30 Years to 65 Years   (Adult, Older Adult)","Phase 1","6","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","CTX-4430-ADME-101","April 1, 2019","April 14, 2019","April 14, 2019","May 28, 2019",,"May 30, 2019","Quotient Sciences, Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03964558"
155,"NCT00543049","Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor",,"Completed","No Results Available","Platinum Refractory Epithelial Ovarian Cancer|Primary Cancer of the Peritoneum|Cancer of the Fallopian Tube","Drug: Sunitinib|Drug: SUNITINIB","objective response rate|tolerability and toxicity, overall survival, duration of response, time to progression, stable disease","AGO Study Group|Philipps University Marburg Medical Center|HSK Reasearch GmbH Wiesbaden","Female","18 Years and older   (Adult, Older Adult)","Phase 2","73","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AGO-OVAR 2.11","September 2007","June 2012",,"October 12, 2007",,"March 7, 2014","Malterser-Krankenhaus Bonn-Rhein/Sieg, Frauenklinik, Bonn, Germany|Klinikum Bremen-Mitte gGmbH, Frauenklinik, Bremen, Germany|Universitätsklinikum Carl Gustav Carus, Klinik u. Poliklinik für Frauenheilkunde und Geburtshilfe, Dresden, Germany|Universitätsklinikum, Universitätsfrauenklinik, Essen, Germany|Klinikum der JWG Universität Frankfurt, Universitätsfrauenklinik, Frankfurt am Main, Germany|Universitätsklinikum Freiburg, Department Universitäts-Frauenklinik, Freiburg, Germany|Klinikum der Ernst-Moritz-Universität, Klinik u. Poliklinik für Gyn. - u. Geb.Hilfe, Greifswald, Germany|Med. Hochschule Hannover, Frauenklinik, Hannover, Germany|St. Vincentius Kliniken AG, Frauenklinik, Karlsruhe, Germany|Universitätsklinikum Schleswig-Holstein Campus Kiel, Klinik f. Gynäkologie u. Geburtshilfe, Kiel, Germany|Otto-von-Guericke-Universität, Klinik für Frauenheilkunde und Geburtshilfe, Magdeburg, Germany|Universitätsklinikum Gießen u. Marburg, Standort Marburg, Klinik f. Gynäkologie, Gyn. Endokrinologie u. Onkologie, Marburg, Germany|Elblandkliniken Meißen-Radebeul GmbH, Gynäkologie, Radebeul, Germany|Universitätsklinikum Tübingen, Frauenklinik, Tübingen, Germany|Universitätsklinikum, Universitätsfrauenklinik, Ulm, Germany|Dr. Horst Schmidt Kliniken GmbH, Klinik f. Gynäkologie u. Gyn. Onkologie, Wiesbaden, Germany",,"https://ClinicalTrials.gov/show/NCT00543049"
156,"NCT01683994","Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer",,"Completed","Has Results","Prostatic Neoplasms","Drug: Cabozantinib|Drug: Docetaxel|Drug: Prednisone","Progression Free Survival (PFS) of Cabozantinib + Docetaxel + Prednisone Compared to Docetaxel + Prednisone Alone|Maximum Tolerated Dose (MTD)|Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Male","18 Years to 99 Years   (Adult, Older Adult)","Phase 1|Phase 2","49","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","120204|12-C-0204","September 7, 2012","July 1, 2018","January 16, 2019","September 12, 2012","November 8, 2019","November 8, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT01683994/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT01683994/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT01683994"
157,"NCT03123016","Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo",,"Completed","No Results Available","Vitiligo","Drug: Apremilast|Procedure: NB-UVB phototherapy","Change in proportion of responders to treatment from Week 16 to Week 32|Body Surface Area (BSA)|VASI score - Vitiligo Area and Severity Index (VASI)|VETF score - Vitiligo European Task Force (VETF) score|Dermatology Life Quality Index|Visual Analogue Scale (VAS)|Number of Adverse Events","Icahn School of Medicine at Mount Sinai|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","23","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO 16-1261","April 14, 2017","August 5, 2019","August 5, 2019","April 21, 2017",,"August 28, 2019","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03123016"
158,"NCT02109328","Alisertib in Chemotherapy-pretreated Urothelial Cancer",,"Completed","No Results Available","Bladder Cancer|Transitional Cell Carcinoma","Drug: Alisertib|Drug: Paclitaxel|Drug: Placebo","Response rate|Progression-free survival|To evaluate the safety and tolerability of Alisertib in a population of chemotherapy pretreated patients with UC.","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","All","18 Years and older   (Adult, Older Adult)","Phase 2","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","UC-Aurora_INT01|2014-000557-36","August 28, 2014","July 2, 2015","October 12, 2016","April 9, 2014",,"April 11, 2019","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Mi, Italy",,"https://ClinicalTrials.gov/show/NCT02109328"
159,"NCT01283945","Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors",,"Completed","No Results Available","Solid Tumors","Drug: Lucitanib","Maximum Tolerated Dose (MTD)|Objective response rate (CR and PR according to RECIST) and rate of non-progressive disease at 24 weeks|Pharmacokinetics following single and multiple dose administration|Tumor perfusion measured by DCE MRI and DCE-US|Circulating markers of angiogenesis: VEGFR2, VEGFR1, VEGF, Collagen IV, bFGF, CEC and CEP|Tumor response according to RECIST; CTC|Safety profile and dose limiting toxicities (DLT)|Free tumor circulating DNA","Institut de Recherches Internationales Servier|Servier","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","134","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","E-3810-I-01","July 2010","September 2016","May 4, 2017","January 26, 2011",,"January 3, 2020","Institute Gustave Roussy, Villejuif, Paris, France|Hopital Louis Pradel, Lyon, France|European Institute of Oncology, Milano, Italy|Vall d' Hebron University Hospital, Barcellona, Spain",,"https://ClinicalTrials.gov/show/NCT01283945"
160,"NCT00901563","Gap Junction Potentiation of Endothelial Function With Rotigaptide",,"Completed","No Results Available","Vascular Disease|Heart Disease","Drug: Rotigaptide|Other: Forearm vascular study","Change in Substance P and ACh vasodilatation caused by potentiation of gap junction communication with Rotigaptide in the context of endothelial dysfunction|Change in Substance P induced t PA release caused by potentiation of gap junction communication with Rotigaptide in the context of endothelial dysfunction","University of Edinburgh|Chief Scientist Office of the Scottish Government|NHS Lothian","All","18 Years to 64 Years   (Adult)","Not Applicable","10","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","CZB/4/520/b","March 2009","August 3, 2015","August 3, 2015","May 14, 2009",,"June 21, 2021","Clincial Research Facility, Royal Infirmary of Edinburgh, 51 Little France Cresc, Edinburgh, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00901563"
161,"NCT01824615","Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma",,"Completed","No Results Available","Ovarian Cancer|Adverse Effects","Drug: Sunitinib","Response rate","Cathay General Hospital","Female","20 Years to 80 Years   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CT99076|TGOG-101","January 2013","January 2016","January 2016","April 5, 2013",,"July 18, 2018","Cathay General Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01824615"
162,"NCT02082821","A P2X7R Single Nucleotide Mutation Promotes Chronic Allograft Vasculopathy",,"Completed","No Results Available","Cardiac Allograft Vasculopathy",,"Cardiac Allograft Vasculopathy|Heart Rejection or Patient Death","Boston Children's Hospital","All","18 Years to 65 Years   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","Pure-Heart-1|14GRNT1873002","January 2014","August 2019","December 2020","March 10, 2014",,"March 3, 2021","Boston Children's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02082821"
163,"NCT01532024","Exploratory Clinical Study of Neutrophil Activation Probe (NAP) for Optical Molecular Imaging in Human Lungs","NAP","Completed","No Results Available","Acute Lung Injury","Other: Microdose of NAP","This is an exploratory clinical study. The primary outcome measure is measurement of fluorescence and imaging parameters determined using pCLE and Cellvizio viewer software.|Safety in part A and part B and initial proof of concept in ICU to detect neutrophil activation.","University of Edinburgh|Medical Research Council","Male","18 Years to 60 Years   (Adult)","Early Phase 1","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","NAP|2011-006169-17","October 2014","September 2, 2016","September 2, 2016","February 13, 2012",,"November 5, 2019","Ward 118, Intensive Care, Royal Infirmary of Edinburgh, Edinburgh, Scotland, United Kingdom|Wellcome Trust Clinical Research Facility, Edinburgh, United Kingdom|Royal Infirmary of Edinbrugh, Edinburgh, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT01532024/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT01532024"
164,"NCT00455039","INST 0514C- Biologic Correlative Study: Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients",,"Completed","No Results Available","Breast Cancer","Drug: GW572016","The primary end point of this study is clinical efficacy of GW572016 in treatment naïve patients with locally advanced breast cancer.|The secondary end points would be the biologic correlative of relevant biomarkers.","University of New Mexico","Female","Child, Adult, Older Adult","Phase 1|Phase 2","55","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INST 0514C","July 2005","October 2009","October 2009","April 3, 2007",,"May 12, 2016","UNM CRTC, Albuquerque, New Mexico, United States",,"https://ClinicalTrials.gov/show/NCT00455039"
165,"NCT02834741","Safety, Tolerability, PK of Oral NYX-2925 in Healthy Volunteers",,"Completed","No Results Available","Healthy Volunteers","Drug: NYX-2925","Number of subjects with adverse events|Cmax of NYX-2925|Tmax of NYX-2925|AUC of NYX-2925|Half-life of NYX-2925|Clearance of NYX-2925|Volume of distribution of NYX-2925|Renal elimination of NYX-2925|Food effect of NYX-2925 following consumption of a high-fat, high-caloric meal|CSF penetration of NYX-2925 in CSF cohort","Aptinyx|Spaulding Clinical Research LLC","All","18 Years to 55 Years   (Adult)","Phase 1","84","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NYX-2925-1001","July 2016","March 2017","March 2017","July 15, 2016",,"April 5, 2017","Spaulding Clinical, West Bend, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02834741"
166,"NCT01210911","Metformin Combined With Chemotherapy for Pancreatic Cancer","GEM","Completed","No Results Available","Locally Advanced Pancreatic Cancer|Metastatic Pancreatic Cancer","Drug: gemcitabine|Drug: erlotinib|Drug: metformin|Drug: placebo","Survival after 6 months|Progression free survival|Objective response rate|toxicity profile","Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AMCmedonc10/003","August 2010","February 2014","April 2014","September 29, 2010",,"April 21, 2021","Academic Medical Center, Amsterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT01210911"
167,"NCT02681055","Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects",,"Completed","No Results Available","Non-alcoholic Steatohepatitis|Hypertriglyceridemia|Non-alcoholic Fatty Liver Disease|Hypercholesterolemia","Drug: MN-001","To measure the change from baseline at 12 weeks of MN-001 on Cholesterol Efflux Capacity in NASH subjects with hypertriglyceridemia|To measure the change from baseline at 12 weeks of MN-001 on serum triglyceride levels in NASH subjects with hypertriglyceridemia|To measure the safety and tolerability of MN-001 by assessing the number of treatment-related adverse events.|To measure blood the concentration of MN-001/MN-002 (metabolite) change from pre-dose after 24 hours|To measure the effect of MN-001 on serum lipid panel|To measure the effect of MN-001/002 on liver enzymes|To measure the effect of MN-001/002 on percentage of fat in the liver by MRI from baseline to Week 12","MediciNova","All","18 Years and older   (Adult, Older Adult)","Phase 2","19","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MN-001-NATG-201","March 2016","May 30, 2018","October 1, 2019","February 12, 2016",,"October 22, 2020","Southern California Research Center, Coronado, California, United States|Scripps Research, La Jolla, California, United States|Harborview Medical Center, Seattle, Washington, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT02681055/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT02681055"
168,"NCT04690751","Bioavailability and Food Effect Study of Cenobamate as an Oral Suspension and Tablet",,"Completed","No Results Available","Healthy","Drug: Cenobamate","Cmax|tmax|Area Under the Concentration Curve to last measurable concentration|Area Under the Concentration Curve from 0 to infinity|Incidence of Treatment-Emergent Adverse Events|Risk of Suicidality","SK Life Science, Inc.","All","18 Years to 50 Years   (Adult)","Phase 1","28","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","YKP3089C037","December 21, 2020","May 17, 2021","May 17, 2021","December 31, 2020",,"October 7, 2021","PRA Health Sciences Salt Lake City, Millcreek, Utah, United States",,"https://ClinicalTrials.gov/show/NCT04690751"
169,"NCT02860286","Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma",,"Completed","Has Results","Mesothelioma|BAP1 Loss of Function","Drug: Tazemetostat","Part 1: Pharmacokinetics Profile of Tazemetostat and Its Metabolite (Plasma): Cmax|Part 1: Pharmacokinetics Profile of Tazemetostat and Its Metabolite (Plasma): Tmax|Part 1: Pharmacokinetics Profile of Tazemetostat and Its Metabolite (Plasma): AUC(0-t)|Part 1: Pharmacokinetics Profile of Tazemetostat and Its Metabolite (Plasma): AUC(0-∞)|Part 1: Pharmacokinetics Profile of Tazemetostat and Its Metabolite (Plasma): t1/2|Part 2: To Assess Disease Control Rate (DCR) Defined as Number of Subjects With Complete Response (CR), Partial Response (PR) and Stable Disease (SD)|Incidence of Treatment-emergent Adverse Events as a Measure of Safety and Tolerability|Part 1 and 2: Objective Response Rate (ORR; Complete Response + Partial Response [CR + PR])|Progression-free Survival (PFS)|Part 1 and 2: Overall Survival (OS)|Part 1 and 2: To Evaluate the Duration of Response (DOR) in Subjects With Confirmed CR or PR|Part 1: To Assess Disease Control Rate (DCR) Defined as Number of Subjects With Complete Response (CR), Partial Response (PR) and Stable Disease (SD)","Epizyme, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","74","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EZH-203","July 2016","June 2018","May 2019","August 9, 2016","April 9, 2021","April 9, 2021","University of California, Los Angeles, Los Angeles, California, United States|City of Hope National Medical Center, Los Angeles, California, United States|University of California San Francisco, San Francisco, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Institut Bergonie, Bordeaux Cedex, France|CHRU de Lille, Lille, France|Institut Gustave Roussy, Villejuif cedex, France|University of Leicester & Leicester University Hospitals, Leicester, United Kingdom|St. Bartholomew's Hospital, London, United Kingdom|University College Hospital, London, United Kingdom|Royal Marsden Hospital - Chelsea, London, United Kingdom|University Hospital of South Manchester, Manchester, United Kingdom|Royal Marsden Hospital - Surrey, Sutton, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT02860286/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02860286"
170,"NCT03251443","A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma",,"Completed","No Results Available","Intrahepatic Cholangiocarcinoma|Second-line Treatment","Drug: Apatinib","Progression-free Survival (PFS)|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Overall Survival (OS)|Incidence of Treatment-Emergent Adverse Event","Peking Union Medical College Hospital|Jiangsu HengRui Medicine Co., Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 2","34","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JS-1392","August 8, 2017","March 8, 2019","May 8, 2019","August 16, 2017",,"December 2, 2020","Peking Union Medical College Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT03251443"
171,"NCT02601937","A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma",,"Completed","No Results Available","Rhabdoid Tumors|INI1-negative Tumors|Synovial Sarcoma|Malignant Rhabdoid Tumor of Ovary","Drug: Tazemetostat","To determine the MTD or the RP2D (Dose Escalation)|Dose expansion: Number of subjects with objective response using disease appropriate standardized response criteria|Dose escalation: Number of subjects with objective response using disease appropriate standardized response criteria|Dose Expansion: Progression-free survival (PFS)|Dose Expansion: Overall Survival (OS)|Incidence of treatment-emergent adverse events as a measure of safety and tolerability|Pharmacokinetics profile of tazemetostat and its metabolite (plasma): Cmax|Pharmacokinetics profile of tazemetostat and its metabolite (plasma): Tmax|Pharmacokinetics profile of tazemetostat and its metabolite (plasma): AUC(0-t)|Pharmacokinetics profile of tazemetostat and its metabolite (plasma): AUC(0-12)|Pharmacokinetics profile of tazemetostat and its metabolite (plasma): t1/2|Pharmacokinetics profile of tazemetostat and its metabolite (plasma): CL/F|Pharmacokinetics profile of tazemetostat and its metabolite (plasma): Vd/F|Pharmacokinetics profile of tazemetostat and its metabolite (plasma): Ka|Pharmacokinetics profile of tazemetostat and its metabolite (plasma): Ctrough","Epizyme, Inc.","All","6 Months to 17 Years   (Child)","Phase 1","109","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EZH-102","January 7, 2016","October 22, 2021","October 22, 2021","November 11, 2015",,"December 27, 2021","Children's Hospital of Los Angeles, Los Angeles, California, United States|University of California San Francisco - Benioff Children's Hospital, San Francisco, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|John Hopkins Kimmel Cancer Center, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital - Cancer Center, Boston, Massachusetts, United States|Memorial Sloan Kettering, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Oregon Health & Science University (OHSU), Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|St. Jude Children's Research Hospital, Inc., Memphis, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Texas Children's Cancer and Hematology Center, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Sydney Children's Hospital, Sydney, New South Wales, Australia|Lady Cilento/Queensland Children's Hospital, South Brisbane, Queensland, Australia|The Royal Children's Hospital, Melbourne, Victoria, Australia|The Childrens Hospital at Westmead Oncology Unit, Westmead, Australia|The Hospital for Sick Children, Toronto, Ontario, Canada|Rigshospitalet Department of Oncology Blegdamsvej, Copenhagen, Denmark|Institut Curie, Paris, France|Institut Gustave Roussy, Villejuif, France|Children's Hospital Augsburg Klinikum, Augsburg, Germany|Charite - Universitatsmedizin Berlin, Berlin, Germany|Universitaetsklinikum Heidelberg, Heidelberg, Germany|Westfalische Wilhelms - Universitat Munster Padiatrische, Munster, Germany|Istituto Giannina Gaslini- UOSD Centro di Neuro-Oncologia, Genova, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy|Erasmus University Medical Center - Sophia Children's Hospital, Rotterdam, Netherlands|Prinses Maxima Centrum voor Kinderoncologie, Utrecht, Netherlands|Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom|Central Manchester University Hospital - Royal Manchester Children's Hospital, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02601937"
172,"NCT03533387","Study of MN-166 (Ibudilast) Extended Release Tablet Formulations Compared With Capsules in Healthy Volunteers",,"Completed","No Results Available","Healthy Volunteers","Drug: MN-166","Compare the PK Profile of two new formulations in Single-day dose of MN-166|Compare the incidence of treatment-emergent adverse events of two new formulations in Single-day dose of MN-166|Compare the PK Profile of two new formulations in Multi-day dose of MN-166|Compare the incidence of treatment-emergent adverse events of two new formulations in Multi-day dose of MN-166","MediciNova","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","MN-166-HDT-001","April 11, 2018","July 6, 2018","September 30, 2018","May 23, 2018",,"May 31, 2019","WCCT Global, Inc., Cypress, California, United States",,"https://ClinicalTrials.gov/show/NCT03533387"
173,"NCT02127710","A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)",,"Completed","Has Results","Papillary Renal Cell Cancer","Drug: AZD6094","Objective Response Rate (RECIST Version 1.1)|Objective Response Rate (RECIST Version 1.1) Stratified by c-MET Status in Efficacy Analysis Set|Objective Response Rate (RECIST Version 1.1) Stratified by c-MET Status in Safety Analysis Set|Progression Free Survival Stratified by c-MET Status in the Efficacy Analysis Set|Overall Survival Stratified by c-MET Status in the Efficacy Analysis Set|Progression Free Survival Stratified by c-MET Status in the Safety Analysis Set|Overall Survival Stratified by c-MET Status in the Safety Analysis Set|Change From Baseline in Target Lesion Tumour Size at 12 Weeks in Efficacy Analysis Set|Change From Baseline in Target Lesion Tumour Size at 12 Weeks in Safety Analysis Set.|Duration of Response|Peak Plasma Concentration of AZD6094 Following Single Dose|Time to Peak Plasma Concentration of AZD6094 After Single Dose|Apparent Volume of Distribution of AZD6094 Following Single Dose|Area Under Plasma Concentration Time Curve for AZD6094 After Single Dose|Area Under Plasma Concentration Time Curve for AZD6094 After Single Dose (Time Zero to Last Measurement)|Apparent Total Clearance of AZD6094 From Plasma After Single Dose|Mean Residence Time of AZD6094 After Single Dose|Elimination Half-Life of AZD6094 After Single Dose","AstraZeneca|SCRI Development Innovations, LLC","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","111","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D5082C00002|GU 111","April 30, 2014","April 14, 2016","April 20, 2020","May 1, 2014","October 12, 2017","April 19, 2021","Research Site, Birmingham, Alabama, United States|Research Site, Duarte, California, United States|Research Site, Palo Alto, California, United States|Research Site, Fort Myers, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Iowa City, Iowa, United States|Research Site, Boston, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, New York, New York, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Barcelona, Spain|Research Site, Cambridge, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02127710"
174,"NCT02711007","Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy",,"Completed","No Results Available","Osteosarcoma|Metastasis","Drug: apatinib","Progression-free survival, PFS|Objective response rate, ORR|Overall survival, OS|Clinical benefit rate, CBR|Duration of response, DOR","GUO WEI|Peking University People's Hospital","All","16 Years and older   (Child, Adult, Older Adult)","Phase 2|Phase 3","37","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PKUPH-sarcoma","March 2016","December 30, 2017","January 8, 2018","March 17, 2016",,"April 23, 2018","Peking University People's Hospital, Beijing, Beijing, China","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT02711007/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT02711007/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02711007"
175,"NCT02107963","A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors",,"Completed","No Results Available","Sarcoma|Osteosarcoma|Neuroblastoma|Melanoma","Biological: Anti-GD2-CAR engineered T cells|Drug: AP1903|Drug: Cyclophosphamide","Feasibility|Determine antitumr effects|Persistence of anti-GD2 CAR T cells and correlate with anti-tumor effects|Evaluate prevalence of GD2 expression|Evaluate effectiveness of AP1903 to mediate clearance of anti-GD2 CAR T cells|Safety","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","1 Year to 35 Years   (Child, Adult)","Phase 1","15","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","140059|14-C-0059","February 28, 2014","August 15, 2016","January 31, 2017","April 9, 2014",,"March 16, 2022","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02107963"
176,"NCT01300026","AMG 319 Lymphoid Malignancy FIH",,"Completed","No Results Available","Cancer|Chronic Lymphocytic Leukemia|Diffuse Large Cell Lymphoma|Hematologic Malignancies|Hematology|Leukemia|Low Grade Lymphoma|Lymphoma|Mantle Cell Lymphoma|Non-Hodgkin's Lymphoma|Oncology|Oncology Patients|T Cell Lymphoma|Tumors","Drug: AMG 319","Clinically significant or > or = to Grade 3 CTCAE changes in safety laboratory tests, physical exams, ECGs or vital signs|PK parameters|Clinical/radiological response rate for CLL subjects|Treatment-emergent adverse events|Phospho-AKT level in circulating CLL cells|Number of patients with clinical/radiological response","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","28","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20101262|AMG 319 FIH Lymphoid","April 2011","October 2013","December 2016","February 21, 2011",,"February 9, 2017","Research Site, Hackensack, New Jersey, United States|Research Site, Durham, North Carolina, United States|Research Site, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01300026"
177,"NCT00922883","A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia Patients",,"Completed","Has Results","Anemia, Aplastic|Anemia, Hypoplastic|Thrombocytopenia","Drug: Eltrombopag","The Portion of Drug Responders as Defined by Hematologic Improvements","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","12 Years and older   (Child, Adult, Older Adult)","Phase 2","43","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","090154|09-H-0154","May 29, 2009","May 7, 2013","April 24, 2018","June 17, 2009","July 16, 2018","October 20, 2020","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00922883"
178,"NCT00540176","The Safety and Efficacy of DCA for the Treatment of Brain Cancer",,"Completed","No Results Available","Malignant Gliomas, Glioblastoma Multiforme","Drug: Dichloroacetate (DCA)","To determine the therapeutic response to oral Dichloroacetate (DCA) in patients with malignant gliomas, utilizing standard criteria for the objective response of tumor size to treatment (CT and/or MRI).|To evaluate the safety and tolerability of oral (DCA) in patients with gliomas.|To determine the progression-free survival (PFS) and overall survival achieved with oral DCA in patients with gliomas.|• To evaluate the in vitro effects of DCA on cell proliferation/apoptosis and mitochondrial function in malignant glioma tissues taken from enrolled patients at the time of surgery and correlate them with clinical data.|• To evaluate glucose uptake using 18F-FDG Positron Emission Tomography (PET) scanning as a biological marker for predicting subsequent therapeutic response to oral DCA in patients with malignant gliomas.","University of Alberta|Capital Health, Canada","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DCA 10002","October 2007","August 2009","August 2009","October 5, 2007",,"October 13, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT00540176"
179,"NCT01253707","A Study of AMG 337 in Subjects With Advanced Solid Tumors",,"Completed","No Results Available","Advanced Malignancy|Advanced Solid Tumors|Cancer|Oncology|Oncology Patients|Tumors","Drug: AMG 337","To evaluate the safety and tolerability of AMG 337 by reviewing clinically significant or ≥ Grade 3 changes in safety laboratory tests, physical examinations, ECGs, or vitals signs in all subjects enrolled.|Characterize the pharmacokinetics of AMG 337 when administered orally. PK parameters will include, but are not limited to, area under the plasma concentration versus time curve (AUC) and Peak Plasma Concentration (Cmax).|Determine the maximum tolerated dose of AMG 337, if possible. The MTD is defined at the highest dose level with an observed incidence of dose limiting toxicity in < 33% of subjects enrolled in a cohort.|Evaluate for clinical responses associated with AMG 337 treatment according to Response Evaluation Criteria In Solid Tumors 1.1 criteria","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","111","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20101132","December 2010","October 2015","December 2016","December 3, 2010",,"December 23, 2016","Research Site, Los Angeles, California, United States|Research Site, Atlanta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Boston, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Columbus, Ohio, United States|Research Site, Nashville, Tennessee, United States|Research Site, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01253707"
180,"NCT00390468","Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases",,"Completed","Has Results","Metastatic Cancer|Pain|Prostate Cancer","Drug: Tandutinib","8-week Freedom-From-Progression (FFP)","National Cancer Institute (NCI)","Male","18 Years and older   (Adult, Older Adult)","Phase 2","18","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2012-02865|P30CA016672|MDA-2005-0717|NCI-7409|CDR0000504104","October 2006","November 2009","November 2009","October 19, 2006","June 7, 2011","May 28, 2014","M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00390468"
181,"NCT01064336","Promacta Pregnancy Registry",,"Completed","No Results Available","Purpura, Thrombocytopaenic, Idiopathic","Drug: Eltrombopag","Outcome of Pregnancy (see Detailed Description for a complete list)","GlaxoSmithKline","All","Child, Adult, Older Adult",,"1","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","113327|WE4032","March 2010","July 2014","July 2014","February 8, 2010",,"July 25, 2016",,,"https://ClinicalTrials.gov/show/NCT01064336"
182,"NCT04054206","Relative Bioavailability of MN-166 (Ibudilast) in Extended Release Tablet vs. Intermediate-release Capsule in Healthy Volunteers",,"Completed","No Results Available","Healthy Volunteers","Drug: MN-166","Compare the pharmacokinetic profile of ER and IR formulations in single-dose administration of MN-166 (ibudilast)|Compare the pharmacokinetic profile of ER and IR formulations in single-dose administration of MN-166 (ibudilast) under fed or fasting states|Number of healthy volunteers with treatment-related adverse events as assessed by CTCAE v.4.0|Changes in physical exam results|Number of participants with clinically significant abnormal laboratory results","MediciNova","All","18 Years to 45 Years   (Adult)","Phase 1","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MN-166-HDT-002","June 24, 2019","July 17, 2019","May 31, 2020","August 13, 2019",,"July 15, 2020","Collaborative Neuroscience Network, Garden Grove, California, United States",,"https://ClinicalTrials.gov/show/NCT04054206"
183,"NCT03690141","An Open-label Study Examining the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC)",,"Completed","No Results Available","Castrate-resistant Prostate Cancer (CRPC)","Drug: tomivosertib (eFT508)","Anti-tumor response as defined by a patient achieving either of the following outcomes:|PSA progression-free survival from start of study therapy until the date PSA progression is first observed.","Effector Therapeutics","Male","18 Years and older   (Adult, Older Adult)","Phase 2","16","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","eFT508-0009","October 12, 2018","April 27, 2020","April 27, 2020","October 1, 2018",,"April 28, 2020","Yale Cancer Center, New Haven, Connecticut, United States|Northwestern University, Chicago, Illinois, United States|Kimmel Center at Johns Hopkins, Baltimore, Maryland, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Washington University, Saint Louis, Missouri, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|The Urology Group, Cincinnati, Ohio, United States|Lancaster Urology, Lancaster, Pennsylvania, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States|University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03690141"
184,"NCT02542787","Study of VSN16R for the Treatment of Spasticity in Multiple Sclerosis",,"Completed","No Results Available","Spasticity in People With Multiple Sclerosis","Drug: VSN16R|Other: Placebo","Numerical Rating Scale|Modified Ashworth Scale","Canbex Therapeutics Ltd","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","160","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CBX-001","August 2015","October 2017","October 2017","September 7, 2015",,"March 2, 2018","The Neuroscience Research Centre, The Walton Centre NHS Foundation Trust, Liverpool, United Kingdom|The Royal London Hospital, London, United Kingdom|The National Hospital for Neurology and Neurosurgery, London, United Kingdom|Royal Hallamshire Hospital, Sheffield Teaching Hospital NHS Foundation Trust, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02542787"
185,"NCT02366312","A Phase 2, Single-center, Single-arm, Open Label Trial of Vismodegib in Patients With Keratocystic Odontogenic Tumors","KCOT","Completed","Has Results","Keratocystic Odontogenic Tumor","Drug: vismodegib","KCOT Volume (Greatest Dimension)","NYU College of Dentistry|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","2","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-00254|ML28859","October 27, 2015","August 2019","August 2019","February 19, 2015","February 18, 2021","February 18, 2021","NYU Bluestone Center For Cllinical Research, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT02366312/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT02366312/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT02366312"
186,"NCT01962363","EPI-743 in Friedreich's Ataxia Point Mutations",,"Completed","No Results Available","Friedreich's Ataxia","Drug: EPI-743","Visual function|Safety parameters|Neurologic function|Physical function|Health related quality of life|Activities of Daily Living|Cardiac indices|Upper extremity function|Disease biomarkers","University of South Florida|Edison Pharmaceuticals Inc|Friedreich's Ataxia Research Alliance","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","4","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EPI-743 PM","October 2013","June 2016","June 2016","October 14, 2013",,"June 29, 2016","University of South Florida, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01962363"
187,"NCT04179071","A Study in Healthy Male Subjects to Understand How Savolitinib Behaves Inside the Body (Pharmacokinetics) When Administered Alone and in Combination With Famotidine",,"Completed","No Results Available","Solid Tumours","Drug: Savolitinib|Drug: Famotidine","Maximum observed plasma concentration (Cmax) ratio|Area under plasma concentration-time curve from zero to infinity (AUC) ratio|Number of subjects with having adverse events and/or abnormal findings in vital signs and/or laboratory evaluation and/or physical examination|AUC geometric means ratio of test treatment (savolitinib+famotidine) relative to reference treatment (savolitinib alone)|Area under the plasma concentration curve from time zero to time of last quantifiable concentration AUC(0-t)|Cmax geometric means ratio of test treatment (savolitinib+famotidine) relative to reference treatment (savolitinib alone)|Cmax metabolite-to-parent ratios (MRCmax)|AUC metabolite-to-parent ratios (MRAUC)|AUC(0-t) metabolite-to-parent ratios [MRAUC(0-t)]|Time to reach maximum observed plasma concentration (tmax)|Half-life associated with terminal slope (λz) of a semi logarithmic concentration-time curve (t½,λz)|Terminal elimination rate constant (λz)|Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F)|Apparent total body clearance of drug from plasma after extravascular administration (CL/F)","AstraZeneca|Parexel","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D5084C00005","December 13, 2019","March 11, 2020","March 11, 2020","November 26, 2019",,"July 7, 2020","Research Site, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04179071"
188,"NCT00858377","A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors",,"Completed","No Results Available","Advanced Malignancy|Advanced Solid Tumors|Cancer|Solid Tumors|Tumors","Drug: Arm 1- Dose Escalation|Drug: Arm 1- Dose Expansion","Safety: subject incidence of adverse events, first-cycle DLTs and clinically significant changes in vital signs, weight, ECGs and clinical laboratory tests|PK profile: AMG 900 PK parameters including, but not limited to, maximum observed concentration (Cmax), minimum observed concentration, area under the plasma concentration-time curve and, if feasible, half-life|Change in levels of p-Histone H3 from baseline (part 1 - dose escalation only)|Response rate in each taxane-resistant tumor type assessed per RECIST guidelines (part 2 - dose expansion only)|Change in tumor volume from baseline measured by volumetric CT or MRI|Tumor response measured by CT or MRI and assessed per RECIST guidelines|Change from baseline in maximum standardized uptake value (SUVmax) using 18FLT-PET/CT (part 2 - dose expansion only)","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","95","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20080016","August 10, 2009","December 31, 2014","April 3, 2019","March 9, 2009",,"May 6, 2019","Research Site, Tucson, Arizona, United States|Research Site, Los Angeles, California, United States|Research Site, Baltimore, Maryland, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Kurralta Park, South Australia, Australia|Research Site, Bentleigh East, Victoria, Australia|Research Site, Parkville, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT00858377"
189,"NCT03376958","Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma",,"Completed","No Results Available","Relapsed and Refractory|Diffuse Large B Cell Lymphoma","Drug: Apatinib","Overall Response Rate|Progression-free Survival|Overall Survival","Zhengzhou University","All","14 Years to 70 Years   (Child, Adult, Older Adult)","Phase 4","32","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","hnslblzlzx2017-1","January 1, 2017","February 1, 2019","April 30, 2019","December 19, 2017",,"July 25, 2019","Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China",,"https://ClinicalTrials.gov/show/NCT03376958"
190,"NCT01815515","Evaluation of 18F-DCFBC PSMA-based PET Imaging for Detection of Metastatic Prostate Cancer",,"Completed","Has Results","Metastatic Prostate Cancer","Drug: 18F-DCFBC","Measurement of Sensitivity of DCFBC-PET as Determined by Agreement of PET/CT Detection of Metastatic Prostate Cancer With Conventional Imaging Modality (CIM)|Sensitivity of Detection of New or Progression of Metastasis","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","Male","18 Years to 100 Years   (Adult, Older Adult)","Phase 1|Phase 2","22","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","J12113|NA_00052383","March 2013","July 2015","November 18, 2015","March 21, 2013","August 20, 2018","August 20, 2018","Johns Hopkins University, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01815515"
191,"NCT02714036","A Biomarker Study to Evaluate MN-166 (Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS)",,"Completed","No Results Available","Amyotrophic Lateral Sclerosis","Drug: ibudilast","To measure the impact of MN-166 (ibudilast) on [11C]-PBR28 uptake in the motor cortices and brain stem measured by positron emission tomography (PET) imaging at 24 weeks|To measure the impact of MN-166 (ibudilast) on several markers of neuro-inflammation measured by blood biomarkers|To evaluate the safety and tolerability of MN-166 by assessing the number of treatment-related adverse events.|To evaluate the effect of ibudilast on ALS functional rating scale-revised (ALSFRS-R)|To evaluate the effect of ibudilast on slow vital capacity (SVC)|To evaluate the effect of ibudilast on strength as measured by Hand-held dynamometry (HHD)","MediciNova|Massachusetts General Hospital|South Shore Neurologic Associates","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","35","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MN-166-ALS-1202","May 6, 2016","December 31, 2019","June 30, 2020","March 21, 2016",,"July 21, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States|South Shore Neurologic Associates, P.C., Patchogue, New York, United States",,"https://ClinicalTrials.gov/show/NCT02714036"
192,"NCT01380756","Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia",,"Completed","No Results Available","Cancer|Hematologic Malignancies|Leukemia|Myeloid Leukemia","Drug: Arm 1- Dose Escalation|Drug: Arm 2- Dose Expansion","Subject incidence of adverse events|Subject incidence of dose limiting toxicities (DLTs)|Maximum observed concentration of AMG 900|Time to maximum observed concentration of AMG 900|Area under the plasma concentration-time curve (AUC) of AMG 900|Half life of AMG 900|Objective response as per Cheson Response Criteria|Change in the number of p-Histone H3 positive cells from baseline","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","35","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20101351","October 4, 2011","September 4, 2014","September 4, 2014","June 27, 2011",,"November 6, 2017","Research Site, Stony Brook, New York, United States|Research Site, Cleveland, Ohio, United States|Research Site, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01380756"
193,"NCT03650075","To Determine Safety and Tolerability of MG-S-2525 and to Evaluate Its PK Profile in Healthy Volunteers",,"Completed","No Results Available","Idiopathic Pulmonary Fibrosis (IPF)","Drug: MG-S-2525","maximum tolerated dose (MTD) (Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) parts)|dose limiting toxicity (DLT) (Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) parts)|total exposure by area under the curve (AUC) (Food Effect Part)|peak concentration (Cmax) under fasting/fed condition (Food Effect Part)","Metagone Biotech Inc.","All","20 Years and older   (Adult, Older Adult)","Phase 1","81","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MEOMGSA20180103","February 25, 2019","December 31, 2019","February 27, 2020","August 28, 2018",,"September 2, 2020","Taipei Medical University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT03650075"
194,"NCT04216082","A Study of Anlotinib in Subjects With Advanced Malignancy",,"Completed","No Results Available","Advanced Malignancy","Drug: Anlotinib","Overall response rate (ORR)|Progression-free survival (PFS)|Disease control rate（DCR）|Duration of Response (DOR)","Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","93","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ALTN-00-II","August 1, 2013","August 31, 2014","August 1, 2015","January 2, 2020",,"January 2, 2020","Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04216082"
195,"NCT00490139","ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D","ALTTO","Completed","Has Results","Neoplasms, Breast","Drug: Lapatinib|Biological: Trastuzumab","Disease-free Survival (DFS)|Overall Survival (OS)|Time to Recurrence|Time to Distant Recurrence|Time to Central Nervous System Recurrence|DFS Ignoring Non-breast Second Primary Malignancies","Novartis Pharmaceuticals|North Central Cancer Treatment Group|National Cancer Institute (NCI)|Breast International Group|Canadian Cancer Trials Group|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","8382","Industry|Other|NIH","Interventional","Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment","EGF106708|CLAP016B2301|2006-000562-36","May 16, 2007","December 6, 2013","July 1, 2021","June 22, 2007","August 18, 2014","July 23, 2021","Novartis Investigative Site, Mobile, Alabama, United States|Novartis Investigative Site, Anchorage, Alaska, United States|Novartis Investigative Site, Fairbanks, Alaska, United States|Novartis Investigative Site, Phoenix, Arizona, United States|Novartis Investigative Site, Tucson, Arizona, United States|Novartis Investigative Site, Tucson, Arizona, United States|Novartis Investigative Site, Jonesboro, Arkansas, United States|Novartis Investigative Site, Berkeley, California, United States|Novartis Investigative Site, Burlingame, California, United States|Novartis Investigative Site, Castro Valley, California, United States|Novartis Investigative Site, Duarte, California, United States|Novartis Investigative Site, Fairfield, California, United States|Novartis Investigative Site, Fremont, California, United States|Novartis Investigative Site, Fresno, California, United States|Novartis Investigative Site, Glendale, California, United States|Novartis Investigative Site, Greenbrae, California, United States|Novartis Investigative Site, La Jolla, California, United States|Novartis Investigative Site, La Jolla, California, United States|Novartis Investigative Site, Loma Linda, California, United States|Novartis Investigative Site, Martinez, California, United States|Novartis Investigative Site, Marysville, California, United States|Novartis Investigative Site, Monterey, California, United States|Novartis Investigative Site, Mountain View, California, United States|Novartis Investigative Site, Murrieta, California, United States|Novartis Investigative Site, Oakland, California, United States|Novartis Investigative Site, Oakland, California, United States|Novartis Investigative Site, Orange, California, United States|Novartis Investigative Site, Palm Springs, California, United States|Novartis Investigative Site, Palo Alto, California, United States|Novartis Investigative Site, Pismo Beach, California, United States|Novartis Investigative Site, Pleasanton, California, United States|Novartis Investigative Site, Sacramento, California, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, San Leandro, California, United States|Novartis Investigative Site, Vallejo, California, United States|Novartis Investigative Site, Aurora, Colorado, United States|Novartis Investigative Site, Boulder, Colorado, United States|Novartis Investigative Site, Colorado Springs, Colorado, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Edwards, Colorado, United States|Novartis Investigative Site, Englewood, Colorado, United States|Novartis Investigative Site, Fort Collins, Colorado, United States|Novartis Investigative Site, Fort Collins, Colorado, United States|Novartis Investigative Site, Glenwood Springs, Colorado, United States|Novartis Investigative Site, Grand Junction, Colorado, United States|Novartis Investigative Site, Greeley, Colorado, United States|Novartis Investigative Site, Lone Tree, Colorado, United States|Novartis Investigative Site, Longmont, Colorado, United States|Novartis Investigative Site, Loveland, Colorado, United States|Novartis Investigative Site, Montrose, Colorado, United States|Novartis Investigative Site, Pueblo, Colorado, United States|Novartis Investigative Site, Thornton, Colorado, United States|Novartis Investigative Site, Wheat Ridge, Colorado, United States|Novartis Investigative Site, Hartford, Connecticut, United States|Novartis Investigative Site, New Haven, Connecticut, United States|Novartis Investigative Site, Stamford, Connecticut, United States|Novartis Investigative Site, Torrington, Connecticut, United States|Novartis Investigative Site, Dover, Delaware, United States|Novartis Investigative Site, Milford, Delaware, United States|Novartis Investigative Site, Washington, District of Columbia, United States|Novartis Investigative Site, Washington, District of Columbia, United States|Novartis Investigative Site, Boca Raton, Florida, United States|Novartis Investigative Site, Fort Lauderdale, Florida, United States|Novartis Investigative Site, Fort Myers, Florida, United States|Novartis Investigative Site, Hollywood, Florida, United States|Novartis Investigative Site, Jacksonville, Florida, United States|Novartis Investigative Site, Jacksonville, Florida, United States|Novartis Investigative Site, Jupiter, Florida, United States|Novartis Investigative Site, Lakeland, Florida, United States|Novartis Investigative Site, Miami Beach, Florida, United States|Novartis Investigative Site, New Port Richey, Florida, United States|Novartis Investigative Site, Ocala, Florida, United States|Novartis Investigative Site, Orange Park, Florida, United States|Novartis Investigative Site, Orlando, Florida, United States|Novartis Investigative Site, Orlando, Florida, United States|Novartis Investigative Site, Titusville, Florida, United States|Novartis Investigative Site, Weston, Florida, United States|Novartis Investigative Site, Athens, Georgia, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Augusta, Georgia, United States|Novartis Investigative Site, Augusta, Georgia, United States|Novartis Investigative Site, Austell, Georgia, United States|Novartis Investigative Site, Columbus, Georgia, United States|Novartis Investigative Site, Decatur, Georgia, United States|Novartis Investigative Site, Fort Gordon, Georgia, United States|Novartis Investigative Site, Gainesville, Georgia, United States|Novartis Investigative Site, Lawrenceville, Georgia, United States|Novartis Investigative Site, Marietta, Georgia, United States|Novartis Investigative Site, Riverdale, Georgia, United States|Novartis Investigative Site, Rome, Georgia, United States|Novartis Investigative Site, Savannah, Georgia, United States|Novartis Investigative Site, Valdosta, Georgia, United States|Novartis Investigative Site, 'Aiea, Hawaii, United States|Novartis Investigative Site, Honolulu, Hawaii, United States|Novartis Investigative Site, Honolulu, Hawaii, United States|Novartis Investigative Site, Honolulu, Hawaii, United States|Novartis Investigative Site, Honolulu, Hawaii, United States|Novartis Investigative Site, Lihue, Hawaii, United States|Novartis Investigative Site, Wailuku, Hawaii, United States|Novartis Investigative Site, Boise, Idaho, United States|Novartis Investigative Site, Boise, Idaho, United States|Novartis Investigative Site, Alton, Illinois, United States|Novartis Investigative Site, Aurora, Illinois, United States|Novartis Investigative Site, Berwyn, Illinois, United States|Novartis Investigative Site, Bloomington, Illinois, United States|Novartis Investigative Site, Canton, Illinois, United States|Novartis Investigative Site, Carthage, Illinois, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Eureka, Illinois, United States|Novartis Investigative Site, Evanston, Illinois, United States|Novartis Investigative Site, Galesburg, Illinois, United States|Novartis Investigative Site, Harvey, Illinois, United States|Novartis Investigative Site, Havana, Illinois, United States|Novartis Investigative Site, Highland Park, Illinois, United States|Novartis Investigative Site, Hopedale, Illinois, United States|Novartis Investigative Site, Joliet, Illinois, United States|Novartis Investigative Site, Joliet, Illinois, United States|Novartis Investigative Site, Kankakee, Illinois, United States|Novartis Investigative Site, Kewanee, Illinois, United States|Novartis Investigative Site, La Grange, Illinois, United States|Novartis Investigative Site, Libertyville, Illinois, United States|Novartis Investigative Site, Macomb, Illinois, United States|Novartis Investigative Site, Maywood, Illinois, United States|Novartis Investigative Site, Moline, Illinois, United States|Novartis Investigative Site, Monmouth, Illinois, United States|Novartis Investigative Site, Mount Vernon, Illinois, United States|Novartis Investigative Site, Naperville, Illinois, United States|Novartis Investigative Site, Niles, Illinois, United States|Novartis Investigative Site, Normal, Illinois, United States|Novartis Investigative Site, Oak Lawn, Illinois, United States|Novartis Investigative Site, Ottawa, Illinois, United States|Novartis Investigative Site, Park Ridge, Illinois, United States|Novartis Investigative Site, Pekin, Illinois, United States|Novartis Investigative Site, Pekin, Illinois, United States|Novartis Investigative Site, Peoria, Illinois, United States|Novartis Investigative Site, Peoria, Illinois, United States|Novartis Investigative Site, Peoria, Illinois, United States|Novartis Investigative Site, Peoria, Illinois, United States|Novartis Investigative Site, Peoria, Illinois, United States|Novartis Investigative Site, Peru, Illinois, United States|Novartis Investigative Site, Princeton, Illinois, United States|Novartis Investigative Site, Rockford, Illinois, United States|Novartis Investigative Site, Skokie, Illinois, United States|Novartis Investigative Site, Spring Valley, Illinois, United States|Novartis Investigative Site, Springfield, Illinois, United States|Novartis Investigative Site, Urbana, Illinois, United States|Novartis Investigative Site, Warrenville, Illinois, United States|Novartis Investigative Site, Winfield, Illinois, United States|Novartis Investigative Site, Beech Grove, Indiana, United States|Novartis Investigative Site, Elkhart, Indiana, United States|Novartis Investigative Site, Fort Wayne, Indiana, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Kokomo, Indiana, United States|Novartis Investigative Site, La Porte, Indiana, United States|Novartis Investigative Site, Michigan City, Indiana, United States|Novartis Investigative Site, Mishawaka, Indiana, United States|Novartis Investigative Site, Muncie, Indiana, United States|Novartis Investigative Site, Richmond, Indiana, United States|Novartis Investigative Site, South Bend, Indiana, United States|Novartis Investigative Site, South Bend, Indiana, United States|Novartis Investigative Site, Ames, Iowa, United States|Novartis Investigative Site, Bettendorf, Iowa, United States|Novartis Investigative Site, Cedar Rapids, Iowa, United States|Novartis Investigative Site, Cedar Rapids, Iowa, United States|Novartis Investigative Site, Des Moines, Iowa, United States|Novartis Investigative Site, Des Moines, Iowa, United States|Novartis Investigative Site, Des Moines, Iowa, United States|Novartis Investigative Site, Des Moines, Iowa, United States|Novartis Investigative Site, Mason City, Iowa, United States|Novartis Investigative Site, Ottumwa, Iowa, United States|Novartis Investigative Site, Sioux City, Iowa, United States|Novartis Investigative Site, Sioux City, Iowa, United States|Novartis Investigative Site, Waterloo, Iowa, United States|Novartis Investigative Site, Waterloo, Iowa, United States|Novartis Investigative Site, Anthony, Kansas, United States|Novartis Investigative Site, Chanute, Kansas, United States|Novartis Investigative Site, Dodge City, Kansas, United States|Novartis Investigative Site, El Dorado, Kansas, United States|Novartis Investigative Site, Fort Scott, Kansas, United States|Novartis Investigative Site, Independence, Kansas, United States|Novartis Investigative Site, Kansas City, Kansas, United States|Novartis Investigative Site, Kingman, Kansas, United States|Novartis Investigative Site, Lawrence, Kansas, United States|Novartis Investigative Site, Liberal, Kansas, United States|Novartis Investigative Site, Newton, Kansas, United States|Novartis Investigative Site, Olathe, Kansas, United States|Novartis Investigative Site, Overland Park, Kansas, United States|Novartis Investigative Site, Overland Park, Kansas, United States|Novartis Investigative Site, Overland Park, Kansas, United States|Novartis Investigative Site, Parsons, Kansas, United States|Novartis Investigative Site, Prairie Village, Kansas, United States|Novartis Investigative Site, Pratt, Kansas, United States|Novartis Investigative Site, Salina, Kansas, United States|Novartis Investigative Site, Shawnee Mission, Kansas, United States|Novartis Investigative Site, Topeka, Kansas, United States|Novartis Investigative Site, Topeka, Kansas, United States|Novartis Investigative Site, Wellington, Kansas, United States|Novartis Investigative Site, Wichita, Kansas, United States|Novartis Investigative Site, Wichita, Kansas, United States|Novartis Investigative Site, Wichita, Kansas, United States|Novartis Investigative Site, Winfield, Kansas, United States|Novartis Investigative Site, Louisville, Kentucky, United States|Novartis Investigative Site, Baton Rouge, Louisiana, United States|Novartis Investigative Site, Baton Rouge, Louisiana, United States|Novartis Investigative Site, Houma, Louisiana, United States|Novartis Investigative Site, New Orleans, Louisiana, United States|Novartis Investigative Site, New Orleans, Louisiana, United States|Novartis Investigative Site, Portland, Maine, United States|Novartis Investigative Site, Scarborough, Maine, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Bethesda, Maryland, United States|Novartis Investigative Site, Easton, Maryland, United States|Novartis Investigative Site, Frederick, Maryland, United States|Novartis Investigative Site, Hagerstown, Maryland, United States|Novartis Investigative Site, Silver Spring, Maryland, United States|Novartis Investigative Site, Towson, Maryland, United States|Novartis Investigative Site, Westminster, Maryland, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Burlington, Massachusetts, United States|Novartis Investigative Site, Gloucester, Massachusetts, United States|Novartis Investigative Site, Hyannis, Massachusetts, United States|Novartis Investigative Site, Lowell, Massachusetts, United States|Novartis Investigative Site, Peabody, Massachusetts, United States|Novartis Investigative Site, Adrian, Michigan, United States|Novartis Investigative Site, Ann Arbor, Michigan, United States|Novartis Investigative Site, Ann Arbor, Michigan, United States|Novartis Investigative Site, Ann Arbor, Michigan, United States|Novartis Investigative Site, Battle Creek, Michigan, United States|Novartis Investigative Site, Big Rapids, Michigan, United States|Novartis Investigative Site, Byron Center, Michigan, United States|Novartis Investigative Site, Dearborn, Michigan, United States|Novartis Investigative Site, Detroit, Michigan, United States|Novartis Investigative Site, Detroit, Michigan, United States|Novartis Investigative Site, Escanaba, Michigan, United States|Novartis Investigative Site, Flint, Michigan, United States|Novartis Investigative Site, Flint, Michigan, United States|Novartis Investigative Site, Grand Rapids, Michigan, United States|Novartis Investigative Site, Iron Mountain, Michigan, United States|Novartis Investigative Site, Jackson, Michigan, United States|Novartis Investigative Site, Kalamazoo, Michigan, United States|Novartis Investigative Site, Kalamazoo, Michigan, United States|Novartis Investigative Site, Lansing, Michigan, United States|Novartis Investigative Site, Livonia, Michigan, United States|Novartis Investigative Site, Monroe, Michigan, United States|Novartis Investigative Site, Muskegon, Michigan, United States|Novartis Investigative Site, Pontiac, Michigan, United States|Novartis Investigative Site, Port Huron, Michigan, United States|Novartis Investigative Site, Saginaw, Michigan, United States|Novartis Investigative Site, Saint Joseph, Michigan, United States|Novartis Investigative Site, Saint Joseph, Michigan, United States|Novartis Investigative Site, Southfield, Michigan, United States|Novartis Investigative Site, Traverse City, Michigan, United States|Novartis Investigative Site, Warren, Michigan, United States|Novartis Investigative Site, Albert Lea, Minnesota, United States|Novartis Investigative Site, Alexandria, Minnesota, United States|Novartis Investigative Site, Bemidji, Minnesota, United States|Novartis Investigative Site, Burnsville, Minnesota, United States|Novartis Investigative Site, Coon Rapids, Minnesota, United States|Novartis Investigative Site, Duluth, Minnesota, United States|Novartis Investigative Site, Edina, Minnesota, United States|Novartis Investigative Site, Fergus Falls, Minnesota, United States|Novartis Investigative Site, Fridley, Minnesota, United States|Novartis Investigative Site, Hutchinson, Minnesota, United States|Novartis Investigative Site, Litchfield, Minnesota, United States|Novartis Investigative Site, Mankato, Minnesota, United States|Novartis Investigative Site, Maplewood, Minnesota, United States|Novartis Investigative Site, Minneapolis, Minnesota, United States|Novartis Investigative Site, Minneapolis, Minnesota, United States|Novartis Investigative Site, Minneapolis, Minnesota, United States|Novartis Investigative Site, Robbinsdale, Minnesota, United States|Novartis Investigative Site, Saint Cloud, Minnesota, United States|Novartis Investigative Site, Saint Louis Park, Minnesota, United States|Novartis Investigative Site, Saint Paul, Minnesota, United States|Novartis Investigative Site, Saint Paul, Minnesota, United States|Novartis Investigative Site, Shakopee, Minnesota, United States|Novartis Investigative Site, Waconia, Minnesota, United States|Novartis Investigative Site, Willmar, Minnesota, United States|Novartis Investigative Site, Woodbury, Minnesota, United States|Novartis Investigative Site, Jackson, Mississippi, United States|Novartis Investigative Site, Keesler Air Force Base, Mississippi, United States|Novartis Investigative Site, Pascagoula, Mississippi, United States|Novartis Investigative Site, Bolivar, Missouri, United States|Novartis Investigative Site, Cape Girardeau, Missouri, United States|Novartis Investigative Site, Cape Girardeau, Missouri, United States|Novartis Investigative Site, Independence, Missouri, United States|Novartis Investigative Site, Joplin, Missouri, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Lee's Summit, Missouri, United States|Novartis Investigative Site, Liberty, Missouri, United States|Novartis Investigative Site, Saint Joseph, Missouri, United States|Novartis Investigative Site, Saint Joseph, Missouri, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Springfield, Missouri, United States|Novartis Investigative Site, Springfield, Missouri, United States|Novartis Investigative Site, Springfield, Missouri, United States|Novartis Investigative Site, Billings, Montana, United States|Novartis Investigative Site, Bozeman, Montana, United States|Novartis Investigative Site, Butte, Montana, United States|Novartis Investigative Site, Great Falls, Montana, United States|Novartis Investigative Site, Havre, Montana, United States|Novartis Investigative Site, Helena, Montana, United States|Novartis Investigative Site, Kalispell, Montana, United States|Novartis Investigative Site, Missoula, Montana, United States|Novartis Investigative Site, Missoula, Montana, United States|Novartis Investigative Site, Missoula, Montana, United States|Novartis Investigative Site, Grand Island, Nebraska, United States|Novartis Investigative Site, Lincoln, Nebraska, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Las Vegas, Nevada, United States|Novartis Investigative Site, Concord, New Hampshire, United States|Novartis Investigative Site, Exeter, New Hampshire, United States|Novartis Investigative Site, Hooksett, New Hampshire, United States|Novartis Investigative Site, Keene, New Hampshire, United States|Novartis Investigative Site, Laconia, New Hampshire, United States|Novartis Investigative Site, Lebanon, New Hampshire, United States|Novartis Investigative Site, Manchester, New Hampshire, United States|Novartis Investigative Site, Portsmouth, New Hampshire, United States|Novartis Investigative Site, Hackensack, New Jersey, United States|Novartis Investigative Site, Hamilton, New Jersey, United States|Novartis Investigative Site, Livingston, New Jersey, United States|Novartis Investigative Site, Marlton, New Jersey, United States|Novartis Investigative Site, Morristown, New Jersey, United States|Novartis Investigative Site, Mount Holly, New Jersey, United States|Novartis Investigative Site, Neptune, New Jersey, United States|Novartis Investigative Site, New Brunswick, New Jersey, United States|Novartis Investigative Site, Pomona, New Jersey, United States|Novartis Investigative Site, Princeton, New Jersey, United States|Novartis Investigative Site, Ridgewood, New Jersey, United States|Novartis Investigative Site, Somerville, New Jersey, United States|Novartis Investigative Site, Sparta, New Jersey, United States|Novartis Investigative Site, Summit, New Jersey, United States|Novartis Investigative Site, Vineland, New Jersey, United States|Novartis Investigative Site, Voorhees, New Jersey, United States|Novartis Investigative Site, Albuquerque, New Mexico, United States|Novartis Investigative Site, Albuquerque, New Mexico, United States|Novartis Investigative Site, Las Cruces, New Mexico, United States|Novartis Investigative Site, Bronx, New York, United States|Novartis Investigative Site, Bronx, New York, United States|Novartis Investigative Site, Bronx, New York, United States|Novartis Investigative Site, Buffalo, New York, United States|Novartis Investigative Site, Clifton Springs, New York, United States|Novartis Investigative Site, Cooperstown, New York, United States|Novartis Investigative Site, East Syracuse, New York, United States|Novartis Investigative Site, Elmhurst, New York, United States|Novartis Investigative Site, Jamaica, New York, United States|Novartis Investigative Site, Lake Success, New York, United States|Novartis Investigative Site, Manhasset, New York, United States|Novartis Investigative Site, Mineola, New York, United States|Novartis Investigative Site, New Hyde Park, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, Rochester, New York, United States|Novartis Investigative Site, Rochester, New York, United States|Novartis Investigative Site, Rochester, New York, United States|Novartis Investigative Site, Stony Brook, New York, United States|Novartis Investigative Site, Syracuse, New York, United States|Novartis Investigative Site, Utica, New York, United States|Novartis Investigative Site, Chapel Hill, North Carolina, United States|Novartis Investigative Site, Fayetteville, North Carolina, United States|Novartis Investigative Site, Gastonia, North Carolina, United States|Novartis Investigative Site, Goldsboro, North Carolina, United States|Novartis Investigative Site, Hendersonville, North Carolina, United States|Novartis Investigative Site, Kinston, North Carolina, United States|Novartis Investigative Site, Raleigh, North Carolina, United States|Novartis Investigative Site, Rutherfordton, North Carolina, United States|Novartis Investigative Site, Statesville, North Carolina, United States|Novartis Investigative Site, Washington, North Carolina, United States|Novartis Investigative Site, Winston-Salem, North Carolina, United States|Novartis Investigative Site, Bismarck, North Dakota, United States|Novartis Investigative Site, Fargo, North Dakota, United States|Novartis Investigative Site, Grand Forks, North Dakota, United States|Novartis Investigative Site, Minot, North Dakota, United States|Novartis Investigative Site, Beachwood, Ohio, United States|Novartis Investigative Site, Bellefontaine, Ohio, United States|Novartis Investigative Site, Bowling Green, Ohio, United States|Novartis Investigative Site, Canton, Ohio, United States|Novartis Investigative Site, Canton, Ohio, United States|Novartis Investigative Site, Chillicothe, Ohio, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Cleveland, Ohio, United States|Novartis Investigative Site, Cleveland, Ohio, United States|Novartis Investigative Site, Clyde, Ohio, United States|Novartis Investigative Site, Columbia, Ohio, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Dayton, Ohio, United States|Novartis Investigative Site, Dayton, Ohio, United States|Novartis Investigative Site, Dayton, Ohio, United States|Novartis Investigative Site, Dayton, Ohio, United States|Novartis Investigative Site, Dayton, Ohio, United States|Novartis Investigative Site, Delaware, Ohio, United States|Novartis Investigative Site, Elyria, Ohio, United States|Novartis Investigative Site, Findlay, Ohio, United States|Novartis Investigative Site, Franklin, Ohio, United States|Novartis Investigative Site, Greenville, Ohio, United States|Novartis Investigative Site, Independence, Ohio, United States|Novartis Investigative Site, Kettering, Ohio, United States|Novartis Investigative Site, Lambertville, Ohio, United States|Novartis Investigative Site, Lima, Ohio, United States|Novartis Investigative Site, Marietta, Ohio, United States|Novartis Investigative Site, Maumee, Ohio, United States|Novartis Investigative Site, Maumee, Ohio, United States|Novartis Investigative Site, Mayfield Heights, Ohio, United States|Novartis Investigative Site, Newark, Ohio, United States|Novartis Investigative Site, Oregon, Ohio, United States|Novartis Investigative Site, Sandusky, Ohio, United States|Novartis Investigative Site, Springfield, Ohio, United States|Novartis Investigative Site, Springfield, Ohio, United States|Novartis Investigative Site, Sylvania, Ohio, United States|Novartis Investigative Site, Tiffin, Ohio, United States|Novartis Investigative Site, Toledo, Ohio, United States|Novartis Investigative Site, Toledo, Ohio, United States|Novartis Investigative Site, Toledo, Ohio, United States|Novartis Investigative Site, Toledo, Ohio, United States|Novartis Investigative Site, Toledo, Ohio, United States|Novartis Investigative Site, Troy, Ohio, United States|Novartis Investigative Site, Wauseon, Ohio, United States|Novartis Investigative Site, Westerville, Ohio, United States|Novartis Investigative Site, Wilmington, Ohio, United States|Novartis Investigative Site, Wooster, Ohio, United States|Novartis Investigative Site, Wright-Patterson Air Force Base, Ohio, United States|Novartis Investigative Site, Xenia, Ohio, United States|Novartis Investigative Site, Zanesville, Ohio, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Novartis Investigative Site, Tulsa, Oklahoma, United States|Novartis Investigative Site, Coos Bay, Oregon, United States|Novartis Investigative Site, Eugene, Oregon, United States|Novartis Investigative Site, Gresham, Oregon, United States|Novartis Investigative Site, Hillsboro, Oregon, United States|Novartis Investigative Site, Klamath Falls, Oregon, United States|Novartis Investigative Site, Milwaukie, Oregon, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Tualatin, Oregon, United States|Novartis Investigative Site, Abington, Pennsylvania, United States|Novartis Investigative Site, Bethlehem, Pennsylvania, United States|Novartis Investigative Site, Bryn Mawr, Pennsylvania, United States|Novartis Investigative Site, Butler, Pennsylvania, United States|Novartis Investigative Site, Danville, Pennsylvania, United States|Novartis Investigative Site, Ephrata, Pennsylvania, United States|Novartis Investigative Site, Hazleton, Pennsylvania, United States|Novartis Investigative Site, Hershey, Pennsylvania, United States|Novartis Investigative Site, Kingston, Pennsylvania, United States|Novartis Investigative Site, Lancaster, Pennsylvania, United States|Novartis Investigative Site, Langhorne, Pennsylvania, United States|Novartis Investigative Site, Lewistown, Pennsylvania, United States|Novartis Investigative Site, Media, Pennsylvania, United States|Novartis Investigative Site, Nashville, Pennsylvania, United States|Novartis Investigative Site, Paoli, Pennsylvania, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Phoenixville, Pennsylvania, United States|Novartis Investigative Site, Pottstown, Pennsylvania, United States|Novartis Investigative Site, Sayre, Pennsylvania, United States|Novartis Investigative Site, Scranton, Pennsylvania, United States|Novartis Investigative Site, Sellersville, Pennsylvania, United States|Novartis Investigative Site, State College, Pennsylvania, United States|Novartis Investigative Site, State College, Pennsylvania, United States|Novartis Investigative Site, West Reading, Pennsylvania, United States|Novartis Investigative Site, Wilkes-Barre, Pennsylvania, United States|Novartis Investigative Site, Wilkes-Barre, Pennsylvania, United States|Novartis Investigative Site, Wynnewood, Pennsylvania, United States|Novartis Investigative Site, Providence, Rhode Island, United States|Novartis Investigative Site, Providence, Rhode Island, United States|Novartis Investigative Site, Providence, Rhode Island, United States|Novartis Investigative Site, Warwick, Rhode Island, United States|Novartis Investigative Site, Anderson, South Carolina, United States|Novartis Investigative Site, Charleston, South Carolina, United States|Novartis Investigative Site, Columbia, South Carolina, United States|Novartis Investigative Site, Greenville, South Carolina, United States|Novartis Investigative Site, Mount Pleasant, South Carolina, United States|Novartis Investigative Site, Spartanburg, South Carolina, United States|Novartis Investigative Site, Aberdeen, South Dakota, United States|Novartis Investigative Site, Rapid City, South Dakota, United States|Novartis Investigative Site, Sioux Falls, South Dakota, United States|Novartis Investigative Site, Sioux Falls, South Dakota, United States|Novartis Investigative Site, Sioux Falls, South Dakota, United States|Novartis Investigative Site, Chattanooga, Tennessee, United States|Novartis Investigative Site, Chattanooga, Tennessee, United States|Novartis Investigative Site, Franklin, Tennessee, United States|Novartis Investigative Site, Germantown, Tennessee, United States|Novartis Investigative Site, Jackson, Tennessee, United States|Novartis Investigative Site, Knoxville, Tennessee, United States|Novartis Investigative Site, Knoxville, Tennessee, United States|Novartis Investigative Site, Knoxville, Tennessee, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Abilene, Texas, United States|Novartis Investigative Site, Amarillo, Texas, United States|Novartis Investigative Site, Austin, Texas, United States|Novartis Investigative Site, Austin, Texas, United States|Novartis Investigative Site, Austin, Texas, United States|Novartis Investigative Site, Austin, Texas, United States|Novartis Investigative Site, Beaumont, Texas, United States|Novartis Investigative Site, Bedford, Texas, United States|Novartis Investigative Site, Cedar Park, Texas, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Fort Sam Houston, Texas, United States|Novartis Investigative Site, Fort Worth, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Lackland Air Force Base, Texas, United States|Novartis Investigative Site, Longview, Texas, United States|Novartis Investigative Site, McAllen, Texas, United States|Novartis Investigative Site, Mesquite, Texas, United States|Novartis Investigative Site, Midland, Texas, United States|Novartis Investigative Site, Paris, Texas, United States|Novartis Investigative Site, Round Rock, Texas, United States|Novartis Investigative Site, Round Rock, Texas, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, San Marcos, Texas, United States|Novartis Investigative Site, Sherman, Texas, United States|Novartis Investigative Site, Sugar Land, Texas, United States|Novartis Investigative Site, Tyler, Texas, United States|Novartis Investigative Site, Waco, Texas, United States|Novartis Investigative Site, Wichita Falls, Texas, United States|Novartis Investigative Site, Salt Lake City, Utah, United States|Novartis Investigative Site, Berlin, Vermont, United States|Novartis Investigative Site, Burlington, Vermont, United States|Novartis Investigative Site, Saint Johnsbury, Vermont, United States|Novartis Investigative Site, Charlottesville, Virginia, United States|Novartis Investigative Site, Danville, Virginia, United States|Novartis Investigative Site, Fredericksburg, Virginia, United States|Novartis Investigative Site, Hampton, Virginia, United States|Novartis Investigative Site, Norfolk, Virginia, United States|Novartis Investigative Site, Richmond, Virginia, United States|Novartis Investigative Site, Roanoke, Virginia, United States|Novartis Investigative Site, Auburn, Washington, United States|Novartis Investigative Site, Bellingham, Washington, United States|Novartis Investigative Site, Bremerton, Washington, United States|Novartis Investigative Site, Burien, Washington, United States|Novartis Investigative Site, Centralia, Washington, United States|Novartis Investigative Site, Federal Way, Washington, United States|Novartis Investigative Site, Kennewick, Washington, United States|Novartis Investigative Site, Kirkland, Washington, United States|Novartis Investigative Site, Mount Vernon, Washington, United States|Novartis Investigative Site, Olympia, Washington, United States|Novartis Investigative Site, Port Angeles, Washington, United States|Novartis Investigative Site, Poulsbo, Washington, United States|Novartis Investigative Site, Puyallup, Washington, United States|Novartis Investigative Site, Renton, Washington, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Spokane, Washington, United States|Novartis Investigative Site, Spokane, Washington, United States|Novartis Investigative Site, Tacoma, Washington, United States|Novartis Investigative Site, Tacoma, Washington, United States|Novartis Investigative Site, Tacoma, Washington, United States|Novartis Investigative Site, Vancouver, Washington, United States|Novartis Investigative Site, Vancouver, Washington, United States|Novartis Investigative Site, Wenatchee, Washington, United States|Novartis Investigative Site, Charleston, West Virginia, United States|Novartis Investigative Site, Huntington, West Virginia, United States|Novartis Investigative Site, Wheeling, West Virginia, United States|Novartis Investigative Site, Chippewa Falls, Wisconsin, United States|Novartis Investigative Site, Eau Claire, Wisconsin, United States|Novartis Investigative Site, Eau Claire, Wisconsin, United States|Novartis Investigative Site, Green Bay, Wisconsin, United States|Novartis Investigative Site, Green Bay, Wisconsin, United States|Novartis Investigative Site, La Crosse, Wisconsin, United States|Novartis Investigative Site, Madison, Wisconsin, United States|Novartis Investigative Site, Manitowoc, Wisconsin, United States|Novartis Investigative Site, Marinette, Wisconsin, United States|Novartis Investigative Site, Marshfield, Wisconsin, United States|Novartis Investigative Site, Milwaukee, Wisconsin, United States|Novartis Investigative Site, Minocqua, Wisconsin, United States|Novartis Investigative Site, Oconto Falls, Wisconsin, United States|Novartis Investigative Site, Oshkosh, Wisconsin, United States|Novartis Investigative Site, Rhinelander, Wisconsin, United States|Novartis Investigative Site, Rice Lake, Wisconsin, United States|Novartis Investigative Site, Stevens Point, Wisconsin, United States|Novartis Investigative Site, Sturgeon Bay, Wisconsin, United States|Novartis Investigative Site, Weston, Wisconsin, United States|Novartis Investigative Site, Wisconsin Rapids, Wisconsin, United States|Novartis Investigative Site, Casper, Wyoming, United States|Novartis Investigative Site, Sheridan, Wyoming, United States|Novartis Investigative Site, Berazategui, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Argentina|Novartis Investigative Site, Mendoza, Argentina|Novartis Investigative Site, Quilmes, Argentina|Novartis Investigative Site, Santa Fe, Argentina|Novartis Investigative Site, Tucuman, Argentina|Novartis Investigative Site, Camperdown, New South Wales, Australia|Novartis Investigative Site, Coffs Harbour, New South Wales, Australia|Novartis Investigative Site, Concord, New South Wales, Australia|Novartis Investigative Site, Kingswood, New South Wales, Australia|Novartis Investigative Site, Liverpool, New South Wales, Australia|Novartis Investigative Site, North Sydney, New South Wales, Australia|Novartis Investigative Site, Port Macquarie, New South Wales, Australia|Novartis Investigative Site, Randwick, New South Wales, Australia|Novartis Investigative Site, Taree, New South Wales, Australia|Novartis Investigative Site, Tweed Heads, New South Wales, Australia|Novartis Investigative Site, Wagga Wagga, New South Wales, Australia|Novartis Investigative Site, Waratah, New South Wales, Australia|Novartis Investigative Site, Westmead, New South Wales, Australia|Novartis Investigative Site, Nambour, Queensland, Australia|Novartis Investigative Site, South Brisbane, Queensland, Australia|Novartis Investigative Site, Woolloongabba, Queensland, Australia|Novartis Investigative Site, Adelaide, South Australia, Australia|Novartis Investigative Site, Bedford Park, South Australia, Australia|Novartis Investigative Site, Woodville, South Australia, Australia|Novartis Investigative Site, Hobart, Tasmania, Australia|Novartis Investigative Site, Box Hill, Victoria, Australia|Novartis Investigative Site, East Bentleigh, Victoria, Australia|Novartis Investigative Site, East Melbourne, Victoria, Australia|Novartis Investigative Site, Fitzroy, Victoria, Australia|Novartis Investigative Site, Footscray, Victoria, Australia|Novartis Investigative Site, Frankston, Victoria, Australia|Novartis Investigative Site, Heidelberg, Victoria, Australia|Novartis Investigative Site, Melbourne, Victoria, Australia|Novartis Investigative Site, Parkville, Victoria, Australia|Novartis Investigative Site, Ringwood East, Victoria, Australia|Novartis Investigative Site, Wendouree, Victoria, Australia|Novartis Investigative Site, Bunbury, Western Australia, Australia|Novartis Investigative Site, Nedlands, Western Australia, Australia|Novartis Investigative Site, Subiaco, Western Australia, Australia|Novartis Investigative Site, Campbelltown, Australia|Novartis Investigative Site, Lismore, Australia|Novartis Investigative Site, Murdoch, Australia|Novartis Investigative Site, Guessing, Austria|Novartis Investigative Site, Linz, Austria|Novartis Investigative Site, Rankweil, Austria|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, Steyr, Austria|Novartis Investigative Site, Vienna, Austria|Novartis Investigative Site, Villach, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Wolfsberg, Austria|Novartis Investigative Site, Aalst, Belgium|Novartis Investigative Site, Antwerpen, Belgium|Novartis Investigative Site, Bonheiden, Belgium|Novartis Investigative Site, Brasschaat, Belgium|Novartis Investigative Site, Brugge, Belgium|Novartis Investigative Site, Brussels, Belgium|Novartis Investigative Site, Brussels, Belgium|Novartis Investigative Site, Brussel, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Charleroi, Belgium|Novartis Investigative Site, Edegem, Belgium|Novartis Investigative Site, Genk, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Haine Saint Paul, Belgium|Novartis Investigative Site, Hasselt, Belgium|Novartis Investigative Site, Huy, Belgium|Novartis Investigative Site, Kortrijk, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Mons, Belgium|Novartis Investigative Site, Namur, Belgium|Novartis Investigative Site, Roeselare, Belgium|Novartis Investigative Site, Sint-Niklaas, Belgium|Novartis Investigative Site, Tournai, Belgium|Novartis Investigative Site, Turnhout, Belgium|Novartis Investigative Site, Verviers, Belgium|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Yvoir, Belgium|Novartis Investigative Site, Salvador, Bahía, Brazil|Novartis Investigative Site, Belo Horizonte, Minas Gerais, Brazil|Novartis Investigative Site, Porte Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Jau, São Paulo, Brazil|Novartis Investigative Site, Santo Andre, São Paulo, Brazil|Novartis Investigative Site, Rio de Janeiro, Brazil|Novartis Investigative Site, Shumen, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Varna, Bulgaria|Novartis Investigative Site, Kelowna, British Columbia, Canada|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Moncton, New Brunswick, Canada|Novartis Investigative Site, Saint John, New Brunswick, Canada|Novartis Investigative Site, Barrie, Ontario, Canada|Novartis Investigative Site, London, Ontario, Canada|Novartis Investigative Site, Sault Ste. Marie, Ontario, Canada|Novartis Investigative Site, St Catharines, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Charlottetown, Prince Edward Island, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Sherbrooke, Quebec, Canada|Novartis Investigative Site, Regina, Saskatchewan, Canada|Novartis Investigative Site, Saskatoon, Saskatchewan, Canada|Novartis Investigative Site, Temuco, Región De La Araucania, Chile|Novartis Investigative Site, Valdivia, Región De Los Lagos, Chile|Novartis Investigative Site, Santiago, Región Metro De Santiago, Chile|Novartis Investigative Site, Santiago, Región Metro De Santiago, Chile|Novartis Investigative Site, Santiago, Región Metro De Santiago, Chile|Novartis Investigative Site, Santiago, Región Metro De Santiago, Chile|Novartis Investigative Site, Valparaiso, Valparaíso, Chile|Novartis Investigative Site, Vina del Mar, Valparaíso, Chile|Novartis Investigative Site, Arica, Chile|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Tianjin, China|Novartis Investigative Site, Varazdin, Croatia|Novartis Investigative Site, Zagreb, Croatia|Novartis Investigative Site, Zagreb, Croatia|Novartis Investigative Site, Brno, Czechia|Novartis Investigative Site, Brno, Czechia|Novartis Investigative Site, Brno, Czechia|Novartis Investigative Site, Ceske Budejovice, Czechia|Novartis Investigative Site, Chomutov, Czechia|Novartis Investigative Site, Jihlava, Czechia|Novartis Investigative Site, Novy Jicin, Czechia|Novartis Investigative Site, Olomouc, Czechia|Novartis Investigative Site, Pardubice, Czechia|Novartis Investigative Site, Praha 10, Czechia|Novartis Investigative Site, Praha 2, Czechia|Novartis Investigative Site, Praha 4, Czechia|Novartis Investigative Site, Praha 5, Czechia|Novartis Investigative Site, Praha 8, Czechia|Novartis Investigative Site, Usti nad Labem, Czechia|Novartis Investigative Site, Aalborg, Denmark|Novartis Investigative Site, Arhus C, Denmark|Novartis Investigative Site, Esbjerg, Denmark|Novartis Investigative Site, Herlev, Denmark|Novartis Investigative Site, Hilleroed, Denmark|Novartis Investigative Site, Koebenhavn Oe, Denmark|Novartis Investigative Site, Naestved, Denmark|Novartis Investigative Site, Odense, Denmark|Novartis Investigative Site, Roskilde, Denmark|Novartis Investigative Site, Vejle, Denmark|Novartis Investigative Site, Viborg, Denmark|Novartis Investigative Site, Tallinn, Estonia|Novartis Investigative Site, Tartu, Estonia|Novartis Investigative Site, ANGERS Cedex 2, France|Novartis Investigative Site, Annecy, France|Novartis Investigative Site, Avignon, France|Novartis Investigative Site, Bayonne, France|Novartis Investigative Site, Bethune, France|Novartis Investigative Site, Bordeaux, France|Novartis Investigative Site, Brive La Gaillarde, France|Novartis Investigative Site, Bron, France|Novartis Investigative Site, Caen Cedex 05, France|Novartis Investigative Site, Caen, France|Novartis Investigative Site, Clermont Ferrand, France|Novartis Investigative Site, Coudekerque Branche, France|Novartis Investigative Site, Dijon Cedex, France|Novartis Investigative Site, Dijon, France|Novartis Investigative Site, Draguignan, France|Novartis Investigative Site, Grenoble Cedex 9, France|Novartis Investigative Site, Grenoble Cedex, France|Novartis Investigative Site, Hyeres, France|Novartis Investigative Site, La Seyne Sur Mer, France|Novartis Investigative Site, Le Chesnay, France|Novartis Investigative Site, Le Havre, France|Novartis Investigative Site, Le Mans, France|Novartis Investigative Site, Lille, France|Novartis Investigative Site, Lyon, France|Novartis Investigative Site, Lyon, France|Novartis Investigative Site, Lyon, France|Novartis Investigative Site, Marseille Cedex 09, France|Novartis Investigative Site, Marseille cedex 5, France|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Metz cedex 01, France|Novartis Investigative Site, Mont de Marsan, France|Novartis Investigative Site, Montauban, France|Novartis Investigative Site, Montbeliard, France|Novartis Investigative Site, Mulhouse, France|Novartis Investigative Site, Nancy, France|Novartis Investigative Site, Nice Cedex 2, France|Novartis Investigative Site, Nimes cedex 9, France|Novartis Investigative Site, Paris Cedex 10, France|Novartis Investigative Site, Paris Cedex 14, France|Novartis Investigative Site, Paris Cedex 5, France|Novartis Investigative Site, Perigueux, France|Novartis Investigative Site, Perin Sur Mer, France|Novartis Investigative Site, Perpignan, France|Novartis Investigative Site, Reims, France|Novartis Investigative Site, Rouen cedex 1, France|Novartis Investigative Site, Rouen, France|Novartis Investigative Site, Saint Gregoire, France|Novartis Investigative Site, Saint Jean, France|Novartis Investigative Site, Saint-Cloud, France|Novartis Investigative Site, Saint-Herblain, France|Novartis Investigative Site, Saint-Martin Boulogne, France|Novartis Investigative Site, Saint-Priest en Jarez Cedex, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Toulouse, France|Novartis Investigative Site, Toulouse, France|Novartis Investigative Site, Tours cedex, France|Novartis Investigative Site, Valenciennes, France|Novartis Investigative Site, Vandoeuvre-Les-Nancy, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Aalen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Baden-Baden, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Boeblingen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Emmendingen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Esslingen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Freiburg, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Goeppingen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Heidelberg, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Heidelberg, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Karlsruhe, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Karlsruhe, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Karlsruhe, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Konstanz, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Loerrach, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Ludwigsburg, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Mannheim, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Mannheim, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Mutlangen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Ostfildern, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Ravensburg, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Reutlingen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Rheinfelden, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Schwaebisch Hall, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Schwetzingen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Sigmaringen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Stuttgart, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Stuttgart, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Tuebingen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Tuttlingen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Ulm, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Villingen-Schwenningen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Ansbach, Bayern, Germany|Novartis Investigative Site, Aschaffenburg, Bayern, Germany|Novartis Investigative Site, Augsburg, Bayern, Germany|Novartis Investigative Site, Bad Reichenhall, Bayern, Germany|Novartis Investigative Site, Bayreuth, Bayern, Germany|Novartis Investigative Site, Coburg, Bayern, Germany|Novartis Investigative Site, Dachau, Bayern, Germany|Novartis Investigative Site, Deggendorf, Bayern, Germany|Novartis Investigative Site, Donauwoerth, Bayern, Germany|Novartis Investigative Site, Ebersberg, Bayern, Germany|Novartis Investigative Site, Eggenfelden, Bayern, Germany|Novartis Investigative Site, Erlangen, Bayern, Germany|Novartis Investigative Site, Forchheim, Bayern, Germany|Novartis Investigative Site, Freising, Bayern, Germany|Novartis Investigative Site, Fuerth, Bayern, Germany|Novartis Investigative Site, Garmisch-Partenkirchen, Bayern, Germany|Novartis Investigative Site, Kempten, Bayern, Germany|Novartis Investigative Site, Kronach, Bayern, Germany|Novartis Investigative Site, Landshut, Bayern, Germany|Novartis Investigative Site, Landshut, Bayern, Germany|Novartis Investigative Site, Marktredwitz, Bayern, Germany|Novartis Investigative Site, Memmingen, Bayern, Germany|Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, Muhr, Bayern, Germany|Novartis Investigative Site, Munchen, Bayern, Germany|Novartis Investigative Site, Nuernberg, Bayern, Germany|Novartis Investigative Site, Nuernberg, Bayern, Germany|Novartis Investigative Site, Regensburg, Bayern, Germany|Novartis Investigative Site, Rosenheim, Bayern, Germany|Novartis Investigative Site, Roth, Bayern, Germany|Novartis Investigative Site, Schwandorf, Bayern, Germany|Novartis Investigative Site, Traunstein, Bayern, Germany|Novartis Investigative Site, Waldmuenchen, Bayern, Germany|Novartis Investigative Site, Weiden, Bayern, Germany|Novartis Investigative Site, Fuerstenwalde, Brandenburg, Germany|Novartis Investigative Site, Koenigs Wusterhausen, Brandenburg, Germany|Novartis Investigative Site, Luckenwalde, Brandenburg, Germany|Novartis Investigative Site, Ludwigsfelde, Brandenburg, Germany|Novartis Investigative Site, Bremerhaven, Bremen, Germany|Novartis Investigative Site, Bad Soden, Hessen, Germany|Novartis Investigative Site, Frankfurt am Main, Hessen, Germany|Novartis Investigative Site, Frankfurt, Hessen, Germany|Novartis Investigative Site, Frankfurt, Hessen, Germany|Novartis Investigative Site, Frankfurt, Hessen, Germany|Novartis Investigative Site, Fulda, Hessen, Germany|Novartis Investigative Site, Hanau, Hessen, Germany|Novartis Investigative Site, Kassel, Hessen, Germany|Novartis Investigative Site, Kassel, Hessen, Germany|Novartis Investigative Site, Limburg, Hessen, Germany|Novartis Investigative Site, Marburg, Hessen, Germany|Novartis Investigative Site, Offenbach, Hessen, Germany|Novartis Investigative Site, Wiesbaden, Hessen, Germany|Novartis Investigative Site, Wiesbaden, Hessen, Germany|Novartis Investigative Site, Wiesbaden, Hessen, Germany|Novartis Investigative Site, Greifswald, Mecklenburg-Vorpommern, Germany|Novartis Investigative Site, Guestrow, Mecklenburg-Vorpommern, Germany|Novartis Investigative Site, Rostock, Mecklenburg-Vorpommern, Germany|Novartis Investigative Site, Schwerin, Mecklenburg-Vorpommern, Germany|Novartis Investigative Site, Stralsund, Mecklenburg-Vorpommern, Germany|Novartis Investigative Site, Aurich, Niedersachsen, Germany|Novartis Investigative Site, Braunschweig, Niedersachsen, Germany|Novartis Investigative Site, Celle, Niedersachsen, Germany|Novartis Investigative Site, Cuxhaven, Niedersachsen, Germany|Novartis Investigative Site, Georgsmarienhuette, Niedersachsen, Germany|Novartis Investigative Site, Goettingen, Niedersachsen, Germany|Novartis Investigative Site, Goslar, Niedersachsen, Germany|Novartis Investigative Site, Hameln, Niedersachsen, Germany|Novartis Investigative Site, Hannover, Niedersachsen, Germany|Novartis Investigative Site, Hannover, Niedersachsen, Germany|Novartis Investigative Site, Hannover, Niedersachsen, Germany|Novartis Investigative Site, Leer, Niedersachsen, Germany|Novartis Investigative Site, Oldenburg, Niedersachsen, Germany|Novartis Investigative Site, Oldenburg, Niedersachsen, Germany|Novartis Investigative Site, Osnabrueck, Niedersachsen, Germany|Novartis Investigative Site, Rotenburg (Wuemme), Niedersachsen, Germany|Novartis Investigative Site, Stade, Niedersachsen, Germany|Novartis Investigative Site, Stadthagen, Niedersachsen, Germany|Novartis Investigative Site, Vechta, Niedersachsen, Germany|Novartis Investigative Site, Westerstede, Niedersachsen, Germany|Novartis Investigative Site, Bergisch Gladbach, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Bielefeld, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Bochum, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Bochum, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Bonn, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Bonn, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Bonn, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Duesseldorf, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Duesseldorf, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Duisburg, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Eschweiler, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Essen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Essen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Essen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Essen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Gummersbach, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Hamm-Heessen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Herne, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Koeln, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Koeln, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Koeln, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Krefeld, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Leverkusen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Minden, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Moenchengladbach, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Muelheim, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Muenster, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Muenster, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Olpe, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Porta Westfalica, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Solingen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Troisdorf, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Velbert, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Wesel, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Witten, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Wuerselen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Wuppertal, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Wuppertal, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Wuppertal, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Ludwigshafen, Rheinland-Pfalz, Germany|Novartis Investigative Site, Mainz, Rheinland-Pfalz, Germany|Novartis Investigative Site, Trier, Rheinland-Pfalz, Germany|Novartis Investigative Site, Homburg/Saar, Saarland, Germany|Novartis Investigative Site, Landstuhl, Saarland, Germany|Novartis Investigative Site, Neunkirchen, Saarland, Germany|Novartis Investigative Site, Saarbruecken, Saarland, Germany|Novartis Investigative Site, Aschersleben, Sachsen-Anhalt, Germany|Novartis Investigative Site, Halle, Sachsen-Anhalt, Germany|Novartis Investigative Site, Halle, Sachsen-Anhalt, Germany|Novartis Investigative Site, Magdeburg, Sachsen-Anhalt, Germany|Novartis Investigative Site, Magdeburg, Sachsen-Anhalt, Germany|Novartis Investigative Site, Stendal, Sachsen-Anhalt, Germany|Novartis Investigative Site, Weissenfels, Sachsen-Anhalt, Germany|Novartis Investigative Site, Chemnitz, Sachsen, Germany|Novartis Investigative Site, Dresden, Sachsen, Germany|Novartis Investigative Site, Dresden, Sachsen, Germany|Novartis Investigative Site, Hoyerswerda, Sachsen, Germany|Novartis Investigative Site, Leipzig, Sachsen, Germany|Novartis Investigative Site, Leipzig, Sachsen, Germany|Novartis Investigative Site, Radebeul, Sachsen, Germany|Novartis Investigative Site, Rodewisch, Sachsen, Germany|Novartis Investigative Site, Schkeuditz, Sachsen, Germany|Novartis Investigative Site, Torgau, Sachsen, Germany|Novartis Investigative Site, Zittau, Sachsen, Germany|Novartis Investigative Site, Zwickau, Sachsen, Germany|Novartis Investigative Site, Bad Oldesloe, Schleswig-Holstein, Germany|Novartis Investigative Site, Flensburg, Schleswig-Holstein, Germany|Novartis Investigative Site, Geesthacht, Schleswig-Holstein, Germany|Novartis Investigative Site, Heide, Schleswig-Holstein, Germany|Novartis Investigative Site, Itzehoe, Schleswig-Holstein, Germany|Novartis Investigative Site, Kiel, Schleswig-Holstein, Germany|Novartis Investigative Site, Kiel, Schleswig-Holstein, Germany|Novartis Investigative Site, Luebeck, Schleswig-Holstein, Germany|Novartis Investigative Site, Neumuenster, Schleswig-Holstein, Germany|Novartis Investigative Site, Rendsburg, Schleswig-Holstein, Germany|Novartis Investigative Site, Erfurt, Thueringen, Germany|Novartis Investigative Site, Gera, Thueringen, Germany|Novartis Investigative Site, Jena, Thueringen, Germany|Novartis Investigative Site, Meiningen, Thueringen, Germany|Novartis Investigative Site, Muehlhausen, Thueringen, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Brandenburg, Germany|Novartis Investigative Site, Bremen, Germany|Novartis Investigative Site, Bremen, Germany|Novartis Investigative Site, Friedrichshafen, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Wuerzburg, Germany|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Heraklion,Crete, Greece|Novartis Investigative Site, Patra, Greece|Novartis Investigative Site, Thessaloniki, Greece|Novartis Investigative Site, Kowloon, Hong Kong|Novartis Investigative Site, Tuen Mun, Hong Kong|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Gyor, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Szombathely, Hungary|Novartis Investigative Site, Gurgaon, India|Novartis Investigative Site, Hyderabad, India|Novartis Investigative Site, Kolkatta (w.b.), India|Novartis Investigative Site, Mangalore, India|Novartis Investigative Site, Mumbai, India|Novartis Investigative Site, Nagpur, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, Trivandrum, India|Novartis Investigative Site, Dublin, Ireland|Novartis Investigative Site, Dublin, Ireland|Novartis Investigative Site, Dublin, Ireland|Novartis Investigative Site, Galway, Ireland|Novartis Investigative Site, Limerick, Ireland|Novartis Investigative Site, Sligo, Ireland|Novartis Investigative Site, Tallaght, Dublin, Ireland|Novartis Investigative Site, Wilton, Cork, Ireland|Novartis Investigative Site, Beer-Sheva, Israel|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Holon, Israel|Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Kfar Saba, Israel|Novartis Investigative Site, Netanya, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Rehovot, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Potenza, Basilicata, Italy|Novartis Investigative Site, Avellino, Campania, Italy|Novartis Investigative Site, Carpi (MO), Emilia-Romagna, Italy|Novartis Investigative Site, Lugo (Ravenna), Emilia-Romagna, Italy|Novartis Investigative Site, Meldola (FC), Emilia-Romagna, Italy|Novartis Investigative Site, Ravenna, Emilia-Romagna, Italy|Novartis Investigative Site, Rimini, Emilia-Romagna, Italy|Novartis Investigative Site, Aviano (PN), Friuli-Venezia-Giulia, Italy|Novartis Investigative Site, Udine, Friuli-Venezia-Giulia, Italy|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Viterbo, Lazio, Italy|Novartis Investigative Site, Genova, Liguria, Italy|Novartis Investigative Site, Alzano Lombardo (BG), Lombardia, Italy|Novartis Investigative Site, Bergamo, Lombardia, Italy|Novartis Investigative Site, Brescia, Lombardia, Italy|Novartis Investigative Site, Brescia, Lombardia, Italy|Novartis Investigative Site, Cremona, Lombardia, Italy|Novartis Investigative Site, Lecco, Lombardia, Italy|Novartis Investigative Site, Mantova, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Monza, Lombardia, Italy|Novartis Investigative Site, Pavia, Lombardia, Italy|Novartis Investigative Site, Rozzano (MI), Lombardia, Italy|Novartis Investigative Site, San Fermo Della Battaglia (Co), Lombardia, Italy|Novartis Investigative Site, Saronno (VA), Lombardia, Italy|Novartis Investigative Site, Treviglio (BG), Lombardia, Italy|Novartis Investigative Site, Varese, Lombardia, Italy|Novartis Investigative Site, Fano (Pesaro Urbino), Marche, Italy|Novartis Investigative Site, Fermo (AP), Marche, Italy|Novartis Investigative Site, Asti, Piemonte, Italy|Novartis Investigative Site, Biella, Piemonte, Italy|Novartis Investigative Site, Candiolo (TO), Piemonte, Italy|Novartis Investigative Site, Brindisi, Puglia, Italy|Novartis Investigative Site, Lecce, Puglia, Italy|Novartis Investigative Site, Monserrato (CA), Sardegna, Italy|Novartis Investigative Site, Sassari, Sardegna, Italy|Novartis Investigative Site, Palermo, Sicilia, Italy|Novartis Investigative Site, Palermo, Sicilia, Italy|Novartis Investigative Site, Ragusa, Sicilia, Italy|Novartis Investigative Site, Firenze, Toscana, Italy|Novartis Investigative Site, Firenze, Toscana, Italy|Novartis Investigative Site, Lido Di Camaiore (LU), Toscana, Italy|Novartis Investigative Site, Livorno, Toscana, Italy|Novartis Investigative Site, Montepulciano (Siena, Toscana, Italy|Novartis Investigative Site, Pisa, Toscana, Italy|Novartis Investigative Site, Poggibonsi (Siena), Toscana, Italy|Novartis Investigative Site, Prato, Toscana, Italy|Novartis Investigative Site, Trento, Trentino-Alto Adige, Italy|Novartis Investigative Site, Chieti, Italy|Novartis Investigative Site, Cosenza, Italy|Novartis Investigative Site, Aichi, Japan|Novartis Investigative Site, Chiba, Japan|Novartis Investigative Site, Ehime, Japan|Novartis Investigative Site, Fukuoka, Japan|Novartis Investigative Site, Ibaraki, Japan|Novartis Investigative Site, Kanagawa, Japan|Novartis Investigative Site, Kyoto, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Saitama, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Gyeonggi-do, Korea, Republic of|Novartis Investigative Site, Incheon, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Suwon-si, Gyeonggi-do, Korea, Republic of|Novartis Investigative Site, Kubang Kerian, Malaysia|Novartis Investigative Site, Sarawak, Malaysia|Novartis Investigative Site, Toluca, Estado De México, Mexico|Novartis Investigative Site, Merida, Yucatán, Mexico|Novartis Investigative Site, Chihuahua, Mexico|Novartis Investigative Site, Mexico City, Mexico|Novartis Investigative Site, Mexico D.F., Mexico|Novartis Investigative Site, Mexico DF, Mexico|Novartis Investigative Site, Amersfoort, Netherlands|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Arnhem, Netherlands|Novartis Investigative Site, Blaricum, Netherlands|Novartis Investigative Site, Delft, Netherlands|Novartis Investigative Site, Den Haag, Netherlands|Novartis Investigative Site, Den Haag, Netherlands|Novartis Investigative Site, Eindhoven, Netherlands|Novartis Investigative Site, Gouda, Netherlands|Novartis Investigative Site, Hoofddorp, Netherlands|Novartis Investigative Site, Leeuwarden, Netherlands|Novartis Investigative Site, Leiden, Netherlands|Novartis Investigative Site, Leidschendam, Netherlands|Novartis Investigative Site, Purmerend, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Sittard-geleen, Netherlands|Novartis Investigative Site, Tilburg, Netherlands|Novartis Investigative Site, Utrecht, Netherlands|Novartis Investigative Site, Hamilton, New Zealand|Novartis Investigative Site, Palmerston North, New Zealand|Novartis Investigative Site, Wellington, New Zealand|Novartis Investigative Site, Forde, Norway|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Tromso, Norway|Novartis Investigative Site, Karachi, Pakistan|Novartis Investigative Site, Karachi, Pakistan|Novartis Investigative Site, Lahore, Pakistan|Novartis Investigative Site, Lahore, Pakistan|Novartis Investigative Site, Rawalpindi, Pakistan|Novartis Investigative Site, Callao, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Cebu, Philippines|Novartis Investigative Site, Quezon City, Philippines|Novartis Investigative Site, Sampaloc Manila, Philippines|Novartis Investigative Site, San Juan, Philippines|Novartis Investigative Site, Bydgoszcz, Poland|Novartis Investigative Site, Elblag, Poland|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Gliwice, Poland|Novartis Investigative Site, Krakow, Poland|Novartis Investigative Site, Krakow, Poland|Novartis Investigative Site, Olsztyn, Poland|Novartis Investigative Site, Olsztyn, Poland|Novartis Investigative Site, Opole, Poland|Novartis Investigative Site, Rzeszow, Poland|Novartis Investigative Site, Szczecin, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Cluj-Napoca, Romania|Novartis Investigative Site, Iasi, Romania|Novartis Investigative Site, Arkhangelsk, Russian Federation|Novartis Investigative Site, Chelyabinsk, Russian Federation|Novartis Investigative Site, Irkutsk, Russian Federation|Novartis Investigative Site, Kazan, Russian Federation|Novartis Investigative Site, Kirov, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Novosibirsk, Russian Federation|Novartis Investigative Site, Omsk, Russian Federation|Novartis Investigative Site, Orenburg, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, Samara, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Voronezh, Russian Federation|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Kosice, Slovakia|Novartis Investigative Site, Poprad, Slovakia|Novartis Investigative Site, Rimavska Sobota, Slovakia|Novartis Investigative Site, Zilina, Slovakia|Novartis Investigative Site, Ljubljana, Slovenia|Novartis Investigative Site, Capital Park, South Africa|Novartis Investigative Site, Groenkloof, Pretoria, 0001, South Africa|Novartis Investigative Site, Johannesburg, South Africa|Novartis Investigative Site, Observatory, South Africa|Novartis Investigative Site, Panorama, South Africa|Novartis Investigative Site, Parktown, South Africa|Novartis Investigative Site, Pretoria, South Africa|Novartis Investigative Site, Pretoria, South Africa|Novartis Investigative Site, Saxonwold, Johannesburg, South Africa|Novartis Investigative Site, Alcoy/Alicante, Spain|Novartis Investigative Site, Barakaldo (Vizcaya), Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Burgos, Spain|Novartis Investigative Site, Cadiz, Spain|Novartis Investigative Site, Castellon, Spain|Novartis Investigative Site, Cordoba, Spain|Novartis Investigative Site, Coria, Spain|Novartis Investigative Site, Elda, Spain|Novartis Investigative Site, Granada, Spain|Novartis Investigative Site, Hospitalet de Llobregat (Barcelona), Spain|Novartis Investigative Site, Huesca, Spain|Novartis Investigative Site, La Laguna (Santa Cruz De Tenerife), Spain|Novartis Investigative Site, Lerida, Spain|Novartis Investigative Site, Lugo, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Malaga, Spain|Novartis Investigative Site, Mataro, Spain|Novartis Investigative Site, Mostoles (Madrid), Spain|Novartis Investigative Site, Murcia, Spain|Novartis Investigative Site, Murcia, Spain|Novartis Investigative Site, Palma de Mallorca, Spain|Novartis Investigative Site, Palma de Mallorca, Spain|Novartis Investigative Site, Pamplona, Spain|Novartis Investigative Site, Salamanca, Spain|Novartis Investigative Site, San Sebastian, Spain|Novartis Investigative Site, Santander, Spain|Novartis Investigative Site, Santiago, Spain|Novartis Investigative Site, Segovia, Spain|Novartis Investigative Site, Sevilla, Spain|Novartis Investigative Site, Sevilla, Spain|Novartis Investigative Site, Tarrasa, Barcelona, Spain|Novartis Investigative Site, Toledo, Spain|Novartis Investigative Site, Valencia, Spain|Novartis Investigative Site, Valencia, Spain|Novartis Investigative Site, Zamora, Spain|Novartis Investigative Site, Zaragoza, Spain|Novartis Investigative Site, Aarau, Switzerland|Novartis Investigative Site, Basel, Switzerland|Novartis Investigative Site, Bellinzona, Switzerland|Novartis Investigative Site, Bern, Switzerland|Novartis Investigative Site, Chur, Switzerland|Novartis Investigative Site, Lausanne, Switzerland|Novartis Investigative Site, Locarno, Switzerland|Novartis Investigative Site, St Gallen, Switzerland|Novartis Investigative Site, Thun, Switzerland|Novartis Investigative Site, Zuerich, Switzerland|Novartis Investigative Site, Zurich, Switzerland|Novartis Investigative Site, Kaohsiung, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Tainan County, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Chiangmai, Thailand|Novartis Investigative Site, Hatyai, Songkhla, Thailand|Novartis Investigative Site, Khon Kaen, Thailand|Novartis Investigative Site, Phitsanulok, Thailand|Novartis Investigative Site, Chernivtsi, Ukraine|Novartis Investigative Site, Donetsk, Ukraine|Novartis Investigative Site, Ivano-Frankivsk, Ukraine|Novartis Investigative Site, Kharkiv, Ukraine|Novartis Investigative Site, Kyiv, Ukraine|Novartis Investigative Site, Lviv, Ukraine|Novartis Investigative Site, Simferopol, Ukraine|Novartis Investigative Site, Uzhgorod, Ukraine|Novartis Investigative Site, Uzhorod, Ukraine|Novartis Investigative Site, Chelmsford, Essex, United Kingdom|Novartis Investigative Site, Epping, Essex, United Kingdom|Novartis Investigative Site, Prittlewell Chase, Essex, United Kingdom|Novartis Investigative Site, Nottingham, Gloucestershire, United Kingdom|Novartis Investigative Site, Canterbury, Kent, United Kingdom|Novartis Investigative Site, Manchester, Lancashire, United Kingdom|Novartis Investigative Site, Preston, Lancashire, United Kingdom|Novartis Investigative Site, Northwood, Middlesex, United Kingdom|Novartis Investigative Site, Edinburgh, Midlothian, United Kingdom|Novartis Investigative Site, Headington, Oxford, Oxfordshire, United Kingdom|Novartis Investigative Site, Ashford, United Kingdom|Novartis Investigative Site, Blackpool, United Kingdom|Novartis Investigative Site, Bournemouth, United Kingdom|Novartis Investigative Site, Brighton, United Kingdom|Novartis Investigative Site, Cheltenham, United Kingdom|Novartis Investigative Site, Cottingham, United Kingdom|Novartis Investigative Site, Dorchester, United Kingdom|Novartis Investigative Site, Exeter, United Kingdom|Novartis Investigative Site, Grimsby, United Kingdom|Novartis Investigative Site, Guildford, United Kingdom|Novartis Investigative Site, Gwynedd, United Kingdom|Novartis Investigative Site, Ipswich, United Kingdom|Novartis Investigative Site, Lancaster, United Kingdom|Novartis Investigative Site, Leeds, United Kingdom|Novartis Investigative Site, Lindley, Huddersfield, United Kingdom|Novartis Investigative Site, Liverpool, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Maidstone, United Kingdom|Novartis Investigative Site, Margate, United Kingdom|Novartis Investigative Site, Newcastle upon Tyne, United Kingdom|Novartis Investigative Site, Nottingham, United Kingdom|Novartis Investigative Site, Plymouth, United Kingdom|Novartis Investigative Site, Poole, Dorset, United Kingdom|Novartis Investigative Site, Portsmouth, United Kingdom|Novartis Investigative Site, Romford, United Kingdom|Novartis Investigative Site, Sheffield, United Kingdom|Novartis Investigative Site, Shrewsbury, United Kingdom|Novartis Investigative Site, Southport, United Kingdom|Novartis Investigative Site, St Helens, United Kingdom|Novartis Investigative Site, Stoke on Trent, United Kingdom|Novartis Investigative Site, Sutton, United Kingdom|Novartis Investigative Site, Swansea, United Kingdom|Novartis Investigative Site, Whitchurch, Cardiff, United Kingdom|Novartis Investigative Site, Worthing, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00490139"
196,"NCT02603081","Study to Evaluate SPI-1005 in Adults With Meniere's Disease",,"Completed","No Results Available","Meniere's Disease","Drug: SPI-1005","Safety and tolerability of SPI-1005 using histories, physical exams, and clinical measures.|Plasma Ebselen levels of SPI-1005 before, during, and after 21 days of dosing|Plasma Selenium levels before, during, and after 21 days of dosing|Impact on Sensorineural Hearing Loss|Impact on Speech Discrimination|Impact on Tinnitus|Impact on Vertigo|Pharmacodynamic response","Sound Pharmaceuticals, Incorporated","All","19 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","SPI-1005-151","December 2015","August 2017","August 2017","November 11, 2015",,"March 18, 2021","House Clinic, Los Angeles, California, United States|New York Otology, New York, New York, United States|MUSC, Charleston, South Carolina, United States|Sound Pharmaceuticals, Inc., Seattle, Washington, United States|Northwest Ear, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02603081"
197,"NCT03353740","Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence",,"Completed","Has Results","Prostate Cancer","Drug: Ga-68 labeled PSMA-11 PET","True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Visceral Tissue Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Bone Tissue Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|True Positive Rate for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up|Positive Predictive Value (PPV) for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Visceral Lesions Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Bone Metastasis Lesions Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|PPV for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up.|True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Visceral Tissue Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Bone Tissue Confirmed by Histology/Pathology Only|True Positive Rate for Detection of Tumor Location in Prostate Bed Confirmed by Histology/Pathology Only|PPV for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Visceral Tissue Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Bone Tissue Confirmed by Histopathology/Biopsy Only|PPV for Detection of Tumor Location in Prostate Bed Confirmed by Histopathology/Biopsy Only|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prostate-specific Antigen (PSA) Value|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prior Cancer Treatment|Detection Rate of 68Ga-PSMA-11 PET Stratified by Prior Use of Androgen Deprivation Therapy (ADT)|Percent of Participants With a Change in Clinical Management|Rate of Inter-reader Reproducibility for Positivity|Number of Participants With Grade 3 or Higher, Treatment-related Adverse Events","Thomas Hope|University of California, San Francisco","Male","18 Years and older   (Adult, Older Adult)","Phase 3","346","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","175518|NCI-2018-00040","September 20, 2017","September 1, 2020","September 1, 2020","November 27, 2017","October 21, 2021","October 21, 2021","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT03353740/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03353740"
198,"NCT02840279","A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects",,"Completed","No Results Available","Alzheimer's Disease","Drug: BPN14770|Drug: Placebo","Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Area Under the Curve from Time Zero to Twelve Hours [AUC0-12]|Area Under the Concentration Time Curve from Zero to 12 Hours, Corrected for Dose [AUC12/D]","Tetra Discovery Partners","All","25 Years to 90 Years   (Adult, Older Adult)","Phase 1","77","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BPN14770-CNS-102","June 2016","November 2016","December 2016","July 21, 2016",,"January 18, 2017","Jasper Clinic, Kalamazoo, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT02840279"
199,"NCT02919111","Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients","PSMA PreRP","Completed","Has Results","Prostate Cancer","Drug: Ga-68 labeled PSMA-11 PET","Sensitivity of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Specificity of of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Positive Predictive Value (PPV) of of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Negative Predictive Value (NPV) of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy|Number of Participants With Grade 3 Treatment-related Adverse Events|Sensitivity of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Specificity of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Positive Predictive Value of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Negative Predictive Value of PSMA PET for the Detection of Extra-pelvic Nodal Metastases|Sensitivity of PSMA PET for the Detection of Visceral Metastases|Specificity of PSMA PET for the Detection of Visceral Metastases|Positive Predictive Value of PSMA PET Visceral Metastases|Negative Predictive Value of PSMA PET for the Detection of Visceral Metastases|Sensitivity of PSMA PET for the Detection of Osseous Metastases|Specificity of PSMA PET for the Detection of Osseous Metastases|Positive Predictive Value of PSMA PET for the Detection of Osseous Metastases|Negative Predictive Value of PSMA PET for the Detection of Osseous Metastases","University of California, San Francisco","Male","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","299","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","16559|NCI-2018-00038","September 23, 2016","December 31, 2019","December 31, 2019","September 29, 2016","December 10, 2020","December 10, 2020","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02919111/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02919111/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT02919111"
200,"NCT02918357","Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence","PSMA BCR","Completed","Has Results","Prostate Cancer","Drug: Ga-68 labeled PSMA-11 PET","Positive Predictive Value (PPV) on a Per-patient Basis With Histologic Validation|Positive Predictive Value (PPV) on a Per-region Basis With Histologic Validation|PPVs on a Per-patient of 68Ga-PSMA-11 PET With Conventional Imaging Follow-up|PPVs on a Per-region of 68Ga-PSMA-11 PET With Conventional Imaging Follow-up|Sensitivity on a Per-patient Basis|Sensitivity on a Per-region Basis|Detection Rates of 68Ga-PSMA-11 PET Stratified by Prostate-specific Antigen (PSA) Value|Inter-reader Agreement Per-region|Percentage of Participants With Change in Clinical Management|Safety Assessment - Heart Rate|Safety Assessment - Blood Pressure","University of California, San Francisco","Male","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","385","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","165510|NCI-2018-00039","September 15, 2016","September 21, 2017","September 21, 2017","September 28, 2016","December 2, 2019","December 2, 2019","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02918357/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02918357/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT02918357"
201,"NCT02648672","BPN14770 Single Ascending Dose Study in Healthy Male and Female Subjects",,"Completed","No Results Available","Alzheimer's Disease","Drug: BPN14770|Drug: Placebo","Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Area Under the Curve from Time Zero Extrapolated to Infinity [AUC0-∞]|Maximum Concentration [Cmax]","Tetra Discovery Partners","All","18 Years to 55 Years   (Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BPN14770-CNS-101","December 2015","February 2016","July 2016","January 7, 2016",,"January 18, 2017","Jasper Clinic, Kalamazoo, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT02648672"
202,"NCT01999738","Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors",,"Completed","No Results Available","Solid Tumors|Non Small Cell Lung Carcinoma","Drug: EC1456 and EC20","Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2) - Part A|Efficacy Analysis - Part B","Endocyte","All","18 Years and older   (Adult, Older Adult)","Phase 1","93","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EC1456-01","October 2013","December 31, 2017","April 26, 2018","December 3, 2013",,"February 7, 2019","Mayo Clinic, Phoenix, Arizona, United States|Honor Health, Scottsdale, Arizona, United States|University of Arizona Cancer Center, Tucson, Arizona, United States|City of Hope, Duarte, California, United States|Northwestern University Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States|IU Health Goshen Center for Cancer Care, Goshen, Indiana, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|Horizon BioAdvance, Lafayette, Indiana, United States|University of Maryland-Greenebaum Cancer Center, Baltimore, Maryland, United States|Henry Ford Hospital - Josephine Ford Cancer Center, Detroit, Michigan, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Weill Cornell Medical College, New York, New York, United States|University Hospitals Case Medical Center - Seidman Cancer Center, Cleveland, Ohio, United States|Westchase Clinical Associates, Houston, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|University of Vermont Cancer Center, Burlington, Vermont, United States",,"https://ClinicalTrials.gov/show/NCT01999738"
203,"NCT01111266","Determination of in Vivo Ultrafiltration Coefficient (KUF) in Patients With Chronic Kidney Disease (CKD)",,"Completed","No Results Available","Kidney Disease","Device: xevonta","in vivo KUF|Determination of removal rates","B.Braun Avitum AG|Labor Limbach, Heidelberg, Germany|Clin-Sol, Würzburg, Germany","All","18 Years and older   (Adult, Older Adult)","Not Applicable","12","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","BA-I-H-09-02","March 2010","August 2011","March 2012","April 27, 2010",,"March 14, 2012","Georg-Haas Dialysezentrum der PHV, Gießen, Hessen, Germany",,"https://ClinicalTrials.gov/show/NCT01111266"
204,"NCT03274011","Efficacy and Safety of Apatinib for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma",,"Completed","No Results Available","Esophageal Neoplasms","Drug: Apatinib","Progression Free Survival|Overall Survival|Overall Response Rate","Fudan University","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ESO-Shanghai11","July 1, 2017","March 15, 2019","June 26, 2019","September 6, 2017",,"January 26, 2021","Shanghai Yangpu District East Hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT03274011"
205,"NCT03397641","A Phase 1 Study of HBI-3000",,"Completed","No Results Available","Atrial Fibrillation","Drug: HBI-3000|Other: Placebo","Physical Examination (Safety and Tolerability)|Safety Labs (Safety and Tolerability)|Urinalysis (Safety and Tolerability)|Pulmonary Function Tests (Safety and Tolerability)|12-Lead ECG (Safety and Tolerability)|Holter ECG (Safety and Tolerability)|Telemetry ECG (Safety and Tolerability)|Vital Signs (Safety and Tolerability)|Adverse Events (Safety and Tolerability)|HBI-3000 Levels Over Time in Plasma (Cmax)|HBI-3000 Levels Over Time in Plasma (Tmax)|HBI-3000 Levels Over Time in Plasma (AUC(0-last))|HBI-3000 Levels Over Time in Plasma (AUC(0-inf))|HBI-3000 Levels Over Time in Plasma (AUC(0-24h))|HBI-3000 Levels Over Time in Plasma (AUC%extrap)|HBI-3000 Levels Over Time in Plasma (lambda-z)|HBI-3000 Levels Over Time in Plasma (T1/2)|HBI-3000 Levels Over Time in Plasma (CL)|HBI-3000 Levels Over Time in Plasma (CLr)|HBI-3000 Levels Over Time in Plasma (Vz)|HBI-3000 Levels Over Time in Plasma (Vss)|HBI-3000 Levels Over Time in Plasma (MRT)|HBI-3000 Levels Over Time in Urine (Ae)|HBI-3000 Levels Over Time in Urine (CumAe)|HBI-3000 Levels Over Time in Urine (%Ae)|HBI-3000 Levels Over Time in Urine (Cum%Ae)","HUYABIO International, LLC.|Quotient Clinical","All","18 Years to 50 Years   (Adult)","Phase 1","47","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HBI-3000-301|2017-003642-24","October 17, 2017","July 10, 2018","July 10, 2018","January 12, 2018",,"August 29, 2018","Quotient Clinical, Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03397641"
206,"NCT01695876","A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Food Effect of AMG 357 in Healthy Subjects",,"Completed","No Results Available","Inflammatory Disease","Drug: AMG 357|Drug: Placebo","Safety and Tolerability|Pharmacodynamics|Effect of Food on AMG 357","Amgen","All","25 Years to 55 Years   (Adult)","Phase 1","58","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20110246|Inflammation","October 2012","September 2014","October 2014","September 28, 2012",,"March 4, 2015","Research Site, Christchurch, New Zealand|Christchurch, New Zealand|Research Site, Grafton, Auckland, New Zealand",,"https://ClinicalTrials.gov/show/NCT01695876"
207,"NCT01703754","Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer.",,"Completed","No Results Available","Breast Cancer Nos Metastatic Recurrent","Genetic: Ad-RTS-hIL-12 and Veledimex|Drug: Palifosfamide","Safety and tolerability of study drug therapy based on type and rate of adverse events and 16-week PFS rate.|Objective response rate (ORR) by modified RECIST v1.1|Clinical Benefit rate: proportion of subjects with CR, PR, or SD by modified RECIST v1.1|Estimate PFS by modified RECIST v1.1|Evaluate Pharmacodynamic tumor markers in tumor tissue samples that may correlate with objective tumor response and/or clinical outcome","Alaunos Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 2","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ATI001-201","March 2013","December 2014","December 2014","October 10, 2012",,"January 27, 2015","Baptist Cancer Institute, Jacksonville, Florida, United States|Henry Ford Health System, Detroit, Michigan, United States|Billings Clinic, Billings, Montana, United States|Signal Point Clinical Research Center, Middletown, Ohio, United States|Greenville Hospital System, Greenville, South Carolina, United States|The Jones Clinic, PC, Germantown, Tennessee, United States|Mary Crowley Medical Research Center, Dallas, Texas, United States|Evergreen Hematology & Oncology, Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01703754"
208,"NCT00813384","A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors",,"Completed","No Results Available","Cancer|Oncology|Tumors|Advanced Malignancy|Advanced Solid Tumors|Oncology Patients","Drug: AMG 208","To determine the maximum tolerated dose (MTD) of AMG 208, if possible|To evaluate for clinical responses associated with AMG 208 treatment in subjects (Dose Expansion) with advanced solid malignancies according to RECIST criteria|To characterize the pharmacokinetic (PK) exposure of AMG 208 when administered orally to subjects with advanced solid malignancies|To evaluate the safety and tolerability of AMG 208 in subjects with advanced solid malignancies|To evaluate for a decrease in tumor cell proliferation associated with AMG 208 treatment in subjects with advanced solid malignancies according to FLT-PET scanning|To assess tumor volume changes after AMG 208 treatment by computed tomography (CT) or magnetic resonance imaging (MRI)|To assess skin specimens for potential biomarkers|To determine whether c-Met expression, mutation, or amplification in tumor specimens correlates with a response to AMG 208","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","54","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20080895","December 2008","February 2013","December 2014","December 23, 2008",,"December 16, 2014","Research Site, Beverly Hills, California, United States|Research Site, St Louis, Missouri, United States|Research Site, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00813384"
209,"NCT02987829","Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients",,"Completed","Has Results","Metastatic Castrate-resistant Prostate Cancer|Adenocarcinoma, Prostate","Drug: TRC253","Number of Patients Who Experience Dose Limiting Toxicities by Dose Level|Number of Participants With a Serum Prostate-specific Antigen (PSA) Response According to Prostate Cancer Working Group (PCWG3) Criteria|Maximum Change in QTcF|Percent Change From Baseline in Standard Uptake Value (SUV) to Assess TRC253 Receptor Occupancy|Median Time to Progression by Dose Level|Number of Patients Who Achieved the Target Concentration of TRC253 at Steady State","Tracon Pharmaceuticals Inc.|Janssen Pharmaceutica N.V., Belgium","Male","18 Years to 99 Years   (Adult, Older Adult)","Phase 1|Phase 2","72","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","253PC101","May 23, 2017","October 6, 2019","November 9, 2020","December 9, 2016","April 23, 2021","April 23, 2021","University of Alabama at Birmingham, Birmingham, Alabama, United States|Honor Health, Scottsdale, Arizona, United States|University of California at Los Angeles, Santa Monica, California, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Utah, Salt Lake City, Utah, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/29/NCT02987829/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02987829"
210,"NCT03773952","Safety and Efficacy of PBF-677 in Ulcerative Colitis Patients","ADENOIBD","Completed","No Results Available","Ulcerative Colitis","Drug: PBF-677|Drug: Placebo oral capsule","Number of subjects with treatment-related adverse events as assessed by CTCAE v4.03""|Effect of PBF-677 on Faecal calprotectin levels|Effect of PBF-677 on Ulcerative Colitis activity|Pharmacokinetic PBF-677 peak concentration in plasma|Pharmacokinetic Time to PBF-677 peak concentration in plasma ""Tmax""|Pharmacokinetic Area under curve (AUC) of PBF-677 in plasma|Pharmacokinetic Ctrough plasma concentration of PBF-677","Palobiofarma SL|Qualitecfarma","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","34","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PBF-677-3","July 1, 2018","May 27, 2021","May 27, 2021","December 12, 2018",,"January 13, 2022","Unidad de Enfermedad Inflamatoria Intestinal / IBD Unit. Servicio de Gastroenterología y Hepatología / Gastroenterology and Hepatology Dpt. Study Medical Coordinator Hospital Universitario Puerta de Hierro, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT03773952"
211,"NCT04102241","Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis",,"Completed","No Results Available","Psoriasis","Drug: 15mg Hemay005|Drug: Placebos","Proportion of subjects who have 75% or more reduction in [Psoriasis area-and-severity index score (PASI)] (PASI75).|Severity of Adverse Events and Serious Adverse Events.|Cmax of Hemay005.|Proportion of subjects achieving an overall sPGA score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline.","Tianjin Hemay Pharmaceutical Co.,Ltd","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","216","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HM005PS2S01","May 30, 2019","October 12, 2020","July 21, 2021","September 25, 2019",,"October 13, 2021","Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT04102241"
212,"NCT03795363","Orkambi Treatment in 2 to 5 Year Old Children With CF",,"Completed","No Results Available","Cystic Fibrosis","Drug: Orkambi","Sleeping or Resting Energy Expenditure|Anthropometric Assessment|Fecal Elastase I/Pancreatic Function|Fecal Calprotectin/Gut Inflammation|Plasma Total Fatty Acids","Children's Hospital of Philadelphia|Vertex Pharmaceuticals Incorporated","All","2 Years to 5 Years   (Child)",,"28","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","18-015669","April 10, 2019","June 16, 2021","June 16, 2021","January 7, 2019",,"December 2, 2021","Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/63/NCT03795363/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/63/NCT03795363/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT03795363"
213,"NCT03229291","A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SM04755 Following Topical Administration to Healthy Subjects",,"Completed","No Results Available","Tendinopathy","Drug: SM04755|Drug: Vehicle","Incidence of adverse events (AEs)|Incidence of clinical laboratory abnormalities|Change in vital signs: blood pressure|Change in vital signs: temperature|Change in vital signs: respiratory rate|Change in vital signs: pulse rate|Change in electrocardiogram (ECG) parameters|Plasma pharmacokinetics (PK): Cmax|Plasma pharmacokinetics (PK):tmax|Plasma pharmacokinetics (PK): AUC|Plasma pharmacokinetics (PK):half-life|Plasma pharmacokinetics (PK):Cmax|Change in skin score assessment: erythema|Change in skin score assessment: scaling|Change in skin score assessment: pruritus/itching|Change in skin score assessment: burning/stinging|Incidence of AEs relative to exposure","Biosplice Therapeutics, Inc.","All","18 Years to 50 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","SM04755-TOP-01","November 3, 2016","June 11, 2017","June 11, 2017","July 25, 2017",,"July 25, 2017","Research Site, Tempe, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT03229291"
214,"NCT03647670","A Study to Determine the Effects of PF-04965842 on Midazolam PK in Healthy Volunteers",,"Completed","No Results Available","Phase 1","Drug: PF-04965842|Drug: Midazolam","AUCinf of midazolam.|AUClast of midazolam|Blood Pressure|Cmax of midazolam.|Tmax of midazolam.|t1/2 of midazolam.|Pulse|Temperature|Adverse Events|Laboratory tests","Pfizer","All","18 Years to 55 Years   (Adult)","Phase 1","25","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","B7451022|2018-001198-26","July 3, 2018","October 16, 2018","October 16, 2018","August 27, 2018",,"March 23, 2020","Pfizer Clinical Research Unit, Brussels, Belgium",,"https://ClinicalTrials.gov/show/NCT03647670"
215,"NCT04006145","A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH",,"Completed","Has Results","NAFLD|NASH","Drug: Elobixibat|Drug: Placebo oral tablet","Change From Baseline in Serum Low Density Lipoprotein-cholesterol (LDL-C) at Week 16","Albireo","All","18 Years and older   (Adult, Older Adult)","Phase 2","47","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","A3309-012","June 6, 2019","June 26, 2020","July 15, 2020","July 5, 2019","September 27, 2021","September 27, 2021","Hope Clinical Research, Canoga Park, California, United States|Inland Empire Clinical Trials, LLC, Rialto, California, United States|Peak Gastroenterology Associates, Colorado Springs, Colorado, United States|Integrity Clinical Research, LLC, Doral, Florida, United States|Nature Coast Clinical Research, Inverness, Florida, United States|Guardian Angel Research Center, Inc., Tampa, Florida, United States|Mercy Medical Center, Baltimore, Maryland, United States|American Research Corporation at the Texas Liver Institute, San Antonio, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|University of Washington, Seattle, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT04006145/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT04006145/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04006145"
216,"NCT03662516","A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects",,"Completed","No Results Available","Healthy Females","Drug: PF-04965842|Drug: Ethinyl estradiol (EE) and levonorgestrel (LN)","AUCinf for EE|AUCinf for LN|Laboratory tests|Adverse Events (AEs)|Vital signs|12-lead ECGs","Pfizer","Female","18 Years to 55 Years   (Adult)","Phase 1","17","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","B7451016","September 26, 2018","January 19, 2019","January 19, 2019","September 7, 2018",,"March 23, 2020","Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT03662516"
217,"NCT03566238","This Study Will Investigate the Efficacy and Safety of A4250 in Children With PFIC Types 1 or 2","PEDFIC 1","Completed","Has Results","PFIC1|PFIC2","Drug: A4250 (odevixibat)|Drug: Placebo","Proportion of Positive Pruritus Assessments at the Participant Level Over the 24-week Treatment Period Based on the Albireo Observer-reported Outcome (ObsRO) Instrument (United States Primary Endpoint)|Percentage of Participants Experiencing at Least a 70% Reduction in Fasting s-BA Concentration From Baseline to the End of Treatment or Reaching a Level <= 70 μmol/L After 24 Weeks of Treatment (European Union and Rest of the World Primary Endpoint)","Albireo","All","6 Months to 18 Years   (Child, Adult)","Phase 3","62","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","A4250-005","May 16, 2018","July 27, 2020","July 28, 2020","June 25, 2018","September 5, 2021","September 5, 2021","Children's Hospital Los Angeles, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|Children's Hospital Colorado, Denver, Colorado, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Johns Hopkins School of Medicine, Baltimore, Maryland, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Medical Center - Presbyterian Hospital Building, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Baylor College of Medicine - Texas Children's Liver Center, Houston, Texas, United States|The Royal Children's Hospital, Melbourne, Australia|UZ Leuven, Leuven, Belgium|Cliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert, Belgium|The Hospital for Sick Children, Toronto, Canada|British Columbia Children's Hospital, Vancouver, Canada|University and Pediatric Hospital of Lyon, Bron, France|Universite Paris SUD - Hopitaux Universitaires Paris-Sud - Hopital Bicetre, le Kremlin Bicetre, France|Hospital de la Timone, Marseille, France|Hospital Necker-Enfants maladies, Paris, France|Uniklinikum Essen- Kinderklinik II, Essen, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Kinderklinik Tübingen, Universitätsklinikum Tübingen, Tubingen, Germany|Rambam Medical Centre, Haifa, Israel|Shaare-Zedek Mc, Jerusalem, Israel|Schneider Children's Medical Center Of Israel, Petach-Tikva, Israel|Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy|University Hospital Of Padova, Padova, Italy|Ospedale Regina Margherita, Torino, Italy|University Medical Center Groningen, Groningen, Netherlands|Universitair Medisch Centrum (UMC) Utrecht, Utrecht, Netherlands|Instytut Pomnik - Centrum Zdrowia Dziecka, Warsaw, Poland|King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Astrid Lindgren Children's Hospital, Karolinska University Hospital, Solna, Sweden|Gazi University, Ankara, Turkey|Hacettepe University Faculty of Medicine, Ankara, Turkey|Akdeniz University, Antalya, Turkey|Istanbul University Medical Faculty, Istanbul, Turkey|Inonu University Medical Faculty, Malatya, Turkey|Birmingham Women's and Children's NHS Foundation Trust, Birmingham, United Kingdom|Leeds General Infirmary, Leeds, United Kingdom|Institute of Liver Studies - Kings College Hospital, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT03566238/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT03566238/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03566238"
218,"NCT02932566","The Efficacy and Safety of Pirfenidone in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction","PIROUETTE","Completed","No Results Available","Cardiac Failure","Drug: Pirfenidone|Drug: Placebo","Extracellular volume fraction (ECV)|Left ventricular (LV) mass|Left ventricular volume|Left ventricular ejection fraction|Left ventricular strain - CMR|Left ventricular strain - Echo|Left ventricular torsion|Myocardial cell structure|Diastolic function|Left atrial volume|Myocardial energetic status|Cardiac biomarkers - N-Terminal-Pro-Brain Natriuretic Peptide (NT-Pro BNP)|Cardiac biomarkers - high-sensitivity Troponin T (hsTnT)|Patient exercise capacity|Patient morbidity|All cause mortality|Cardiovascular mortality|Hospitalisation for heart failure","Manchester University NHS Foundation Trust|National Institute for Health Research, United Kingdom|University of Manchester|University of Liverpool, Clinical Trials Research Centre|Hoffmann-La Roche","All","40 Years and older   (Adult, Older Adult)","Phase 2","129","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2016CD004","March 2, 2017","November 29, 2019","April 29, 2020","October 13, 2016",,"July 2, 2020","Manchester University NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02932566"
219,"NCT00124280","Study Investigating the Effect of Everolimus Monotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)",,"Completed","No Results Available","Non-small-cell Lung Carcinoma","Drug: RAD001","Clinical efficacy based on the evaluation of objective tumor response rate (RR)|To assess safety of RAD001 monotherapy|To assess additional clinical efficacy of RAD001|To assess the steady state levels of RAD001 in blood|To investigate potential molecular markers predictive of clinical effect","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 2","85","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CRAD001C2235","July 2005","October 2007",,"July 27, 2005",,"November 18, 2016","Nevada Cancer Institute, Las Vegas, Nevada, United States|MD Anderson Cancer Center, Department of Thoracic /Head and Neck Medical Oncology, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00124280"
220,"NCT04044664","Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder",,"Completed","No Results Available","Post-Traumatic Stress Disorder","Drug: Placebo oral capsule|Drug: NYX-783","CAPS-5 (Clinician-Administered PTSD Scale for DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition)) Total Score and Subscores|PCL-5 (PTSD-Checklist for DSM-5)|PSQI (Pittsburgh Sleep Quality Index) Global Score|PSQI-A (Pittsburgh Sleep Quality Index-Addendum) Global Score|BAC Symbol Coding (Brief Assessment of Cognition)|CGI-S (Clinical Global Impression - Severity)|HADS (Hospital Anxiety and Depression Scale)","Aptinyx|Premier Research Group plc|Massachusetts General Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","160","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NYX-783-2004","January 25, 2019","August 5, 2020","August 5, 2020","August 5, 2019",,"December 22, 2020","Aptinyx Clinical Site, Tuscaloosa, Alabama, United States|Aptinyx Clinical Site, Phoenix, Arizona, United States|Aptinyx Clinical Site, Little Rock, Arkansas, United States|Aptinyx Clinical Site, Bellflower, California, United States|Aptinyx Clinical Site, Glendale, California, United States|Aptinyx Clinical Site, Imperial, California, United States|Aptinyx Clinical Site, Oakland, California, United States|Aptinyx Clinical Site, Oceanside, California, United States|Aptinyx Clinical Site, Orange, California, United States|Aptinyx Clinical Site, Riverside, California, United States|Aptinyx Clinical Site, San Diego, California, United States|Aptinyx Clinical Site, San Marcos, California, United States|Aptinyx Clinical Site, Santa Ana, California, United States|Aptinyx Clinical Site, Temecula, California, United States|Aptinyx Clinical Site, Torrance, California, United States|Aptinyx Clinical Site, Colorado Springs, Colorado, United States|Aptinyx Clinical Site, Norwich, Connecticut, United States|Aptinyx Clinical Site, Jacksonville, Florida, United States|Aptinyx Clinical Site, Lauderhill, Florida, United States|Aptinyx Clinical Site, Orlando, Florida, United States|Aptinyx, Atlanta, Georgia, United States|Aptinyx Clinical Site, Atlanta, Georgia, United States|Aptinyx Clinical Site, Hoffman Estates, Illinois, United States|Aptinyx Clinical Site, Boston, Massachusetts, United States|Aptinyx Clinical Site, Las Vegas, Nevada, United States|Aptinyx Clinical Site, Berlin, New Jersey, United States|Aptinyx Clinical Site, Cedarhurst, New York, United States|Aptinyx Clinical Site, New York, New York, United States|Aptinyx Clinical Site, Staten Island, New York, United States|Aptinyx Clinical Site, Salisbury, North Carolina, United States|Aptinyx Clinical Site, Canton, Ohio, United States|Aptinyx Clinical Site, Cincinnati, Ohio, United States|Aptinyx Clinical Site, Oklahoma City, Oklahoma, United States|Aptinyx Clinical Site, Memphis, Tennessee, United States|Aptinyx Clinical Site, Austin, Texas, United States|Aptinyx Clinical Site, San Antonio, Texas, United States|Aptinyx Clinical Site, Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04044664"
221,"NCT03249103","Evaluate the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia",,"Completed","No Results Available","Fibromyalgia","Drug: NYX-2925|Drug: Placebo oral capsule","Changes in markers of central pain processing as measured by functional magnetic resonance imaging.|Evaluate safety as measured by the incidence of adverse events|Evaluate the safety as measure by the change in vital sign measurements|Evaluate the changes in clinical laboratory test results|Evaluate the changes in electrocardiogram results|Evaluate the changes in physical examination findings|Evaluating suicidal ideation and behavior as measure by the Columbia-Suicide Severity Rating Scale","Aptinyx|inVentiv Health Clinical","Female","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","22","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","NYX-2925-2002","August 14, 2017","April 18, 2019","April 18, 2019","August 15, 2017",,"June 25, 2019","Aptinyx Clinical Site, Ann Arbor, Michigan, United States|Aptinyx Clinical Site, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03249103"
222,"NCT03219320","Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy","DPN","Completed","Has Results","Diabetic Peripheral Neuropathy","Drug: NYX-2925|Drug: Placebo","Numeric Rating Scale (NRS) Average Pain Intensity|Numeric Rating Scale (NRS) Average Pain Intensity in Patients Who Did Not Use a Concomitant Medication at Baseline","Aptinyx|Syneos Health","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","301","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","NYX-2925-2001","June 27, 2017","November 2, 2018","November 2, 2018","July 17, 2017","June 9, 2020","June 9, 2020","Aptinyx Clinical Site, Phoenix, Arizona, United States|Aptinyx Clinical Site, Anaheim, California, United States|Aptinyx Clinical Site, Fresno, California, United States|Aptinyx Clinical Site, Norco, California, United States|Aptinyx Clinical Site, Santa Monica, California, United States|Aptinyx Clinical Site, Tustin, California, United States|Aptinyx Clinical Site, New London, Connecticut, United States|Aptinyx Clinical Site, Bradenton, Florida, United States|Aptinyx Clinical Site, Brandon, Florida, United States|Aptinyx Clinical Site, Fort Myers, Florida, United States|Aptinyx Clinical Site, Hallandale Beach, Florida, United States|Aptinyx Clinical Site, Jupiter, Florida, United States|Aptinyx Clinical Site, Miami, Florida, United States|Aptinyx Clinical Site, Miami, Florida, United States|Aptinyx Clinical Site, Miami, Florida, United States|Aptinyx Clinical Site, Ocoee, Florida, United States|Aptinyx Clinical Site, Orlando, Florida, United States|Aptinyx Clinical Site, Orlando, Florida, United States|Aptinyx Clinical Site, Tampa, Florida, United States|Aptinyx Clinical Site, West Palm Beach, Florida, United States|Aptinyx Clinical Site, Columbus, Georgia, United States|Aptinyx Clinical Site, Decatur, Georgia, United States|Aptinyx Clinical Site, Meridian, Idaho, United States|Aptinyx Clinical Site, Flossmoor, Illinois, United States|Aptinyx Clinical Site, Hazelwood, Missouri, United States|Aptinyx Clinical Site, Berlin, New Jersey, United States|Aptinyx Clinical Site, Rochester, New York, United States|Aptinyx Clinical Site, Dayton, Ohio, United States|Aptinyx Clinical Site, Knoxville, Tennessee, United States|Aptinyx Clinical Site, Memphis, Tennessee, United States|Aptinyx Clinical Site, Tullahoma, Tennessee, United States|Aptinyx Clinical Site, Austin, Texas, United States|Aptinyx Clinical Site, Houston, Texas, United States|Aptinyx Clinical Site, Plano, Texas, United States|Aptinyx Clinical Site, Norfolk, Virginia, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT03219320/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT03219320/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03219320"
223,"NCT02798627","Trial Of NS2359 For The Treatment of Cocaine Dependence",,"Completed","Has Results","Cocaine Use Disorder","Drug: NS2359|Drug: placebo","The Number of Participants Who Achieved Abstinence From Cocaine During the Last Three Weeks of the Trial|Average Weekly Cocaine Craving Scores NS2359 Group Versus the Placebo Group Comparator [ Time Frame: Once Per Week in Weeks 2 Through 8 ]","University of Pennsylvania|Saniona|The Dana Foundation","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","55","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","824109","May 2016","March 2020","October 2020","June 14, 2016","May 24, 2021","May 24, 2021","University of Pennsylvania, Philadelphia, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT02798627/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02798627"
224,"NCT02207504","Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer",,"Completed","No Results Available","Castration-resistant Prostate Cancer","Drug: Crizotinib|Drug: Enzalutamide","Rate of dose limiting toxicity (DLT)|Pharmacokinetics profiles of crizotinib and enzalutamide when used in combination|The number of patients who experience adverse events and laboratory abnormalities","Dana-Farber Cancer Institute|Astellas Pharma Inc|Pfizer","Male","18 Years and older   (Adult, Older Adult)","Phase 1","24","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14-230","August 2014","February 2, 2018","January 3, 2022","August 4, 2014",,"January 6, 2022","Dana Farber Cancer Institute, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02207504"
225,"NCT02644525","Efficacy and Microfilaricidal Kinetics of Imatinib for the Treatment of Loa Loa",,"Completed","No Results Available","Loaisis","Drug: Imatinib Mesylate|Drug: Placebo","To determine the short-term microfilaricidal kinetics of imatinib against Loa loa.|To assess the safety of a single dose of imatinib in Loa loa infection","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","115","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","999916042|16-I-N042","September 16, 2019","December 31, 2020","March 19, 2021","January 1, 2016",,"June 10, 2021","Centre de Recherche sur les Filarioses et Autres Maladies Tropicales, Mbalmayo, Cameroon",,"https://ClinicalTrials.gov/show/NCT02644525"
226,"NCT03575598","Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study","SNOW","Completed","No Results Available","Squamous Cell Carcinoma, Head And Neck|Squamous Cell Carcinoma Mouth|Squamous Cell Carcinoma of the Oral Cavity","Drug: Sitravatinib|Biological: Nivolumab","Pharmacodynamic effects with biomarker analyses|Immune effects with biomarker analyses|Toxicities as per NCI CTCAE v5.0|Rate of completion of surgery within the initially planned window|Rate of post-operative complications|Rate of disease progression as per RECIST v1.1 during the pre-operative treatment period|Pathologic treatment effect in tumor and/ or lymph nodes|Rate of nodal extracapsular extension and positive margins|Analysis of plasma Sitravatinib concentration before and after Nivolumab therapy","University Health Network, Toronto|Mirati Therapeutics Inc.","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SNOW-001","August 30, 2018","February 18, 2020","February 18, 2020","July 2, 2018",,"April 1, 2021","Princess Margaret Cancer Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03575598"
227,"NCT03641417","Investigating the Role of Ghrelin in Regulating Appetite and Energy Intake in Patients Following Bariatric Surgery (BARI-INSIGHT)","BARI-INSIGHT","Completed","No Results Available","Obesity|Bariatric Surgery Candidate|Appetitive Behavior","Drug: GLWL-01|Other: Placebo","Within-subject acute energy intake|Fasted appetite scores|Area-under-the-curve for appetite scores|Macronutrient selection|Subjective aspects of appetite|24-hour energy intake|Gut hormones levels|Adipokine levels|Body weight|Body composition|Inflammatory markers and cytokines","University College, London","All","18 Years to 64 Years   (Adult)","Not Applicable","35","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","17/0887","February 15, 2019","March 6, 2020","March 13, 2020","August 22, 2018",,"May 20, 2020","University College London, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03641417"
228,"NCT01039948","A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer",,"Completed","No Results Available","Carcinoma, Non-Small Cell-Lung|Lung Neoplasms|Lung Cancer|Respiratory Tract Neoplasms","Biological: AV-299 + gefitinib|Drug: Gefitinib","Phase Ib: Dose Limiting Toxicity and Recommended Phase II Dose|Phase 2: Objective Response Rate|Phase 1b: Cmax, Tmax, AUC, t1/2, clearance, and Vd|Phase 2: Progression Free Survival, Overall Survival, Safety","AVEO Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","203","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P06162","December 2009","August 2013","August 2013","December 25, 2009",,"April 8, 2015","Investigational Site 1, Shatin N.T., Hong Kong|Investigational Site 2, Chungcheongbuk-do, Korea, Republic of|Investigational Site 3, Gyeonggi-do, Korea, Republic of|Investigational Site 4, Jeollanam-do, Korea, Republic of|Investigational Site 5, Seoul, Korea, Republic of|Investigational Site 6, Seoul, Korea, Republic of|Investigational Site 7, Seoul, Korea, Republic of|Investigational Site 8, Seoul, Korea, Republic of|Investigational Site 10, Kuala Lumpur, Malaysia|Investigational Site 9, Kuala Lumpur, Malaysia|Investigational Site 11, Pahang, Malaysia|Investigational Site 12, Manila, Philippines|Investigational Site 13, Pasig City, Philippines|Investigational Site 14, Quezon City, Philippines|Investigational Site 15, Singapore, Singapore|Investigational Site 16, Changhua, Taiwan|Investigational Site 17, Chiayi, Taiwan|Investigational Site 18, Taichung, Taiwan|Investigational Site 19, Tainan, Taiwan|Investigational Site 20, Taipei, Taiwan|Investigational Site 21, Taipei, Taiwan|Investigational Site 22, Taoyuan, Taiwan|Investigational Site 23, Bangkok, Thailand|Investigational Site 24, Chiang Mai, Thailand|Investigational Site 25, KhonKaen, Thailand|Investigational Site 26, Songkla, Thailand",,"https://ClinicalTrials.gov/show/NCT01039948"
229,"NCT03078738","Safety and Pharmacokinetic Study of OMT-28 in Healthy Subjects",,"Completed","No Results Available","Healthy Volunteers","Drug: OMT-28|Other: Matching Placebo","Safety assessed by frequency and nature of treatment-emergent adverse events|Pharmacokinetics (PK) measured by AUC0-t of OMT-28 in plasma in the SAD|Pharmacokinetics (PK) measured by AUC0-∞ of OMT-28 in plasma in the SAD|Pharmacokinetics (PK) measured by Cmax of OMT-28 in plasma in the SAD|Pharmacokinetics (PK) measured by AUC0-24h of OMT-28 in plasma after single dosing in the SAD|Pharmacokinetics (PK) measured by AUC0-τ after multiple dosing on Day 7 and 14 in the MAD|Pharmacokinetics (PK) of OMT28 measured Cmax after multiple dosing on Day 7 and 14 in the MAD|Pharmacokinetics (PK) in Food Effect and Gender Part measured by AUC0-t of OMT-28 in plasma|Pharmacokinetics (PK) in Food Effect and Gender Part measured by AUC0-∞ of OMT-28 in plasma|Pharmacokinetics (PK) of OMT28 in Food Effect and Gender Part measured by Cmax of OMT-28 in plasma|Change-from-baseline of QTcF (∆QTcF)|Change from-baseline of heart rate|Change from-baseline of PR interval in ECG|Change from-baseline of QRS interval (∆HR, ∆PR and ∆QRS)","Omeicos Therapeutics GmbH","Male","18 Years to 45 Years   (Adult)","Phase 1","75","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","OMT28-C0101","February 8, 2017","March 12, 2018","March 12, 2018","March 13, 2017",,"September 28, 2018","CRS-Mönchengladbach, Monchengladbach, Germany",,"https://ClinicalTrials.gov/show/NCT03078738"
230,"NCT03291314","Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma","GliAvAx","Completed","No Results Available","Recurrent Glioblastoma (WHO-Grade IV Glioma)","Drug: Axitinib|Drug: Avelumab","6-month PFS%|Median OS (Overall survival)|Objective Tumor Response (OR)|Overall Safety profile|Evolution of neuro-cognitive function|Continuous activity","Universitair Ziekenhuis Brussel","All","18 Years and older   (Adult, Older Adult)","Phase 2","52","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017-BN-001","May 3, 2017","January 1, 2019","January 1, 2019","September 25, 2017",,"January 23, 2019","UZ Brussel, Brussel, Belgium",,"https://ClinicalTrials.gov/show/NCT03291314"
231,"NCT03197623","Safety and Tolerability of Intravenous LLP2A-Alendronate for Osteopenia Secondary to Glucocorticoids",,"Completed","No Results Available","Osteopenia|Osteoporosis|Osteonecrosis","Drug: LLP2A-ALENDRONATE|Drug: Placebo","Dose limiting Adverse events|Severe infusion reactions|Grade 2 elevated creatinine","Nancy E. Lane, MD|California Institute for Regenerative Medicine (CIRM)|University of California, Davis","All","20 Years to 85 Years   (Adult, Older Adult)","Phase 1","58","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20161825|LLP2A-001","October 14, 2016","March 15, 2021","March 31, 2021","June 23, 2017",,"August 6, 2021","West Coast Clinical Trials (WCCT), Cypress, California, United States|Diablo Clinical Research, Walnut Creek, California, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Metroplex Clinical Research Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03197623"
232,"NCT01621204","A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients",,"Completed","No Results Available","Immune Thrombocytopenic Purpura","Drug: Eltrombopag|Drug: IVIG infusion","Achievement of a platelet count level that is above the platelet count threshold for surgery preoperatively and that is maintained above the threshold during the post-hemostasis period without the use of rescue treatment|Time to treatment failure|Surgical delays or cancellations|Bleeding|Thrombocytosis|Blood product transfusions|Rescue treatment|Platelet count change over time|Patient satisfaction with treatment|Hospitalizations|Thrombosis|Adverse Events","McMaster University|GlaxoSmithKline|Hamilton Health Sciences Corporation|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","74","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","M-EIBS-A-12","October 2012","June 2019","August 2019","June 18, 2012",,"September 9, 2020","University of Alberta Hospital, Edmonton, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Hamilton Health Sciences, Hamilton, Ontario, Canada|London Health Sciences Center, London, Ontario, Canada|Ottawa Hospital, Ottawa, Ontario, Canada|Sunnybrook Hospital, Toronto, Ontario, Canada|St.Micheal's Hospital, Toronto, Ontario, Canada|Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada|The Haga Hospital, The Hague, Netherlands",,"https://ClinicalTrials.gov/show/NCT01621204"
233,"NCT03811145","An Investigation of Tendoncel, a Novel Topical Platelet Lysate Gel, in the Treatment of Lateral Epicondylitis",,"Completed","No Results Available","Lateral Epicondylitis","Biological: Tendoncel|Other: Placebo control gel","Patient-Rated Tennis Elbow Evaluation (PRTEE) questionnaire|Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire|Pain free grip strength|Safety - Number of participants in each group with adverse events.|Safety: Immune response - blood IgE levels. Difference between test and control groups.|Safety: Immune response - blood IgE levels. Number of participants in each group with a normal baseline reading and a subsequently elevated reading.","Cell Therapy Ltd.|George Papanicolaou Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CTL/LE/01/0514","May 2014","November 2015","November 2015","January 22, 2019",,"December 12, 2019","Orthopaedic Clinic of Aristotle University of Thessaloniki, General Hospital of Papanikolaou, Thessaloniki, Greece",,"https://ClinicalTrials.gov/show/NCT03811145"
234,"NCT00158782","Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients",,"Completed","No Results Available","Carcinoma, Renal Cell","Drug: GW786034|Drug: lapatinib","Changes in pre and post treatment lab values and monitoring/reporting AES.AE's throughout study|Labs every wk first cycle:day 1 subsequent cycles|find max conc of drugs in blood and time it occurs find out if drugs are taken up by the body, how much/for how long find out if drugs affect the size of the tumor. Blood taken day 15, 22 or 37 and tumor assessed every 8 wks","GlaxoSmithKline","All","21 Years and older   (Adult, Older Adult)","Phase 1","75","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VEG10006","September 28, 2004","August 21, 2007","August 21, 2007","September 12, 2005",,"November 17, 2017","GSK Investigational Site, Durham, North Carolina, United States|GSK Investigational Site, Rotterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT00158782"
235,"NCT01329991","Phase 1b Study of PLX5622 in Rheumatoid Arthritis Patients Who Are Receiving Methotrexate",,"Completed","No Results Available","Rheumatoid Arthritis","Drug: PLX5622|Drug: Placebo","Safety-Number of patients with adverse events|Pharmacokinetic profile: Measurement of area under the plasma-concentration-time curve|Pharmacokinetic evaluation: Measurement of Peak Concentration|Pharmacokinetic profile: Measurement of half life, apparent systemic clearance, and apparent volume of distribution, terminal phase.|Pharmacodynamics-Effect of PLX5622 on the body","Plexxikon","All","18 Years and older   (Adult, Older Adult)","Phase 1","26","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PLX115-02","May 2011","October 2011","October 2011","April 6, 2011",,"April 12, 2012","Pinnacle Research Group, Anniston, Alabama, United States|Medical Practice of Justus Fiechtner, MD, Lansing, Michigan, United States|Altoona Center for Clinical research, Duncansville, Pennsylvania, United States|Metroplex Clinical Research Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01329991"
236,"NCT01282684","Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PLX5622 in Healthy Adult Volunteers",,"Completed","No Results Available","Healthy","Drug: PLX5622|Drug: Placebo","Safety-Number of patients with adverse events|Tolerability-Number of patients with adverse events|Pharmacokinetic profile: Measurement of area under the plasma-concentration-time curve|Pharmacokinetic evaulation: Measurement of Peak Concentration|Pharmacokinetic profile: Measurement of half life and terminal elimination rate constant","Plexxikon","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PLX115-01","January 2011","April 2011","April 2011","January 25, 2011",,"March 30, 2015","Cetero Research, Fargo, North Dakota, United States",,"https://ClinicalTrials.gov/show/NCT01282684"
237,"NCT00370383","A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 Non-small-cell Lung Cancer (NSCLC)",,"Completed","No Results Available","Lung Cancer","Drug: Erlotinib|Drug: Satraplatin","To compare Progression-Free Survival (PFS) in patients ≥ 70 years of age, PS 0-1, with advanced or metastatic NSCLC in patients treated with a first-line regimen of either sequential satraplatin and erlotinib or continuous single-agent erlotinib.|To assess Overall Survival in patients ≥ 70 years of age, PS 0-1, with advanced or metastatic NSCLC in patients treated with a first-line regimen of either sequential satraplatin and erlotinib or continuous single-agent erlotinib.|To compare response rates.|To compare the toxicity profiles between patients treated with satraplatin and erlotinib and single-agent erlotinib","Agennix","All","70 Years and older   (Older Adult)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SAT2-05-07","July 2006","February 2009","March 2009","August 31, 2006",,"August 7, 2012","Pacific Cancer Medical Center, Anaheim, California, United States|Scripps Clinic, La Jolla, California, United States|Kenmar Research Institute, Los Angeles, California, United States|Memorial Cancer Institute, Hollywood, Florida, United States|University of Miami Sylvester Cancer Center, Miami, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Highlands Oncology Group, Bentonville, Ohio, United States|Gabrail Cancer Center, Canton, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Signal Point Hematology/Oncology, Middleton, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|McGill University, Montreal, Canada|Princess Margaret Hospital, Toronto, Canada|Hospital San Borja Arriaran, Santiago, Chile|Instituto Nacional del Cancer, Santiago, Chile|Research Center, Santiago, Chile",,"https://ClinicalTrials.gov/show/NCT00370383"
238,"NCT04187456","A Study in Healthy Male Subjects to Understand How Savolitinib When Taken With Midazolam Behaves Inside the Body",,"Completed","No Results Available","Solid Tumors","Drug: Savolitinib|Drug: Midazolam","Midazolam: Area under the plasma concentration-time curve from time zero to infinity (AUC) ratio of geometric means of test treatment (midazolam + savolitinib), relative to reference treatment (midazolam alone).|Midazolam: Maximum observed plasma concentration (Cmax) ratio of geometric means of test treatment (midazolam + savolitinib), relative to reference treatment (midazolam alone).|Midazolam: Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-t)] ratios of geometric means of test treatment (midazolam + savolitinib), relative to reference treatment (midazolam alone).|Midazolam: Cmax|Midazolam: [AUC(0-t)]|Midazolam: Time to reach maximum observed plasma concentration (tmax)|Midazolam: Half-life associated with terminal slope (λz) of a semi-logarithmic concentration time curve (t½,λz)|Midazolam: Terminal elimination rate constant (λz)|Midazolam and savolitinib: Apparent total body clearance of drug from plasma after extravascular administration (CL/F)|Midazolam and savolitinib: Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F)|Number of subjects with adverse events|Number of subjects with abnormal systolic blood pressure (BP)|Number of subjects with abnormal diastolic blood pressure (BP)|Number of subjects with abnormal findings in pulse rate|Number of subjects with abnormal findings in physical examination|Number of subjects with abnormal findings in White blood cell (WBC) count|Number of subjects with abnormal findings in Red blood cell (RBC) count|Number of subjects with abnormal findings in Hemoglobin (Hb)|Number of subjects with abnormal findings in Hematocrit (HCT)|Number of subjects with abnormal findings in Mean corpuscular volume (MCV)|Number of subjects with abnormal findings in Mean corpuscular hemoglobin (MCH)|Number of subjects with abnormal findings in Mean corpuscular hemoglobin concentration (MCHC)|Number of subjects with abnormal findings in Neutrophils absolute count|Number of subjects with abnormal findings in Monocytes absolute count|Number of subjects with abnormal findings in Eosinophils absolute count|Number of subjects with abnormal findings in Basophils absolute count|Number of subjects with abnormal findings in Platelets|Number of subjects with abnormal findings in Reticulocytes absolute count|Number of subjects with abnormal findings in sodium|Number of subjects with abnormal findings in pottasium|Number of subjects with abnormal findings in urea|Number of subjects with abnormal findings in creatinine|Number of subjects with abnormal findings in albumin|Number of subjects with abnormal findings in calcium|Number of subjects with abnormal findings in phosphate|Number of subjects with abnormal findings in glucose (fasting)|Number of subjects with abnormal findings in C-reactive protein (CRP)|Number of subjects with abnormal findings in T4|Number of subjects with abnormal findings in Thyroid-Stimulating Hormone (TSH)|Number of subjects with abnormal findings in Alkaline phosphatase (ALP)|Number of subjects with abnormal findings in Alanine aminotransferase (ALT)|Number of subjects with abnormal findings in Aspartate aminotransferase (AST)|Number of subjects with abnormal findings in Gamma glutamyl transpeptidase (GGT)|Number of subjects with abnormal findings in total bilirubin|Number of subjects with abnormal findings in unconjugated bilirubin|Number of subjects with abnormal findings in urinalysis|Number of subjects with abnormal findings in pulse oximetry","AstraZeneca|Parexel","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","14","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D5084C00004","December 27, 2019","March 6, 2020","March 6, 2020","December 5, 2019",,"August 19, 2021","Research Site, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04187456"
239,"NCT04121910","A Study to Evaluate the Amount of Drug That Becomes Available in the Blood Circulation When Savolitinib is Administered Alone and in Combination With Itraconazole",,"Completed","No Results Available","Solid Tumour","Drug: Savolitinib|Drug: Itraconazole","Savolitinib area under plasma concentration-time curve from time zero to infinity (AUC) ratios of geometric means of test treatment (savolitinib+itraconazole), relative to reference treatment (savolitinib alone)|Savolitinib maximum observed plasma concentration (Cmax) ratios of geometric means of test treatment (savolitinib+itraconazole), relative to reference treatment (savolitinib alone)|Savolitinib:Area under the plasma concentration-curve from time zero to time of last quantifiable concentration [AUC(0-t)] ratios of geometric means of test treatment (savolitinib+itraconazole), relative to reference treatment (savolitinib alone)|M2 and M3: Cmax ratios of geometric means of test treatment (savolitinib+itraconazole), relative to reference treatment (savolitinib alone)|M2 and M3: AUC ratios of geometric means of test treatment (savolitinib+itraconazole), relative to reference treatment (savolitinib alone)|M2 and M3: AUC(0-t) ratios of geometric means of test treatment (savolitinib+itraconazole), relative to reference treatment (savolitinib alone)|Savolitinib, M2 and M3: Cmax|Savolitinib, M2 and M3: AUC|Savolitinib, M2 and M3: AUC(0-t)|Savolitinib, M2 and M3: tmax|Savolitinib, M2 and M3: t½,λz|Savolitinib, M2 and M3: λz|Savolitinib: CL/F|Savolitinib: Vz/F|Metabolite-to-parent ratios (MRCmax)|Metabolite-to-parent ratios (MRAUC)|Metabolite-to-parent ratios [MRAUC(0-t)]|Number of subjects with adverse events|Number of subjects with abnormal findings in systolic blood pressure (BP)|Number of subjects with abnormal findings in diastolic BP|Number of subjects with abnormal findings in pulse rate|Number of subjects with abnormal findings in electrocardiogram (ECG)|Number of subjects with abnormal findings in physical examination|Number of subjects with abnormal findings in white blood cell (WBC) count|Number of subjects with abnormal findings in red blood cell (RBC) count|Number of subjects with abnormal findings in hemoglobin (Hb)|Number of subjects with abnormal findings in hematocrit (HCT)|Number of subjects with abnormal findings in mean corpuscular volume (MCV)|Number of subjects with abnormal findings in mean corpuscular hemoglobin (MCH)|Number of subjects with abnormal findings in mean corpuscular hemoglobin concentration (MCHC)|Number of subjects with abnormal findings in neutrophils absolute count|Number of subjects with abnormal findings in lymphocytes absolute count|Number of subjects with abnormal findings in monocytes absolute count|Number of subjects with abnormal findings in eosinophils absolute count|Number of subjects with abnormal findings in basophils absolute count|Number of subjects with abnormal findings in platelets|Number of subjects with abnormal findings in reticulocytes absolute count|Number of subjects with abnormal findings in sodium|Number of subjects with abnormal findings in potassium|Number of subjects with abnormal findings in urea|Number of subjects with abnormal findings in creatinine clearence|Number of subjects with abnormal findings in albumin|Number of subjects with abnormal findings in calcium|Number of subjects with abnormal findings in phosphate|Number of subjects with abnormal findings in glucose (fasting)|Number of subjects with abnormal findings in C-reactive protein (CRP)|Number of subjects with abnormal findings in alkaline phosphatase (ALP)|Number of subjects with abnormal findings in alanine aminotransferase (ALT)|Number of subjects with abnormal findings in aspartate aminotransferase (AST)|Number of subjects with abnormal findings in gamma glutamyl transpeptidase (GGT)|Number of subjects with abnormal findings in total bilirubin (TBL)|Number of subjects with abnormal findings in unconjugated bilirubin|Number of subjects with abnormal findings in urinalysis","AstraZeneca|Parexel","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","16","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","D5084C00002","November 7, 2019","January 12, 2020","January 12, 2020","October 10, 2019",,"January 23, 2020","Research Site, Glendale, California, United States",,"https://ClinicalTrials.gov/show/NCT04121910"
240,"NCT03313297","Glucocorticoids and Skin Healing in Diabetes (GC-SHealD)","GC-SHealD","Completed","No Results Available","Diabetes Mellitus, Type 2","Drug: AZD4017|Drug: Placebo","Skin 11β-HSD1 activity|Urinary cortisol / cortisone metabolites|AZD4017 in plasma|AZD4017 in skin|Discontinuation due to Adverse Event|Body mass index|Waist-hip ratio|Blood pressure (sphygmomanometer)|Sudomotor function|Skin hydration|Epidermal barrier function|Epidermal barrier integrity|Skin thickness|Wound healing|Skin RNA-seq gene expression profiling","University of Leeds","All","18 Years and older   (Adult, Older Adult)","Phase 2","28","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ED17/93260","April 10, 2018","February 27, 2019","March 13, 2019","October 18, 2017",,"March 22, 2019","Leeds Teaching Hospitals Trust, Leeds, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03313297"
241,"NCT03111992","Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma",,"Completed","No Results Available","Multiple Myeloma","Drug: PDR001|Drug: CJM112|Drug: LCL161","Number of patients reporting dose limiting toxicities|The number of patients who experience a treatment-related adverse event after being treated with a single dose of single agent CJM112, or two doses of PDR001 in combination with CJM112 or LCL161|The number of patients requiring interruptions after a single dose of single agent CJM112, or two doses of PDR001 in combination with CJM112 or LCL161|The number of patients treated with single agent CJM112, or PDR001 in combination with either CJM112 or LCL161, who discontinued treatment|The number of patients requiring a dose reduction after a single dose of single agent CJM112, or two doses of PDR001 in combination with CJM112 or LCL161|Immunogenicity of PDR001 and CJM112|Overall Response Rate (ORR)|Best Overall Response (BOR)|Progression Free Survival (PFS)|Disease Control Rate (DCR)|AUC of PDR001, CJM112 and LCL161|Cmax of PDR001, CJM112 and LCL161|Tmax of PDR001, CJM112 and LCL161|Half-life of PDR001, CJM112 and LCL161|Concentration vs time profile of PDR001, CJM112 and LCL161","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 1","26","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CPDR001X2106","December 18, 2017","March 2, 2020","March 2, 2020","April 13, 2017",,"February 9, 2022","Mayo Clinic Arizona, Phoenix, Arizona, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Novartis Investigative Site, Freiburg, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Salamanca, Castilla Y Leon, Spain|Novartis Investigative Site, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT03111992"
242,"NCT04247815","Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA",,"Completed","No Results Available","Rheumatoid Arthritis","Drug: ATI-450|Drug: Placebo oral tablet|Drug: Methotrexate","The primary outcome measure is the determination of the safety and tolerability of ATI-450 plus Methotrexate in patients with moderate to severe rheumatoid arthritis: Adverse Events (AEs)|Percent change in high sensitivity C-reactive protein (hsCRP) levels|Change from baseline in Disease Activity Score|Change from baseline in Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS) Hand-Wrist Assessments|Proportion of patients with American College of Rheumatology (ACR) 20/50/70","Aclaris Therapeutics, Inc.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","19","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ATI-450-RA-201","March 16, 2020","February 4, 2021","February 4, 2021","January 30, 2020",,"March 25, 2021","Aclaris Investigational Site, Anniston, Alabama, United States|Aclaris Investigational Site, Tampa, Florida, United States|Aclaris Investigational Site, Atlanta, Georgia, United States|Aclaris Investigational Site, Duncansville, Pennsylvania, United States|Aclaris Investigational Site, Mesquite, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04247815"
243,"NCT00553358","Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study","Neo ALTTO","Completed","Has Results","Neoplasms, Breast","Drug: Lapatinib|Biological: Trastuzumab|Drug: Paclitaxel","Number of Participants With Pathological Complete Response (pCR) at the Time of Surgery|Number of Participants With Overall Response at Week 6|Overall Response at the Time of Surgery|Number of Participants With Negative Lymph Nodes at the Time of Surgery|Number of Participants With Actual Indicated Surgery|Mean Change From Baseline in Tumor Size at Week 6 and at Surgery|Number of Participants Starting Paclitaxel Before Completing 6 Weeks of Treatment With Either Lapatinib or Trastuzumab|Event-free Survival (EFS) - Median Clinical Follow-up|Event-free Survival (EFS) - Events and Censoring|Overall Survival (OS) - Median Survival Follow-up|Overall Survival (OS) - Deaths and Censoring|Assess Associations Between Locoregional Pathological Complete Response (pCR) and Event-free Survival (EFS) - Median Clinical Follow-up (EFS Landmark Population)|Assess Associations Between Locoregional Pathological Complete Response (pCR) and Event-free Survival (EFS) - Number of Participants With EFS Events (EFS Landmark Population)|Assess Associations Between Locoregional Pathological Complete Response (pCR) and and Overall Survival (OS) - Median Clinical Follow-up (OS Landmark Population)|Assess Associations Between Locoregional Pathological Complete Response (pCR) and and Overall Survival (OS) - Number of Participants Who Died (OS Landmark Population)|To Assess Safety Via a Comparison of the Three Treatment Arms - to Measure On-treatment Primary Cardiac Endpoints|Metabolic Response Rate Determined by Positron Emission Tomography/Computed Tomography (PET/CT)|Percentage of Participants With the Indicated Biomarker Expression - PIK3CA.|Percentage of Participants With the Indicated Biomarker Expression - PTEN.|Ratio (95% CI) of Geometric Means in p95HER2 Expression in HR Positive Patients With pCR vs no pCR|Percentage of Participants With Circulating Tumor Cells (CTC) in the Bloodstream","Novartis Pharmaceuticals|Breast International Group|SOLTI Breast Cancer Research Group|Novartis","Female","18 Years and older   (Adult, Older Adult)","Phase 3","455","Industry|Other","Interventional","Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment","EGF106903|2006-000564-81|CLAP016B2302","January 5, 2008","May 27, 2010","December 23, 2019","November 4, 2007","October 13, 2011","September 21, 2021","Novartis Investigative Site, Berazategui, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Quilmes, Argentina|Novartis Investigative Site, Santa Fe, Argentina|Novartis Investigative Site, Tucuman, Argentina|Novartis Investigative Site, Brussels, Belgium|Novartis Investigative Site, Brussel, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Namur, Belgium|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Santo Andre, São Paulo, Brazil|Novartis Investigative Site, Sao Paulo, São Paulo, Brazil|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Brno, Czechia|Novartis Investigative Site, Novy Jicin, Czechia|Novartis Investigative Site, Praha 10, Czechia|Novartis Investigative Site, Bayonne, France|Novartis Investigative Site, Bordeaux, France|Novartis Investigative Site, Le Mans, France|Novartis Investigative Site, Levallois-Perret, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Reims, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Toulouse, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Freiburg, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Karlsruhe, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Fuerth, Bayern, Germany|Novartis Investigative Site, Nuernberg, Bayern, Germany|Novartis Investigative Site, Fuerstenwalde, Brandenburg, Germany|Novartis Investigative Site, Frankfurt am Main, Hessen, Germany|Novartis Investigative Site, Rostock, Mecklenburg-Vorpommern, Germany|Novartis Investigative Site, Stralsund, Mecklenburg-Vorpommern, Germany|Novartis Investigative Site, Celle, Niedersachsen, Germany|Novartis Investigative Site, Hannover, Niedersachsen, Germany|Novartis Investigative Site, Dortmund, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Essen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Koeln, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Witten, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Halle, Sachsen-Anhalt, Germany|Novartis Investigative Site, Kiel, Schleswig-Holstein, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Kowloon, Hong Kong|Novartis Investigative Site, Wanchai, Hong Kong|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Bangalore, India|Novartis Investigative Site, Hyderabad, India|Novartis Investigative Site, Mumbai, India|Novartis Investigative Site, Nagpur, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, Pune, India|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Genova, Liguria, Italy|Novartis Investigative Site, Lecco, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Monza, Lombardia, Italy|Novartis Investigative Site, Sondrio, Lombardia, Italy|Novartis Investigative Site, Trento, Trentino-Alto Adige, Italy|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Songpa-gu, Seoul, Korea, Republic of|Novartis Investigative Site, Vilnius, Lithuania|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Karachi, Pakistan|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Cluj-Napoca, Romania|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Pretoria, Gauteng, South Africa|Novartis Investigative Site, Athlone Park, Amanzimtoti, South Africa|Novartis Investigative Site, Capital Park, South Africa|Novartis Investigative Site, Parktown, South Africa|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Girona, Spain|Novartis Investigative Site, Lerida, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Mataro, Spain|Novartis Investigative Site, Santiago de Compostela, Spain|Novartis Investigative Site, Sevilla, Spain|Novartis Investigative Site, Toledo, Spain|Novartis Investigative Site, Torrevieja (Alicante), Spain|Novartis Investigative Site, Valencia, Spain|Novartis Investigative Site, Goteborg, Sweden|Novartis Investigative Site, Changhua, Taiwan|Novartis Investigative Site, Tainan, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Chernivtsi, Ukraine|Novartis Investigative Site, Dnipropetrovsk, Ukraine|Novartis Investigative Site, Kharkiv, Ukraine|Novartis Investigative Site, Kiev, Ukraine|Novartis Investigative Site, Krivoy Rog, Ukraine|Novartis Investigative Site, Kyiv, Ukraine|Novartis Investigative Site, Lviv, Ukraine|Novartis Investigative Site, Odessa, Ukraine|Novartis Investigative Site, Simferopol, Ukraine|Novartis Investigative Site, Epping, Essex, United Kingdom|Novartis Investigative Site, Bournemouth, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00553358"
244,"NCT02260661","Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours",,"Completed","No Results Available","Advanced Solid Malignancies|Breast Cancer - ER+, HER2 -|Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation","Drug: AZD8835|Drug: AZD8835 in combination with fulvestrant","Determine the maximum tolerated dose (MTD) or recommended Phase II dose of oral AZD8835 as a single agent and in combination with fulvestrant|Establish the preliminary safety and tolerability profile of oral AZD8835 as a single agent and in combination with fulvestrant|To establish the pharmacokinetic profile of oral AZD8835 as a single agent and in combination with fulvestrant|To evaluate the preliminary efficacy and anti-tumor activity of oral AZD8835 as a single agent or in combination with fulvestrant|To evaluate the pharmacodynamic (PDc) effect of oral AZD8835 as a single agent and in combination with fulvestrant","AstraZeneca","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D6140C00001","November 2014","July 2016","July 2016","October 9, 2014",,"October 10, 2016","Research Site, Denver, Colorado, United States|Research Site, Greenville, South Carolina, United States|Research Site, Nashville, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Cambridge, United Kingdom|Sarah Cannon Research Institute, United Kingdom, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02260661"
245,"NCT03028766","WEE1 Inhibitor With Cisplatin and Radiotherapy: A Trial in Head and Neck Cancer","WISTERIA","Completed","No Results Available","Hypopharynx Squamous Cell Carcinoma|Oral Cavity Squamous Cell Carcinoma|Larynx Cancer","Drug: AZD1775|Drug: Cisplatin|Radiation: Radiotherapy","Recommended dose(s) of AZD1775|Safety profile of AZD1775 for Group A and Group B by reporting of all Adverse Events, Serious Adverse Events, Suspected Unexpected Adverse Reactions, deaths, deviations and withdrawal as assessed by the Safety Committee.|Disease-free survival in Groups A and B","University of Birmingham|AstraZeneca|Cancer Research UK","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","9","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RG_15-139|2015-003583-37|ISRCTN76291951","June 22, 2017","October 31, 2019","February 3, 2021","January 23, 2017",,"March 16, 2021","University Hospital Birmingham Nhs Foundation Trust, Birmingham, West Midlands, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|St. James' University Hospital, Leeds Teaching Hospital NHS Trust, Leeds, United Kingdom|The Royal Marsden Hospital, London, United Kingdom|University College London Hospitals, London, United Kingdom|Clatterbridge Cancer Centre, Wirral, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03028766"
246,"NCT01937923","A Pre-Cellular Therapy Observational Study in Early Huntington's Disease","PRE-CELL","Completed","No Results Available","Huntington Disease",,"Rate of change from baseline in white matter volume on magnetic resonance imaging (MRI) brain scan.|Rate of change from baseline on the UHDRS total motor score|Rate of change from baseline on the Total Functional Capacity score","University of California, Davis","All","18 Years and older   (Adult, Older Adult)",,"29","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","455690|DR2A-05415","August 2013","July 2016","July 2016","September 10, 2013",,"November 1, 2016","UC Davis Medical Center, Clinical Research Center, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT01937923"
247,"NCT02807597","Real-time Intraoperative Breast Cancer Visualization for Margin Assessment",,"Completed","No Results Available","Breast Cancer|Cancer of the Breast","Drug: LS301|Device: Cancer Vision Goggles|Procedure: Surgery","Safety of LS301 in breast as measured by related adverse events (Phase I)|Optimal imaging dose of LS301 (Phase I)|Ability of LS301 to predict presence of positive margins around partial mastectomy (Phase II)","Washington University School of Medicine|Kingdom Capital","All","18 Years and older   (Adult, Older Adult)","Phase 1","11","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","201907135","February 18, 2020","January 26, 2022","January 26, 2022","June 21, 2016",,"February 22, 2022","Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT02807597"
248,"NCT02512562","A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers",,"Completed","No Results Available","Chronic Hepatitis C","Drug: AL-335|Drug: ACH-3102|Drug: Simeprevir","Multiple dose PK Profile, Cmax and AUC: effect of ACH-3102 on AL-335 and metabolites|Multiple dose PK Profile, Cmax and AUC: effect of Simeprevir on AL-335 and metabolites|Multiple dose PK Profile, Cmax and AUC: effect of ACH-3102 and Simeprevir on AL-335 and metabolites|Safety Data: Composite number and frequency of treatment emergent adverse events, physical examination findings, abnormal vital signs, 12 lead ECG and abnormal clinical laboratory results|Steady-state PK Profile from Clast, t1/2, Tmax, Tlast, CL/F, Vz/F, λz: effect of AL-335 and ACH-3102 on Simeprevir|Steady-state PK Profile from Clast, t1/2, Tmax, Tlast, CL/F, Vz/F, λz: effect of AL-335 and Simeprevir on ACH-3102","Alios Biopharma Inc.|Alexion Pharmaceuticals","All","18 Years to 60 Years   (Adult)","Phase 1","32","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AL-335-602","July 31, 2015","August 31, 2015","August 31, 2015","July 31, 2015",,"October 16, 2019","Biotrial, Rennes, France",,"https://ClinicalTrials.gov/show/NCT02512562"
249,"NCT02341456","Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours",,"Completed","Has Results","Advanced Solid Tumours","Drug: AZD1775|Drug: Paclitaxel|Drug: carboplatin","Number of Patients With Treatment-Emergent Adverse Events|Number of Treatment-Emergent Adverse Events (TEAE)|Number of Patients With Treatment-Emergent Adverse Events During AZD1775 Monotherapy Cycle by System Organ Class and Preferred Term|Number of Patients With Clinically Important Changes in Haematology and Coagulation TEAEs by System Organ Class and Preferred Term|Number of Patients With Clinically Important Abnormalities in Clinical Chemistry by Preferred Term|Number of Patients With Clinically Important Abnormalities in Vital Signs by Preferred Term|Best Overall Response|Number of Patients With an Objective Response|Percentage of Patients With an Objective Response|Number of Patients With Clinical Benefit|Percentage of Patients With Clinical Benefit|Duration of Response|Peak Plasma Concentration (Cmax) of AZD1775 Following Single Dose Administration of AZD1775 Monotherapy|Time to Maximum Plasma Concentration (Tmax) of AZD1775 Following Single Dose Administration of AZD1775 Monotherapy|Area Under the Plasma Concentration-time Curve From Zero to the Time of the Last Measurable Concentration (AUC0-t) Following Single Dose Administration of AZD1775 Monotherapy|Plasma Concentration of AZD1775 8 Hours After Single Dose Administration (C8h) of AZD1775 Monotherapy|Peak Plasma Concentration (Cmax) of AZD1775 Following Oral Dose of AZD1775 in Combination With IV Infusion of Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Time to Maximum Plasma Concentration (Tmax) of AZD1775 Following Single Dose of AZD1775 in Combination With IV Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Area Under the Plasma Concentration-time Curve From Zero to the Time of the Last Measurable Concentration (AUC0-t) Following Single Dose of AZD1775 in Combination With IV Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Plasma Concentration of AZD1775 8 Hours After Single Dose Administration (C8h) of AZD1775 in Combination With IV Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Peak Plasma Concentration (Cmax) of AZD1775 at Steady State When Given in Combination With IV Infusion of Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Time to Maximum Plasma Concentration (Tmax) of AZD1775 at Steady State When Given in Combination With IV Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Area Under the Plasma Concentration-time Curve From Zero to the Time of the Last Measurable Concentration (AUC0-t) at Steady State for AZD1775 in Combination With IV Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Plasma Concentration of AZD1775 8 Hours After Administration (C8h) at Steady State in Combination With IV Paclitaxel and Carboplatin (Cohorts 1 and 2) or Carboplatin Alone (Cohort 1a)|Peak Plasma Concentration (Cmax) of Paclitaxel Following Single IV Infusion in Combination With Single Dose Oral AZD1775 and IV Carboplatin|Area Under the Plasma Concentration-time Curve (AUC0-t) of Paclitaxel Following Single IV Infusion in Combination With Single Dose Oral AZD1775 and IV Carboplatin|Plasma Concentration of Paclitaxel at the End of Infusion (Ceoi) When Given Combination With Oral AZD1775 and IV Carboplatin.|Time to Maximum Plasma Concentration (Tmax) of IV Paclitaxel When Given in Combination With Oral AZD1775 and IV Carboplatin|Time to Last Detectable Concentration (Tlast) of Paclitaxel When Given in Combination With Oral AZD1775 and IV Carboplatin|Peak Plasma Concentration (Cmax) of Platinum Following Single IV Infusion of Carboplatin Over 1 Hour in Combination With Single Oral Dose AZD1775 Alone (Cohort 1a) or With IV Paclitaxel (Cohorts 1 and 2)|Area Under Plasma Concentration-time Curve From 0 to Last Measurable Conc. (AUC0-t) of Platinum Following Single IV Infusion of Carboplatin Over 1 Hour in Combination With Single Oral Dose AZD1775 Alone (Cohort 1a) or With IV Paclitaxel (Cohorts 1 & 2)|Plasma Concentration of Platinum at the End of Infusion (Ceoi) When Given as a 1 Hour Infusion in Combination With Oral AZD1775 and IV Paclitaxel.|Time to Peak Plasma Concentration of Platinum (Tmax) When Given as a 1 Hour Infusion in Combination With Oral AZD1775 and IV Paclitaxel.|Time to Last Detectable Concentration of Platinum (Tlast) When Given as a 1 Hour Infusion in Combination With Oral AZD1775 and IV Paclitaxel.|Peak Plasma Concentration (Cmax) of Platinum Following Single IV Infusion of Carboplatin Over 2 Hours in Combination With Single Oral Dose AZD1775 Alone (Cohort 1a) or With IV Paclitaxel (Cohorts 1 and 2)|Area Under Plasma Concentration-time Curve From 0 to Last Measurable Conc. (AUC0-t) of Platinum Following Single IV Infusion of Carboplatin Over 2 Hours in Combination With Single Oral Dose AZD1775 Alone (Cohort 1a) or With IV Paclitaxel (Cohorts 1 & 2)|Plasma Concentration of Platinum at the End of Infusion (Ceoi) When Given as a 2 Hour Infusion in Combination With Oral AZD1775 and IV Paclitaxel.|Time to Peak Plasma Concentration of Platinum (Tmax) When Given as a 2 Hour Infusion in Combination With Oral AZD1775 and IV Paclitaxel.|Time to Last Detectable Concentration of Platinum (Tlast) When Given as a 2 Hour Infusion in Combination With Oral AZD1775 and IV Paclitaxel.","AstraZeneca","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 1","19","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D6011C00003","January 16, 2015","December 14, 2016","July 9, 2018","January 19, 2015","March 25, 2019","March 25, 2019","Research Site, Liverpool, Australia|Research Site, Melbourne, Australia|Research Site, Kashiwa, Japan|Research Site, Sapporo-shi, Japan|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02341456"
250,"NCT03803475","Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients",,"Completed","Has Results","Prostate Cancer","Drug: Ga-68 labeled PSMA-11|Device: Positron emission tomography-computed tomography (PET/CT)|Device: Positron emission tomography-magnetic resonance imaging (PET/MRI)","Detection Rate of PSMA-11 PET for Positive Disease by Prostate Specific Antigen (PSA) Group|Detection Rate of PSMA-11 PET for Positive Disease in Prostate Bed by PSA Group|Detection Rate of PSMA-11 PET for Positive Disease in Pelvic Nodes by PSA Group|Detection Rate of PSMA-11 PET for Positive Disease in Distant Soft Tissues by PSA Group|Detection Rate of PSMA-11 PET for Positive Disease in Bones (Osseous Lesions) by PSA Group","Thomas Hope|University of California, San Francisco","Male","18 Years and older   (Adult, Older Adult)","Phase 3","485","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","185513|NCI-2019-01394","October 11, 2018","August 25, 2020","August 25, 2020","January 14, 2019","August 24, 2021","August 24, 2021","University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT03803475/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03803475"
251,"NCT02015065","Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors",,"Completed","Has Results","GIST","Drug: Vandetanib","Number of Participants With a Clinical Activity-radiographic Response|Count of Participants With Serious and Non-serious Adverse Events|Percentage of Participants Overall Survival|Progression Free-Survival|Maximum Standardized Uptake Value (SUVmax) on Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","3 Years to 99 Years   (Child, Adult, Older Adult)","Phase 2","9","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","130208|13-C-0208","December 14, 2013","May 4, 2016","December 10, 2019","December 19, 2013","July 23, 2019","March 30, 2020","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT02015065/Prot_SAP_000.pdf|""Informed Consent Form: Standard consent"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT02015065/ICF_001.pdf|""Informed Consent Form: Parent QOL consent"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT02015065/ICF_002.pdf","https://ClinicalTrials.gov/show/NCT02015065"
252,"NCT01287598","BAY73-4506 Probe Substrate Study",,"Completed","No Results Available","Neoplasms","Drug: Regorafenib (Stivarga, BAY73-4506)|Drug: Warfarin|Drug: Omeprazole|Drug: Midazolam|Drug: Rosiglitazone","Pharmacokinetics of probe substrates (AUC, Cmax, etc.)|Tumor Response evaluation measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1)|Adverse event collection","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 1","41","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12434","August 2, 2011","July 3, 2018","July 30, 2018","February 1, 2011",,"July 10, 2019","Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Agency-Vancouver Centre, Vancouver, British Columbia, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01287598"
253,"NCT01553188","AMG 386 and Abiraterone for Advanced Prostate Cancer",,"Completed","Has Results","Prostatic Neoplasms|Prostate Cancer|Neoplasm, Prostate|Neoplasm,Prostatic","Drug: AMG 386|Drug: Abiraterone|Drug: Prednisone","Progression Free Survival (PFS)|Radiographic Progression Free Survival|Overall Survival|Count of Participants With Serious and Non-serious Adverse Events","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Male","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","36","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","120079|12-C-0079","February 8, 2012","April 20, 2017","July 1, 2018","March 14, 2012","October 16, 2018","March 5, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT01553188/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT01553188"
254,"NCT00996671","Phase I Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of GSK2256098 in Healthy Volunteers","FTIH","Completed","No Results Available","Cancer","Drug: GSK2256098|Drug: Placebo","To characterize the safety of single doses of GSK2256098 in adult healthy subjects|To characterize the single dose pharmacokinetics of GSK2256098 in blood and urine in adult healthy subjects|To examine the dose proportionality of GSK2256098 pharmacokinetic parameters following single dose administration in healthy subjects|To explore dose- and concentration-effect relationships for various safety parameters, if appropriate|To estimate the effect of high fat/calorie meal on the pharmacokinetics, safety, and tolerability of a single dose of GSK2256098.|To explore and potentially identify small molecules or cytokines in plasma which may serve as biomarkers for future studies","GlaxoSmithKline","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","38","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","113581","November 6, 2009","March 17, 2010","March 17, 2010","October 16, 2009",,"June 14, 2017","GSK Investigational Site, Melbourne, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT00996671"
255,"NCT03028103","Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients",,"Completed","Has Results","Diffuse Large B Cell Lymphoma|Primary Mediastinal Lymphoma|Mantle Cell Lymphoma|Advanced Solid Tumor|Marginal Zone Lymphoma","Drug: Tazemetostat|Drug: Fluconazole|Drug: Omeprazole|Drug: Repaglinide","Part A: Effect of CYP3A Inhibition by Fluconazole on the PK of Tazemetostat (AUC0-t, AUC0-8)|Part A: Cmax of Tazemetostat During Co-administration With Fluconazole|Part B: The Potential of Tazemetostat to Inhibit or Induce CYP2C8 Using Repaglinide as a Probe Substrate (AUC0-t, AUC0-∞)|Part B: Cmax of Repaglinide During Co-administration With Tazemetostat|Part B: The Potential of Tazemetostat to Inhibit or Induce CYP2C19 Using Omeprazole as Probe a Substrate (AUC0-t, AUC0-∞)|Part B: Cmax of Omeprazole During Co-administration With Tazemetostat|Part B: Effect of Increased Gastric pH by Omeprazole on the PK of Tazemetostat (AUC0-t, AUC0-8)|Part B: Cmax of Tazemetostat During Co-administration With Omeprazole|Incidence of Treatment-emergent Adverse Events as a Measure of Safety|Part A: PK of Tazemetostat and Its Metabolites After Administration Alone and With Fluconazole (AUC0-t, AUC0-8)|Part A: Tmax of Tazemetostat After Administration Alone and With Fluconazole|Part A: t1/2 of Tazemetostat After Administration Alone and With Fluconazole|Part A: Cmax of Tazemetostat Metabolites After Administration Alone and With Fluconazole|Part A: Tmax of Tazemetostat Metabolites After Administration Alone and With Fluconazole|Part A: t1/2 of Tazemetostat Metabolites After Administration Alone and With Fluconazole|Part A: Exposure of Fluconazole After Administration of 400 mg Once Daily for 4 Days (AUC0-8)|Part A: Cmax of Fluconazole After Administration of 400mg Once Daily for 4 Days|Part A: Tmax of Fluconazole After Administration of 400mg Once Daily for 4 Days|The Antitumor Activity of Tazemetostat Will be Assessed in Patients With Diffuse Large B-cell Lymphoma (DLBCL), Marginal Zone Lymphoma (MZL), Follicular Lymphoma (FL) or Advanced Solid Tumors .","Epizyme, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","32","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EZH-105","March 27, 2017","October 31, 2019","November 29, 2019","January 23, 2017","April 19, 2021","April 19, 2021","University of Arizona Cancer Center, Tucson, Arizona, United States|Moffitt Cancer Center, Tampa, Florida, United States|Columbia University Medical Center, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT03028103/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03028103"
256,"NCT04150250","Cholera Anti-Secretory Treatment Trial","CAST","Completed","Has Results","Cholera","Drug: iOWH032|Drug: Placebo|Other: V. cholerae Challenge|Drug: Antibiotics","Diarrheal Stool Output Rate|Diarrheal Stool Output Rate Including Participants With Symptom Onset After 48 Hours|Number of Participants With Treatment-emergent Serious Adverse Events|Percentage of Participants With Moderate to Severe Diarrhea With Onset Within 48 Hours Following Cholera Challenge|Attack Rate of Any Diarrhea Following Cholera Challenge|Area Under the Curve (AUC) of Diarrheal Stool Volume Between Challenge Dose and Initiation of Antibiotics|Peak Shedding of Cholera Organisms|Duration of Diarrheal Episodes|Total Number of Loose (Grade 3-5) Stools|Percentage of Participants With Fever Following Cholera Challenge|Percentage of Participants With Vomiting Following Cholera Challenge|Number of Participants With Solicited Adverse Effects|Number of Participants With Unsolicited Treatment-emergent Adverse Events (TEAE)","PATH|University of Maryland, Baltimore|Pharmaron","All","18 Years to 44 Years   (Adult)","Phase 2","47","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DRG-032-PO-2-01-USA","November 4, 2019","July 27, 2020","July 27, 2020","November 4, 2019","March 25, 2021","March 25, 2021","Pharmaron, Baltimore, Maryland, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT04150250/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT04150250/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04150250"
257,"NCT03437538","Reduction Ratio and Clearance During Hemodialysis With MCO-filter Compared to HDF With Standard High-flux Filter",,"Completed","No Results Available","Chronic Kidney Failure|Uremia|Dialysis","Device: MCO-HD|Device: High-flux HDF","Reduction ratio (RR) of middle molecules (Beta-2-microglobulin, Cystatin C, Myoglobin, Beta-Trace Protein, Troponin T, Prealbumin)|Instantaneous arteriovenous clearance of middle molecules (Beta-2-microglobulin, Cystatin C, Myoglobin, Beta-Trace Protein, Troponin T, Prealbumin)|RR of large molecules (Albumin, Transferrin, IgG)|RR of small molecules (Urea, Phosphate, Creatinine)|Number of Adverse Events|Instantaneous arteriovenous clearance of large molecules (Albumin, Transferrin, IgG)|Instantaneous arteriovenous clearance of small molecules (Urea, Phosphate, Creatinine)","Region Skane|Lund University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","18","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017/830/1","May 21, 2018","April 16, 2019","April 16, 2019","February 19, 2018",,"November 13, 2019","Skane University Hospital, Malmö, Sweden",,"https://ClinicalTrials.gov/show/NCT03437538"
258,"NCT00367471","Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.",,"Completed","No Results Available","Neoplasms, Breast","Drug: lapatinib|Drug: carboplatin|Drug: trastuzumab|Drug: paclitaxel","Adverse events and safety evaluations|Tumor response by RECIST version 1.0|Duration of Response (DOR)|Progression-free survival (PFS)","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 1","31","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EGF103892|CLAP016A2102","December 7, 2006","December 22, 2010","September 12, 2019","August 23, 2006",,"September 9, 2020","Novartis Investigative Site, La Jolla, California, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Greensboro, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00367471"
259,"NCT05219656","Efficacy of Cyclosporine Rescue Therapy in Acute Ulcerative Colitis.","Cyclo","Completed","No Results Available","Ulcerative Colitis Acute","Drug: Cyclosporine A","Response|Remission|Adverse events|Surgical complications","Tampere University Hospital","All","16 Years and older   (Child, Adult, Older Adult)",,"182","Other","Observational","Observational Model: Other|Time Perspective: Other","R19617","January 1, 2009","December 30, 2018","January 1, 2022","February 2, 2022",,"February 2, 2022",,,"https://ClinicalTrials.gov/show/NCT05219656"
260,"NCT00550485","Pharmacokinetic and Pharmacodynamic Effects of Escitalopram Depending on Genetic Polymorphisms of the ABCB1-gene",,"Completed","No Results Available","Pharmacokinetics","Drug: escitalopram","Time spent in rapid-eye-movement (REM) sleep assessed by polysomnography.|Sleep stages|Sleep continuity|ABCB1 gene expression|Metabolic changes","Max-Planck-Institute of Psychiatry","Male","20 Years to 30 Years   (Adult)","Not Applicable","79","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","L3/2005","October 2007","July 6, 2018","July 6, 2018","October 30, 2007",,"March 27, 2019","Max Planck Institute of Psychiatry, Munich, Germany",,"https://ClinicalTrials.gov/show/NCT00550485"
261,"NCT03289832","Effect of Orally Delivered Phytochemicals on Aging and Inflammation in the Skin",,"Completed","No Results Available","Healthy Adults","Dietary Supplement: Crucera-SGS|Dietary Supplement: Meriva 500-SF","Change in Erythema 1 Day After UV Exposure|Change in Erythema 2 Days After UV Exposure|Change in Erythema 3 Days After UV Exposure|Bioavailability of Supplement Metabolites in bodily fluids|Change in metabolomic profile|Change in tissue-based RNA biomarkers of inflammation|Change in tissue-based protein biomarkers of inflammation|Change in blood-based biomarkers of inflammation|Change in urine-based biomarkers of inflammation|Change in RNA markers of aging and protection from UV damage|Change in protein and small-molecule markers of aging and protection from UV damage","Johns Hopkins University","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","25","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","IRB00117754","September 25, 2017","October 23, 2019","October 23, 2019","September 21, 2017",,"July 21, 2020","Johns Hopkins, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03289832"
262,"NCT04834921","MCO Membrane Efficiency in Septic Shock Patients",,"Completed","No Results Available","Septic Shock|Acute Kidney Injury","Device: Ultraflux® EMiC®2","improvement in haemodynamic parameters|clerance of cytokine|Efficiency for middle molecules|Efficiency for small molecules|removal of antibiotics","Fiorenza Ferrari|International Renal Research Institute Vicenza|University of Giessen|IRCCS Policlinico S. Matteo","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care","46/15A","December 31, 2017","February 21, 2020","January 31, 2021","April 8, 2021",,"April 12, 2021","Fiorenza Ferrari, Pavia, PV, Italy",,"https://ClinicalTrials.gov/show/NCT04834921"
263,"NCT00055380","Chemical and Genetic Effects of the Experimental Anti-Cancer Drugs in Cheek Cells in Cancer Patients",,"Completed","No Results Available","Cancer","Procedure: Oral cytobrushing",,"National Institute of Dental and Craniofacial Research (NIDCR)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","Phase 1","120","NIH","Interventional","Primary Purpose: Treatment","030115|03-D-0115","February 2003",,"October 2005","February 28, 2003",,"March 4, 2008","National Institute of Dental And Craniofacial Research (NIDCR), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00055380"
264,"NCT00692159","Study of TRC102 in Combination With Pemetrexed in Cancer Patients",,"Completed","No Results Available","Neoplasm","Drug: TRC102 + pemetrexed","To determine the recommended Phase 2 dose and overall safety and tolerability of TRC102 when given alone and when combined with pemetrexed for the treatment of patients with advanced solid or metastatic cancer for whom curative therapy is unavailable.|Characterize pharmacokinetics, assess anti-tumor activity, and assess pharmacodynamics","Tracon Pharmaceuticals Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","28","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","102ST101","June 2008","June 2010","September 2010","June 6, 2008",,"September 10, 2010","Scottsdale, Arizona, United States|Santa Monica, California, United States|Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00692159"
265,"NCT03783637","Measuring Single-Serving Grain Intake",,"Completed","No Results Available","Healthy Volunteers","Other: Whole grain oats|Other: Whole grain wheat","Identification of unknown biomarkers of grain intake immediately after grain consumption|Identification of unknown biomarkers of grain intake a day after grain consumption|Identification of unknown biomarkers of grain intake 2 days after grain consumption|Blood glucose|Serum insulin|Serum c-peptide|Non-esterified fatty acids in blood|Triglycerides in blood","USDA Beltsville Human Nutrition Research Center","All","21 Years to 75 Years   (Adult, Older Adult)","Not Applicable","12","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Other","HS62 - Single Grain","May 13, 2019","June 19, 2019","June 19, 2019","December 21, 2018",,"July 5, 2019","USDA-ARS Beltsville Human Nutrition Research Center, Beltsville, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03783637"
266,"NCT01192165","Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel",,"Completed","No Results Available","Cancer","Drug: Trametinib (GSK1120212)|Drug: Docetaxel|Drug: Erlotinib|Drug: Pemetrexed|Drug: Carboplatin|Drug: nab-Paclitaxel|Drug: Cisplatin","To determine the safety, tolerability, and recommended phase II dosing regimen of each GSK1120212-based treatment combination|To characterize population pharmacokinetic parameters|To evaluate the anti-tumor activity as assessed by tumor response rate according to RECIST v1.1","GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 1","169","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","113486|2012-000257-32","September 14, 2010","October 7, 2013","October 7, 2013","August 31, 2010",,"November 13, 2017","GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Duarte, California, United States|GSK Investigational Site, Sacramento, California, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Albany, New York, United States|GSK Investigational Site, Greenville, South Carolina, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Tyler, Texas, United States|GSK Investigational Site, Norfolk, Virginia, United States|GSK Investigational Site, Vancouver, Washington, United States|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Caen Cedex 9, France|GSK Investigational Site, Marseille cedex 5, France|GSK Investigational Site, Saint-Herblain cedex, France|GSK Investigational Site, Toulouse cedex, France|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01192165"
267,"NCT00902018","Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP)",,"Completed","Has Results","Immune Thrombocytopenia","Drug: Eltrombopag|Drug: Romiplostim|Other: healthy controls","Number of Patients for Whom Eltrombopag Increases the Platelet Count to > 50,000/uL|Number of Patients Who Received Romiplostim and Increased Their Platelet Counts to > 50,000/uL|How Many Patients Developed SAEs and/or Abnormal Liver Tests to a Level > 2 Times the Upper Limit of Normal","Weill Medical College of Cornell University|GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 2","20","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0809009980","January 2009","September 7, 2015","September 7, 2015","May 14, 2009","March 18, 2019","March 18, 2019","Weill Cornell Medical College, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00902018"
268,"NCT03995056","Exercise Study in Subjects With NAFLD","BestTreat","Completed","No Results Available","Non-Alcoholic Fatty Liver Disease|Gastrointestinal Microbiome|Exercise","Behavioral: high-intensity aerobic interval training","Changes in liver fat content|Gut microbiota changes|Changes in glucose profile|Changes in protein expression in adipose tissue|Changes in low-grade inflammation|The effect on body composition|Changes in metabolomics","University of Eastern Finland|European Commission|Leibniz Institute for Natural Product Research and Infection Biology|Afekta|Novogene|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Clinical Microbiomics|Kuopio Research Institute of Exercise Medicine|Kuopio University Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","49","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","BestTreat","April 19, 2019","June 18, 2020","June 18, 2020","June 21, 2019",,"June 23, 2020","University of Eastern Finland, Kuopio, Finland",,"https://ClinicalTrials.gov/show/NCT03995056"
269,"NCT01453153","Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer",,"Completed","Has Results","Stage IV Pancreatic Cancer","Drug: Gemcitabine|Drug: PEGPH20|Drug: Placebo","Number of Participants With a Dose-limiting Toxicity (DLT)|Recommended Phase 2 Dose (RP2D)|Observed Maximum Plasma Concentration (Cmax) Following Single PEGPH20 Doses|Cmax Following Twice-weekly PEGPH20 Doses for 3 Consecutive Weeks|Last Measurable Observed Plasma Concentration (Cmin) Following Single PEGPH20 Doses|Cmin Following Twice-weekly PEGPH20 Doses for 3 Consecutive Weeks|Time to Reach Cmax (Tmax) Following Single PEGPH20 Doses|Tmax Following Twice-weekly PEGPH20 Doses for 3 Consecutive Weeks|Apparent Half-life (t1/2) Following Single PEGPH20 Doses|t1/2 Following Twice-weekly PEGPH20 Doses for 3 Consecutive Weeks|Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Measurable Plasma Concentration (AUC0-T) Following Single PEGPH20 Doses|AUC0-T Following Twice-weekly PEGPH20 Doses for 3 Consecutive Weeks|Plasma Hyaluronan (HA) Concentration at Baseline and After PEGPH20 Administration|H-scores, as an Assessment of HA Staining Changes in Tumor Biopsies|Percent Change in in the Maximum Standardized Uptake Value (SUVmax), as an Assessment of Total Lesion Metabolic Activity|Mean Volume Transfer Constant (Ktrans) for Scans Across Tissue Sites|Mean Extravascular-Extracellular Volume Fraction (Ve) for Scans Across Tissue Sites|Number of Participants With the Indicated Best Response, Per Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1|Objective Response Rate|Disease Control Rate|Progression-free Survival (PFS)|Overall Survival|Change From Baseline in Carbohydrate Antigen 19-9 or Sialylated Lewis(a) Antigen (CA19-9)|Change From Baseline in CA19-9 in Participants With a Baseline Value >=59 U/ml|Change From Baseline in CA19-9 in Participants Classified as Responders and Non-responders","Halozyme Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Halo-109-201","September 2011","February 2014","May 2015","October 17, 2011","November 30, 2018","November 30, 2018","Highlands Oncology Group, Fayetteville, Arkansas, United States|California Pacific Medical Center, San Francisco, California, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|UMDNJ - New Jersey Medical School, Newark, New Jersey, United States|NSLIJ Health System, Monter Cancer Center, New Hyde Park, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Chelyabinsk Regional Clinical Oncology Center, Chelyabinsk, Russian Federation|Russian Oncological Research Center n.a. N.N. Blokhin, Moscow, Russian Federation|Medical Radiological Research Center, Obninsk, Russian Federation|Omsk Regional Budget Medical Institution, Omsk, Russian Federation",,"https://ClinicalTrials.gov/show/NCT01453153"
270,"NCT02666235","Remote Ischaemic Conditioning and Coronary Endothelial Function (RIC-COR)","RIC-COR","Completed","No Results Available","Ischemic Preconditioning|Coronary Disease","Procedure: Remote ischaemic conditioning|Procedure: Arm cuff placement, no inflation;","Coronary artery diameter change|Circulating molecules reflecting endothelial function and oxidative stress|Mean percentage change in coronary lumen diameter (delta CAD)|Mean percentage coronary vasoconstriction|Coronary endothelial dysfunction|Mean percentage coronary vasodilatation|Epicardial coronary artery spasm|Microvascular spasm|ST-segment deviation","NHS National Waiting Times Centre Board|University of Glasgow|Chest, Heart and Stroke Association Scotland|Chief Scientist Office of the Scottish Government","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","11/CARD/03|R11/A136|10/S0704/52","July 2011","May 2016","May 2016","January 28, 2016",,"July 20, 2016","Golden Jubilee National Hospital, Glasgow, Dunbartonshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02666235"
271,"NCT03764696","Maternal Oxygen Administration for Fetal Distress II",,"Completed","No Results Available","Oxygen Inhalation Therapy|Labour|Fetal Distress","Device: tight-fitting simple facemask","Cord arterial pH values|Cord arterial partial pressure of oxygen|Cord arterial partial pressure of carbon dioxide|Cord venous pH values|Cord venous partial pressure of oxygen|Cord venous partial pressure of carbon dioxide|Rate of abnormal fetal heart tracing","Navy General Hospital, Beijing","Female","18 Years to 40 Years   (Adult)","Not Applicable","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CYH002","January 1, 2021","October 31, 2021","December 31, 2021","December 5, 2018",,"January 4, 2022","Department of Obstetrics and Gynecology, PLA Strategic Support Force Characteristic Medical Center, Beijing, China|Department of Obstetrics and Gynecology, Seventh Medical Center, Chinese PLA General Hospital, Beijing, China|Department of Obstetrics and Gynecology, Sixth Medical Center, Chinese PLA General Hospital, Beijing, China",,"https://ClinicalTrials.gov/show/NCT03764696"
272,"NCT01729728","Pharmacokinetic, Efficacy and Safety Study of Tapentadol Oral Solution in Children With Postoperative Pain",,"Completed","Has Results","Postoperative Pain|Acute Pain","Drug: Tapentadol","Pharmacokinetic Profile of Serum Concentrations of Tapentadol After a Single Dose of Tapentadol Oral Solution in Adolescents (Age 12 to Less Than 18 Years).|Pharmacokinetic Profile of Serum Concentrations of Tapentadol-O-glucuronide After a Single Dose of Tapentadol Oral Solution in Adolescents (Age 12 to Less Than 18 Years).|Pharmacokinetic Profile of Serum Concentrations of Tapentadol After a Single Dose of Tapentadol Oral Solution in Older Children (Age 6 to Less Than 12 Years).|Pharmacokinetic Profile of Serum Concentrations of Tapentadol-O-glucuronide After a Single Dose of Tapentadol Oral Solution in Older Children (Age 6 to Less Than 12 Years).|Pharmacokinetic Profile of Serum Concentrations of Tapentadol After a Single Dose of Tapentadol Oral Solution in Younger Children (Age 3 to Less Than 6 Years).|Pharmacokinetic Profile of Serum Concentrations of Tapentadol-O-glucuronide After a Single Dose of Tapentadol Oral Solution in Younger Children (Age 3 to Less Than 6 Years).|Pharmacokinetic Profile of Serum Concentrations of Tapentadol After a Single Dose of Tapentadol Oral Solution in Very Young Children (Age 2 to Less Than 3 Years).|Pharmacokinetic Profile of Serum Concentrations of Tapentadol-O-glucuronide After a Single Dose of Tapentadol Oral Solution in Very Young Children (Age 2 to Less Than 3 Years).|Non-Compartmental Pharmacokinetic (PK) Parameter of Tapentadol Area Under the Concentration-Time Curve (AUC 0-15) After a Single Dose of Tapentadol in Adolescent Participants (Age 12 to Less Than 18 Years).|Non-Compartmental Pharmacokinetic (PK) Parameter: Cmax (Maximum Concentration) of Tapentadol After a Single Dose of Tapentadol in Adolescents (Age 12 to Less Than 18 Years).|Non-Compartmental Pharmacokinetic (PK) Parameter: Time to Maximum Concentration (Tmax) of Tapentadol After a Single Dose of Tapentadol in Adolescents (Age 12 to Less Than 18 Years).|Non-Compartmental Pharmacokinetic (PK) Parameter of Tapentadol-O-glucuronide Area Under the Concentration-Time Curve (AUC 0-15) After a Single Dose of Tapentadol in Adolescents (Age 12 to Less Than 18 Years).|Non-Compartmental Pharmacokinetic (PK) Parameter: Cmax (Maximum Concentration) of Tapentadol-O-glucuronide After a Single Dose of Tapentadol in Adolescents (Age 12 to Less Than 18 Years).|Non-Compartmental Pharmacokinetic (PK) Parameter: Time to Maximum Concentration (Tmax) of Tapentadol-O-glucuronide After a Single Dose of Tapentadol in Adolescents (Age 12 to Less Than 18).|Pain Intensity Assessments Using the Visual Analog Scale (VAS) in Adolescents (Age 12 to Less Than 18 Years).|Pain Intensity Assessments Using the McGrath Color Analog Scale in Adolescent Participants and Older Children (Age 6 to Less Than 18 Years).|Pain Intensity Assessments Using the Faces Pain Scale (Revised) in Children Age 3 to Less Than 12 Years.|Pain Intensity Assessment Using the Face, Legs, Activity, Cry, Consolability Scale in Young and Very Young Children (Age 2 to Less Than 6 Years).|Sum of Pain Intensity Differences Over the 4 Hours After Dosing Derived From the Different Pain Scales and for All Age Groups|Respiratory Rate Assessments|Oxygen Saturation Assessments|Systolic and Diastolic Blood Pressure Assessments|Change From Enrollment in 12-lead Electrocardiogram Parameters|Change From Enrollment in 12-lead Electrocardiogram Heart Rate Parameter|Treatment Emergent Adverse Events by Intensity|Intake of Additional Analgesic Medication During the Trial|Hematology Safety Laboratory Assessments: Hemoglobin Concentration|Hematology Safety Laboratory Assessments: Hematocrit|Hematology Safety Laboratory Assessments: Erythrocyte Mean Corpuscular Volume (Mean Corpuscular Volume)|Hematology Safety Laboratory Assessments: Platelet Count|Hematology Safety Laboratory Assessments: Leukocyte Concentration|Biochemistry Safety Laboratory Parameters: Blood Glucose Concentration|Biochemistry Safety Laboratory Parameters: Blood Sodium Concentration|Biochemistry Safety Laboratory Parameters: Blood Potassium Concentration|Biochemistry Safety Laboratory Parameters: Blood Calcium Concentration|Biochemistry Safety Laboratory Parameters: Blood Chloride Concentration|Biochemistry Safety Laboratory Parameters: Blood Phosphate Concentration|Biochemistry Safety Laboratory Parameters: Blood Urea Nitrogen (BUN) Concentration|Biochemistry Safety Laboratory Parameters: Creatinine Concentration|Biochemistry Safety Laboratory Parameters: Aspartate Aminotransferase (AST) Enzyme Activity|Biochemistry Safety Laboratory Parameters: Triglycerides Concentration|Biochemistry Safety Laboratory Parameters: Serum Albumin Concentration|Biochemistry Safety Laboratory Parameters: Urate in the Blood|Biochemistry Safety Laboratory Parameters: Calculated Glomerular Filtration Rate|Biochemistry Safety Laboratory Parameters: Urine Specific Gravity|Biochemistry Safety Laboratory Parameters: Urine pH (Acid, Alkalinity) Test|Biochemistry Safety Laboratory Parameters: Liver Function Test - Alanine Aminotransferase (ALT) Enzyme Activity|Biochemistry Safety Laboratory Parameters: Liver Function Test - Gamma-Glutamyl Transferase (GGT) Enzyme Activity|Biochemistry Safety Laboratory Parameters: Liver Function Test - Bilirubin Concentration|Biochemistry Safety Laboratory Parameters: Liver Function Test - Lactate Dehydrogenase (LDH) Enzyme Activity|Biochemistry Safety Laboratory Parameters: Blood Protein Concentration|Biochemistry Safety Laboratory Parameters: Creatine Kinase (CK) Enzyme Activity|Biochemistry Safety Laboratory Parameters: Alkaline Phosphatase (ALP) Enzyme Activity|Biochemistry Safety Laboratory Parameters: Triacylglycerol Lipase (TL) Enzyme Activity","Grünenthal GmbH|Janssen Research & Development, LLC","All","2 Years to 17 Years   (Child)","Phase 2","86","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KF5503/68|2013-002016-27","November 2012","February 2014","February 2014","November 20, 2012","November 27, 2014","November 4, 2019","Jean Brown Research, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01729728"
273,"NCT02099968","Comprehensive Lifestyle Modification for Patients With Hypertension and Metabolic Syndrome: a Multicenter Randomized Controlled Trial",,"Completed","No Results Available","Hypertension|Metabolic Syndrome","Behavioral: Comprehensive Lifestyle Modification|Behavioral: Standard Lifestyle Modification / modified DASH","Systolic blood pressure|HOMA Index|Blood pressure|Pulse wave velocity|PROCAM|SCORE|Waist circumference|Weight|Blood glucose level|Blood insulin level|HbA1C|Blood creatinine level|Total cholesterol|LDL cholesterol|HDL cholesterol|Medication use|HADS|POMS|CPSS|SWE|SF-36|MAAS|SCS|Lifestyle questionnaire|Hair steroid analysis|Bioelectrical impedance analysis|Waist/hip ratio|Immunophenotyping|Intestinal microbiota|Metabolomics|Gene expression profiling|Interleukin- 6|CRP|Uric acid|Insulin-like growth factor (IGF-1)|Adverse events|Framingham-Score|JBS3-Score","Universität Duisburg-Essen|Kliniken Essen-Mitte|Immanuel Hospital Berlin, Berlin, Germany|Charite University, Berlin, Germany|University of Witten/Herdecke","All","25 Years to 75 Years   (Adult, Older Adult)","Not Applicable","145","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","CORONA","April 2014","March 2015","December 2015","March 31, 2014",,"July 10, 2019","Immanuel Hospital Berlin, Department of Internal and Complementary Medicine, Berlin, Germany|Department of Internal and Integrative Medicine, Kliniken Essen-Mitte, Faculty of Medicine, University of Duisburg-Essen, Essen, Germany",,"https://ClinicalTrials.gov/show/NCT02099968"
274,"NCT03453840","Extended Duration Artemether-lumefantrine Treatment for Malaria in Children","EXALT","Completed","No Results Available","Uncomplicated Plasmodium Falciparum Malaria","Drug: Artemether-lumefantrine","Area under the plasma concentration versus time curve (AUC) for all drug analytes|Recurrent malaria following treatment by day 42 (recrudescence or new infection)|Safety of 5-day vs 3-day AL regimens evaluated via graded toxicity|Prevalence of gametocytemia following treatment in 3-day vs 5-day AL regimens determined by thick blood smears|Weight-for-age (WFA) associations with PK|Height-for-age (HFA) associations with PK|Weight-for-height (WFH) associations with PK|Diagnostic sensitivity of LAMP, HS-RDT, and microscopy for the detection of recurrent parasitemia|Metabolomic measurements in HIV infected vs HIV uninfected children|Relationship between drug resistance and treatment failure","University of California, San Francisco|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yale University|Infectious Diseases Research Collaboration, Uganda","All","6 Months to 10 Years   (Child)","Phase 4","305","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-22578|2R01HD068174-06A1","February 19, 2018","January 9, 2020","January 9, 2020","March 5, 2018",,"July 29, 2021","MGH campus, Busia, Uganda|IDRC- Tororo Research Clinic and Tororo District Hospital, Tororo, Uganda","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT03453840/Prot_SAP_002.pdf|""Informed Consent Form: Informed Consent Forms"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT03453840/ICF_003.pdf|""Informed Consent Form: Assent and consent for future use of specimen"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT03453840/ICF_004.pdf","https://ClinicalTrials.gov/show/NCT03453840"
275,"NCT04262310","Standardizing Method and Development of Normal Values to Measure Human Small Intestinal and Colonic Permeability",,"Completed","No Results Available","Healthy","Other: Small Bowel and Colonic Permeability Test","Standard Method to Measure Intestinal Permeability","Mayo Clinic","All","18 Years to 70 Years   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","19-008541","October 11, 2019","February 1, 2021","February 26, 2021","February 10, 2020",,"March 30, 2021","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04262310"
276,"NCT00259753","Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular Degeneration",,"Completed","No Results Available","Macular Degeneration","Drug: Bevasiranib","change from baseline at the 12-week evaluation in macular edema as measured by optical coherence tomography.|The secondary endpoint is the mean BCVA line/letters change from baseline at the 12-week evaluation.","OPKO Health, Inc.","All","50 Years and older   (Adult, Older Adult)","Phase 2","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ACU201","July 2005","December 2007","December 2007","December 1, 2005",,"August 5, 2008","Acuity Participating Site, Phoenix, Arizona, United States|Retina Centers PC, Tucson, Arizona, United States|Sall Research Medical Center, Artesia, California, United States|Bay Area Retina Associates, Walnut Creek, California, United States|Florida Eye Microsurgical Institute, Inc., Boynton Beach, Florida, United States|Retina Specialist, Towson, Maryland, United States|Vitreo-Retinal Associates PC, Grand Rapids, Michigan, United States|Associated Retinal Consultants, Grand Rapids, Michigan, United States|Associated Retinal Consultants, P.C., Royal Oak, Michigan, United States|VitreoRetinal Surgery, P.A., Edina, Minnesota, United States|Eye Foundation of Kansas City, UMKC School of Medicine, Kansas City, Missouri, United States|Retina-Vitreous Center, Lakewood, New Jersey, United States|Retina-Vitreous Consultants, Livingston, New Jersey, United States|OCLI, Lynbrook, New York, United States|LuEsther T. Mertz Retinal Research Center, New York, New York, United States|Southeast Clinical Research, Charlotte, North Carolina, United States|Retina Associates of Cleveland, Beachwood, Ohio, United States|Retina Associates of Cleveland, Inc., Lakewood, Ohio, United States|Black Hills Eye Institute, Rapid City, South Dakota, United States|Retina Reseach Center, Austin, Texas, United States|Ophthalmology Associates, Fort Worth, Texas, United States|Vitreoretinal Consultants Houston TX, Houston, Texas, United States|Medical College of Wisconsin Eye Institute, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00259753"
277,"NCT00306904","Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic Macular Edema",,"Completed","No Results Available","Diabetic Macular Edema","Drug: bevasiranib","Change from baseline at the 12-week evaluation in macular edema as measured by optical coherence tomography.|Mean BCVA line/letters change from baseline at the 12-week evaluation.","OPKO Health, Inc.","All","21 Years and older   (Adult, Older Adult)","Phase 2","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ACU211","January 2006","September 2007","December 2007","March 27, 2006",,"July 25, 2008","Retina Associates of Cleveland, Beechwood, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00306904"
278,"NCT01177475","Effect of Intake in Bioactive Molecules From Natural or Pasteurised Milk on Gut Maturation in Very Premature Newborns",,"Completed","No Results Available","Premature Birth","Other: blood samples , feces samples|Other: blood samples, feces samples","pasteurized milk|natural milk","Assistance Publique Hopitaux De Marseille","All","up to 1 Week   (Child)","Not Applicable","55","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","2009-A00666-51|2009 09","February 2010","June 2012","June 2012","August 9, 2010",,"October 1, 2015","Assistance Publique Hopitaux de Marseille, Marseille, France",,"https://ClinicalTrials.gov/show/NCT01177475"
279,"NCT00636389","Molecule Removal and Ease of Use: A Comparison of Two Different Dialyzers",,"Completed","Has Results","Chronic Kidney Disease","Device: Polyflux 210H dialyzer|Device: Polyflux HD-C4","Comparison of Urea Removal Under Conditions of Routine Hemodialysis.|A Comparison of Pre- to Post-dialysis Reduction of Small and Large Molecules Under Conditions of Routine Hemodialysis.|Comparison of Dialyzer Ease of Use Between the Polyflux HD-C4 Dialyzer and the Polyflux 210H","Baxter Healthcare Corporation|Gambro Renal Products, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Gambro 1460","February 2008","December 2008","March 2009","March 14, 2008","August 11, 2011","May 10, 2017","DaVita Clinical Research Facility, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT00636389"
280,"NCT01920906","Comparative Analysis of Small and Large Plaque Psoriasis",,"Completed","No Results Available","Psoriasis","Procedure: Skin biopsy and blood test","The primary outcome measure is the RT-PCR measurement of IL-17 in lesional psoriasis skin samples collected from patients in Korea.|The secondary outcome measure is the RT-PCR measurement of IL-17 in lesional psoriasis skin samples collected from patients at The Rockefeller Hospital, New York.","Rockefeller University","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","13","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","JWK-0816","January 2014","June 2015","June 2015","August 12, 2013",,"May 6, 2016","The Rockefeller University, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01920906"
281,"NCT03211676","Comparison of Hemodialysis With Medium Cut-off Dialyzer (Theranova) and High Flux Dialyzer","THERANOVA","Completed","No Results Available","End Stage Renal Disease|Dialysis Related Complication|Dialysis Amyloidosis","Device: Theranova-500 dialyzer|Device: Elisio-21H","Removal of myoglobin|Removal of beta2 microglobulin|Removal of urea|Removal of creatinine|Removal of interleukin 6|Removal of IL-1beta|Removal of TNF alpha|Removal of leptin|Removal of alpha 1 microglobulin|Removal of retinol binding protein|Removal of hyaluronic acid|Removal of FGF 23 (fibroblast growth factor 23)|Removal of prolactin|Removal of free light chain kappa|Removal of free light chain lambda|comparison of pre dialysis level of hepcidin|comparison of pre dialysis level of superoxide dismutase|comparison of pre dialysis level of isoprostan|comparison of pre dialysis level of human oxidized LDL|comparison of pre dialysis level of albumin|comparison of pre dialysis level of prealbumin|comparison of post dialysis level of albumin|comparison of level of middle molecules and albumin in the dialysate|comparison of use of erythrpoietin|comparison of hemoglobin levels|comparison of pre dialysis level of CRP|comparison of pre dialysis level of SAA","Poitiers University Hospital|Baxter Healthcare Corporation","All","18 Years and older   (Adult, Older Adult)","Not Applicable","49","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","2016-A01679-42","June 7, 2017","March 14, 2018","June 14, 2018","July 7, 2017",,"April 13, 2020","CHU DE Poitiers, Poitiers, France",,"https://ClinicalTrials.gov/show/NCT03211676"
282,"NCT01638546","Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer",,"Completed","Has Results","Recurrent Small Cell Lung Carcinoma","Other: Laboratory Biomarker Analysis|Other: Placebo|Drug: Temozolomide|Drug: Veliparib","Progression-free Survival, Calculated as the Proportion of Patients Alive and Without Evidence of Disease|Overall Response (ORR) by RECIST 1.1 Criteria|Overall Survival|Number of Participants With Adverse Events","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","97","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NCI-2012-01130|IRB #12-021|12-021|CDR0000737062|9026|N01CM00039|P30CA008748|U01CA070095|UM1CA186691","June 2012","January 2017","January 2017","July 11, 2012","March 27, 2018","November 19, 2019","Moffitt Cancer Center, Tampa, Florida, United States|Emory University/Winship Cancer Institute, Atlanta, Georgia, United States|Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Case Western Reserve University, Cleveland, Ohio, United States|M D Anderson Cancer Center, Houston, Texas, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01638546"
283,"NCT01306149","Natural History of Mineral Metabolism Parameters and Protein-bound Toxins in Incident Peritoneal Dialysis Patients",,"Completed","No Results Available","Complication of Peritoneal Dialysis",,"natural history of clearances and serum parameters of mineral metabolism and protein-bound toxins|determinants of generation rate of uremic retention solutes","Universitaire Ziekenhuizen Leuven","All","18 Years and older   (Adult, Older Adult)",,"96","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","FWO01-03-21","July 2002","January 31, 2017","January 31, 2017","March 1, 2011",,"October 25, 2017","University Hospital, Leuven, Vlaams-Brabant, Belgium",,"https://ClinicalTrials.gov/show/NCT01306149"
284,"NCT00935792","Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",,"Completed","Has Results","Lymphocytic Leukemia","Drug: alemtuzumab|Drug: everolimus","Clinical Response (Complete or Partial Remission)|Number of Participants With Dose-Limiting Toxicities|Test the Safety and Tolerability of the Combination of Everolimus and Alemtuzumab.|Survival Time|Progression-free Survival|Duration of Response|Time to Subsequent Therapy","Mayo Clinic","All","18 Years to 120 Years   (Adult, Older Adult)","Phase 1|Phase 2","28","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MC088C|NCI-2009-00935|08-008775","July 2009","December 2015","December 2015","July 9, 2009","December 12, 2016","September 26, 2017","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT00935792"
285,"NCT01456767","Effects of Administration of L.Plantarum WCFS1, L.Plantarum CIP104448, L.Plantarum CIP104450 on Small Intestinal Mucosa",,"Completed","No Results Available","Gastro Intestinal Infection","Dietary Supplement: Probiotics","Change in sugar recovery in urine, as indicator of intestinal permeability, after seven days probiotics supplementation.|Differences of measurements in duodenal biopsy specimens between the separate arms.|Change in measurements in whole blood, after the seven days probiotics supplementation period.","Maastricht University Medical Center","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","NL35728.068.11/METC11-2-011","October 2011","April 2012",,"October 21, 2011",,"July 19, 2012","Health, Medicine and Life Sciences, Maastricht, Limburg, Netherlands",,"https://ClinicalTrials.gov/show/NCT01456767"
286,"NCT02393274","Microcirculation in Venoarterial Extracorporeal Membrane Oxygenation Life Support",,"Completed","No Results Available","Heart Failure|Respiratory Failure","Device: Extra-corporeal membrane oxygenation life support","Perfused small vessel density|Total small vessel density|Endocan level|Microvascular flow index","National Taiwan University Hospital","All","20 Years to 79 Years   (Adult, Older Adult)",,"48","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","201412045RINA","April 2015","August 2016","December 2016","March 19, 2015",,"April 23, 2018","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT02393274"
287,"NCT02872961","SIBO, Immune Activation, and FGIDs in Children","SIBO","Completed","No Results Available","Small Intestinal Bacterial Overgrowth|Irritable Bowel Syndrome|Functional Dyspepsia|Functional Abdominal Pain",,"Abdominal Pain Index|Duodenal fluid microbiota|Serum biomarker levels|Duodenal tissue inflammatory cell infiltration|Duodenal tissue toll-like receptor expression|Duodenal tissue cytokine levels|Wong-Baker FACES Pain Rating Scale","The University of Texas Health Science Center, Houston","All","4 Years to 17 Years   (Child)",,"54","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","HSC-MS-11-0726","April 2013","February 13, 2017","February 13, 2017","August 19, 2016",,"March 29, 2021","The University of Texas of Health Science Center at Houston, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02872961"
